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ABSTRACT 
Colorectal cancer (CRC) is the carcinoma of the colon and rectum in the gastrointestinal 
system. CRC is the third most common cancer in men and the second in women 
worldwide. The limitations of the currently available biomarkers and technologies for 
CRC screening and surveillance have highlighted the necessity of finding novel 
biomarkers. Recently, microRNA (miRNA)-based studies have rendered remarkable 
contribution in the elucidation of mechanisms of carcinogenesis. miRNAs are short, 
non-coding RNA molecules that act as regulators of gene expression through messenger 
RNA (mRNA) degradation or translational inhibition. Blood miRNA expression 
profiles offer great potential as non-invasive biomarkers. In the present study, the aims 
were to characterise and correlate the tissue and blood miRNA expression patterns of 
primary CRC patients, and establish the functional roles of the identified miRNAs in the 
carcinogenesis of CRC. Firstly, the miRNA profiling study was divided into two phases: 
(I) marker discovery by miRNA microarray using paired cancer tissues (n = 30) and 
blood samples (CRC, n = 42; control, n = 18); (II) marker validation by reverse 
transcription-quantitative real-time polymerase chain reaction (RT-qPCR) using an 
independent set of paired cancer tissues (n = 30) and blood samples (CRC, n = 70; 
control, n = 32). Logistic regression and receiver operating characteristic curve analyses 
were applied to obtain diagnostic utility of the miRNAs. Seven miRNAs (miR-150, 
miR-193a-3p, miR-23a, miR-23b, miR-338-5p, miR-342-3p and miR-483-3p) were 
found to be differentially expressed in both tissue and blood samples. Significant 
positive correlations were observed in the tissue and blood levels of miR-193a-3p, miR-
23a and miR-338-5p. These miRNAs were demonstrated as a classifier for CRC 
detection, with a receiver operating characteristic curve area of 0.887 (80.0% sensitivity, 
84.4% specificity and 83.3% accuracy). Next, these miRNAs were subjected to 
functional and miRNA:mRNA target validation studies via miRNA mimics and 
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inhibitors transfections. SW480 and SW620 CRC cell lines were utilised. Cell viability, 
apoptosis, migration and invasion assays were conducted. Luciferase assays were 
performed for the validation of target mRNAs. The expression levels of target mRNAs 
and proteins in clinical CRC samples and cell lines were assessed using RT-qPCR and 
Western blot. miR-193a-3p was identified to be involved in CRC cell migration and 
invasion by targeting FOXO4. miR-23a was determined to possess apoptosis resistance 
function by targeting APAF1. However, the transfection of miR-338-5p did not reveal 
significant findings in the cell viability, apoptosis, migration and invasion analyses. In 
conclusion, miRNA deregulation in the blood is reflective of that in the CRC tissue. The 
triple miRNA classifier of miR-193a-3p, miR-23a and miR-338-5p may serve as 
potential blood biomarkers for CRC detection. The miRNA:mRNA target validation 
studies have highlighted the potential application of miR-193a-3p:FOXO4 and miR-
23a:APAF1 regulation axes in miRNA-based therapy and prognostication. 
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ABSTRAK 
Kanser kolorektal adalah karsinoma kolon dan rektum dalam sistem gastrointestinal. 
Kanser kolorektal adalah kanser ketiga paling lazim di kalangan lelaki dan yang kedua 
di kalangan wanita di seluruh dunia. Batasan dalam biomarker dan teknologi sedia ada 
bagi pemeriksaan dan pemantauan kanser kolorektal telah mengetengahkan keperluan 
untuk mencari biomarker yang novel. Kebelakangan ini, kajian berasaskan microRNA 
(miRNA) amat menyerlah dalam penerangan mengenai mekanisme karsinogenesis. 
miRNA adalah molekul RNA pendek, bukan pengekodan yang terlibat dalam 
penyeliaan gen melalui degradasi ‘messenger RNA (mRNA)’ atau perencatan 
translasional protein. Profil ekspresi miRNA darah menawarkan potensi besar sebagai 
biomarker tidak invasif. Objektif-objektif penyelidikan ini adalah demi mencirikan dan 
mengaitkan pola ekspresi miRNA tisu dan darah pesakit kanser kolorektal, dan 
menentukan peranan miRNA yang terpilih dalam karsinogenesis kanser kolorektal. 
Pertama sekali, kajian profil miRNA telah dibahagikan kepada dua fasa: (I) penemuan 
marker melalui miRNA microarray dengan menggunakan sampel tisu (n = 30) dan 
darah (kanser, n = 42; kawalan, n = 18); (II) pengesahan marker melalui ‘reverse 
transcription-quantitative real-time polymerase chain reaction (RT-qPCR)’ dengan 
menggunakan set sampel tisu (n = 30) dan darah (kanser, n = 70; kawalan, n = 32) yang 
baru. Analisis-analisis seperti ‘logistic regression’ dan ‘receiver operating characteristic 
curve’ telah dilaksanakan untuk memperoleh utiliti diagnostik daripada miRNA-miRNA 
yang terlibat. Berdasarkan sampel-sampel tisu dan darah yang telah diuji, tujuh 
miRNAs (miR-150, miR-193a-3p, miR-23a, miR-23b, miR-338-5p, miR-342-3p dan 
miR-483-3p) telah memaparkan tahap ekspresi yang unik. Tahap miR-193a-3p, miR-
23a dan miR-338-5p telah menunjukkan korelasi positif yang ketara di antara sampel 
tisu dan darah. miRNA-miRNA tersebut telah didemonstrasikan sebagai sekumpulan 
miRNA yang boleh digunakan dalam pengesanan kanser kolorektal, dengan keluasan 
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‘receiver operating characteristic curve’ sebanyak 0.887 (sensitiviti 80.0%, kekhususan 
84.4% dan ketepatan 83.3%). Seterusnya, kajian fungsional dan pengesahan target 
miRNA:mRNA melalui transfeksi mimik dan perencatan telah dijalankan. Sel kanser 
kolorektal SW480 dan SW620 telah digunakan. Eksperimen-eksperimen seperti tahap 
kegiatan sel, apoptosis, migrasi dan invasi telah dijalankan. Uji kaji ‘luciferase’ telah 
dilaksanakan bagi pengesahan target mRNA. Tahap ekspresi target mRNA dan protein 
dalam sampel klinikal dan sel kanser kolorektal telah dinilai melalui ‘RT-qPCR’ dan 
‘Western blot’. Penglibatan miR-193a-3p dalam sel migrasi dan invasi melalui target 
FOXO4 telah dikenal pasti manakala miR-23a telah didapati mempunyai fungsi 
rintangan apoptosis melalui target APAF1. Walau bagaimanapun, transfeksi miR-338-
5p tidak memaparkan penemuan penting dalam analisis-analisis tahap kegiatan sel, 
apoptosis, migrasi dan invasi. Kesimpulannya, ketidakseimbangan tahap miRNA dalam 
darah telah mencerminkan tahap miRNA dalam tisu kanser kolorektal. Sekumpulan tiga 
miRNA, miR-193a-3p, miR-23a dan miR-338-5p dicadangkan sebagai biomarker-
biomarker yang berpotensi dalam pengesanan kanser kolorektal. Kajian pengesahan 
target miRNA:mRNA juga menekankan bahawa paksi pengawalseliaan tahap miR-
193a-3p:FOXO4 dan miR-23a:APAF1 berkemungkinan boleh diterapkan dalam terapi 
berasaskan miRNA dan pemantauan kanser. 
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CHAPTER 1  
INTRODUCTION 
 
Colorectal cancer (CRC) is the carcinoma of the colon and rectum in the gastrointestinal 
system. CRC is the third most common cancer in men and the second in women 
worldwide, with an estimation of 1.36 million new cases, 0.69 million deaths and 3.54 
million people living with CRC (Ferlay et al., 2013). The carcinogenesis of CRC is 
heterogeneous, multi-factorial and may take several decades. CRC is a curable disease if 
the growth is detected at an early, localised stage. However, most cases are diagnosed at 
late stages due to low population compliance to CRC screening. The concerns of 
invasive nature, radiation exposure and false-positivity of currently available screening 
tests have highlighted the necessity of exploring other non-invasive biomarkers to 
complement and improve CRC screening in the average-risk population. Blood-based 
tests are easy to perform as only standard blood collection procedure is required. The 
deregulation of various messenger RNAs (mRNAs), tumour associated antigens, 
cytokines, anti-apoptotic proteins and cell proliferation proteins has been detected in the 
blood circulation of CRC patients (Creeden, Junker, Vogel-Ziebolz, & Rex, 2011). In 
recent years, the emergence of microRNAs (miRNAs) as endogenous regulators of gene 
expression has rendered remarkable contribution in the elucidation of cancer initiation, 
promotion and progression. miRNAs are short, non-coding RNA molecules of 
approximately 22 nucleotides that bind to the 3’-untranslated region (3’-UTR) of target 
mRNAs (Bartel, 2004). In the event of full complementarity, the target mRNA will be 
subjected to mRNA cleavage. In contrast, partial complementarity will lead to 
translational repression and/or deadenylation whereby the mRNA will be localised to 
processing body (P-body) for storage or degradation (Bartel, 2009; Chan & Slack, 2006; 
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L. Wu, Fan, & Belasco, 2006). miRNAs appear to be cell type- and disease-specific, 
enabling them to serve as more superior biomarkers than mRNAs or proteins (Esquela-
Kerscher & Slack, 2006). miRNA expression patterns are being extensively studied in 
order to aid in the diagnosis and treatment of cancer. Nevertheless, most publications on 
miRNA deregulation in CRC are focused either on the tissue or blood component. The 
absolute hypothesis of whether the circulating blood miRNAs are reflective of those in 
the CRC tissues is yet to be answered. The ideal blood biomarker should be able to 
detect the early presence of a tumour before the growth could otherwise be easily 
detected.  
Hence, the main objective of the present study was to characterise and correlate the 
tissue and blood miRNA expression patterns of primary CRC patients. The specific 
objectives are as follows: 
(a) To assess the diagnostic utility of the significantly correlated miRNAs in the 
tissue and blood samples. 
(b) To establish the functional roles of the identified miRNAs in the carcinogenesis 
of CRC. 
(c) To identify the potential genes and pathways targeted by the identified miRNAs. 
(d) To determine the feasibility of the identified miRNA:mRNA markers for 
discriminating early and advanced CRC. 
On the whole, the present study revolved around a marker discovery phase via miRNA 
microarray and a marker validation phase via reverse transcription-quantitative real-
time polymerase chain reaction (RT-qPCR). Since a single miRNA is capable of 
regulating multiple targets and regulatory pathways in a particular disease, the 
identification of concurrently expressed miRNAs was of utmost importance in this 
research. The potential exploitation of miRNAs in therapeutic intervention has driven 
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the investigation of their biological functions in the carcinogenesis of CRC via in vitro 
miRNA mimics and inhibitors studies. SW480 and SW620 cell lines derived from the 
spontaneous progression of a human CRC in a single patient were used for the analysis 
of gene expression changes during the transition from early to advanced carcinoma. A 
focused approach on the effects of the deregulated miRNAs in cell viability, apoptosis, 
migration and invasion were examined. Eventually, the causal associations between the 
differentially expressed miRNAs and the predicted target genes were established. The 
findings from this study would contribute to the scientific knowledge pertaining to the 
feasibility of the identified miRNAs as diagnostic, prognostic and therapeutic 
biomarkers in CRC.  
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CHAPTER 2  
LITERATURE REVIEW 
 
2.1   Colorectal cancer (CRC) 
2.1.1   Overview of large intestine  
Large intestine is part of the gastrointestinal system. The length of the large intestine is 
about five feet long (American Cancer Society, 2011). It functions to absorb water and 
minerals from food and excrete the indigestible waste from the body as faeces. The 
large intestine is made up of several sections: caecum, ascending colon, transverse colon, 
descending colon, sigmoid colon and rectum (Tortora & Derrickson, 2007).  
 
2.1.2   Prevalence of CRC 
CRC is the carcinoma of the colon and rectum in the gastrointestinal system. CRC is the 
third most common cancer in men and the second in women worldwide (Bray, Jemal, 
Grey, Ferlay, & Forman, 2012; Ferlay et al., 2013). Data from the latest GLOBOCAN 
2012 project conducted by the International Agency for Research on Cancer (IARC) 
have revealed an estimation of 1.36 million new CRC cases, 0.69 million deaths and 
3.54 million people living with CRC in 2012 worldwide (Ferlay et al., 2013). Almost  
55% of the cases occur in the developed regions. The CRC burden is predicted to rise at 
1% per year by 2030, assuming the population growth and ageing occur based on the 
United Nations’s world population prospects (Bray et al., 2012; United Nations 
Population Division, 2013). The incidence rate of CRC has been increasing in Asian 
countries as well (Wan Puteh et al., 2013). In Malaysia, it ranks the second after lung 
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cancer and breast cancer in men and women, respectively (Zainal Ariffin & Nor Saleha, 
2011). Among Malaysians, the highest incidence of CRC has been observed in the 
Chinese population, followed by the Malay and Indian populations (Sung, Lau, Goh, & 
Leung, 2005; Zainal Ariffin & Nor Saleha, 2011). Moreover, the incidence is 
disproportionately higher in males as compared to females. The five-year survival rate 
exceeds 90% when CRC is detected at an early, localised stage (McFarland et al., 2008). 
However, most cases are diagnosed at late stages due to insufficient public awareness 
and inconvenient nature of certain screening tests. 
 
2.1.3   Aetiology of CRC 
The pathogenesis of CRC is heterogeneous, multi-factorial and may take several 
decades. CRC may develop sporadically (85%) with no well-defined aetiology, as part 
of hereditary cancer syndrome (10%) such as familial adenomatous polyposis (FAP) 
and hereditary non-polyposis colorectal cancer (HNPCC), or on a background of 
inflammatory bowel disease (5%) (Half, Bercovich, & Rozen, 2009; Lynch & Lynch, 
2005; Robinson et al., 2007; Søreide et al., 2009). Nevertheless, the development of 
sporadic CRC has been suggested to arise from randomly acquired somatic mutations in 
several of the common genes found in hereditary CRC (Choong & Tsafnat, 2012). 
The hallmarks of CRC include autonomous growth signals, insensitivity to anti-growth 
signals, evasion of apoptosis, unlimited replicative potential, sustained angiogenesis and 
the ability for tumour invasion and metastasis (Hanahan & Weinberg, 2011). Genetic 
and epigenetic alterations that cause the disruption of homeostatic regulation between 
cell proliferation and cell death transform the normal colonic epithelium to an 
adenomatous intermediate and eventually into invasive adenocarcinoma. 
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2.1.4   Genomic instability pathways in CRC 
The loss of genomic stability greatly influences the development of CRC by facilitating 
the acquisition of various tumour-associated mutations (Markowitz & Bertagnolli, 
2009). The three major genomic instabilities in CRC are chromosomal instability (CIN), 
microsatellite instability (MSI) and epigenetic silencing through cytosine-phosphate-
guanine (CpG) island methylator phenotype (CIMP) (Søreide et al., 2009).  
The CIN pathway is recognised by cytogenetic abnormalities, aneuploidy and allelic 
losses at chromosomal arms (Harrison & Benziger, 2011; Lanza et al., 2007). FAP is an 
autosomal dominant disorder associated with CIN and caused by germline mutations of 
the adenomatous polyposis coli (APC) gene (Konishi et al., 1996). FAP is defined by 
the presence of numerous polyps in the colon (Harrison & Benziger, 2011).  
The MSI pathway is characterised by mutations in nucleotide repetitive sequences, 
especially due to defects in the DNA mismatch repair system (Harrison & Benziger, 
2011; Lanza et al., 2007). HNPCC is an autosomal dominant condition associated with 
MSI and caused by germline mutations of the DNA mismatch repair (MMR) genes 
(MLH1, MSH2, MSH6 and PMS2) (Earle et al., 2010; Konishi et al., 1996).  
CIMP is a phenomenon of epigenetic silencing of genes through aberrant DNA 
methylation at certain cytosine residues of the cytosine- and guanine-rich regions 
known as the CpG islands (Markowitz & Bertagnolli, 2009). Although the molecular 
mechanism of the CIMP pathway has not been fully elucidated, several studies on DNA 
methylation have revealed that sporadic CRC exhibits concurrent methylation of at least 
three loci from a selected panel of CpG island-associated genes (S. Lee, Cho, Yoo, Kim, 
& Kang, 2008; McKenna & Roberts, 2009; Toyota et al., 1999). CIMP-positive tumours 
can be sub-divided into CIMP-high and CIMP-low, characterised by the quantitative 
differences in CpG island methylation (Teodoridis, Hardie, & Brown, 2008). These 
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tumours are associated with poorer prognosis in CRC (S. Lee et al., 2008; Toyota et al., 
1999; Weisenberger et al., 2006). Based on a study by Shen et al. (2007), the CIMP-
high tumours are usually presented with MSI status and B-Raf proto-oncogene (BRAF) 
mutations while the CIMP-low tumours are less microsatellite unstable but possess 
higher percentages of Kirsten rat sarcoma viral oncogene homologue (KRAS) mutations. 
In contrast, CIMP-negative tumours have a high rate of TP53 mutations and low rates of 
BRAF and KRAS mutations (Shen et al., 2007).  
 
2.1.5   Risk factors of CRC 
There are many risk factors underlying the pathogenesis of CRC. The presence of 
colorectal polyps, which may be hyperplastic or adenomatous in nature, places one at 
increased risk of acquiring CRC (Morimoto et al., 2002). Colorectal polyps are benign 
growths protruding from the colon and rectal mucosa. The polyps may undergo genetic 
changes to become malignant. An individual with a family history of CRC or colorectal 
adenoma may have an increased risk of developing CRC (Levin et al., 2008). In 
addition, a background of an inflammatory bowel disease such as Crohn’s disease or 
ulcerative colitis, may also lead to CRC (Monteleone, Pallone, & Stolfi, 2012). Other 
risk factors of CRC are environmental exposure to carcinogens and unhealthy lifestyle 
such as high intakes of red meats and animal fats, low intakes of vegetables, fruits and 
fibres, smoking, alcohol consumption, obesity and physical inactivity (American Cancer 
Society, 2011; Bruce, Wolever, & Giacca, 2000). Moreover, the risk of CRC increases 
with age, whereby most cases are diagnosed in the older generation above 50 years old 
(Levin et al., 2008).  
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2.1.6   Symptoms of CRC 
Patients with pre-cancerous polyps or early-stage CRC seldom reveal any symptom 
until the growth obstructs the large intestine (Sung et al., 2005). In addition, several 
gastrointestinal tract diseases such as irritable bowel syndrome, inflammatory bowel 
disease, diverticulosis, haemorrhoid and peptic ulcer disease may mimic the symptoms 
of CRC. The main symptoms of CRC are rectal bleeding and blood in the stool (Levin 
et al., 2008). Other symptoms may include a change in the shape of the stool, prolonged 
constipation or diarrhoea, weight loss, abdominal cramp and frequent urge for bowel 
movements (American Cancer Society, 2011). Since the growth can be present for a 
long duration before any symptom develops, CRC screening is vital for early detection 
of CRC. 
 
2.1.7   Screening, diagnostic and prognostic tests for CRC  
CRC is a curable disease if the growth is detected at an early, localised stage. Screening 
can reduce CRC morbidity and mortality by prevention through polypectomy or early 
diagnosis for immediate surgical resection. Nonetheless, the awareness of CRC 
screening in Malaysia is low and community-based screening programmes are limited 
(Wan Puteh et al., 2013). CRC screening is strongly recommended for high-risk 
population at young ages and average-risk population aged 50 years old and above 
(Levin et al., 2008). The advantages and disadvantages of the common screening, 
diagnostic and prognostic tests for CRC are discussed in the following sub-sections.  
 
 9 
 
2.1.7.1   Colonoscopy 
Colonoscopy is an invasive endoscopic procedure that allows the visualisation of the 
entire colon and rectum. Bowel preparation with laxative agents is necessary. Sedation 
is often administered to reduce abdominal discomfort. Colonoscopy is the most 
sensitive and ultimate tool in the screening, diagnosis and post-operative surveillance of 
CRC (Young & Womeldorph, 2013). Patients with positive findings from other 
screening tests are commonly referred for a colonoscopy. Polypectomy and biopsy can 
be performed during the procedure. Colonoscopy is greatly recommended for high-risk 
individuals and those aged 50 and above with the screening interval of five and ten 
years, respectively (Levin et al., 2008). Numerous studies have shown that colonoscopy 
screening has significant contribution in the detection of neoplastic lesions and 
reduction of CRC incidence and mortality (Brenner et al., 2013; Kahi, Imperiale, Juliar, 
& Rex, 2009; Young & Womeldorph, 2013). However, the requirement of bowel 
preparation and sedation, and possible bowel complications such as perforation and 
bleeding, have hindered its widespread application as a screening tool (Castro, Azrak, 
Seeff, & Royalty, 2013).  
 
2.1.7.2   Flexible sigmoidoscopy 
Flexible sigmoidoscopy is similar to colonoscopy, but the examination is limited to the 
inner lining of the rectum and sigmoid colon up to 60 cm (Austin et al., 2009). Bowel 
preparation is needed prior to the procedure. No sedation is required and the procedure 
typically lasts about few minutes with minimal discomfort. Bowel perforation and 
infection following flexible sigmoidoscopy are rare (Schoen et al., 2012). However, 
colonoscopy is necessary if large polyps or growths are discovered. Flexible 
sigmoidoscopy is recommended to be done every five years (Levin et al., 2008).  
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2.1.7.3   Computed tomographic colonography (CTC) 
CTC is an imaging technique characterised by the generation of cross-sectional two- or 
three-dimensional x-ray images of the colon and rectum (Fenlon et al., 1999). It is also 
known as virtual colonoscopy (Cotton et al., 2004). A flexible tube is inserted into the 
rectum; air is blown to insufflate the colon and the patient is positioned through a 
helical computed tomography scanner (Fenlon et al., 1999). Bowel preparation is 
needed but does not require sedation. CTC can be performed fairly quickly with 
minimal discomfort or risk. This procedure is less invasive as it involves low-dose 
radiation (Halligan et al., 2013). The feasibility of the CTC test in average-risk 
symptomatic patients has been investigated (Simons, Van Steenbergen, De Witte, & 
Janssen-Heijnen, 2013). The results revealed a detection sensitivity of 94.3% with a 
miss rate of only 3.8%. Colonoscopy is then conducted if abnormality is discovered. 
Moreover, two independent population studies by Gluecker et al. (2003) and Moawad 
(2010) have revealed higher preferences of CTC to colonoscopy in CRC screening. The 
suggested test time interval for CTC is every five years (Levin et al., 2008). 
 
2.1.7.4   Double contrast barium enema (DCBE) 
DCBE is a radiological examination of the colon (Halligan et al., 2013). Bowel 
preparation is needed prior to the procedure. Barium sulphate enema is injected into the 
colon via a rectal tube followed by insufflation with air (Gluecker et al., 2003). X-ray 
images of the colon are captured and analysed. However, small polyps may be missed 
and referral for a colonoscopy is needed if there is any positive finding. The screening 
interval for DCBE is every five years (Levin et al., 2008). This radiological imaging 
technique is less preferable today as CTC has been shown to possess higher precision 
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and lower radiation effects as compared to DCBE (Halligan et al., 2013; Neri et al., 
2010)  
 
2.1.7.5   Faecal-based tests 
Faecal-based tests are non-invasive screening tests. The two common faecal-based tests 
are faecal occult blood test (FOBT) and stool DNA test.  
Large polyps or growths may cause intermittent bleeding into the large intestine. Dark- 
or black-coloured stool is one of the symptoms of CRC. FOBT detects blood in the 
stool and is available as a test kit. The procedure involves placing a tiny stool sample on 
a special card and adding the provided chemicals to detect the presence of blood 
(Allison, Tekawa, Ransom, & Adrain, 1996). FOBT can be divided into guaiac-based 
FOBT (gFOBT) and immunochemical-based FOBT, known as faecal immunochemical 
test (FIT) (Levin et al., 2008). gFOBT is a low-cost test that involves several samplings 
of bowel movements. Although gFOBT does not require a bowel preparation, there is a 
pre-test dietary restriction on certain types of food and drugs such as red meats, citrus 
juices, vitamin C and non-steroidal anti-inflammatory drugs (American Cancer Society, 
2011). Since gFOBT detects blood from any source, there is a higher rate of false-
positivity (Bandi, Cokkinides, Smith, & Jemal, 2012). In contrast, FIT detects only 
human blood and thus, gives a better accuracy as compared to gFOBT (Flitcroft, Irwig, 
Carter, Salkeld, & Gillespie, 2012). The cost for FIT is slightly higher but it does not 
involve a pre-test dietary restriction. Moreover, FIT is more convenient as it requires 
fewer samplings of stool samples. gFOBT or FIT is recommended to be performed 
annually in conjunction with flexible sigmoidoscopy (Levin et al., 2008). Patients with 
positive FOBT results will then be referred for further examination via colonoscopy. 
Although FOBT is confined by low sensitivity and specificity against the detection of 
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small polyps and pre-malignant lesions, FOBT is considered a useful screening method 
due to its non-invasive property (Bandi et al., 2012; Quintero et al., 2012). 
Stool DNA test is an emerging technology in CRC screening. It detects abnormal DNA 
shed from polyp or tumour cells in the stool using a panel of molecular markers 
(McFarland et al., 2008). KRAS, BRAF, APC and TP53 are the common targets 
incorporated in the stool DNA test (Imperiale, Ransohoff, Itzkowitz, Turnbull, & Ross, 
2004; Zou et al., 2009). The test enables the discovery of somatic mutations (U.S. 
Preventive Services Task Force, 2008). Several limitations of the stool DNA test are 
uncertainty of screening interval, high cost and inadequacy in the number of markers 
tested (McFarland et al., 2008). Numerous studies are being carried out to improve the 
panel of molecular markers. A recent investigation by Ahlquist et al. (2012) on next-
generation stool DNA test has revealed promising preliminary results that warrant 
further optimisation and validation in a larger population. The method integrates the use 
of a preservative buffer during stool collection, direct measurement of target genes from 
the stool supernatant, a panel of molecular markers that are more specific in the 
detection of CRC and a highly sensitive assay known as quantitative allele-specific real-
time target and signal amplification. Patients with positive findings will then be referred 
for further examination via colonoscopy. 
 
2.1.7.6   Blood-based tests 
Blood-based tests for CRC screening and surveillance provide substantial clinical 
benefits. Blood-based tests are easy to perform and non-invasive as only standard blood 
collection procedure is required. Moreover, the tests can be repeated regularly with 
minimal risk to the patients. The potential classes of blood biomarkers are tumour 
associated antigens, cytokines, anti-apoptotic proteins, cell proliferation proteins, cell 
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free DNAs, hypermethylated genes, mRNAs and miRNAs (Creeden et al., 2011). 
Among these, the two clinically available blood-based screening tests are ColonSentry 
mRNA expression panel test and septin 9 (SEPT9) methylated DNA test (Heichman, 
2014).  
ColonSentry test was developed by GeneNews Limited in 2008 and it is the world’s 
first blood-based molecular test that can be used to evaluate an individual’s risk of 
developing CRC (Novak, Liew, & Liew, 2012). mRNA from whole blood is subjected 
to RT-qPCR for the measurement of a seven-gene biomarker panel (ANXA3, CLEC4D, 
IL2RB, LMNB1, PRRG4, TNFAIP6 and VNN1) (Marshall et al., 2010). Based on the 
gene profiles, a current relative risk score that compares the probability of developing 
CRC over the prevalence of the disease is calculated (Novak et al., 2012). A validation 
study in the Malaysian population has revealed a test sensitivity of 61%, specificity of 
77% and accuracy of 70% (Yip et al., 2010). The ColonSentry test is currently available 
in Canada, China, Malaysia and the USA.  
SEPT9 methylated DNA test was developed by Epigenomics AG in 2008 and 
subsequently licensed to several companies such as Quest Diagnostics, ARUP 
Laboratories, Warnex Medical Laboratories and QIAGEN (deVos et al., 2009; 
Heichman, 2014). The sample needed is blood plasma (Lofton-Day et al., 2008). 
Methylation-based real-time PCR principle is used in the measurement of the SEPT9 
methylated DNA expression (deVos et al., 2009). The test has been shown to exhibit a 
sensitivity of 90% and specificity of 88% in defining CRC (Warren et al., 2011). 
On the other hand, carcinoembryonic antigen (CEA) test is a common blood-based test 
used in post-operative surveillance and monitoring therapy in patients with advanced 
CRC (H. Kobayashi et al., 2007; Tan et al., 2009). CEA is an oncofoetal antigen 
discovered in 1965 (Gold & Freedman, 1965). It is produced mainly by normal foetal 
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gut, liver and pancreas tissues, and by epithelial tumours of the gastrointestinal system 
(Gold & Freedman, 1965). CEA is not a highly sensitive and specific marker as the 
level can rise in smokers and patients with inflammatory bowel disease, liver disease, 
pancreatitis or epithelial tumours at other areas (Tan et al., 2009). The test is often 
dependent on the cut-off value for a positive result and some CRC patients do not show 
elevated serum CEA levels during recurrence (C. Liu et al., 2010; Su, Shi, & Wan, 
2012). Carbohydrate antigen 19-9 (CA19-9) test works the same way as CEA test (Sisik, 
Kaya, Bas, Basak, & Alimoglu, 2013). It may serve as an additional marker for CRC 
patients with normal CEA levels (P. C. Lin et al., 2012).  
 
2.1.8   Staging of CRC 
The most commonly used staging system in cancer is tumour-node-metastasis (TNM) 
system (Edge & Compton, 2010). The system is based on the size and degree of primary 
tumour invasion (T), regional lymph node involvement (N) and distant metastasis (M). 
It is maintained collaboratively by the International Union for Cancer Control (UICC) 
and the American Joint Committee on Cancer (AJCC) (Edge & Compton, 2010). The 
TNM system is revised periodically in every six to eight years. The latest revision was 
released on January 1, 2010 and is known as the 7th edition of the AJCC Cancer Staging 
Manual (Obrocea, Sajin, Marinescu, & Stoica, 2011). Nevertheless, the older versions 
such as the 5th and 6th editions of the AJCC Cancer Staging Manual are still being used 
among clinicians (Hari et al., 2013). The TNM system encompasses both clinical (pre-
operative) and pathological (post-operative) classifications (Compton et al., 2012; 
Labianca, Nordlinger, Beretta, Brouquet, & Cervantes, 2010). The clinical classification 
is designated as cTNM and it forms the basis of treatment regimen selection. The 
pathological classification is designated as pTNM and it is crucial for prognostic 
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evaluation. Other less commonly used staging systems are Dukes’ classification and 
modified Astler-Coller (MAC) classification (Dukes & Bussey, 1958). The Dukes’ 
classification is a pathological staging that relies only on the degree of primary tumour 
invasion while the MAC classification is a modification of the Dukes’ classification. 
The definitions of the terms used in the latest TNM system are listed in Table 2.1. The 
TNM system, together with the equivalent Dukes’ and MAC classifications are 
summarised in Table 2.2.  
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Table 2.1: Definitions of TNM system.  
TNM system Description 
Primary tumour (T) 
TX Assessment of primary tumour cannot be performed 
T0 No evidence of primary tumour 
Tis Carcinoma in situ: tumour confinement within the glandular 
basement membrane or mucosal lamina propria 
T1 Tumour invasion into sub-mucosa  
T2 Tumour invasion into muscularis propria 
T3 Tumour invasion through the muscularis propria into 
pericolorectal tissues  
T4a Tumour penetration to the surface of the visceral peritoneum 
T4b Tumour invasion and adherence to other organs or structures 
Regional lymph nodes (N) 
NX Assessment of regional nodes cannot be performed 
N0 No regional lymph node metastasis 
N1 Metastasis in one to three regional lymph nodes 
N1a Metastasis in one regional lymph node 
N1b Metastasis in two to three regional lymph nodes 
N1c Tumour deposit(s) in the sub-serosa, mesentery, or non-
peritonealised pericolic or perirectal tissues without regional 
nodal metastasis 
N2 Metastasis in four or more regional lymph nodes 
N2a Metastasis in four to six regional lymph nodes 
N2b Metastasis in seven or more regional lymph nodes 
Distant metastasis (M) 
M0 No distant metastasis 
M1 Distant metastasis 
M1a Metastasis confined to one organ or site 
M1b Metastases in more than one organ or site or the peritoneum 
(Source: Compton et al., 2012) 
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Table 2.2: TNM system with equivalent Dukes’ and MAC classifications for CRC.  
Stage TNM Dukes MAC 
0  Tis, N0, M0 - - 
I T1, N0, M0 A A 
 T2, N0, M0 A B1 
IIA T3, N0, M0 B B2 
IIB T4a, N0, M0 B B2 
IIC T4b, N0, M0 B B3 
IIIA T1-T2, N1/N1c, M0 C C1 
 T1, N2a, M0 C C1 
IIIB T3-T4a, N1/N1c, M0 C C2 
 T2-T3, N2a, M0 C C1/C2 
 T1-T2, N2b, M0 C C1 
IIIC T4a, N2a, M0 C C2 
 T3-T4a, N2b, M0 C C2 
 T4b, N1-N2, M0 C C3 
IVA Any T, Any N, M1a - - 
IVB Any T, Any N, M1b - - 
(Source: Compton et al., 2012) 
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2.1.9   Treatment of CRC 
Surgical resection is the ultimate treatment for CRC. Based on the data published by 
Labianca et al. (2010), the five-year survival rate after surgical resection alone was 85-
95% for stage I cancer, 60-80% for stage II cancer and 30-60% for stage III cancer. 
Adjuvant therapies, which include chemotherapy (anti-cancer drug), radiotherapy 
(radiation) and chemoradiotherapy (anti-cancer drug and radiation), are standard 
treatments for patients with advanced CRC (Carrato, 2008). Fluoropyrimidine drugs are 
common chemotherapeutic agents used in the treatment of CRC (Wolpin, Meyerhardt, 
Mamon, & Mayer, 2007). A widely used example is 5-fluorouracil (5-FU). It is often 
administered in combination with other cytotoxic drugs like oxaliplatin, irinotecan or 
leucovorin (André et al., 2009; Thorn et al., 2011).  
Post-surgical adjuvant therapies are normally administered to stage IIB, IIC and III 
colon cancer patients to improve their survival rates (Labianca et al., 2010). Besides 
adjuvant therapies, neoadjuvant chemoradiotherapy is highly recommended for stage 
IIB, IIC and III rectal cancer patients to increase the chances of curative resection 
(Carrato, 2008). Although stage I and IIA cancers carry a better prognosis, some of the 
patients still develop recurrence. The routine use of adjuvant therapies in early-stage 
patients is controversial, as not all of them are likely to benefit, which may lead to the 
adverse effects of under-treatments or over-treatments (Schepeler et al., 2008; Wolpin et 
al., 2007).  
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2.1.10   Prognosis of CRC 
Prognosis of CRC plays an important role in the prediction of distant metastasis and 
recurrence, thus allowing adjuvant therapy or surgery where appropriate. Prevention of 
recurrence is crucial as CRC relapse is often life-threatening. Based on the TNM system, 
the extent of tumour penetration, the involvement of regional lymph nodes and the 
presence of metastasis are crucial prognostic parameters (Compton et al., 2012). 
Adenocarcinomas can be graded based on the percentages of gland formation, grade 1 
(G1): well differentiated (> 95%), grade 2 (G2): moderately differentiated (50-95%), 
grade 3 (G3): poorly differentiated (5-50%) and grade 4 (G4): undifferentiated (< 5%) 
(Hamilton & Aaltonen, 2000). The tumour grading system is considered as a stage-
independent prognostic factor in CRC, in which G1 and G2 tumours give better 
prognosis than G3 and G4 tumours. Other prognostic factors that are independent of the 
TNM system include pre-operative CEA level, tumour deposits, circumferential 
resection margin, perineural invasion, MSI status, tumour regression grade following 
neoadjuvant therapy, KRAS mutation analysis and 18q loss of heterozygosity status 
(Compton et al., 2012). All in all, compliance to surgical follow-up is the utmost goal in 
CRC surveillance. 
 
2.2   microRNA (miRNA) 
2.2.1   miRNA discovery 
miRNAs are short (~22 nucleotides), endogenous, non-coding RNA molecules that act 
as regulators of gene expression (Bartel, 2004; He & Hannon, 2004). The pioneer 
discovery of miRNAs was initiated by Lee and his colleagues in 1993 when they found 
lin-4, a small RNA molecule that is capable of controlling the larval development of 
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Caenorhabditis elegans via post-transcriptional regulation of lin-14 gene at the 3’-UTR 
(R. C. Lee, Feinbaum, & Ambros, 1993). Seven years later, the discovery of the second 
miRNA, let-7, that shares a similar role as a regulator of developmental transition, has 
incurred more curiosity in miRNA research (Reinhart et al., 2000). The let-7 has been 
determined to bind to the 3’-UTR of lin-41 and hbl-1 mRNAs (He & Hannon, 2004). To 
date, there are more than 2000 entries of human miRNAs in the latest miRBase release 
(version 21; June 2014) (http://www.mirbase.org/), constituting around 1% of total 
genes that can regulate up to one third of the human genome (Babashah & Soleimani, 
2011; Koturbash, Zemp, Pogribny, & Kovalchuk, 2011; Kozomara & Griffiths-Jones, 
2014). 
miRBase is the primary online repository for all miRNA sequences and annotation. The 
numbering of miRNA genes is based on chronological discovery (Kozomara & 
Griffiths-Jones, 2014). The miRBase registry for mature miRNA sequences begins with 
the accession MIMAT. The naming convention for mature miRNA is “miR” while the 
precursor stem-loop or miRNA gene is designated as “mir” (Ambros et al., 2003). For 
instance, miR-338 represents the mature miRNA sequence while mir-338 represents the 
precursor stem-loop sequence. Distinct precursor sequences that produce identical 
mature sequences are named as mir-338-1 and mir-338-2 (Lagos-Quintana, Rauhut, 
Lendeckel, & Tuschl, 2001). On the other hand, lettered suffixes are used to 
differentiate closely related mature sequences, like miR-23a, miR-23b and miR-23c 
(Ambros et al., 2003). miR/miR* nomenclature has been widely used to determine the 
predominantly expressed mature miRNA arm from a stem-loop precursor (Griffiths-
Jones, Grocock, van Dongen, Bateman, & Enright, 2006). For example, miR-150 is the 
predominant sequence while miR-150* is from the opposite arm of the precursor. 
However, the use of the miR/miR* nomenclature has been ceased in the latest release of 
miRBase version 21 (Kozomara & Griffiths-Jones, 2014). It is replaced by the inclusion 
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of a -5p or -3p suffix to specify the arm origin of the mature miRNA sequence. For 
instance, miR-150-5p is derived from the 5’ end of the stem-loop precursor while miR-
150-3p is derived from the 3’ end. Nonetheless, the names for miRNAs (e.g. lin-4 and 
let-7) that are discovered prior to the invention of the miRBase naming convention are 
being retained for historical reasons (Griffiths-Jones et al., 2006). 
 
2.2.2   miRNA biogenesis  
miRNA genes are located either within the intragenic (protein-coding) or intergenic 
(non-protein-coding) regions of the genome (V. N. Kim, Han, & Siomi, 2009). In 
human, most of the miRNA genes are localised within the intragenic regions (70%) 
(Garzon, Calin, & Croce, 2009). There are two types of processing pathways in miRNA 
biogenesis, namely, canonical and mirtron pathways (Sotillo & Thomas-Tikhonenko, 
2011) (Figure 2.1).  
Canonical maturation involves miRNA genes that are found in either the intronic or 
exonic regions of the protein-coding genes (V. N. Kim et al., 2009). The miRNA gene is 
transcribed by RNA polymerase II (RNA pol II) into a long primary transcript (pri-
miRNA) that contains a 7-methylguanosine cap and a poly-adenosine tail (Weimer, 
2007). The pri-miRNA is cleaved by ribonuclease (RNase) III Drosha-DiGeorge 
syndrome critical region gene 8 (DGCR8) microprocessor complex to generate a ~70-
nucleotide-long precursor stem-loop structure (pre-miRNA) (Garzon et al., 2009). The 
pre-miRNA is then exported from the nucleus to the cytoplasm by Exportin 5-Ran-GTP 
complex for a second cleavage by the cytoplasmic RNA-induced silencing complex 
(RISC) to yield a double-stranded miRNA:miRNA* duplex (Winter, Jung, Keller, 
Gregory, & Diederichs, 2009). The RISC is made up of RNase III Dicer, transactivation 
response RNA-binding protein (TRBP) and protein kinase RNA activator (PACT) 
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(Redfern et al., 2013). The miRNA strand with weaker thermodynamic stability at the 5’ 
end will complex with Argonaute (Ago) proteins in the RISC to form a miRNA-RISC 
(miRISC) complex that guides the interaction with the target mRNA (Weimer, 2007). 
On the contrary, the non-functional miRNA* passenger strand will be degraded 
(Khvorova, Reynolds, & Jayasena, 2003; X. Liu, Fortin, & Mourelatos, 2008). In 
mirtron pathway, miRNA genes are transcribed from small intronic regions of the non-
protein-coding genes (Garzon et al., 2009). They share similar processing steps with the 
canonical pathway except that the Drosha-mediated cleavage is replaced by splicing in 
the generation of pre-miRNA (Sotillo & Thomas-Tikhonenko, 2011). 
 
2.2.3   miRNA mechanism of action  
Once the mature miRNA is incorporated into the RISC complex, the miRISC complex 
guides the interaction with the target mRNA based on their sequence complementarity 
(Figure 2.1). The common pairing region is between the miRNA seed sequence 
(nucleotides 2-8 from the 5’ end of miRNA) and the 3’-UTR of mRNA (Filipowicz, 
2005). In the event of full complementarity, the miRISC complex is directed to cleave 
and degrade the target mRNA (Bartel, 2004). This mechanism is also known as post-
transcriptional silencing or RNA interference (RNAi). In the event of partial 
complementarity, the mechanism of action is achieved through translational repression 
at the pre-initiation and/or post-initiation stages of protein synthesis (Garzon et al., 
2009). Translational repression is only reflected at the protein level as the mRNA level 
is unaffected. Perfect complementarity is commonly observed in plants while partial 
complementarity is usually detected in animals (Bartel, 2004). Nevertheless, partial 
complementarity has also resulted in both mRNA degradation and translational 
inhibition, as in the case of lin-4 and let-7 in C. elegans (Bagga et al., 2005). This 
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mechanism is accomplished through mRNA destabilisation or deadenylation in which 
deadenylases and decapping enzymes are recruited to the target region (Bagga et al., 
2005; Bartel, 2009;). The target mRNA is then localised to P-body for degradation or 
storage (Chan & Slack, 2006; L. Wu et al., 2006). Nonetheless, in response to certain 
stress stimuli, the translationally repressed mRNA in the P-body can re-enter the 
translational machinery (Bhattacharyya, Habermacher, Martine, Closs, & Filipowicz, 
2006). On the other hand, several reports have indicated that miRNAs may positively 
induce gene transcription (L. C. Li et al., 2006; Place, Li, Pookot, Noonan, & Dahiya, 
2008). Although the exact mechanism of RNA activation is yet to be determined, the 
binding of a miRNA to the 5’ non-coding regulatory region in the gene promoter has 
been suggested to result in a sequence-specific induction process that redirects the 
sequence into the nucleus for gene activation (L. C. Li et al., 2006).  
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Figure 2.1: miRNA biogenesis and mechanism of action. The two processing pathways 
in miRNA biogenesis are canonical and mirtron pathways. Once the mature miRNA is 
loaded onto the RISC complex and bound to the 3’-UTR of the target mRNA, the 
mechanism of action involved is either mRNA degradation or translational repression. 
(Source: Sotillo & Thomas-Tikhonenko, 2011) 
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2.2.4   miRNA target prediction and validation 
2.2.4.1   Computational prediction 
Computational prediction of miRNA targets in plants is straightforward as most plant 
miRNAs show perfect complementarity with their target genes (Sun et al., 2013). 
Simple pattern matching or National Centre for Biotechnology Information-Basic Local 
Alignment Search Tool (NCBI-BLAST) search is usually sufficient (Rehmsmeier, 
Steffen, Hochsmann, & Giegerich, 2004). In contrast, prediction of miRNA targets in 
animals is more complicated as partial complementarity produces many secondary 
structures of miRNA:mRNA duplexes (Rehmsmeier et al., 2004). The binding of a 
mature miRNA to its target is largely dependent on the free energy of binding between 
the miRNA seed region and the 3’-UTR of mRNA (Doench & Sharp, 2004). Some 
common miRNA target prediction programmes are DIANA-microT, miRanda, 
MirTarget2/miRDB, PicTar, RNA22, RNAhybrid and TargetScan/TargetScanS (Table 
2.3). The common principles governing these target prediction programmes are base 
pairing pattern, thermodynamic stability of miRNA:mRNA hybrid, comparative 
sequence analysis, determination of multiple targets sites per target transcript and 
statistical evaluation (Min & Yoon, 2010; Sotillo & Thomas-Tikhonenko, 2011). 
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Table 2.3: Computational tools for miRNA target prediction. 
Programme Recommended 
target species 
Algorithm Web address Reference 
DIANA-microT Any species Thermodynamics http://diana.cslab.ece.ntua.gr/microT/ Maragkakis et al. (2009) 
miRanda Flies, vertebrates Seed complementarity http://www.microrna.org/microrna/home.do Enright et al. (2003) 
MirTarget2/miRDB Humans, mice, 
rats, dogs, chickens 
Support vector 
machine classifier 
http://mirdb.org/miRDB/ X. Wang  (2008) 
PicTar Vertebrates, flies, 
worms 
Thermodynamics http://www.pictar.org/ Krek et al. (2005) 
RNA22 Any species Pattern recognition http://cbcsrv.watson.ibm.com/rna22.html Miranda et al. (2006) 
RNAhybrid Any species Thermodynamics, 
statistical model 
http://bibiserv.techfak.uni-
bielefeld.de/rnahybrid/ 
Rehmsmeier, Steffen, 
Hochsmann, and Giegerich 
(2004) 
TargetScan/TargetScanS Vertebrates Seed complementarity http://www.targetscan.org/ Lewis, Burge, and Bartel 
(2005); Lewis, Shih, Jones-
Rhoades, Bartel, and Burge 
(2003) 
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2.2.4.2   Experimental validation 
Computationally predicted miRNA targets require experimental validation. It is 
necessary to determine whether a target is directly regulated by a particular miRNA in 
order to provide substantial evidence of their interaction in the biological context. Each 
technology has its own advantages and disadvantages. It is important to identify the 
appropriate experimental design that fits the objective of the study. 
The determination of miRNA and target mRNA expression levels in a particular disease 
is a prerequisite step in miRNA studies. miRNA/mRNA microarray and next-generation 
sequencing are recent technological advancements in miRNA profiling. Microarray 
technology is based on nucleic acid hybridisation between the target miRNAs/mRNAs 
and their corresponding complementary probes (Callari et al., 2012). Next-generation 
sequencing is a high-throughput technology that allows parallel sequencing of millions 
of DNA and/or RNA fragments from the genome, transcriptome and epigenome of any 
species within a short duration (Burgos et al., 2013; Grada & Weinbrecht, 2013). On the 
other hand, quantitative real-time polymerase chain reaction (qPCR) is the preferred 
method in the validation and quantification of miRNA and mRNA expression levels 
(Min & Yoon, 2010). Besides qPCR, in situ hybridisation is applicable in determining 
the relative abundance and localisation of a particular miRNA/mRNA at the cellular 
level (Nielsen, 2012). Northern blot analysis is another experimental technique that 
provides information on the size and expression of the predicted mRNA targets 
(Berezikov, Cuppen, & Plasterk, 2006). However, northern blot assay has limited 
sensitivity and is rarely used today. For the determination of target protein expression 
levels, the common approaches include Western blot, enzyme-linked immunosorbent 
assay and immunocytochemistry (Min & Yoon, 2010). 
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In terms of miRNA:mRNA target validation, luciferase reporter assay is the preferred 
technique (Nicolas, 2011). The 3’-UTR of mRNA containing the miRNA seed pairing 
site is cloned into a luciferase reporter. miRNA mimic or inhibitor is co-transfected with 
the luciferase reporter into a cell line and the binding of the miRNA will either suppress 
or enhance the luciferase protein production (Takane et al., 2010). A luciferase assay is 
then used to measure the luminescence generated by the luciferase reporter. 
Simultaneously, the 3’-UTR of the mRNA with mutated miRNA seed pairing region is 
included as the experimental control. This is to confirm that the mediation of luciferase 
activity is based on the base pairing between the miRNA seed sequence and the 
predicted 3’-UTR pairing region, and is not due to secondary indirect effects (Sotillo & 
Thomas-Tikhonenko, 2011). Once the regulation of a particular miRNA:mRNA has 
been confirmed, it is possible to demonstrate this interaction in the biological context 
via various in vitro cell-based assays (e.g. cell proliferation, cell differentiation and cell 
death assays). In addition, in vivo effects of a specific miRNA can be investigated via 
the use of animal models. For instance, S. L. Lin, Chang, and Ying (2006) have shown 
that transgene-like animal models that are generated using intronic miRNAs are useful 
in the study of miRNA-associated target genes. 
 
2.2.5   miRNAs as novel molecular biomarkers  
Recent advances in microRNAome have made miRNAs a compelling novel class of 
molecular biomarker to complement and improve current screening, diagnostic, 
prognostic and therapeutic tools in various diseases. miRNAs are detectable in tissue, 
blood, faeces and other body fluids such as saliva, tears and urine (Link et al., 2010; 
Volinia et al., 2006; Weber et al., 2010; D. C. Yu, Li, Ding, & Ding, 2011). miRNAs 
are evolutionary conserved across species and expressed in a tissue-specific manner 
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(Esquela-Kerscher & Slack, 2006). They have been shown to participate in many 
biological processes such as cell proliferation, differentiation, apoptosis and metastasis 
(Koturbash et al., 2011). A single miRNA is predicted to have multiple mRNA targets 
(~200 transcripts) that work in concert in controlling a common pathway (Krek et al., 
2005). 
In cancer, miRNA genes are frequently located at fragile sites and genomic regions of 
deletion and amplification (Calin et al., 2004). The first report on miRNA down-
regulation in cancer was published in 2002 when Calin and his colleagues discovered 
that the down-regulation of miR-15a and miR-16-1 in chronic lymphocytic leukaemia 
has contributed to the enhanced expression of oncogene B-cell lymphoma 2 (BCL2) 
(Calin et al., 2002). On the other hand, miR-155 was the first miRNA that was 
demonstrated to have an increased expression in cancer, with 10- to 30-fold higher copy 
number in the diffuse large B-cell lymphoma than the normal circulating B cells (Eis et 
al., 2005). 
 
2.2.6   Therapeutic modulation of miRNAs in cancer pathophysiology  
miRNA deregulation has been characterised in many human cancers. Thus, normalising 
the miRNA expression may pose a new dimension for therapeutic approach. The 
therapeutic modulation of miRNAs involves the inhibition and restoration of miRNA 
activity. The delivery of exogenous miRNA inhibition and restoration strategies can be 
achieved through transient or stable transfection, liposomal nanoparticles and viral 
transduction (Sotillo & Thomas-Tikhonenko, 2011). Efficiency in the delivery, dosage, 
sustainability in the in vivo condition and off-target effects are the main concerns of 
miRNA-based therapeutic intervention.  
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2.2.6.1   Inhibition of miRNA activity 
A common modulator in miRNA inhibition is antisense oligonucleotides (ASOs). ASOs, 
also known as antagomirs, are short, single-stranded RNA or DNA molecules that can 
trigger the degradation of miRNAs or mRNAs by Watson-Crick base pairing 
mechanism and tailling at the adenosines or uridines bases (Broderick & Zamore, 2011). 
The common backbone modifications in ASOs are phosphorothioate, 2’-O-methyl, 2’-
O-methoxyethyl, 2’-fluoro and locked nucleic acid (LNA) modifications (Broderick & 
Zamore, 2011; Seto, 2010) (Figure 2.2). The incorporation of several backbone 
modifications within a single construct such as 2’-O-methyl/LNA/phosphorothioate 
ASO has been shown to greatly increase the efficiency of miRNA inhibition in HeLa 
cervical cancer cells (Lennox & Behlke, 2010). A cholesterol-conjugated 2’-O-methyl 
ASO with phosphorothioate modification has been administered successfully to inhibit 
the liver-specific miR-122 in mice (Krützfeldt et al., 2005). Its use has also been shown 
to inhibit the autonomous cell proliferation caused by the over-expression of miR-221 
and miR-222 in MDA-MB-231 breast and U87 glioblastoma cell lines (le Sage et al., 
2007). Although an unconjugated 2’-O-methoxyethyl ASO with phosphorothioate 
backbone has also been tested, the use of an ASO with cholesterol conjugation has been 
determined to improve cell penetration and association with the transmembrane 
lipoproteins (C. Esau et al., 2006; Krützfeldt et al., 2005). In other instance, the 
administration of a miR-21-2’-O-methyl-modified ASO has been shown to inhibit 
tumour growth and angiogenesis in HCT116 CRC cells (Castanotto et al., 2007; Song & 
Rossi, 2014).  
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Figure 2.2: ASOs of different backbone modifications for miRNA inhibition. RNA with 
phosphorothioate contains a sulphur substitution of a non-bridging oxygen; 2’-O-methyl 
RNA contains a methyl group bound to the 2’ oxygen of the ribose; 2’-O-methoxyethyl 
RNA contains a methoxy group bound to the 2’ oxygen of the ribose; 2’-fluoro RNA 
contains a fluorine molecule bound to the 2’ oxygen of the ribose; locked nucleic acid 
contains a 2’,4’ methylene bridge in the ribose that formed a bicyclic nucleotide.      
(Source: Broderick & Zamore, 2011) 
 
An alternative method to the use of ASOs is miRNA ‘sponges’. miRNA ‘sponges’ are 
miRNA inhibitory transgenes that possess multiple tandem binding sites to miRNAs of 
interest (Ebert & Sharp, 2010). The advantages of using miRNA ‘sponges’ are extensive 
binding affinity and sequence complementarity to a specific miRNA seed region and 
possibility of delivery via viral vectors (Ebert & Sharp, 2010). Open reading frames for 
reporter genes and selectable markers such as fluorescent tags and antibiotic resistant 
genes can be included to monitor the characteristics of ‘sponge’-expressing cells 
(Sotillo & Thomas-Tikhonenko, 2011). Recently, Kluiver et al. (2012) have 
demonstrated the usage of a single miRNA ‘sponge’ that inhibits a whole seed family of 
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miRNAs from miR-17-92 cluster in murine WEHI231 B-cell lymphoma cell line. Even 
though the use of miRNA ‘sponges’ in CRC is still in the infancy stage, this approach 
has been applied by Valastyan et al. (2009) to confirm the tumour suppressor role of 
miR-31 in breast cancer. The miR-31 ‘sponge’-expressing breast cancer cells (MCF7-
Ras-sp31) have been identified to be more invasive and metastatic when compared to 
the control MCF7-Ras cells.  
 
2.2.6.2   Restoration of miRNA activity 
The restoration of miRNA activity caused by the absence or reduced expression of 
miRNAs can be achieved through the introduction of miRNA mimics. miRNA mimics 
are chemically modified double-stranded RNAs with similarity to the endogenous Dicer 
products (Z. Liu, Sall, & Yang, 2008). They can be loaded directly onto RISC to restore 
the levels of altered miRNAs. For instance, the restoration of miR-195 expression in 
CRC via miR-195 mimic has been shown to promote apoptosis and suppress 
tumourigenicity by down-regulating the level of the anti-apoptotic BCL2 gene (L. Liu, 
Chen, Xu, Li, & Du, 2010). Furthermore, the use of miR-101 mimic in CRC has been 
demonstrated to suppress the expression of the oncogenic cyclooxygenase 2 (COX2) 
mRNA (Strillacci et al., 2009). In prostate cancer, systemic delivery of miR-34a mimic 
has been shown to inhibit clonogenic expansion, tumour regeneration and metastasis by 
down-regulating the CD44 expression (C. Liu et al., 2011). Based on a recent report by 
S. Li et al. (2014), the re-introduction of miR-206 into CAOV3 and BG1 estrogen 
receptor alpha(α)-positive ovarian cancer cell lines has successfully inhibited cell 
proliferation and invasion.  
 
 33 
 
Besides the use of miRNA mimics, small interfering RNA (siRNA) approach has also 
been utilised for gene knockdown in RNAi-based silencing. The characteristic of a 
siRNA duplex that binds to the target mRNA can attenuate the oncogenic expression of 
the gene. siRNAs have been used to inhibit the over-expression of c-MYC proto-
oncogene and vascular endothelial growth factor (VEGF) gene that control cell 
proliferation, apoptosis and invasion in Volo CRC cells (Tai et al., 2012). 
Intraperitoneal delivery of a siRNA targeting the neural precursor cell expressed, 
developmentally down-regulated 1 (NEDD1) gene has been shown to improve the 
survival of a mouse scirrhous gastric cancer model (Fujita et al., 2013). However, 
miRNA mimics and siRNAs have short term duration of effects. Multiple doses may be 
necessary to achieve a desired regulation (John et al., 2007). 
Another method to restore reduced miRNAs involves the use of short hairpin RNAs 
(shRNAs), delivered through DNA or viral vectors. shRNAs are tight hairpin RNAs 
generated from polymerase II or III promoters and processed by Dicer into mature 
miRNAs prior loading onto the RISC complex (C. C. Esau & Monia, 2007). 
Lentiviruses have been widely used as vectors for shRNA expression in cancer  (Blosser 
et al., 2014; Wei, Lv, Chen, & Guan, 2014). This technique provides a more stable and 
persistent silencing as compared to the use of miRNA mimics and siRNAs. However, 
the possibility of insertional mutagenesis in the expression vectors and the potentiality 
of Exportin 5 pathway saturation may impede the therapeutic usage of shRNAs (Grimm 
et al., 2006).  
Recently, the development of artificial miRNAs that combines the existing miRNA and 
siRNA technologies has emerged as a major breakthrough in RNAi-based therapeutics. 
An artificial miRNA is constructed using a pre-miRNA transcript as the scaffold or 
backbone, with the central stem sequence being substituted with a synthetic siRNA 
(Boudreau, Martins, & Davidson, 2009). The artificial miRNA is then processed like the 
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pre-miRNA transcript used for the scaffold. It is noteworthy that the administration of 
artificial miRNAs does not disrupt miRNA biogenesis and is well tolerated by 
endogenous miRNAs (McManus, Petersen, Haines, Chen, & Sharp, 2002). The use of 
artificial miRNAs for gene silencing has resolved the cytotoxicity issue caused by the 
saturation of shRNAs (Maczuga et al., 2012). A recombinant adenoviral construct that 
expresses p53 protein and harbours an artificial miRNA targeting the 3’-UTR of p21 
mRNA has been experimented in the p53-mutated DLD1 CRC cell line to induce p53-
mediated apoptosis and enhance the chemosensitivity of the cancer cells to doxorubicin 
(Idogawa et al., 2009). Moreover, the use of a lentiviral-mediated artificial miRNA that 
targets the signal transducer and activator of transcription 5 (STAT5) gene has been 
shown to increase the chemosensitivity of SW1116 CRC cells to cisplastin and 5-FU 
(Hong et al., 2012). This technique has also been applied to target the up-regulated 
multidrug resistance ATP-binding cassette, sub-family C 1 and 2 (ABCC1 and ABCC2) 
genes in a mouse hepatocellular carcinoma model (Borel et al., 2011).  
 
2.2.6.3   miRNA therapeutics in clinical trial 
The first miRNA-based therapeutic that enters into human clinical trial is an inhibitor of 
miR-122 (Miravirsen, a β-D-oxy-LNA-modified phosphorothioate ASO developed by 
Santaris Pharma A/S), and it is currently in phase 2a for the treatment of chronic 
Hepatitis C virus (HCV) infection  (Gupta, Swaminathan, Martin-Garcia, & Navas-
Martin, 2012; Janssen et al., 2013). Miravirsen can be administered via sub-cutaneous 
injection and its use has demonstrated dose-dependent reductions in HCV RNA levels 
with absence of viral resistance. Following that, the second miRNA-based therapeutic, 
mimic of miR-34a (MRX34, a double-stranded RNA oligonucleotide developed by 
Mirna Therapeutics), has reached phase 1 trial as a replacement therapy for primary 
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liver cancer and metastatic cancers with liver involvement (Bouchie, 2013). MRX34 
can be administered systemically to liver via NOV340 liposome technology 
(SMARTICLES) developed by Marina Biotech (Bader, 2012). Data generated in animal 
studies have confirmed that the use of MRX34 is well-tolerated by normal tissues and 
effectively inhibits tumour growth (Bouchie, 2013).  
 
2.2.7   miRNA involvement in the carcinogenesis of CRC  
miRNAs can confer both oncogenic and tumour suppressive roles, depending upon their 
downstream targets (Esquela-Kerscher & Slack, 2006; Garzon et al., 2009). Based on 
the Fearon and Vogelstein model of colorectal carcinogenesis, the adenoma-carcinoma 
sequence begins with Wnt/beta(β)-catenin pathway activation, epidermal growth factor 
receptor (EGFR) signalling activation, transforming growth factor beta (TGF-β) 
response inactivation, loss of p53 function and finally extracellular matrix (ECM) 
breakdown and epithelial-to-mesenchymal transition (EMT) (Fearon & Vogelstein, 
1990) (Figure 2.3). Up-regulation and down-regulation of various miRNAs have been 
reported in CRC. The up-regulation of mature miRNAs is possible during 
transcriptional activation or amplification of the miRNA genes while the down-
regulation is due to deletions from chromosomal regions, epigenetic silencing and 
defects in the biogenesis (Rossi, Kopetz, Davuluri, Hamilton, & Calin, 2010). The 
involvement of miRNAs in the molecular events that drive the initiation, promotion and 
progression of CRC is being extensively investigated. 
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Figure 2.3: Molecular events in the carcinogenesis of CRC.  
(Source: Fearon & Vogelstein, 1990; Slaby, Svoboda, Michalek, & Vyzula, 2009) 
 
2.2.7.1   Wnt/beta(β)-catenin pathway  
The Wnt/β-catenin pathway is essential for cell proliferation and tissue development via 
the regulation of β-catenin level (Willert & Jones, 2006). In the absence of Wnt ligand, 
cytoplasmic β-catenin is dissociated from the E-cadherin/β-catenin/α-catenin complex, 
phosphorylated by the activated glycogen synthase kinase 3β (GSK3β) and directed for 
ubiquitination and degradation (Giles, van Es, & Clevers, 2003). On the contrary, the 
binding of Wnt to the transmembrane receptor frizzled (FZD) and low density 
lipoprotein receptor-related protein 5 and 6 (LRP5 and LRP6) will result in the 
activation of phosphoprotein dishevelled (DVL) that inhibits the GSK3β and prevents β-
catenin degradation (C. Liu et al., 2002). The free β-catenin in the nucleus will then 
bind to the T-cell factor/lymphocyte enhancer factor (TCF/LEF) to form a β-
catenin/TCF/LEF complex, leading to the transcriptional activation of genes involved in 
cell proliferation and differentiation (e.g. c-MYC, cyclin D1 [CCND1] and matrix 
metalloproteinase 7 [MMP7]) (Tejpar & Van Cutsem, 2002; Willert & Jones, 2006). In 
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colorectal neoplasia, mutations in the genes encoding Wnt, β-catenin, GSK3β, Axin and 
APC proteins are associated with the advancement of dysplasia in aberrant crypt foci 
during the initiation of adenoma-carcinoma sequence (Suehiro et al., 2008). 
Various miRNAs have been determined to regulate the Wnt/β-catenin pathway during 
early transformation of colonic epithelial cells. Nagel et al. (2008) have demonstrated 
the ability of miR-135a and miR-135b to down-regulate the translation of APC 
transcript in CRC cells and to activate the Wnt/β-catenin signalling in the absence of 
Wnt ligand. miR-122a, which was initially recognised as a liver-specific miRNA, has 
been found to function as a novel tumour suppressor in colorectal and other 
gastrointestinal cancers (X. Wang, Lam, Zhang, Jin, & Sung, 2009). The inhibition of 
miR-122a has been shown to reverse the wild-type APC-induced cell growth inhibition 
while the restoration of miR-122a has been demonstrated to inhibit cell growth. Several 
validated targets of miR-122a include ADAM metallopeptidase domain 17 (ADAM17), 
BCL2-like 2 (BCL2L2) and cyclin G1 (CCNG1) genes (Gramantieri et al., 2007; Tsai et 
al., 2009; H. Xu et al., 2010). Moreover, the activated c-MYC gene in the Wnt/β-catenin 
pathway has been identified as a direct target of miR-145 (Slaby, Svoboda, Michalek, & 
Vyzula, 2009). Elevation of c-MYC expression as a result of miR-145 down-regulation 
is associated with aggressive and poorly differentiated tumours (J. Zhang et al., 2010). 
Besides that, the down-regulation of several downstream c-MYC targets such as anti-
angiogenic thrombospondin 1 (TSP1) and connective tissue growth factor (CTGF) 
genes has been shown to be under the influence of miR-18 and miR-19 from the miR-
17-92 cluster (Dews et al., 2006; Sachdeva & Mo, 2010). The down-regulation of TSP1 
and CTGF has been linked to increased proliferation, angiogenesis and metastasis. 
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2.2.7.2   Epidermal growth factor receptor (EGFR) pathway 
EGFR is a member of the v-erb-b2 erythroblastic leukaemia viral oncogene homologue  
(ERBB) family of transmembrane tyrosine kinase receptors (Krasinskas, 2011). EGFR 
signalling cascade begins with extracellular ligand binding, receptor dimerisation and 
phosphorylation of cytoplasmic tyrosine kinase residues, leading to the activation of 
intracellular signal transduction pathways (Fang & Richardson, 2005). EGFR signalling 
is made up of two interlinked pathways, namely, mitogen-activated protein kinase 
(MAPK) pathway and phosphatidylinositol 3-kinase (PI3K)-protein kinase B (AKT) 
pathway. Deregulation in the EGFR signalling has been linked to tumour promotion and 
progression of numerous malignancies, including CRC.  
Growth factor stimulation in the EGFR-MAPK pathway will initiate the intrinsic 
activation of two adaptor proteins, namely, SH2-containing (SHC) protein and growth 
factor receptor-bound protein 2 (GRB2) (Fang & Richardson, 2005). These proteins will 
trigger the activation of RAS, in particularly KRAS in CRC, and the signalling cascade 
involving RAF-MEK-MAPK. The KRAS oncoprotein is a GTPase that is involved in 
the regulation of cell proliferation, differentiation and apoptosis. In the normal state, 
KRAS activity is switched off when it cleaves the terminal phosphate of guanosine 
triphosphate (GTP) and converts it to guanosine diphosphate (GDP) (Krasinskas, 2011). 
miR-143, miR-18a* and let-7 have been reported to regulate KRAS expression (Slaby 
et al., 2009). These miRNAs have been validated to possess inverse relationship with 
KRAS protein levels in clinical CRC samples and cell culture studies (Akao, Nakagawa, 
& Naoe, 2006; X. Chen et al., 2009; Tsang & Kwok, 2009).  
In the EGFR-PI3K pathway, growth factor stimulation will lead to the generation of a 
second messenger phosphatidylinositol-3,4,5-triphosphate (PIP3) that promotes AKT 
activation (Vara et al., 2004). PI3K is a lipid kinase that is made up of a p110 catalytic 
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sub-unit and a p85β regulatory sub-unit (Vara et al., 2004). The PI3K is a mediator that 
controls downstream processes affecting cell growth, proliferation and survival 
(Krasinskas, 2011). The down-regulation of miR-126 in CRC has been found to 
promote cell proliferation via an increase in the level of p85β regulatory protein (C. Guo 
et al., 2008). Recently, miR-375 involvement has been demonstrated to inhibit CRC cell 
proliferation and cell cycle arrest by targeting the phosphatidylinositol-4,5-bisphosphate 
3-kinase, catalytic sub-unit alpha (PIK3CA) gene (Y. Wang, Tang, Li, Jiang, & Wang, 
2014). In addition, the up-regulation of miR-223 and the down-regulation of miR-133a, 
miR-143 and miR-145 have been reported to be associated with both PI3K-AKT and 
insulin growth factor pathways in inflammation-induced CRC (Josse et al., 2014). On 
the other hand, the tumour suppressor phosphatase and tensin homologue (PTEN) gene, 
a negative regulator in the PI3K-AKT signalling with a function to dephosphorylate 
PIP3 to the initial substrate phosphatidylinositol-4,5-biphosphate (PIP2), has been 
determined to be repressed by miR-21, miR-92a and miR-103 in CRC (Geng et al., 
2014; Krasinskas, 2011; Krichevsky & Gabriely, 2009; G. Zhang et al., 2014). 
 
2.2.7.3   Transforming growth factor-beta (TGF-β) pathway 
TGF-β pathway is involved in the regulation of cell proliferation, differentiation and 
apoptosis (Massagué, Blain, & Lo, 2000). TGF-β signalling is initiated via the binding 
of TGF-β ligand to TGF-β receptor type II (TGFBR2), followed by the phosphorylation 
of TGF-β receptor type I (TGFBR1) (Y. Xu & Pasche, 2007). Several downstream 
mediators of TGF-β signalling are mothers against decapentaplegic homologue (SMAD) 
proteins and components of the MAPK, c-Jun N-terminal kinase (JNK) and PI3K-AKT 
pathways (ten Dijke & Hill, 2004). TGF-β signalling may exert opposite effects of 
tumour-suppressive functions in normal intestinal epithelium and tumour-promoting 
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functions in late stages of colorectal carcinogenesis (Y. Xu & Pasche, 2007). Mutated 
TGFBR1 and TGFBR2 genes are commonly associated with malignant transformation 
of CRC (Biswas et al., 2004; Grady et al., 1999). Moreover, the diminishing expression 
of SMAD proteins, typically SMAD2, SMAD3 and SMAD4, greatly contributes to the 
loss of growth inhibitory effect in TGF-β signalling (ten Dijke & Hill, 2004; Y. Xu & 
Pasche, 2007). miR-106a, a highly up-regulated miRNA in metastatic CRC, has been 
found to exert its function by targeting the TGFBR2 gene (Feng et al., 2012). In addition, 
L. Liu et al. (2013) have revealed an association between the up-regulation of miR-
130a/301a/454 family and the down-regulation of SMAD4 protein in CRC. The miR-
130a/301a/454 family has been suggested to possess oncogenic functions by enhancing 
cell proliferation and migration. Recently, Reid et al. (2012) have unveiled several 
novel miRNAs that are involved in the TGF-β signalling pathway, namely, miR-130b, 
miR-21 and miR-301b that target the activin A receptor, type 1C (ACVR1C); miR-424 
that targets the SMAD3; miR-130, miR-135b, miR-183, miR-19a, miR-19b, miR-449a 
and miR-449b that target the SMAD4. 
 
2.2.7.4   p53 pathway 
TP53 gene mutation is considered a mandatory event during the transition of a large 
adenoma into an invasive carcinoma in CRC. Generally, in response to DNA damage, 
cellular stress and hypoxia, the p53 transcription factor functions to regulate a variety of 
genes involved in cell cycle arrest and apoptosis (Levine, 1997). The p53 expression is 
tightly regulated by E3 ubiquitin ligase mouse double minute 2 homologue (MDM2) 
and p19ARF (Juven-Gershon & Oren, 1999). The MDM2 binds and exports the nuclear 
p53 to cytoplasm for ubiquitination and degradation. In contrast, the p19ARF, a tumour 
suppressor protein transcribed from the INK4a-ARF locus, acts to attenuate the MDM2-
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mediated degradation of p53 by forming a complex with the MDM2 in the nucleus (Tao 
& Levine, 1999). miRNA involvement in the p53 pathway has been greatly reported. 
Members of the miR-34a-c family have been validated as transcriptional regulators of 
p53 pathway (Corney, Flesken-Nikitin, Godwin, Wang, & Nikitin, 2007; Yamakuchi, 
Ferlito, & Lowenstein, 2008). The miR-34a, miR-34b and miR-34c are considered as 
tumour suppressors in CRC (Slaby et al., 2009). These miRNAs have been found to 
regulate several downstream genes of the p53 pathway (e.g. delta-like 1 [DLL1], 
enhancer of zeste homologue 2 [EZH2], MET, NOTCH1 and silent information 
regulator 1 [SIRT1]) (Corney et al., 2007; Yamakuchi et al., 2008). miR-16 is a miRNA 
that shares similar roles with the miR-34a-c family. The target genes of miR-16 include 
survivin, CCND1 and cyclin-dependent kinase 6 (CDK6) (Q. Ma et al., 2013). The miR-
16 acts as a tumour suppressor in CRC and its expression is often found to be down-
regulated (Yan et al., 2013). On the other hand, miR-107 functions as a mediator of p53 
regulation in hypoxic signalling and tumour angiogenesis in CRC (Yamakuchi et al., 
2010). The miR-107 decreases hypoxic signalling by down-regulating the hypoxia 
inducible factor 1 (HIF1) expression. Another miRNA with validated involvement in 
the p53 signalling is miR-124 (K. Liu et al., 2013). The expression of miR-124 has been 
identified to be down-regulated in CRC (J. Zhang et al., 2013). It is capable of 
regulating the proliferation of CRC cells by targeting the inhibitor of apoptosis-
stimulating protein of p53 (iASPP) and STAT3 genes (K. Liu et al., 2013; J. Zhang et al., 
2013). 
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2.2.7.5   Extracellular matrix (ECM) breakdown and epithelial-to-mesenchymal 
transition (EMT) 
Metastasis is a complex process involving tumour cells detachment from the primary 
tumour, local invasion into the stroma, intravasation into blood or lymphatic vessels, 
extravasation at a distant organ and proliferation into clinically detectable metastases 
(Liotta, Steeg, & Stetler-Stevenson, 1991; Wan, Pantel, & Kang, 2013). The tumour 
stroma mainly consists of basement membrane, ECM, fibroblasts, immune cells and 
vasculature (Bremnes et al., 2011). Among these, ECM breakdown is the definite step 
in tumour invasion. The key enzymes involved are urokinase-type plasminogen 
activator (uPA) and matrix metalloproteinases (MMPs) (Takayama, Miyanishi, Hayashi, 
Sato, & Niitsu, 2006). The involvement of miR-21 in ECM remodelling and cell 
motility has been described (Asangani et al., 2008). mir-21, a miRNA that targets the 
programmed cell death 4 (PDCD4) gene, has been found to be up-regulated in CRC (K. 
H. Chang et al., 2011). Generally, PDCD4 is a tumour suppressor gene that inhibits the 
tissue plasminogen activator-induced neoplastic transformation (Jansen, Camalier, & 
Colburn, 2005). Loss of PDCD4 often leads to tumour invasion and metastasis. In other 
instance, Ke et al. (2014) have revealed that the restoration of miR-224 in CRC can 
inhibit the expression of cell division control protein 42 homologue (CDC42) gene that 
is involved in filamentous actin-mediated cell migration.  
Following ECM remodelling, the tumour cells are able to detach from the primary 
epithelial cluster by undergoing EMT. EMT is characterised by the reduction of 
epithelial markers (e.g. E-cadherin and claudin) and the up-regulation of mesenchymal 
markers (e.g. N-cadherin, vimentin and fibronectin), leading to the loss of cell adhesion 
and increase in cell motility (Natalwala, Spychal, & Tselepis, 2008). The mesenchymal-
like cells are able to move freely into the vasculature (van Zijl, Krupitza, & Mikulits, 
2011). The transcriptional repressor zinc finger E-box binding homeobox 1 and 2 
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(ZEB1 and ZEB2) are crucial inducers of EMT (Paterson et al., 2013). During EMT, 
members of the miR-200 family (miR-200a, miR-200b, miR-200c, miR-141 and miR-
429) are commonly suppressed by the ZEB factors (Lamouille, Subramanyam, Blelloch, 
& Derynck, 2013). However, the miR-200 family may initiate a miRNA-mediated 
feedforward loop that inhibits the expression of TGF-β2 and ZEB factors, thereby 
stabilising the EMT process (Burk et al., 2008; Slaby et al., 2009). Besides ZEB factors, 
other downstream EMT factors that have been shown to be targeted by miRNAs include 
Snail (miR-34 and miR-203), Slug (miR-1 and miR-200b) and vimentin (miR-138) 
(Lamouille et al., 2013; J. Zhang & Ma, 2012).  
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CHAPTER 3  
MATERIALS AND METHODS 
 
3.1   Materials 
3.1.1   Sterile deionised water (sdH2O) 
The sdH2O was prepared by autoclaving ultrapure water obtained from PURELAB 
Option S-R 7-15 water purification system (ELGA LabWater, High Wycombe, UK). 
The water was used in the preparation of buffers and solutions. 
 
3.1.2   Cell lines and culture reagents 
3.1.2.1   Cell lines  
SW480 (CCL-228) and SW620 (CCL-227) CRC cell lines were obtained from 
American Type Culture Collection (ATCC, Manassas, VA, USA). 
 
3.1.2.2   Commercially available cell culture reagents 
Dulbecco's modified Eagle's medium (DMEM), 1X trypsin-ethylenediaminetetraacetic 
acid (EDTA) solution and dimethyl sulphoxide (DMSO) were purchased from Sigma-
Aldrich (St. Louis, MO, USA). Foetal bovine serum (FBS) and 100X penicillin-
streptomycin were obtained from Gibco (Carlsbad, CA, USA). 
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3.1.2.3   Complete medium  
   Basal DMEM     445 ml 
   FBS       50 ml 
   100X Penicillin-streptomycin   5 ml 
 
3.1.2.4   Freezing medium  
  Basal DMEM      3 ml 
   FBS       7 ml 
   DMSO      100 µl 
Freshly prepared freezing medium was used for cryopreservation. 
 
3.1.2.5   1X Phosphate-buffered saline (PBS) 
The 1X PBS was prepared by mixing one part of 10X PBS (Vivantis, Oceanside, CA, 
USA) with nine parts of sdH2O.  
 
3.1.3   1X siRNA resuspension buffer   
  5X siRNA buffer     50 μl 
  Nuclease-free water     200 μl 
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The 5X siRNA buffer was purchased from Dharmacon (Lafayette, CO, USA). 
Nuclease-free water was purchased from Ambion (Carlsbad, CA, USA). The 1X siRNA 
resuspension buffer was used to resuspend lyophilised miRIDIAN miRNA mimics and 
inhibitors (Dharmacon, Lafayette, CO, USA) of 5 nmol into 20 μM stocks. miRIDIAN 
miRNA mimics are double-stranded RNA oligonucleotides designed to mimic the 
function of endogenous mature miRNAs. miRIDIAN miRNA inhibitors are single-
stranded, chemically enhanced RNA oligonucleotides designed to inhibit the function of 
endogenous mature miRNAs.  
 
3.1.4   Reagents for total RNA extraction 
3.1.4.1   5 M Sodium chloride (NaCl) 
  NaCl       29.22 g 
  sdH2O      100 ml 
NaCl (Sigma-Aldrich, St. Louis, MO, USA) was dissolved in sdH2O. The solution was 
autoclaved and kept at room temperature. 
 
3.1.4.2   Wash solution 1 (70% Ethanol:30% Denaturation solution)  
  Absolute ethanol     70 ml 
  Denaturation solution    30 ml 
Absolute ethanol was obtained from Sigma-Aldrich (St. Louis, MO, USA). 
Denaturation solution was purchased from Ambion (Carlsbad, CA, USA).  
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3.1.4.3   Wash solution 2 (80% Ethanol:50 mM NaCl)  
  Absolute ethanol      80 ml 
  5 M NaCl (section 3.1.4.1)    1 ml 
  Nuclease-free water     19 ml 
 
3.1.5   Reagents for RNA agarose gel electrophoresis 
3.1.5.1   1X 3-(N-Morpholino)propanesulphonic acid (MOPS) buffer 
The 1X MOPS running buffer was prepared by diluting one part of 10X MOPS buffer 
(Nacalai Tesque, Nakagyo-ku, Kyoto, Japan) with nine parts of sdH2O.  
 
3.1.5.2   RNA loading buffer 
  Glycerol, 50% (v/v)       5 ml 
  Bromophenol blue, 0.25% (w/v)   25 mg 
     EDTA, 1 mM     3.72 mg  
  sdH2O      Top up to 10 ml 
Glycerol was purchased from VWR (Lutterworth, Leicestershire, UK). Bromophenol 
blue and EDTA were purchased from Sigma-Aldrich (St. Louis, MO, USA). 
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3.1.5.3   RNA sample buffer (per sample) 
  10X MOPS buffer      2 μl  
  37% Formaldehyde      3.5 μl 
  Deionised formamide     10 μl 
  RNA loading buffer (section 3.1.5.2)  2 μl 
The 37% formaldehyde and deionised formamide were purchased from Sigma-Aldrich 
(St. Louis, MO, USA). 
 
3.1.5.4   1% RNA agarose gel 
  Agarose       0.5 g 
  sdH2O       43.5 ml 
  37% Formaldehyde      1.5 ml 
  10X MOPS buffer     5 ml 
  Ethidium bromide (EtBr) (10 mg/ml)   1 μl 
Agarose powder and EtBr reagent were purchased from Sigma-Aldrich (St. Louis, MO, 
USA). Agarose was first dissolved in sdH2O and heated to 100°C in a microwave oven. 
The solution was then cooled to approximately 60°C before the addition of 37% 
formaldehyde, 10X MOPS buffer and EtBr.  
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3.1.6   Reagents for RNA polyacrylamide gel electrophoresis (PAGE) 
3.1.6.1   1X Tris-borate-ethylenediaminetetraacetic acid (TBE) buffer 
The 1X TBE running buffer was prepared by diluting one part of 10X TBE buffer 
(Vivantis, Oceanside, CA, USA) with nine parts of sdH2O.  
 
3.1.6.2   10% Ammonium persulphate (APS) 
  APS        0.1 g 
  sdH2O      1 ml 
APS was obtained from Bio-Rad (Hercules, CA, USA). The solution was prepared fresh 
for each use. 
 
3.1.6.3   15% RNA polyacrylamide gel 
  Urea        3.6 g 
  40% Acrylamide/bis-acrylamide (29:1)   2.82 ml 
  10X TBE buffer      0.75 ml 
  sdH2O       0.95 ml 
  10% APS (section 3.1.6.2)    37.5 μl 
  Tetramethylethylenediamine (TEMED)  7.5 μl 
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Urea, 40% acrylamide/bis-acrylamide (29:1) and TEMED were obtained from Bio-Rad 
(Hercules, CA, USA). The mixture of urea, 40% acrylamide/bis-acrylamide (29:1) and 
10X TBE buffer was initially heated to 60°C. Once urea has dissolved, sdH2O, 10% 
APS and TEMED were added to the gel mixture. 
 
3.1.6.4   RNA sample buffer (per sample) 
  10X TBE buffer      2 μl 
  Deionised formamide     10 μl 
  RNA loading buffer (section 3.1.5.2)   3 μl 
  EtBr (10 mg/ml)     1 μl 
 
3.1.7   Reagents for miRNA microarray 
3.1.7.1   1 M Tris-HCl, pH 8 
  Tris base       6 g 
  sdH2O      Top up to 50 ml 
Tris base (Sigma-Aldrich, St. Louis, MO, USA) was dissolved in 30 ml of sdH2O. The 
pH was adjusted to 8 using concentrated hydrochloric acid (HCl). The stock solution 
was then adjusted to 50 ml and autoclaved. The working concentration, 1 mM Tris-HCl 
was prepared by mixing 5 μl of the stock solution with 4.995 ml of nuclease-free water. 
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3.1.7.2   ATP mix dilution (1:500) 
  ATP mix stock     1 μl 
  1 mM Tris-HCl, pH 8    499 μl 
The ATP mix stock was obtained from the FlashTag Biotin HSR RNA Labelling kit 
(Affymetrix, Santa Clara, CA, USA). 
 
3.1.7.3   Poly(A) tailling master mix (per sample) 
  10X Reaction buffer     1.5 μl 
  25 mM MnCl2     1.5 μl 
  ATP mix dilution (section 3.1.7.2)   1 μl 
  PAP enzyme      1 μl 
The individual components were obtained from the FlashTag Biotin HSR RNA 
Labelling kit (Affymetrix, Santa Clara, CA, USA). 
 
3.1.7.4   Array hybridisation cocktail (per sample) 
  2X Hybridisation mix    50 μl 
  27.5% Formamide     15 μl 
  DMSO      10 μl 
  20X Eukaryotic hybridisation controls  5 μl 
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  3 nM Control oligo B2     1.7 μl 
The 2X hybridisation mix and DMSO were obtained from the GeneChip Hybridisation, 
Wash and Stain kit (Affymetrix, Santa Clara, CA, USA). The 20X eukaryotic 
hybridisation controls and 3 nM control oligo B2 were obtained from the GeneChip 
Eukaryotic Hybridisation Control kit (Affymetrix, Santa Clara, CA, USA). The 27.5% 
formamide was obtained from the FlashTag Biotin HSR RNA Labelling kit (Affymetrix, 
Santa Clara, CA, USA). 
 
3.1.8   Reagents for enzyme-linked oligosorbent assay (ELOSA)  
3.1.8.1   1X PBS, 0.02% Tween-20  
  10X PBS      10 ml 
  Tween-20      20 μl 
  sdH2O      90 ml 
Tween-20 was obtained from Sigma-Aldrich (St. Louis, MO, USA). 
 
3.1.8.2   5% Bovine serum albumin (BSA) in 1X PBS  
  BSA       0.5 g 
  1X PBS (section 3.1.2.5)    10 ml 
BSA powder (Sigma-Aldrich, St. Louis, MO, USA) was dissolved in 1X PBS. The 
resulting solution was aliquoted and kept at -20°C. 
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3.1.8.3   10% Sodium dodecyl sulphate (SDS) 
  SDS       10 g 
  sdH2O      100 ml 
SDS powder (Bio-Rad, Hercules, CA, USA) was dissolved in sdH2O. The resulting 
solution was filtered using a 0.2 μm syringe filter (Sartorius, Goettingen, Germany). 
 
3.1.8.4   5X Saline-sodium citrate (SSC), 0.05% SDS, 0.005% BSA 
  20X SSC buffer     1.25 ml 
  10% SDS (section 3.1.8.3)    25 μl 
  5% BSA in 1X PBS (section 3.1.8.2)  5 μl 
  sdH2O      3.72 ml 
The 20X SSC buffer was purchased from Sigma-Aldrich (St. Louis, MO, USA). The 
resulting solution was aliquoted and kept at -20°C. 
 
3.1.8.5   ELOSA hybridisation cocktail (per sample)    
  5X SSC, 0.05% SDS, 0.005% BSA (section 3.1.8.4)  48 μl   
  25% Dextran sulphate        2.5 μl  
The 25% dextran sulphate was obtained from Genisphere (Hatfield, PA, USA). 
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3.1.8.6   Streptavidin-horseradish peroxidase (HRP) dilution (1:6000) 
  Streptavidin-HRP     1 μl 
  5% BSA in 1X PBS (section 3.1.8.2)  5.999 ml 
Streptavidin-HRP was purchased from Pierce (Rockford, IL, USA).  
 
3.1.9   Reagents for reverse transcription (RT) 
3.1.9.1   RT master mix for miRNA (per sample) 
  10X TaqMan RT buffer     1.5 μl 
  100 mM dNTPs     0.15 μl 
  20 U/μl RNase inhibitor     0.19 μl 
  50 U/μl MultiScribe reverse transcriptase   1 μl 
  Nuclease-free water      4.16 μl  
The individual components were obtained from the TaqMan miRNA RT kit (Applied 
Biosystems, Carlsbad, CA, USA).  
 
3.1.9.2   RT master mix for mRNA (per sample) 
  10X TaqMan RT buffer     1 μl 
  25 mM MgCl2      2.2 μl 
  2.5 mM dNTPs      2 μl 
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  50 μM Random hexamers     0.5 μl 
  20 U/μl RNase inhibitor     0.2 μl 
  50 U/μl MultiScribe reverse transcriptase   0.25 μl 
The individual components were obtained from the TaqMan RT kit (Applied 
Biosystems, Carlsbad, CA, USA). 
 
3.1.10   Reagents for quantitative real-time polymerase chain reaction (qPCR) 
3.1.10.1   qPCR for miRNA (96-well) 
    2X TaqMan Fast Advanced master mix  10 μl 
    20X TaqMan miRNA assay   1 μl 
    Nuclease-free water     7.67 μl 
The 2X TaqMan Fast Advanced master mix and 20X TaqMan miRNA assay were 
purchased from Applied Biosystems (Carlsbad, CA, USA). The assays obtained were 
hsa-miR-150 (Assay ID: 000473; MIMAT0000451), hsa-miR-16 (Assay ID: 000391; 
MIMAT0000069), hsa-miR-193a-3p (Assay ID: 002250; MIMAT0000459), hsa-miR-
23a (Assay ID: 000399; MIMAT0000078), hsa-miR-23b (Assay ID: 000400; 
MIMAT0000418), hsa-miR-338-5p (Assay ID: 002658; MIMAT0004701), hsa-miR-
342-3p (Assay ID: 002260; MIMAT0000753), hsa-miR-483-3p (Assay ID: 002339; 
MIMAT0002173) and RNU48 (Assay ID: 001006; NR_002745). 
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3.1.10.2   qPCR for mRNA (96-well) 
    2X TaqMan Fast Advanced master mix  10 μl 
    20X TaqMan gene expression assay   1 μl 
    Nuclease-free water     8 μl 
The 20X TaqMan gene expression assay was purchased from Applied Biosystems 
(Carlsbad, CA, USA). The assays obtained were β-actin (Assay ID: Hs99999903_m1; 
NM_001101.3), APAF1 (Assay ID: Hs00559441_m1; NM_013229.2), FOXO4 (Assay 
ID: Hs00936217_g1; NM_005938.3) and GAPDH (Assay ID: Hs99999905_m1; 
NM_002046.5).  
 
3.1.11   Reagent for total protein quantification 
  Triton X-100      5 ml 
  sdH2O      45 ml 
A 10% Triton X-100 working solution was prepared by diluting one part of Triton X-
100 (Sigma-Aldrich, St. Louis, MO, USA) with nine parts of sdH2O. 
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3.1.12   Reagents for sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
(SDS-PAGE) 
3.1.12.1   0.5% Bromophenol blue 
    Bromophenol blue     0.5 g 
    sdH2O      100 ml 
 
3.1.12.2   1.5 M Tris-HCl, pH 8.8 
    Tris base       27.23 g 
    sdH2O      Top up to 150 ml 
Tris base was dissolved in 100 ml of sdH2O. The pH of the solution was adjusted to 8.8 
using concentrated HCl. The solution was then adjusted to 150 ml and stored at 4°C.  
 
3.1.12.3   0.5 M Tris-HCl, pH 6.8 
    Tris base       6 g 
    sdH2O      Top up to 100 ml 
Tris base was dissolved in 70 ml of sdH2O. The pH of the solution was adjusted to 6.8 
using concentrated HCl. The solution was then adjusted to 100 ml and stored at 4°C.  
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3.1.12.4   SDS reducing sample buffer 
    sdH2O      3.55 ml 
    0.5 M Tris-HCl, pH 6.8 (section 3.1.12.3)  1.25 ml 
    Glycerol      2.5 ml 
    10% SDS (section 3.1.8.3)    2 ml 
    0.5% Bromophenol blue (section 3.1.12.1) 0.2 ml 
The above stock solution was prepared. Fifty μl of β-mercaptoethanol (Bio-Rad, 
Hercules, CA, USA) was added to an aliquot of 950 μl of SDS reducing sample buffer 
prior to use.  
 
3.1.12.5   10X Electrode stock buffer, pH 8.3 
    Tris base      30.3 g 
    Glycine      144 g 
    SDS       10 g 
    sdH2O      Top up to 1 L 
Tris base, glycine (Bio-Rad, Hercules, CA, USA) and SDS were dissolved in sdH2O to 
produce a 10X electrode stock buffer. The stock buffer was further diluted to 1X 
strength for each electrophoresis run. 
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3.1.12.6   Tris-glycine SDS-PAGE gel 
10%     4% 
Resolving gel (10 ml)  Stacking gel (5 ml) 
    sdH2O    4.1 ml    3 ml 
    30% acrylamide/bis (37.5:1)  3.3 ml    650 μl 
    Gel buffer      2.5 ml    1.25 ml 
                                           (section 3.1.12.2)                  (section 3.1.12.3) 
    10% SDS (section 3.1.8.3)   100 μl    50 μl 
    10% APS (section 3.1.6.2)  50 μl    25 μl 
    TEMED     5 μl    5 μl 
The 30% acrylamide/bis (37.5:1) was purchased from Bio-Rad (Hercules, CA, USA). 
The 10% APS and TEMED were added to the gel mixture just prior to gel-casting. 
 
3.1.13   Reagent for membrane transfer 
  Tris base       3.03 g 
  Glycine       14.4 g 
  Methanol      200 ml 
  sdH2O      Top up to 1 L 
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Methanol was purchased from Sigma-Aldrich (St. Louis, MO, USA). The transfer 
buffer was kept cold at 4°C. 
 
3.1.14   Reagents for Western blot 
Western blot was performed using the Fast Western Blot kit, ECL substrate (Pierce, 
Rockford, IL, USA). Preparations of the working solutions were based on an 8 x 10 cm 
blot probed with either a mouse or rabbit primary antibody. All working solutions were 
prepared just prior to use. 
 
3.1.14.1   Fast Western 1X wash buffer 
    Fast Western 10X wash buffer   10 ml 
    sdH2O      90 ml 
Fast Western 1X wash buffer was prepared by mixing one part of the Fast Western 10X 
wash buffer with nine parts of sdH2O. 
 
3.1.14.2   Primary antibody working solution 
    Primary antibody      10 μl 
    Fast Western antibody diluent   10 ml 
Primary antibody was diluted at a ratio of 1:1000 with Fast Western antibody diluent. 
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3.1.14.3   Fast Western optimised HRP reagent working solution  
    Fast Western optimised HRP reagent  1 ml 
    Fast Western antibody diluent   10 ml  
 
3.1.14.4   Detection reagent working solution  
    Detection reagent 1     2 ml 
    Detection reagent 2     2 ml 
 
3.1.15   Reagents for sub-cloning 
3.1.15.1   1% DNA agarose gel 
    Agarose       0.25 g 
    1X TBE (section 3.1.6.1)    25 ml 
    EtBr (10 mg/ml)      0.5 μl 
Agarose powder was dissolved in 1X TBE and heated to 100°C in a microwave oven. 
The mixture was cooled to about 60°C before the addition of EtBr. 
 
3.1.15.2   Restriction enzyme digestion 
    10X FastDigest green buffer    2 μl 
    FastDigest enzyme (HindIII and/or SpeI)  1 μl 
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    Nuclease-free water     Top up to 20 μl 
The 10X FastDigest green buffer and enzymes were purchased from Fermentas 
(Waltham, MA, USA). 
 
3.1.15.3   Luciferase reporter and plasmid DNA vectors 
The luciferase reporter vectors used in this study were pMIR-REPORT firefly luciferase 
miRNA expression reporter vector (Ambion, Carlsbad, CA, USA) and pRL-SV40 
Renilla luciferase control reporter vector (Promega, Madison, WI, USA). 
Plasmid DNA vectors containing the putative 3’-UTR fragments or the site-directed 
mutants were assembled from synthetic oligonucleotides and/or PCR products and 
cloned into pMA-T vectors using GeneArt gene synthesis service (Invitrogen, Carlsbad, 
CA, USA). The gene fragment sequences were derived from the NCBI database. Each 
customised fragment was inclusive of HindIII and SpeI restriction sites. 
 
3.1.15.4   Ligation 
    10X T4 DNA ligase buffer    2 μl 
    T4 DNA ligase (5 U/μl)    0.5 μl 
    Vector DNA:insert DNA    1:5 
    Nuclease-free water    Top up to 10 μl 
The T4 DNA ligase buffer and enzyme were purchased from Fermentas (Waltham, MA, 
USA). 
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3.1.15.5   Ampicillin (10 mg/ml) 
A stock solution at 10 mg/ml was made by dissolving 200 mg of ampicillin, sodium salt 
(Gibco, Carlsbad, CA, USA) in 20 ml of nuclease-free water. The stock solution was 
aliquoted into smaller volumes and stored at -80°C.  
 
3.1.15.6   Luria-Bertani (LB)-ampicillin broth 
    LB broth       12.5 g 
    sdH2O      500 ml 
    Ampicillin (10 mg/ml) (section 3.1.15.5)  5 ml 
LB broth, Miller powder (BD Biosciences, Franklin Lakes, NJ, USA) was dissolved in 
500 ml of sdH2O with frequent agitation. The medium was autoclaved and cooled to 50-
55°C before the addition of ampicillin. The working concentration for ampicillin was 
100 μg/ml. The medium was stored at 4°C and warmed to room temperature before use.  
 
3.1.15.7   LB-ampicillin agar plates 
    LB agar      20 g 
    sdH2O      500 ml 
    Ampicillin (10 mg/ml) (section 3.1.15.5)  5 ml 
LB agar, Miller powder (BD Biosciences, Franklin Lakes, NJ, USA) was dissolved in 
500 ml of sdH2O with frequent agitation. The medium was autoclaved and cooled to 50-
55°C before the addition of ampicillin. The working concentration for ampicillin was 
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100 μg/ml. The molten agar was poured into 10 cm sterile petri dishes until 1/3 full and 
allowed to be hardened at room temperature. The LB-ampicillin agar plates were sealed 
with parafilm and stored at 4°C in an inverted position. The plates were pre-warmed at 
37°C for 30 minutes before use. 
 
3.1.15.8   80% Glycerol 
    Glycerol      80 ml 
    sdH2O      20 ml 
The 80% glycerol solution was autoclaved and kept at room temperature. 
 
3.1.16   1X 3-(4,5-Dimethylthiazol-2-yl)-2,5,-diphenyltetrazolium bromide (MTT) 
The MTT Cell Proliferation kit from OZ Biosciences (Marseille, France) was utilised. 
The 10X MTT stock solution in the kit was diluted to 1X working solution using sterile 
1X PBS. The 1X MTT was stored at -20°C for three months. 
 
3.1.17   Reagents for migration and invasion assays 
3.1.17.1   0.01 M Tris (pH 8), 0.7% NaCl  
    NaCl      0.7 g 
    1 M Tris-HCl (pH 8) (section 3.1.7.1)  1 ml 
    sdH2O      99 ml 
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NaCl was dissolved in the mixture of 1 M Tris-HCl and sdH2O. The solution was 
filtered using a 0.2 μm syringe filter (Sartorius, Goettingen, Germany) and kept at 4°C. 
 
3.1.17.2   Matrigel coating solution (250 μg/ml) 
    Matrigel basement membrane matrix (8.5 mg/ml)    29.4 μl 
    0.01 M Tris (pH 8), 0.7% NaCl (section 3.1.17.1)    70.6 μl 
The Matrigel basement membrane matrix was purchased from BD Biosciences 
(Franklin Lakes, NJ, USA). The concentration of the Matrigel matrix is lot-specific. 
Aliquots of the Matrigel matrix were stored at -80°C and thawed overnight on ice at 4°C 
prior to use. A 100 μl of Matrigel coating solution with the working concentration of 
250 μg/ml was sufficient to coat one 24-well cell culture insert. The coating solution 
was prepared fresh for each use. 
 
3.1.17.3   3.7% Formaldehyde in 1X PBS 
    37% Formaldehyde     1 ml 
    1X PBS      9 ml 
The solution was prepared fresh for each use. 
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3.1.18   Essential research services 
RNA integrity analysis via Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA, USA) 
was outsourced to Malaysia Genome Institute, Selangor, Malaysia. RNA integrity 
number (RIN) was obtained using Eukaryote Total RNA Nano Chip (Agilent, Santa 
Clara, CA, USA).  
Oligonucleotide synthesis and DNA sequencing services were obtained from First 
BASE Laboratories Sdn. Bhd., Selangor, Malaysia. The company is using the Applied 
Biosystems BigDye® Terminator v3.1 Cycle Sequencing kit chemistry on 3730XL 
Genetic Analyzer platform (Carlsbad, CA, USA) for all de novo sequencing and re-
sequencing purposes. 
 
3.2   Methods 
3.2.1   Clinical study design and sample collection 
A case-control study was designed to identify blood miRNAs that are reflective of those 
in CRC tissues. The study was performed according to the principles of the Declaration 
of Helsinki and has gained an approval from the Medical Ethics Committee of the 
University of Malaya Medical Centre (UMMC), Malaysia (reference number: 805.9) 
(Appendix 1). A total of 112 whole blood samples and a sub-set of 60 paired cancer 
tissue with normal colonic mucosa samples were collected from primary CRC patients. 
The tissue samples were obtained from the same group of patients who have donated 
their blood samples. All patients were diagnosed and treated at the UMMC, Malaysia, 
from January 2011 to January 2013. The recruited patients did not receive any pre-
operative chemotherapy and/or radiotherapy prior to sample collection. Tumour 
histology was confirmed by pathological analysis and staged according to the TNM 
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staging system (Edge & Compton, 2010). For the control group, 50 whole blood 
samples that were age-, gender- and race-matched were collected from colonoscopy-
confirmed colonic disease-free individuals. All clinical samples were obtained with 
written informed consent. Demographic data and medical record were retrieved from 
the Department of Medical Records, UMMC, Malaysia.  
Whole blood samples were collected in EDTA blood collection tubes (BD Vacutainer, 
BD Diagnostics, Franklin Lakes, NJ, USA). An aliquot of 400 μl of whole blood was 
mixed with 1.3 ml of RNAlater solution (Ambion, Carlsbad, CA, USA) to stabilise and 
protect the cellular RNA. Tissue samples, cut into small pieces, were collected directly 
in 5 ml of RNAlater solution immediately after resection. The blood and tissue samples 
were stored at -80°C.  
 
3.2.2   Cell culture 
SW480 and SW620 CRC cells were cultured in complete medium (section 3.1.2.3). The 
cells were maintained in a 5% CO2-humidified incubator (MCO-17A1, Sanyo, Osaka, 
Japan) at 37°C. The SW480 and SW620 cell lines were adherent cell lines. Cell culture 
experiments were performed in the laminar flow cabinet and culture media were 
warmed to 37°C in a water bath before use. 
 
3.2.2.1   Thawing of frozen culture 
A cryovial containing cryopreserved cells was obtained from liquid nitrogen tank or -
80°C freezer and thawed immediately in a water bath at 37°C with gentle swirling. The 
content was transferred to a 15 ml centrifuge tube and 3 ml of complete medium was 
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added. The cell suspension was centrifuged at 2,000 rpm for 5 minutes and the 
supernatant was discarded. The cell pellet was resuspended with 5 ml of complete 
medium and transferred to a T-25 culture flask. The culture flask was maintained in the 
5% CO2-humidified incubator. Complete medium was changed every 2-3 days. 
 
3.2.2.2   Sub-culturing of adherent cells 
Cells were sub-cultured when the confluency reached 80-90%. T-75 culture flask was 
used for subsequent sub-culturing of the cells. The medium in the culture flask was 
discarded and the cells were rinsed twice with 10 ml of 1X PBS. The cells were 
trypsinised with 1 ml of trypsin-EDTA at 37°C for 10-15 minutes. The cells were 
viewed under a phase contrast microscope for detachment. Two ml of complete medium 
was then added into the flask to stop the trypsinisation procedure. The cell suspension 
was transferred to a 15 ml centrifuge tube and centrifuged at 2,000 rpm for 5 minutes. 
The supernatant was discarded and the cell pellet was resuspended with 3 ml of 
complete medium. Meanwhile, the required number of T-75 culture flask was prepared 
and 9 ml of complete medium was added into each flask. The cell suspension was then 
dispensed in equal volume into each flask.  
 
3.2.2.3   Cryopreservation 
Freezing medium (section 3.1.2.4) was freshly prepared for cryopreservation. After the 
cells were trypsinised and centrifuged, the supernatant was discarded and the cell pellet 
was resuspended with the freezing medium. Cells from one T-75 culture flask could be 
stocked up into five cryovials, with 1 ml each. The cryovials were then labelled and 
stored in -80°C freezer for short term storage or liquid nitrogen for long term storage. 
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3.2.2.4   Cell counting by haemocytometer 
Following trypsinisation and resuspension with complete medium, a small aliquot of the 
cells was obtained for cell counting. Ten μl of the cell suspension was diluted with 10 μl 
of trypan blue solution (Bio-Rad, Hercules, CA, USA) for cell viability screening. Ten 
μl of the mixture was pipetted onto a haemocytometer and viewed under a phase 
contrast microscope at 100X magnification. The mean number of cells from the four 
edges was counted using a tally counter. 
The total cell count was calculated as follows: 
Total cell count = mean number of cells x dilution factor x volume of cell suspension x   
      104 
 
3.2.3   miRNA transfection 
miRNA transfections for mRNA and protein analyses were performed on 48-well and 6-
well plates, respectively. Cells were seeded in antibiotic-free complete medium at 1 x 
105 cells per well (48-well) or 1 x 106 cells per well (6-well) one day before transfection. 
These cell densities were chosen after seeding optimisation. Lipofectamine 2000 
transfection reagent (Invitrogen, Carlsbad, CA, USA) and Opti-MEM I reduced serum 
medium (Gibco, Carlsbad, CA, USA) were complexed at a ratio of 0.5:25 μl (48-well) 
or 5:250 μl (6-well) and incubated at room temperature for 5 minutes. miRIDIAN 
miRNA mimic or inhibitor (Dharmacon, Lafayette, CO, USA) was diluted to a 
concentration of 10 pmol in 25 μl (48-well) or 100 pmol in 250 μl (6-well) of Opti-
MEM I reduced serum medium. Both mixtures were then combined and incubated at 
room temperature for another 20 minutes. After the incubation, the plated medium was 
removed and the miRNA-transfection mixture was added dropwise to each well. The 
medium was changed to antibiotic-free complete medium after 6 hours of transfection. 
 70 
 
The cells were incubated in the 5% CO2-humidified incubator at 37°C for 48 hours for 
mRNA analysis or 72 hours for protein analysis.  
The miRNA mimics and inhibitors tested were for hsa-miR-193a-3p, hsa-miR-23a and 
hsa-miR-338-5p. miRNA mimic negative control (mimic NC) and miRNA inhibitor 
negative control (inhibitor NC) were included in each transfection experiment. The 
negative control molecules were based on the mature sequence of C. elegans cel-miR-
67-3p (MIMAT0000039). The molecules have been confirmed to have minimal 
sequence identity with human miRNAs and no identifiable effect on tested miRNAs. 
Moreover, miRNA mimic positive control that targets the 3’-UTR of glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) gene and miRNA inhibitor positive control that 
targets the endogenous miR-16 were also included. Other experimental controls include 
non-transfected control (NTC) cells and mock-transfected control cells with only the 
transfection reagent. Each transfection experiment was performed in triplicates in three 
independent experiments. 
 
3.2.4   Total RNA extraction 
3.2.4.1   Total RNA extraction from whole blood 
The procedure was adapted from RiboPure-Blood RNA Purification kit (Ambion, 
Carlsbad, CA, USA) with slight modification to enable the isolation of miRNA and 
other small RNAs. RNAlater-stabilised blood sample that was kept at -80°C was 
thawed on ice and centrifuged at maximum speed for 5 minutes. The supernatant was 
discarded and 1 ml of lysis solution was added. The mixture was vigorously vortexed to 
resuspend the pellet. Next, 10 μl of acetic acid was added and the cell lysate was 
vortexed and kept on ice for 5 minutes. Following that, 400 μl of acid-
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phenol:chloroform from beneath the overlying layer of the aqueous buffer was added. 
The cell lysate was vortexed and centrifuged at maximum speed for 5 minutes to 
separate the aqueous and organic phases. The aqueous phase containing the RNA was 
then transferred to a 15 ml centrifuge tube while the organic phase was discarded. One 
ml of Denaturation solution (Ambion, Carlsbad, CA, USA) was added and vortexed. 
The solution was then mixed with 2.7 ml of absolute ethanol. A clear suspension should 
be observed. Otherwise, 300 μl increments of nuclease-free water were added until the 
suspension turned clear. The clear solution was filtered through the provided spin 
column by successively centrifuging 700 μl of sample for 10 seconds. The column flow-
through was discarded. The spin column was washed with 700 μl of wash solution 1 
(section 3.1.4.2) once and 700 μl of wash solution 2 (section 3.1.4.3) twice via brief 
centrifugation. After the washing steps, the spin column was spun at maximum speed 
for 1 minute to remove any residual fluid before being transferred to a new collection 
tube. A volume of 150 μl of elution solution (pre-heated to 78°C) was applied to the 
centre of the column. The column was left at room temperature for 1 minute before the 
final centrifugation for 2 minutes to elute the RNA into the collection tube. The sample 
was aliquoted in equal volume into two tubes and stored at -80°C.  
 
3.2.4.2   Total RNA extraction from CRC tissue and cultured cells 
Total RNA extraction from CRC tissue and cultured cells was performed based on the 
protocol in miRNeasy Mini kit (Qiagen, Venlo, Limburg, Netherlands). For CRC tissue, 
30 mg of RNAlater-stabilised tissue was weighed and placed in 700 μl of QIAzol 
reagent. The sample was homogenised until no visible piece of tissue was observed. For 
cultured cells, the cells were washed with 1X cold PBS and 200 μl of QIAzol reagent 
was added into three wells of a 48-well plate. The reagent was pipetted up and down to 
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lyse the cells. The lysed cells from the three wells were pooled into a 1.5 ml 
microcentrifuge tube. The tissue/cell lysate was either subjected to immediate extraction 
or stored at -80°C.  
The sample extraction began with a vigorous mixing of the tissue/cell lysate with 140 μl 
chloroform for 15 seconds. The mixture was incubated at room temperature for 3 
minutes and centrifuged at maximum speed for 15 minutes at 4°C. The aqueous phase 
was transferred to a new collection tube and 525 μl of absolute ethanol was added. The 
solution was mixed and 700 μl of the solution was successively centrifuged through the 
provided spin column at 10,000 rpm for 15 seconds at room temperature. The column 
flow-through was discarded. Next, 350 μl of buffer RWT was added and centrifuged at 
10,000 rpm for 15 seconds. DNase I solution (80 μl) was added and the spin column 
was incubated at room temperature for 15 minutes before the addition of another 350 μl 
of buffer RWT. The spin column was again centrifuged at 10,000 rpm for 15 seconds. 
Following that, 500 μl of buffer RPE was added and briefly centrifuged. The step was 
repeated with another 500 μl of buffer RPE and centrifuged at 10,000 rpm for 2 minutes. 
After the washing steps, the spin column was spun at maximum speed for 1 minute to 
remove any residual fluid before being transferred to a new collection tube. A volume 
of 50 μl of nuclease-free water was applied to the centre of the column and incubated at 
room temperature for 1 minute. Finally, the column was centrifuged at maximum speed 
for 2 minutes to elute the RNA. The sample was aliquoted in equal volume into two 
tubes and stored at -80°C. 
 
3.2.5   Quantification of total RNA 
The concentration and purity of the extracted total RNA was determined by NanoDrop 
2000 spectrophotometer (Thermo Scientific, Waltham, MA, USA). Nuclease-free water 
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was used as the blank. The A260/A280 and A260/A230 ratios indicate the purity of the RNA. 
Values ranging from 1.8-2.2 are acceptable for downstream experiments. 
 
3.2.6   Assessment of RNA quality  
3.2.6.1   Denaturing RNA agarose gel electrophoresis 
Molten RNA gel (section 3.1.5.4) was allowed to set in the gel-casting tray with a comb 
inserted to create wells for sample loading. After the gel has solidified, it was placed in 
the electrophoresis tank filled with 1X MOPS buffer (section 3.1.5.1). RNA sample of 
200-300 ng was mixed with 17.5 μl of sample buffer (section 3.1.5.3) and placed in a 
water bath at 65°C for 10 minutes to denature the RNA. The sample was placed on ice 
until loading. Electrophoresis was conducted at 90V for approximately 40 minutes. 
RNA marker (18S + 28S ribosomal RNA [rRNA] from calf liver) (Sigma-Aldrich, 
St.Louis, MO, USA) was loaded as the positive control. The gel image was captured 
using a gel documentation system (UVP, Upland, CA, USA). RNA of good quality 
should reveal two distinct bands at the intensity ratio of 2:1 for 28S:18S rRNA. 
 
3.2.6.2   Denaturing RNA PAGE 
Denaturing RNA PAGE was used to assess the integrity of small RNAs (5.8S rRNA, 5S 
rRNA and transfer RNA [tRNA]). Molten RNA gel (section 3.1.6.3) was poured into 
the gel-casting tray with a comb inserted to create wells for sample loading. After the 
gel has solidified, it was placed in the electrophoresis tank filled with 1X TBE buffer 
(section 3.1.6.1) and pre-run at 100V for 30 minutes. RNA sample of 200-300 ng was 
mixed with 16 μl of sample buffer (section 3.1.6.4). The mixture was placed in a water 
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bath at 95°C for 2 minutes to denature the RNA. The sample was placed on ice until 
loading. Electrophoresis was conducted at 100V for approximately 1.5 hours. The gel 
image was captured using a gel documentation system (UVP, Upland, CA, USA). RNA 
of good quality should reveal three distinct bands, indicating the presence of 5.8S rRNA, 
5S rRNA and tRNA. 
 
3.2.7   miRNA microarray 
Two independent miRNA microarray profiling studies of tissue and blood were 
conducted. In tissue miRNA array, 30 paired cancer tissue and the normal colonic 
mucosa samples were pooled according to stages II (n = 10), III (n = 10) and IV (n = 
10). In blood miRNA array, blood samples from 42 CRC cases were grouped by tumour 
location (colon; rectum) and pooled into stages I (n = 3; n = 3), II (n = 9; n = 3), III (n = 
9; n = 3) and IV (n = 9; n = 3). Blood samples from 18 healthy controls were used for 
the profiling study. Due to limited availability of stage I CRC cases, only one replicate 
was performed for both colon and rectal samples. Similarly, the profiling analyses of 
rectal samples for stages II, III and IV were also performed in one replicate. On the 
other hand, the profiling analyses of colon samples for stages II, III and IV were 
performed in triplicates and control samples in six replicates, with n = 3 each.  
 
3.2.7.1   Sample labelling  
The FlashTag Biotin HSR RNA Labelling kit (Affymetrix, Santa Clara, CA, USA) was 
used to label total RNA samples for the analysis by GeneChip miRNA 2.0 array 
(Affymetrix, Santa Clara, CA, USA). The array contains 15,644 probe sets, covering 
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131 organisms and detecting 1,105 human mature miRNAs. The content was derived 
from miRBase database version 15.0.  
Total RNA was adjusted to a concentration of 1 μg in 8 μl of nuclease-free water. Two 
μl of RNA spike control oligos and 5 μl of poly(A) tailling master mix (section 3.1.7.3) 
were added. The sample was mixed and briefly centrifuged. The tube was incubated at 
37°C in a thermal cycler for 15 minutes. After the incubation, 4 μl of 5X FlashTag 
biotin HSR ligation mix and 2 μl of T4 DNA ligase were added. The sample was mixed 
and briefly centrifuged. The tube was incubated at room temperature for 30 minutes. 
The enzyme reaction was inactivated by adding 2.5 μl of HSR stop solution. The 23.5 μl 
of biotin-labelled sample was mixed and briefly centrifuged. Two μl of the sample was 
transferred to a new PCR tube for ELOSA quality control (QC) assay (section 3.2.7.2). 
The remaining 21.5 μl of the sample was kept on ice until the sample hybridisation 
procedure (section 3.2.7.3).   
 
3.2.7.2   ELOSA QC assay 
ELOSA is a colorimetric assay that serves as a quality assurance test that the sample 
labelling has taken place. The assay is designed to detect successful hybridisation of 
RNA spike control oligos to ELOSA spotting oligos immobilised onto the ELOSA plate 
(Genisphere, Hatfield, PA, USA). Appropriate negative and positive controls were 
included. The negative control was the biotin-labelled sample without RNA spike 
control oligos and total RNA. The positive control was the biotinylated ELOSA positive 
control provided in the FlashTag Biotin HSR Labelling kit (Affymetrix, Santa Clara, 
CA, USA).  
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The number of wells needed was calculated accordingly. Each well was coated with 1.5 
μl of ELOSA spotting oligos in 73.5 μl of 1X PBS. The ELOSA plate was sealed and 
incubated overnight at 4°C. After the overnight incubation, the coated plate was 
equilibrated to room temperature for 5 minutes. The plate was rinsed twice with 1X 
PBS, 0.02% Tween-20 (section 3.1.8.1) and blotted to dry. A volume of 150 μl of 5% 
BSA in 1X PBS (blocking solution) (section 3.1.8.2) was added into each well and the 
plate was incubated at room temperature for 1 hour. Meanwhile, the 2 μl of biotin-
labelled sample (section 3.2.7.1) and the negative and positive controls for ELOSA 
assay were mixed with 50.5 μl of ELOSA hybridisation cocktail (section 3.1.8.5) and 
briefly centrifuged. After the 1 hour incubation, the blocking solution was discarded and 
the plate was blotted to dry. The 52.5 μl of hybridisation solution was loaded into each 
well and the plate was incubated at room temperature for another 1 hour. Following that, 
the hybridisation solution was discarded and the plate was rinsed thrice with 1X PBS, 
0.02% Tween-20 and blotted to dry. An aliquot of 75 μl of the streptavidin-HRP 
dilution (section 3.1.8.6) was loaded into each well and left at room temperature for 30 
minutes. The solution was then discarded and the wells were rinsed thrice with 1X PBS, 
0.02% Tween-20. Subsequently, 100 μl of TMB substrate (Pierce, Rockford, IL, USA) 
was added into each well and the plate was incubated at room temperature for 30 
minutes in the dark. The substrate would turn to blue colour for a successful sample 
labelling reaction or remain colourless for an unsuccessful reaction. After a successful 
ELOSA QC assay, the remaining 21.5 μl of biotin-labelled sample from section 3.2.7.1 
was used for sample hybridisation. 
 
3.2.7.3   Sample hybridisation 
The Hybridisation Oven 640 (Affymetrix, Santa Clara, CA, USA) was switched on and 
the temperature and rotation speed were set at 48°C and 60 rpm, respectively. The 
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GeneChip miRNA 2.0 array (Affymetrix, Santa Clara, CA, USA) was warmed to room 
temperature for 15 minutes. The GeneChip Hybridisation, Wash and Stain kit 
(Affymetrix, Santa Clara, CA, USA) and the GeneChip Eukaryotic Hybridisation 
Control kit (Affymetrix, Santa Clara, CA, USA) were used in the sample preparation for 
hybridisation. The GeneChip Hybridisation, Wash and Stain kit consists of a 
hybridisation module (2X hybridisation mix and DMSO), a stain module (stain cocktail 
1, stain cocktail 2 and array holding buffer), wash buffer A and wash buffer B. The 
GeneChip Eukaryotic Hybridisation Control kit consists of a vial of 20X eukaryotic 
hybridisation controls and a vial of 3 nM control oligo B2. The 20X eukaryotic 
hybridisation controls vial was thawed and heated at 65°C for 5 minutes. The 21.5 μl of 
biotin-labelled sample (section 3.2.7.1) was mixed with 81.7 μl of array hybridisation 
cocktail (section 3.1.7.4). The mixture was initially incubated at 99°C for 5 minutes and 
then at 45°C for 5 minutes. A 200 μl yellow tip was inserted into the upper right septum 
of the array to enable proper venting during sample injection. At the end of the 
incubation, 100 μl of the sample was injected into the array via the lower left septum. 
Precaution was taken to avoid any air bubble. The yellow tip was then removed from 
the upper right septum and both septa were sealed to minimise evaporation and prevent 
leaks. The array was placed into the hybridisation tray and loaded into the hybridisation 
oven. The array was incubated at 48°C; 60 rpm for 16 hours. 
 
3.2.7.4   Washing, staining and scanning 
After 16 hours of hybridisation, the array was recovered from the hybridisation oven. 
The sample was extracted from the array and discarded. The array was filled with 100 
μl of array holding buffer and equilibrated to room temperature for 15 minutes. The 
Fluidics Station 450 with fluidics script FS450_0003 (Affymetrix, Santa Clara, CA, 
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USA) was employed in the automation of the washing and staining steps. Three 1.5 ml 
microcentrifuge tubes were each filled with 600 μl of stain cocktail 1, 600 μl of stain 
cocktail 2 and 800 μl of array holding buffer. These tubes were placed into the tube 
holders on the fluidics station. The washing and staining steps lasted about 1.5 hours. 
The GeneChip Command Console software (Affymetrix, Santa Clara, CA, USA) was 
used to operate the washing, staining and scanning interfaces. 
At the end of the washing and staining steps, the array was filled with array holding 
buffer. If there were air bubbles, the array holding buffer would be extracted and re-
filled manually. Once the array was confirmed to be free from air bubbles, both septa 
were re-sealed and sent for scanning. Scanning of the miRNA array was performed 
using the GeneChip Scanner 3000 7G (Affymetrix, Santa Clara, CA, USA). Data 
summarisation, normalisation and quality control of the raw signal intensity data in 
relation to the RNA spike control oligos (spike in-control-2, -23, -29, -31 and -36) were 
performed using miRNA QC Tool software (Affymetrix, Santa Clara, CA, USA). Each 
probe set of the RNA spike control oligos should reveal a signal background higher than 
1,000 units. The data were then saved as CEL file format and exported into third party 
software for further analysis. 
 
3.2.7.5   Microarray data analysis  
The miRNA microarray data analysis was conducted using GeneSpring GX 12.0 
software (Agilent, Santa Clara, CA, USA). Robust multichip averaging (RMA) 
algorithm was applied for background correction and probe summarisation of perfect 
match values in each array. Median intensity values for each miRNA from the same 
replicates were calculated and subjected to quantile normalisation to normalise the data 
across different arrays (Irizarry et al., 2003). The normalised data were analysed using t-
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test/analysis of variance (ANOVA) with p-value computation done asymptotically at p 
< 0.05. Subsequently, the gene list was filtered at a fold change cut-off of 1.5. 
Hierarchical clustering was computed using similarity measure of Euclidean distance 
and average-linkage rule, and expressed in the form of heat map and three dimensional 
(3D) principal component analysis (PCA) plot (Gibbons & Roth, 2002).  
 
3.2.8   RT 
3.2.8.1   RT for miRNA 
RT procedure is needed to synthesise complementary DNA strands. For a 15 μl of 
miRNA RT reaction, 7 μl of RT master mix (section 3.1.9.1) was mixed with 3 μl of 
miRNA RT primer and 5 μl of total RNA (10 ng) in a 0.2 ml PCR tube. The mixture 
was mixed gently and centrifuged. RT was carried out in a thermal cycler (PerkinElmer, 
Waltham, MA, USA) at 16°C for 30 minutes; 42°C for 30 minutes; 85°C for 5 minutes 
and hold at 4°C. miRNA RT primer was supplied as a separate tube in the TaqMan 
miRNA assay (Applied Biosystems, Carlsbad, CA, USA).  
 
3.2.8.2   RT for mRNA 
For a 10 μl of mRNA RT reaction, 6.15 μl of RT master mix (section 3.1.9.2) was 
mixed with 3.85 μl of total RNA (200 ng) in a 0.2 ml PCR tube. The mixture was mixed 
gently and centrifuged. RT was performed using a thermal cycler (PerkinElmer, 
Waltham, MA, USA) at 25°C for 10 minutes; 48°C for 30 minutes; 95°C for 5 minutes 
and hold at 4°C.  
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3.2.9   qPCR for miRNA and mRNA 
For miRNA, qPCR mastermix of 18.67 μl (section 3.1.10.1) was prepared and mixed 
with 1.33 μl of miRNA RT product (section 3.2.8.1). For mRNA, qPCR mastermix of 
19 μl (section 3.1.10.2) was prepared and mixed with 1 μl of mRNA RT product 
(section 3.2.8.2). qPCR reaction was performed in triplicates using MicroAmp Fast 
Optical 96-well reaction plate (Applied Biosystems, Carlsbad, CA, USA). The plate was 
sealed with MicroAmp Optical adhesive film (Applied Biosystems, Carlsbad, CA, 
USA). qPCR reaction was conducted using StepOnePlus Real-Time PCR machine 
(Applied Biosystems, Carlsbad, CA, USA) based on the fast mode parameters: uracil N-
glycosylase incubation (50°C for 2 minutes); AmpliTaq Fast DNA polymerase 
activation (95°C for 20 seconds); 40 cycles of denaturing (95°C for 1 second) and 
annealling/extending (60°C for 20 seconds).  
Relative expression was determined using comparative cycle threshold (CT) method, via   
2–ΔΔCT formula (Schmittgen & Livak, 2008). A CT value above 36 was set as the cut-off 
for defining as non-detected (Caraguel, Stryhn, Gagné, Dohoo, & Hammell, 2011; 
Jordan & Durso, 2005). The expression of each miRNA or mRNA relative to the 
respective endogenous control, RNU48 or β-actin, was presented as ΔCT (CT gene of 
interest – CT endogenous control). The ΔCT values of the cancer and control groups 
were subjected to paired/unpaired t-test (Yuan, Reed, Chen, & Stewart Jr, 2006). The 
fold change (2–ΔΔCT) value was calculated using the equation: 2– (ΔCT
 
cancer sample – ΔCT control 
sample)
. 
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3.2.10   Total protein extraction from CRC tissue and cultured cells  
Total protein from CRC tissue and cultured cells was extracted using T-PER tissue 
protein extraction reagent (Pierce, Rockford, IL, USA) and radio-immunoprecipitation 
assay (RIPA) buffer (Pierce, Rockford, IL, USA), respectively. Halt protease and 
phosphatase inhibitor cocktail (Pierce, Rockford, IL, USA) was added at the 
concentration of 10 μl/ml prior to use. For CRC tissue, 30 mg of tissue was weighed and 
immersed in 600 μl of T-PER reagent. The sample was homogenised until no visible 
piece of tissue was observed. For cultured cells, the cells were washed twice with 1X 
cold PBS before the addition of 250 μl of RIPA buffer into three wells of a 6-well plate. 
The plate was placed on a shaker for 5 minutes and the cells were scraped using a cell 
scraper. The lysed cells from the three wells were pooled into a 1.5 ml microcentrifuge 
tube. The tissue/cell lysate was centrifuged at maximum speed for 10 minutes. The 
supernatant containing the total protein was collected and aliquoted in equal volume 
into two tubes. The extracted total protein was stored at -80°C. 
 
3.2.11   Quantification of total protein 
The concentration of the extracted total protein was determined by Pierce 660 nm assay 
(Pierce, Rockford, IL, USA). Pre-diluted BSA protein assay standards (125 μg/ml; 250 
μg/ml; 500 μg/ml; 750 μg/ml; 1000 μg/ml; 1500 μg/ml; 2000 μg/ml) (Pierce, Rockford, 
IL, USA) were utilised to generate a standard curve for the determination of protein 
concentration from unknown samples. Nuclease-free water was used as the blank. 
Protein quantification was carried out with a sample:protein assay reagent ratio of 1:15. 
One μl of each assay standard/unknown sample/blank was added to 15 μl of protein 
assay reagent. The mixture was vortexed and incubated at room temperature for 5 
minutes in the dark. The absorbance was measured at a wavelength of 660 nm by 
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NanoDrop 2000 spectrophotometer (Thermo Scientific, Waltham, MA, USA). For cell 
lysates prepared in RIPA buffer, 0.4 μl of 10% Triton X-100 (section 3.1.11) was added 
to 4.6 μl of each sample prior to the addition of protein assay reagent. The exact protein 
concentration was calculated by multiplying the concentration obtained with a dilution 
factor of 1.087. 
 
3.2.12   SDS-PAGE and Western blot 
3.2.12.1   Preparation of SDS-PAGE 
The apparatus for SDS-PAGE, Mini-PROTEAN Tetra Cell (Bio-Rad, Hercules, CA, 
USA) was set up. Briefly, the spacer and short plates were sandwiched together. The 
comb was inserted and a line around 1 cm from the bottom of the comb was marked. 
The line served as the maximum level for resolving gel loading. The glass cassette 
sandwich was then placed in the casting frame and casting stand. The recipe for the 
preparation of resolving (10%) and stacking (4%) gels is provided in section 3.1.12.6. 
Resolving gel was prepared first and loaded until the marked line. Distilled water was 
added immediately to the top of the gel to level the surface and remove any air bubble. 
The resolving gel was allowed to set for 45 minutes. After the resolving gel has 
polymerised, the distilled water was decanted and excess water was blotted by using an 
absorbent tissue. Stacking gel was then loaded to fill the glass cassette sandwich. A 1 
mm comb was inserted to create wells for sample loading. The stacking gel was left to 
polymerise for 30 minutes. The glass cassette sandwich was then assembled in the 
electrophoresis tank and filled with 1X electrode running buffer (section 3.1.12.5). 
Forty μg of protein sample (10 μl) was mixed with 10 μl of SDS reducing sample buffer 
(section 3.1.12.4) and heated at 95°C for 10 minutes. The sample was loaded into the 
well and SDS-PAGE was run at 100V for about 1.5 hours. Five μl of SuperSignal 
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molecular weight protein ladder (Pierce, Rockford, IL, USA) was also loaded and used 
to monitor the electrophoresis run and membrane transfer. 
 
3.2.12.2   Membrane transfer 
After the completion of SDS-PAGE, the stacking gel was discarded while the resolving 
gel was equilibrated in cold transfer buffer (section 3.1.13) for 15 minutes with agitation. 
Wet transfer system using Mini Trans-Blot Cell (Bio-Rad, Hercules, CA, USA) was 
applied. Nitrocellulose transfer membrane of 0.45 μm (Pierce, Rockford, IL, USA) was 
utilised. The 8 x 10 cm nitrocellulose membrane, sponges and thick blot papers needed 
for the membrane transfer were also soaked in cold transfer buffer for 15 minutes. The 
transfer cassette sandwich was assembled from anode to cathode in the following order: 
sponge, thick blot paper, nitrocellulose membrane, resolving gel, thick blot paper and 
sponge. A 15 ml centrifuge tube was used to roll over the thick blot paper to remove any 
air bubble. The assembly was then placed in the transfer tank and filled with cold 
transfer buffer. Membrane transfer was performed at 100V for 1 hour.  
After the 1 hour of membrane transfer, the transfer cassette sandwich was disassembled 
and the membrane was stained using the MemCode Reversible Protein Stain kit (Pierce, 
Rockford, IL, USA) to evaluate the transfer efficiency. The blot was initially rinsed with 
distilled water prior to incubation with 25 ml of MemCode reversible protein stain for 1 
minute with agitation. Protein bands would appear turquoise-blue. Once the presence of 
protein bands was confirmed, the blot was rinsed thrice with 25 ml of MemCode destain 
reagent. The procedure was followed by rinsing the blot with distilled water for four 
times. Thirty ml of MemCode stain eraser was then added and incubated for 5 minutes 
with agitation. The blot was eventually rinsed with distilled water for four times and 
followed by a final wash for 5 minutes with agitation. 
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3.2.12.3   Western blot 
After confirming the efficiency of protein transfer, the blot was processed using the Fast 
Western Blot kit (Pierce, Rockford, IL, USA). The blot was briefly rinsed with 15 ml of 
Fast Western 1X wash buffer (section 3.1.14.1). Primary antibody working solution 
(section 3.1.14.2) of mouse monoclonal anti-β-actin, rabbit polyclonal anti-APAF1 or 
rabbit polyclonal anti-FOXO4 (Pierce, Rockford, IL, USA) was added to the blot and 
incubated at 4°C for 1 hour. After the primary antibody incubation, the blot was placed 
in a clean tray and rinsed with 15 ml of Fast Western 1X wash buffer. Fast Western 
optimised HRP reagent working solution (section 3.1.14.3) was added and incubated at 
room temperature for 15 minutes. The blot was then placed in a clean tray and washed 
with 20 ml of Fast Western 1X wash buffer for 5 minutes with agitation. The washing 
step was repeated twice. Subsequently, the blot was removed and placed in a plastic 
wrap. Four ml of detection reagent working solution (section 3.1.14.4) was applied onto 
the blot and incubated at room temperature for 1 minute. Precaution was taken to avoid 
any air bubble. The blot was visualised via a chemiluminescence imager (UVP, Upland, 
CA, USA) with 3-5 minutes exposure. The intensities of the bands were quantitated 
using the imager’s VisionWorksLS software. 
 
3.2.12.4   Resolving polyacrylamide gel staining  
After the membrane transfer procedure in section 3.2.12.2, the resolving gel was 
retrieved from the transfer cassette sandwich and rinsed twice with distilled water for 5 
minutes on a shaking platform. The resolving gel was submerged in 50 ml of Bio-Safe 
Coomassie stain (Bio-Rad, Hercules, CA, USA) for 30 minutes. Following that, the 
stain solution was decanted and the gel was destained with distilled water for 15 
minutes. Protein bands would be visible on the gel if the membrane transfer was 
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unsuccessful. This method serves as an additional assay to access the efficiency of 
protein transfer.  
 
3.2.13   Bacterial culture and sub-cloning 
3.2.13.1   Bacterial culture 
The pMIR-REPORT firefly luciferase miRNA expression reporter vector (Ambion, 
Carlsbad, CA, USA) was supplied as Escherichia coli glycerol stock and stored at          
-80°C. GeneArt pMA-T vectors containing the putative 3’-UTR fragments or the site-
directed mutants (Invitrogen, Carlsbad, CA, USA) were supplied as stab cultures of E. 
coli and stored at -20°C. All stock cultures were slightly thawed on ice and two loopfuls 
(around 20 μl) of each culture were transferred aseptically into round bottom tubes 
containing 2 ml of LB-ampicillin broth (section 3.1.15.6). The bacterial cultures were 
grown overnight at 37°C; 180 rpm to propagate the plasmids. 
 
3.2.13.2   Plasmid DNA extraction 
Plasmid DNA extraction was carried out using the PureLink Quick Plasmid Miniprep 
kit (Invitrogen, Carlsbad, CA, USA). Two ml of an overnight culture was transferred to 
a microcentrifuge tube and spun at maximum speed for 5 minutes. The supernatant was 
discarded by pouring. The steps were repeated twice for a total of 6 ml of bacterial 
culture. The pellet was then resuspended with 250 μl of L7 lysis buffer and incubated at 
room temperature for 5 minutes. Next, 350 μl of N4 precipitation buffer was added. The 
tube was mixed by inversion and centrifuged at 12,000 rpm for 10 minutes at room 
temperature. The supernatant was loaded onto the provided spin column and centrifuged 
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at 12,000 rpm for 1 minute. The flow-through was discarded and 500 μl of W10 wash 
buffer was added. The spin column was left at room temperature for 1 minute and 
centrifuged at 12,000 rpm for 1 minute. The flow-through was again discarded and 700 
μl of W9 wash buffer was added and centrifuged at 12,000 rpm for 1 minute. A final 
centrifugation at maximum speed for 1 minute was performed to remove any residual 
wash buffer from the spin column. Subsequently, the spin column was transferred to a 
new microcentrifuge tube and 75 μl of TE buffer (pre-heated to 67°C) was added to the 
centre of the column. The spin column was incubated at room temperature for 3 minutes 
and centrifuged at maximum speed for 2 minutes to elute the plasmid DNA. The 
purified plasmid DNA was stored at -20°C. The concentration of the plasmid DNA was 
determined by NanoDrop 2000 spectrophotometer, similar to the method in section 
3.2.5. The quality of the plasmid DNA was assessed using DNA gel electrophoresis 
(section 3.2.13.4).  
 
3.2.13.3   Restriction enzyme digestion 
Restriction enzyme digestion was carried out to linearise and create sticky ends at the 
pMIR-REPORT firefly luciferase vector and the 3’-UTR fragment of the pMA-T vector 
prior to sub-cloning. This procedure was also performed to determine the presence of 
the cloned fragment after transformation. One μg of plasmid DNA was added to the 
restriction enzyme mixture (section 3.1.15.2). The mixture was incubated at 37°C in a 
thermal cycler for 20 minutes. The enzymes were then inactivated via incubation at 
80°C for 10 minutes. The restriction enzyme digestion was analysed using DNA gel 
electrophoresis (section 3.2.13.4).  
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3.2.13.4   DNA gel electrophoresis 
Molten DNA gel (section 3.1.15.1) was allowed to set in the gel-casting tray with a 
comb inserted to create wells for sample loading. Once the gel has solidified, it was 
placed in the electrophoresis tank filled with 1X TBE buffer (section 3.1.6.1). An 
aliquot of 2.5 μl of plasmid DNA sample (section 3.2.13.2) was mixed with 0.5 μl of 6X 
DNA loading dye (Fermentas, Waltham, MA, USA) prior to sample loading. For 
restriction enzyme digestion (section 3.2.13.3), the usage of FastDigest green buffer 
enabled a direct loading of the reaction mixture. Two μl of GeneRuler 1 kb DNA ladder 
(Fermentas, Waltham, MA, USA) was used as the molecular weight marker. 
Electrophoresis was conducted at 100V for approximately 40 minutes. The gel image 
was captured using a gel documentation system (UVP, Upland, CA, USA). For sub-
cloning purposes, the digested fragments were excised using a clean scalpel and used in 
DNA gel extraction (section 3.2.13.5). 
 
3.2.13.5   DNA gel extraction 
DNA gel extraction was carried out using the GeneJET Gel Extraction and DNA 
Cleanup Micro kit (Thermo Scientific, Waltham, MA, USA). A total of 200-250 mg of 
gel slice containing the DNA fragment was excised using a clean scalpel and transferred 
to a microcentrifuge tube. The gel slice was loaded with 200 μl of extraction buffer and 
incubated at 58°C for 10-20 minutes until the gel slice has completely dissolved. The 
tube was mixed by inversion every 3 minutes to facilitate the melting process. A volume 
of 200 μl of absolute ethanol was added and mixed by pipetting. The sample was loaded 
onto the provided purification column and centrifuged at 14,000 rpm for 1 minute. The 
flow-through was discarded and the column was washed once with 200 μl of prewash 
buffer and twice with 700 μl of wash buffer via centrifugation at 14,000 rpm for 1 
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minute. Subsequently, the column was spun at maximum speed for 1 minute to remove 
any residual wash buffer. The column was then transferred to a new microcentrifuge 
tube and 10 μl of elution buffer was loaded. The column was incubated at room 
temperature for 2 minutes. The DNA was eluted by centrifuging the column at 
maximum speed for 2 minutes. The extracted DNA was stored at -20°C. The 
concentration of the extracted DNA was determined by NanoDrop 2000 
spectrophotometer, similar to method in section 3.2.5. 
 
3.2.13.6   Ligation and transformation 
Ligation reaction between vector DNA and insert DNA was performed using a vector 
DNA:insert DNA molar ratio of 1:5, which indicated a reaction involving 50 ng of 
vector DNA (pMIR-REPORT firefly luciferase vector) and 250 ng of excised insert 
DNA. The ligation mixture (section 3.1.15.4) was incubated at 22°C in a thermal cycler 
for 1 hour. The ligation mixture was then used for transformation.  
One vial (50 μl) of One Shot Top10 Chemically Competent E. coli cells (Invitrogen, 
Carlsbad, CA, USA) was thawed on ice. Five μl of the ligation mixture was added into 
the vial. The vial was mixed by flicking and left standing on ice for 30 minutes. Next, 
heat shock method was conducted, whereby the vial was immediately returned to ice 
after a short incubation at 42°C for 1 minute. Two hundred and fifty μl of the provided 
SOC medium was then added and the vial was incubated at 37°C; 180 rpm in a shaking 
incubator for 1 hour. Finally, the transformation mix was spreaded onto two LB-
ampicillin agar plates (section 3.1.15.7), each with 150 μl of transformation mix. The 
agar plates were incubated overnight at 37°C. Single colonies were then picked using 
sterile loops and allowed to grow overnight in tubes containing 2 ml of LB-ampicillin 
broth (section 3.1.15.6) at 37°C; 180 rpm. Two loopfuls (around 20 μl) of each 
 89 
 
overnight culture were then transferred to new tubes containing LB-ampicillin broth to 
propagate more clones necessary for plasmid DNA extraction (section 3.2.13.2). An 
aliquot of 0.5 ml of the bacterial culture was stocked in 0.5 ml of 80% glycerol (section 
3.1.15.8).  
 
3.2.13.7   Plasmid DNA sequencing 
Ten μl of the purified plasmid DNA (50 ng/μl) was sent for sequencing service. 
According to the sequencing primers listed in the pMIR-REPORT firefly luciferase 
miRNA expression reporter vector system (Ambion, Carlsbad, CA, USA), three 
sequencing primers were chosen: forward 5'–AGGCGATTAAGTTGGGTA–3', forward 
5'–GAGGTAGATGAGATGTGA–3' and reverse 5'–ATTGCAACGATTTAGGTG–3'. 
Sequence alignment was then conducted via BLASTN software offered by the NCBI 
database. This step was performed to confirm a successful ligation reaction between the 
vector backbone and insert DNA after transformation. 
 
3.2.14   miRNA and luciferase reporter co-transfection 
SW480 cell line was used as the host in the co-transfection study. Cells were seeded in 
antibiotic-free complete medium at 2 x 104 cells per well on a 96-well white plate one 
day before transfection. In the first phase of transfection involving miRNA, 0.25 μl of 
Lipofectamine 2000 transfection reagent (Invitrogen, Carlsbad, CA, USA) was diluted 
in 25 μl of Opti-MEM I reduced serum medium (Gibco, Carlsbad, CA, USA) and 
incubated at room temperature for 5 minutes. miRIDIAN miRNA mimic or inhibitor 
(Dharmacon, Lafayette, CO, USA) was diluted to a concentration of 5 pmol in 25 μl of 
Opti-MEM I reduced serum medium. Both mixtures were combined and incubated at 
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room temperature for 20 minutes. After the incubation, the plated medium was removed 
and the miRNA-transfection mixture was added into each well. The plate was incubated 
in the 5% CO2-humidified incubator at 37°C for 3 hours.  
In the second phase of transfection involving plasmid DNA, 0.25 μl of Lipofectamine 
2000 transfection reagent was complexed with 25 μl of Opti-MEM I reduced serum 
medium and incubated at room temperature for 5 minutes. pMIR-REPORT firefly 
luciferase reporter vector containing either the target recognition or mutated site (100 ng) 
and pRL-SV40 Renilla luciferase control reporter vector (10 ng) were diluted in 25 μl of 
Opti-MEM I reduced serum medium. Both mixtures were combined and incubated at 
room temperature for 20 minutes.  
At the end of the 3 hours of miRNA transfection, the medium was removed and the 
cells were washed with 50 μl of Opti-MEM I reduced serum medium. The plasmid-
transfection mixture was then added into each well and incubated in the 5% CO2-
humidified incubator for another 3 hours. After that, the medium was changed to 
antibiotic-free complete medium and the cells were left to grow for 48 hours, following 
which luciferase assay (section 3.2.15) was conducted. The transfection controls 
included were NTC cells and cells co-transfected with miRNA and pMIR-REPORT 
firefly luciferase reporter vector without target recognition or mutated site. Each 
transfection experiment was performed in triplicates in three independent experiments. 
 
3.2.15   Luciferase assay 
The Dual-Glo Luciferase assay (Promega, Madison, WI, USA) was used to study the 
interaction between miRNA and its predicted target gene. The assay allows the 
measurement of two independent reporter enzymes within a single system. Firefly 
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luciferase vector was the main reporter used in the evaluation of miRNA interaction 
while Renilla luciferase vector was used to determine the transfection efficiency. After 
48 hours of co-transfection (section 3.2.14), the plate was equilibrated to room 
temperature for 5 minutes and 75 μl of Dual-Glo Luciferase reagent was added into 
each well. The plate was incubated for 10 minutes in the dark before the measurement 
of firefly luminescence. Once the measurement has completed, 75 μl of Dual-Glo Stop 
and Glo reagent was added to quench the luminescence signal from the firefly reaction. 
The plate was incubated for 10 minutes in the dark and the Renilla luminescence was 
measured. Infinite M200-Pro plate reader (Tecan, Männedorf, Zurich, Switzerland) was 
used for the luminescence measurements. Transfection efficiency was normalised by 
dividing the firefly luciferase signal with the Renilla luciferase signal.  
 
3.2.16   MTT assay  
MTT assay was performed according to the guidelines in MTT Cell Proliferation kit 
(OZ Biosciences, Marseille, France). It is a colorimetric assay that measures the activity 
of mitochondrial reductase enzyme in reducing MTT to formazan dye in viable cells. 
Cell viability following miRNA mimics and inhibitors transfections was determined. 
Cells (2 x 104) were seeded in 96-well plate and miRNA transfections were carried out 
accordingly in triplicates for 24, 48 and 72 hours. At the end of each transfection period, 
cultured cells were washed with pre-warmed 1X PBS. One hundred μl of 1X MTT 
(section 3.1.16) was added into each well and the plate was incubated in the 5% CO2-
humidified incubator at 37°C for 4 hours. At the end of the incubation, 100 μl of 
solubilisation solution was added. The plate was placed on a shaker for 15 minutes to 
ensure that the converted dye has completed dissolved. The absorbance was measured at 
a wavelength of 570 nm and a reference wavelength at 650 nm using Infinite M200-Pro 
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plate reader (Tecan, Männedorf, Zurich, Switzerland). Wells with complete medium 
were used as the blank. The viability of the transfected sample was expressed as a 
percentage of the NTC sample.  
 
3.2.17   Apoptosis assay and image-based cytometry 
Apoptosis assay was performed using the Annexin V-Fluorescein Isothiocyanate (FITC) 
Apoptosis Detection kit (BioVision, Milpitas, CA, USA). During apoptosis, membrane 
phosphatidylserine is translocated from the inner surface to the outer surface of the 
plasma membrane. Annexin V is a calcium-dependent phospholipid-binding protein that 
has a high affinity for phosphatidylserine. Annexin V-FITC fluorescent dye is used to 
stain cells that are undergoing apoptosis while propidium iodide (PI) stain is used to 
identify necrotic cells that have lost their membrane integrity. Cells that are stained 
positive for Annexin V-FITC but negative for PI are apoptotic cells. Cells with positive 
results for both Annexin V-FITC and PI are either late apoptotic or dead cells while 
cells with negative results for both Annexin V-FITC and PI are live cells. 
miRNA transfection procedure was conducted according to section 3.2.3 using 6-well 
plate. After 48 hours of transfection, the cells were harvested and a cell pellet containing 
5 x 105 cells was collected in a microcentrifuge tube. The cell pellet was resuspended 
with 500 μl of 1X binding buffer. Five μl of both Annexin V-FITC and PI reagents were 
added. The cell suspension was gently vortexed and left in the dark at room temperature. 
Measurement was performed within one hour of staining. The sample (25 µl) was 
loaded onto a Tali cellular analysis slide (Invitrogen, Carlsbad, CA, USA). Quantitative 
analysis of live (Annexin V-negative/PI-negative), dead (Annexin V-positive/PI-
positive) and apoptotic (Annexin V-positive/PI-negative) cell populations was evaluated 
using Tali image-based cytometer (Invitrogen, Carlsbad, CA, USA). An unstained 
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sample was initially analysed and set as the background in order to determine the 
fluorescent thresholds. Each sample was then gated according to the initial thresholds. 
An anti-cancer drug doxorubicin (50 μM) was used as the positive control. All assays 
were performed in triplicates in three separate experiments. 
 
3.2.18   Caspase 3/7 assay 
The Caspase-Glo 3/7 assay (Promega, Madison, WI, USA) was used to measure the 
activation of caspase-3 and -7 activities. Cells (2 × 104 cells/well) were seeded in 96-
well white plate and miRNA transfections were carried out accordingly in triplicates. 
After 48 hours of transfection, the plate was removed from the incubator and 
equilibrated to room temperature for 5 minutes. One hundred µl of Caspase-Glo 3/7 
reagent was added into each well and the plate was incubated at room temperature for 3 
hours prior to luminescence detection using Infinite M200-Pro plate reader (Tecan, 
Männedorf, Zurich, Switzerland). Wells with complete medium were used as the blank. 
The caspase 3/7 activity of the transfected sample was expressed as a percentage of the 
NTC sample. 
 
3.2.19   Migration and invasion assays 
Migration and invasion assays were performed on 24-well transwell plates containing 
inserts of 8 µm pore size (BD Biosciences, Franklin Lakes, NJ, USA). Uncoated 
chambers were used for migration assay while Matrigel-coated chambers were used for 
invasion assay. Matrigel matrix aliquot was thawed overnight on ice in a cold room at 
4°C. Since Matrigel matrix would gel at a temperature above 10°C, pre-cooled pipettes, 
tips and tubes have to be used during the handling of the Matrigel matrix. Matrigel 
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coating solution with a working concentration of 250 μg/ml (section 3.1.17.2) was 
prepared and the solution was kept on ice until use. A volume of 100 μl of Matrigel 
coating solution was sufficient to coat one 24-well cell culture insert. The transwell 
plate was allowed to coat in the 5% CO2-humidified incubator at 37°C for 2 hours. An 
equal number of uncoated inserts was prepared. Following incubation, the inserts were 
rinsed with 200 μl of serum-free basal medium. 
miRNA transfection procedure was carried out according to section 3.2.3 using 6-well 
plate. After 48 hours of transfection, the cells were harvested and a 500 μl of cell 
suspension containing 2.5 x 105 cells in basal medium was prepared. The cell 
suspension was loaded onto the 24-well cell culture insert. Complete medium 
containing 10% serum (750 μl) was used as the chemoattractant in the lower chamber. 
The plate was incubated in the 5% CO2-humidified incubator at 37°C for 24 hours. 
Following that, the medium was removed and the inner side of the 24-well insert was 
swabbed to remove the non-migrating or non-invading cells. Cells on the lower surface 
of the insert were rinsed with 1X PBS, fixed with 3.7% formaldehyde in 1X PBS 
(section 3.1.17.3) for 5 minutes and permeabilised with 100% methanol for 15 minutes. 
The cells were then stained with Wright-Giemsa stain (Sigma-Aldrich, St.Louis, MO, 
USA) for 15 minutes, rinsed twice with 1X PBS and air-dried for 15 minutes. Finally, 
the cells were counted using an inverted microscope (ECLIPSE Ti-S, Nikon, Tokyo, 
Japan) at 100X magnification. Five random fields from each insert were captured and 
analysed using Image-J software (National Institute of Health; http://imagej.nih.gov/ij/). 
The migration and invasion assays were repeated in three independent experiments.  
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3.2.20   miRNA target prediction analysis 
miRNA target prediction was computed using miRWalk (http://www.umm.uni-
heidelberg.de/apps/zmf/mirwalk), a database that integrates several miRNA target 
prediction programmes (Dweep, Sticht, Pandey, & Gretz, 2011). An informative 
prediction was assumed when a putative target was concordantly identified by five of 
the most common algorithms (DIANA-MicroT, miRanda, miRWalk, 
MirTarget2/miRDB, PicTar, RNA22, RNAhybrid and TargetScan Human). TargetScan 
Human (version 6.2) was chosen as the main algorithm in determining the predicted 
miRNA:mRNA pairing region. The algorithm produces a list of hundreds of target 
genes based on the presence of conserved sites (8mer, 7mer-m8 or 7mer-1A) at the 3’-
UTR of mRNAs that match the seed region of the selected miRNA. Human miRNA is 
typically represented with the prefix “hsa”, which stands for Homo sapiens. For 
simplicity, all miRNAs stated in the present study are human miRNAs, unless stated 
otherwise.   
 
3.2.21   Statistical analysis 
The patients’ demographics were reported as mean ± standard deviation (SD) or 
frequencies and percentages for continuous and categorical variables, respectively. Chi-
square test was used in the analysis of age distribution while Fisher’s exact test was 
used in the analysis of gender and race distributions. Microarray data analysis was 
carried out as outlined in section 3.2.7.5. Data from RT-qPCR and cell culture 
experiments were expressed as mean ± standard error of mean (SEM). Statistical 
significance was determined by paired/unpaired t-test and a two-tailed p-value of < 0.05 
was considered to be statistically significant. Correlation analysis was determined by 
Pearson’s test. Logistic regression and receiver operating characteristic (ROC) curve 
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analyses were applied to obtain diagnostic utility of the selected miRNAs. Statistical 
analysis was performed using SPSS version 16.0 software (IBM, Armonk, NY, USA). 
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CHAPTER 4  
RESULTS 
 
4.1   Demographics  
A total of 112 CRC patients and 50 healthy controls were recruited in this study. Tables 
4.1 and 4.2 summarise the distribution of the whole blood and paired cancer tissue 
cohorts. No significant differences were observed between the CRC patients and 
controls in the distribution of age (p = 0.171) and gender (p = 0.174). Malaysia is made 
up of a multi-ethnic population. The National Cancer Registry of Malaysia has reported 
a higher proportion of CRC cases in the Malaysian Chinese population (Zainal Ariffin 
& Nor Saleha, 2011). Thus, approximately 52.47% of the samples obtained were from 
the Malaysian Chinese and the remainders were from the Malays (25.31%) and 
Malaysian Indians (22.22%) (p = 0.202). All CRC cases in this study were 
adenocarcinomas. The detailed demographic data of the participants are given in 
Appendix 2. 
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Table 4.1: Distribution of the CRC patient and healthy control blood cohorts.  
Characteristics CRC patient  
blood cohort 
(n = 112), n (%) 
Control  
blood cohort 
(n = 50), n (%) 
p-valuea 
Age (mean year ± SD) 64.43 ± 9.05 61.54 ± 10.31 0.171 
Gender Male 67 (59.82%) 24 (48.00%) 0.174 
 Female 45 (40.18%) 26 (52.00%)  
Race Malay 26 (23.12%) 15 (30.00%) 0.202 
 Chinese 64 (57.14%) 21 (42.00%)  
 Indian 22 (19.64%) 14 (28.00%)  
TNM stage I 25 (22.32%)   
 II 32 (28.57%)   
 III 31 (27.68%)   
 IV 24 (21.43%)   
Tumour location Colon 72 (64.29%)   
 Rectum 40 (35.71%)   
Tumour grading G1 25 (22.32%)   
(adenocarcinoma) G2 76 (67.86%)   
 G3 11 (9.82%)   
ap-value for age was calculated by chi-square test; p-values for gender and race were 
calculated by Fisher’s exact test.  
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Table 4.2: Distribution of the sub-set of paired cancer tissue. 
Characteristics Sub-set of paired cancer tissue 
(n = 60), n (%) 
Age (mean year ± SD) 63.78 ± 8.55 
Gender Male 33 (55.00%) 
 Female 27 (45.00%) 
Race Malay 10 (16.67%) 
 Chinese 38 (63.33%) 
 Indian 12 (20.00%) 
TNM stage I 0 
 II 20 (33.33%) 
 III 20 (33.33%) 
 IV 20 (33.33%) 
Tumour location Colon 60 (100.00%) 
 Rectum 0 
Tumour grading G1 13 (21.67%) 
(adenocarcinoma) G2 43 (71.67%) 
 G3 4 (6.67%) 
 
4.2   Assessment of RNA quality and integrity 
High quality total RNA is crucial for obtaining reliable microarray and RT-qPCR results. 
The concentration and purity of the extracted total RNA from blood and tissue samples 
were determined spectrophotometrically. The A260/A280 and A260/A230 ratios for all the 
extracted total RNA samples were in the range of 1.8-2.2. The 1.8-2.2 range indicates 
the absence of protein, phenol and other contaminants in a sample. The RNA band 
integrity was assessed using denaturing RNA agarose and polyacrylamide gels. High 
quality RNA would reveal two sharp bands at the intensity ratio of 2:1 for 28S:18S 
rRNA on the agarose gel (Figure 4.1) and three distinct bands for 5.8S rRNA, 5S rRNA 
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and tRNA on the polyacrylamide gel (Figure 4.2) (Skrypina, Timofeeva, Khaspekov, 
Savochkina, & Beabealashvilli, 2003; Yeh & Lee, 1988). All the agarose and 
polyacrylamide gel electrophoresis images are shown in Appendices 3 and 4, 
respectively. Moreover, samples that were used in miRNA microarray assays were 
evaluated using Agilent 2100 Bioanalyzer (Figure 4.3). A RIN of 1.0 represents almost 
fragmented and degraded RNA while a RIN of 10.0 represents intact and non-
fragmented RNA (Schroeder et al., 2006). RNA samples with RIN ≥ 7.0 and absence of 
DNA contamination were used (Appendix 5). 
 
 
 
Figure 4.1: Denaturing agarose gel electrophoresis. High quality total RNA preparation 
was demonstrated by the sharp bands for 28S rRNA and 18S rRNA. 
      Lane M: 18S + 28S rRNA marker 
      Lane 1: CRC blood RNA 
      Lane 2: Control blood RNA 
      Lane 3: CRC tissue RNA 
      Lane 4: Normal colonic tissue RNA 
  
  M           1            2            3           4                     
28S rRNA 
18S rRNA 
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Figure 4.2: Denaturing polyacrylamide gel electrophoresis. High quality total RNA 
preparation was demonstrated by the distinct bands for 5.8S rRNA, 5S rRNA and 
tRNA. 
      Lane 1: CRC blood RNA 
      Lane 2: Control blood RNA 
      Lane 3: CRC tissue RNA 
      Lane 4: Normal colonic tissue RNA 
  
5.8S rRNA 
   5S rRNA 
tRNA 
1               2               3                4                     
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Figure 4.3: RNA integrity analysis. The figure shows the gel (left) and 
electropherogram (right) of the RNA ladder and sample obtained from Agilent 2100 
Expert software. The RNA integrity analysis for Sample 8 (CRC blood RNA) revealed a 
RIN of 9. The two distinct 18S and 28S peaks observed in the sample electropherogram 
indicated high integrity total RNA. 
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4.3   Tissue and blood miRNA microarray profiling studies 
In the discovery of global miRNA expression in cancer tissue and whole blood, two 
independent miRNA microarray profiling studies were conducted. Prior to pursuing 
with the microarray data analysis, data summarisation, normalisation and quality control 
of the raw signal intensity data for all arrays (n = 26) were performed (Figure 4.4).  
 
 
Figure 4.4: miRNA QC Tool analysis. Data summarisation, normalisation and quality 
control of the raw signal intensity data in relation to the RNA spike control oligos (spike 
in-control-2, -23, -29, -31 and -36) were conducted. Each probe set of the RNA spike 
control oligos revealed a signal background higher than 1,000 units. Thus, all arrays 
have passed the quality control analysis. 
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The miRNA microarray data reported in this study are in accordance with the Minimum 
Information About a Microarray Experiment (MIAME) guidelines (Brazma et al., 2001). 
The data have been submitted to the NCBI Gene Expression Omnibus (GEO) database 
(Accession: GSE39845). Hierarchical clustering analysis was performed based on the 
similarity measure of Euclidean distance and average-linkage rule, and expressed in the 
form of heat map and 3D PCA plot (Gibbons & Roth, 2002). The heat map indicated the 
number of miRNAs that were differentially regulated between the cancer and the 
normal/control group. Many miRNAs that were poorly expressed in the normal/control 
samples have been determined to be highly expressed in the CRC samples. The 3D PCA 
plot was computed to provide a visual representation of the samples. The samples were 
distributed into a three dimensional space based on the variances in miRNA gene 
expression. Samples from the same group or stage were found to be clustered together 
in distinctive patterns.  
 
4.3.1   Tissue miRNA array 
In tissue miRNA array, 30 paired cancer tissue with normal colonic mucosa samples 
were included (Appendix 6). At the fold change cut-off of 1.5, the tissue miRNA array 
revealed 40 significantly up-regulated and 32 significantly down-regulated miRNAs 
(Table 4.3). Since the profiling experiment for each cancer stage was performed in only 
one replicate, the miRNA expression was calculated as a general fold change of cancer 
tissue versus normal colonic mucosa. The heat map and 3D PCA plot for the tissue 
miRNA array are depicted in Figures 4.5 and 4.6, respectively. 
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Table 4.3: List of 72 significantly deregulated miRNAs in tissue miRNA array. The 
miRNA expression was calculated as a general fold change of cancer tissue versus 
normal colonic mucosa (p < 0.05). Positive values denote up-regulation and negative 
values denote down-regulation.  
miRNA  Fold 
change 
miRNA  Fold 
change 
miRNA  Fold 
change 
hsa-let-7i-star 1.76 hsa-miR-193a-3p 8.72 hsa-miR-378-star -2.75 
hsa-miR-10b -1.79 hsa-miR-195 -2.03 hsa-miR-383 -3.45 
hsa-miR-10b-star -1.86 hsa-miR-198 1.54 hsa-miR-422a -2.72 
hsa-miR-105 2.13 hsa-miR-20a 1.94 hsa-miR-424-star 2.20 
hsa-miR-1224-5p 1.63 hsa-miR-203 3.54 hsa-miR-429 2.03 
hsa-miR-124 -6.64 hsa-miR-21-star 2.33 hsa-miR-431 1.75 
hsa-miR-1244 1.77 hsa-miR-215 -3.21 hsa-miR-483-3p 1.63 
hsa-miR-1246 4.74 hsa-miR-224 8.44 hsa-miR-493-star 2.25 
hsa-miR-1247 8.74 hsa-miR-23a 2.79 hsa-miR-497 -2.90 
hsa-miR-1292 1.62 hsa-miR-23b 3.56 hsa-miR-501-5p 1.71 
hsa-miR-1296 -1.63 hsa-miR-23b-star -2.20 hsa-miR-503 2.42 
hsa-miR-1308 3.43 hsa-miR-27b -1.72 hsa-miR-509-3p 3.65 
hsa-miR-138 -3.56 hsa-miR-27b-star -1.80 hsa-miR-548x -1.76 
hsa-miR-139-3p -5.91 hsa-miR-28-3p -2.29 hsa-miR-550-star 2.57 
hsa-miR-139-5p -5.61 hsa-miR-29b-2-star -2.10 hsa-miR-552 8.89 
hsa-miR-140-3p -1.79 hsa-miR-30a -2.76 hsa-miR-622 8.66 
hsa-miR-146b-3p 2.34 hsa-miR-30a-star -4.25 hsa-miR-663b 5.40 
hsa-miR-148a 1.82 hsa-miR-30c-1 -2.48 hsa-miR-767-5p 2.62 
hsa-miR-149 -2.41 hsa-miR-30c-2 -4.12 hsa-miR-887 -2.02 
hsa-miR-150 -1.61 hsa-miR-3162 1.90 hsa-miR-940 1.58 
hsa-miR-18a-star 3.47 hsa-miR-338-5p 8.20 hsa-miR-941 2.65 
hsa-miR-181d 1.63 hsa-miR-342-3p -1.59 hsa-miR-96 1.86 
hsa-miR-182 3.64 hsa-miR-378 -2.81 hsa-miR-99a -1.57 
hsa-miR-183-star 5.01 hsa-miR-378c -3.15 hsa-miR-99b -1.85 
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Figure 4.5: Heat map of tissue miRNA array. The heat map shows the hierarchical 
clustering analysis of 72 miRNAs that were found to be differentially regulated between 
the cancer tissue and the normal colonic mucosa. 
 107 
 
 
Figure 4.6: 3D PCA plot of tissue miRNA array. The 3D PCA plot shows a 
distinguished distribution of the paired cancer tissue and normal colonic mucosa. Colour 
by type, red: cancer tissue; blue: normal colonic mucosa.  
 
4.3.2   Blood miRNA array 
In blood miRNA array, 42 CRC and 18 healthy control samples were included 
(Appendix 6). Blood miRNAs with fold change values of ≥ 1.5 or ≤ -1.5 in any TNM 
stage were included. A total of 15 significantly up-regulated and 9 significantly down-
regulated miRNAs were discovered (Table 4.4). The heat map and 3D PCA plot for the 
blood miRNA array are depicted in Figures 4.7 and 4.8, respectively. 
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Table 4.4: List of 24 significantly deregulated miRNAs in blood miRNA array. The 
miRNA expression was calculated as a fold change of TNM stage (I, II, III or IV) 
versus control group (p < 0.05). Values of ≥ 1.5 or ≤ -1.5 are highlighted in bold. 
Positive values denote up-regulation and negative values denote down-regulation. 
miRNA 
 
Fold change 
Stage I  Stage II  Stage III  Stage IV 
hsa-miR-122 -1.90 1.89 -1.18 7.34 
hsa-miR-122-star 1.10 -1.08 1.52 -1.02 
hsa-miR-1245 1.55 -1.01 1.12 1.08 
hsa-miR-1274b 1.79 -1.03 -1.14 1.00 
hsa-miR-130a-star 1.64 -1.04 -1.15 -1.02 
hsa-miR-150 -2.56 -1.52 -3.91 -1.47 
hsa-miR-18b-star 1.54 -1.03 1.41 1.09 
hsa-miR-193a-3p 1.01 1.21 -1.00 1.85 
hsa-miR-2116-star 2.21 1.13 1.17 -1.05 
hsa-miR-23a -1.05 1.55 -1.07 1.45 
hsa-miR-23b 1.58 1.51 1.41 1.74 
hsa-miR-296-5p 1.88 -1.05 1.31 -1.07 
hsa-miR-3122 -1.58 1.07 -1.04 -1.20 
hsa-miR-3183 2.22 1.00 -1.13 -1.16 
hsa-miR-338-5p -1.32 1.74 -1.04 2.40 
hsa-miR-342-3p -1.37 -1.30 -1.77 -1.25 
hsa-miR-409-5p -1.28 1.08 1.18 1.66 
hsa-miR-4267 -1.28 -1.04 1.56 1.06 
hsa-miR-483-3p -1.04 1.24 1.71 1.04 
hsa-miR-513a-3p 1.64 1.06 1.24 -1.01 
hsa-miR-520a-3p 1.52 -1.04 -1.04 -1.01 
hsa-miR-548u 1.95 -1.34 -1.30 -1.24 
hsa-miR-587 1.53 1.03 1.04 -1.14 
hsa-miR-92a-2-star 1.98 -1.06 -1.06 -1.12 
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Figure 4.7: Heat map of blood miRNA array. The heat map shows the hierarchical 
clustering analysis of 24 miRNAs that were found to be differentially regulated between 
the cancer and the control groups. 
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Figure 4.8: 3D PCA plot of blood miRNA array. Samples from the same stage were 
found to be clustered together. Colour by type, red: control; blue: stage I; brown: stage 
II; grey: stage III; green: stage IV. 
 
4.4   Selection of miRNAs for validation study 
The tissue miRNA array revealed a higher number of deregulated miRNAs and those 
that were concurrently expressed in the blood miRNA array were selected for further 
validation. The selected miRNAs consisted of five up-regulated (miR-193a-3p, miR-23a, 
miR-23b, miR-338-5p and miR-483-3p) and two down-regulated (miR-150 and miR-
342-3p) miRNAs (Figure 4.9).  
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Figure 4.9: Venn diagram of differentially expressed miRNAs.  
 
A two-step validation protocol involving the RT step using miRNA-specific primer and 
the qPCR technology using TaqMan probe was utilised. An independent set of 30 
paired cancer tissues (stage II, n = 10; stage III, n = 10; stage IV, n = 10), 70 blood 
samples from CRC patients (stage I, n = 19; stage II, n = 20; stage III, n = 19; stage IV, 
n = 12) and 32 blood samples from healthy controls were used in the validation study 
(Appendix 6). The clinical samples were grouped into early-stage tumour (stage I-II) 
and advanced-stage tumour (stage III-IV) for statistical analysis.  
RNU48 was chosen as the endogenous control for data normalisation. Its expression has 
been found to be reasonably stable and reproducible in CRC (K. H. Chang, Mestdagh, 
Vandesompele, Kerin, & Miller, 2010; Davoren, McNeill, Lowery, Kerin, & Miller, 
2008). The tissue (p = 0.311) and blood (p = 0.524) levels of RNU48 between the 
cancer and normal/control samples were confirmed to be statistically insignificant.  
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4.4.1   Validation of the panel of seven miRNAs in tissue samples 
The validation study was performed using 30 paired cancer tissues. The tissue RT-
qPCR analysis indicated that the CT values for the panel of seven miRNAs and 
endogenous control were within the detectable limit of less than 36 (Figure 4.10). 
Significant deregulations were noticed in the panel of seven miRNAs using paired t-test 
(p = 0.039 for miR-150, p = 0.037 for miR-193a-3p, p = 0.031 for miR-23a, p = 0.025 
for miR-23b, p = 0.023 for miR-338-5p, p = 0.025 for miR-342-3p and p = 0.009 for 
miR-483-3p). The bar charts of paired tissue miR-150, miR-193a-3p, miR-23a, miR-
23b, miR-338-5p, miR-342-3p and miR-483-3p expressions are illustrated in Figures 
4.11 to 4.17. The basal fold change of the normal colonic mucosa was set at 1. Hence, a 
fold change above 1 in the cancer tissue was determined as up-regulation while a fold 
change below 1 was determined as down-regulation. The miRNAs expression levels of 
each sample are tabulated in Appendix 7. 
 
 
Figure 4.10: CT values of miRNAs and endogenous control in tissue validation. Colour 
legend, black: miR-150; red: miR-193a-3p, orange: miR-23a; light blue: miR-23b, 
green: miR-338-5p; dark blue: miR-342-3p; purple: miR-483-3p; grey: RNU48. 
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Figure 4.11: Paired tissue miR-150 expression. Relative expression is expressed as fold 
change of cancer tissue versus normal colonic mucosa. Fold change below 1 indicates 
down-regulation. Data are presented as mean ± SEM. * p < 0.05. 
 
  
Figure 4.12: Paired tissue miR-193a-3p expression. Relative expression is expressed as 
fold change of cancer tissue versus normal colonic mucosa. Fold change above 1 
indicates up-regulation. Data are presented as mean ± SEM. * p < 0.05. 
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Figure 4.13: Paired tissue miR-23a expression. Relative expression is expressed as fold 
change of cancer tissue versus normal colonic mucosa. Fold change above 1 indicates 
up-regulation. Data are presented as mean ± SEM. * p < 0.05. 
 
  
Figure 4.14: Paired tissue miR-23b expression. Relative expression is expressed as fold 
change of cancer tissue versus normal colonic mucosa. Fold change below 1 indicates 
down-regulation. Data are presented as mean ± SEM. * p < 0.05. 
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Figure 4.15: Paired tissue miR-338-5p expression. Relative expression is expressed as 
fold change of cancer tissue versus normal colonic mucosa. Fold change above 1 
indicates up-regulation. Data are presented as mean ± SEM. * p < 0.05. 
 
  
Figure 4.16: Paired tissue miR-342-3p expression. Relative expression is expressed as 
fold change of cancer tissue versus normal colonic mucosa. Fold change below 1 
indicates down-regulation. Data are presented as mean ± SEM. * p < 0.05. 
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Figure 4.17: Paired tissue miR-483-3p expression. Relative expression is expressed as 
fold change of cancer tissue versus normal colonic mucosa. Fold change above 1 
indicates up-regulation. Data are presented as mean ± SEM. ** p < 0.01. 
 
4.4.2   Validation of the panel of seven miRNAs in blood samples 
The validation study was conducted using 70 CRC and 32 healthy control samples. The 
blood RT-qPCR analysis revealed that the CT values for the panel of seven miRNAs and 
endogenous control were within the detectable limit of less than 36 (Figure 4.18). 
Significant up-regulations were detected in the levels of miR-193a-3p (p < 0.001), miR-
23a (p = 0.043), miR-23b (p = 0.045), miR-338-5p (p < 0.001) and miR-483-3p (p = 
0.010) using unpaired t-test. However, no significant differences were observed in the 
levels of miR-150 (p = 0.450) and miR-342-3p (p = 0.560). The bar charts of blood 
miR-150, miR-193a-3p, miR-23a, miR-23b, miR-338-5p, miR-342-3p and miR-483-3p 
expressions are illustrated in Figures 4.19 to 4.25. The basal fold change of the control 
group was set at 1. Hence, a fold change above 1 in the CRC group was determined as 
up-regulation while a fold change below 1 was determined as down-regulation. The 
miRNAs expression levels of each sample are tabulated in Appendix 8. 
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Figure 4.18: CT values of miRNAs and endogenous control in blood validation. Colour 
legend, black: miR-150; red: miR-193a-3p, orange: miR-23a; light blue: miR-23b, 
green: miR-338-5p; dark blue: miR-342-3p; purple: miR-483-3p; grey: RNU48. 
 
 
Figure 4.19: Blood miR-150 expression. Data are expressed as fold change of TNM 
stage versus control. The blood miR-150 expression was not statistically significant. 
Data are presented as mean ± SEM. 
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Figure 4.20: Blood miR-193a-3p expression. Data are expressed as fold change of TNM 
stage versus control. Fold change above 1 indicates up-regulation. Data are presented as 
mean ± SEM. ** p < 0.01. 
 
 
Figure 4.21: Blood miR-23a expression. Data are expressed as fold change of TNM 
stage versus control. Fold change above 1 indicates up-regulation. Data are presented as 
mean ± SEM. * p < 0.05. 
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Figure 4.22: Blood miR-23b expression. Data are expressed as fold change of TNM 
stage versus control. Fold change above 1 indicates up-regulation. Data are presented as 
mean ± SEM. * p < 0.05. 
 
 
Figure 4.23: Blood miR-338-5p expression. Data are expressed as fold change of TNM 
stage versus control. Fold change above 1 indicates up-regulation. Data are presented as 
mean ± SEM. ** p < 0.01. 
 
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
Control I-II III-IV
Bl
o
o
d 
m
iR
-
23
b 
ex
pr
es
sio
n
 
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
Control I-II III-IVB
lo
o
d 
m
iR
-
33
8-
5p
 
ex
pr
es
sio
n
 
* 
* 
** 
** 
Fold change         1.00          2.54 ± 0.50       1.86 ± 0.29
Fold change          1.00          2.23 ± 0.26       2.82 ± 0.34
 120 
 
 
Figure 4.24: Blood miR-342-3p expression. Data are expressed as fold change of TNM 
stage versus control. The blood miR-342-3p expression was not statistically significant. 
Data are presented as mean ± SEM. 
 
 
Figure 4.25: Blood miR-483-3p expression. Data are expressed as fold change of TNM 
stage versus control. Fold change above 1 indicates up-regulation. Data are presented as 
mean ± SEM. * p < 0.05. 
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4.5   Relationship between tissue and blood miRNAs 
The miR-193a-3p, miR-23a, miR-23b, miR-338-5p and miR-483-3p expressions were 
found to be significantly deregulated in both tissue and blood validation studies. The 
correlation between the tissue and blood miRNAs was investigated. The purpose is to 
provide a stronger confirmation that the deregulated miRNAs in the systemic circulation 
may serve as potential indicators of what is happening at the tissue level. Controlling for 
age, gender, race and staging, correlation analyses between tissue and blood RT-qPCR 
data for miR-193a-3p (r = 0.811; p < 0.001), miR-23a (r = 0.827; p < 0.001), miR-23b 
(r = 0.044; p = 0.819), miR-338-5p (r = 0.831; p < 0.001) and miR-483-3p (r = 0.373; p 
= 0.042) were conducted. The results indicated significant positive correlations in the 
levels of miR-193a-3p, miR-23a and miR-338-5p between the tissue and blood samples. 
The miR-23b expression was not significantly correlated while the miR-483-3p 
expression revealed weak correlation. Thus, miR-193a-3p, miR-23a and miR-338-5p 
were selected as the triple miRNA classifier in this study. Moreover, an increasing trend 
of expression was observed in these circulating blood miRNAs as the tumour 
progressed from stage I-II to stage III-IV when compared with the control group 
(Figures 4.20, 4.21 and 4.23). 
 
4.6   Diagnostic value of the triple miRNA classifier: miR-193a-3p, miR-23a 
and miR-338-5p in CRC 
The predictive performance of the individual blood miRNA and the triple miRNA 
classifier for defining CRC were demonstrated by multivariate logistic regression 
analysis (Table 4.5). The triple miRNA classifier of miR-193a-3p, miR-23a and miR-
338-5p gave the best performance and thus, suggested as a potential group of 
biomarkers in the detection of CRC. The optimal cut-off value for sensitivity and 
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specificity was determined based on the highest Youden’s Index in ROC curve analysis 
(Obuchowski, 2005). The triple miRNA classifier has a stronger differentiation power 
than individual or double combination of miRNAs. The classifier has an increased area 
under the ROC curve (AUC) of 0.887 (95% confidence interval [CI]: 0.821 - 0.953) 
with 80.0% sensitivity, 84.4% specificity and 83.3% accuracy, illustrating an improved 
diagnostic value of these triple combination of miRNAs (Figure 4.26).  
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Table 4.5: Multivariate logistic regression analysis of individual blood miRNA and triple miRNA classifier of miR-193a-3p, miR-23a and miR-338-5p. 
Statistical 
parameters 
miR-193a-3p miR-23a miR-338-5p miR-193a-3p + 
miR-23a 
miR-193a-3p + 
miR-338-5p 
miR-23a + miR-
338-5p 
miR-193a-3p + 
miR-23a + miR-
338-5p 
AUC 0.852 0.787 0.871 0.852 0.872 0.873 0.887 
95% CI 0.768 - 0.935 0.685 - 0.889 0.800 - 0.942 0.770 - 0.935 0.798 - 0.946 0.803 - 0.942 0.821 - 0.953 
Sensitivity (%) 100.0 94.3 81.4 74.3 94.3 81.4 80.0 
Specificity (%) 56.2 53.1 75.0 81.2 65.6 75.0 84.4 
Accuracy (%) 83.3 81.4 83.3 83.3 83.3 82.4 83.3 
Youden’s Indexa 0.562 0.474 0.564 0.555 0.599 0.564 0.644 
Cut-off value 0.346 0.502 0.640 0.745 0.474 0.636 0.728 
aYouden’s Index = sensitivity + specificity – 1 
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Figure 4.26: ROC curve analysis for the triple miRNA classifier of miR-193a-3p, miR-
23a and miR-338-5p. The triple miRNA classifier yielded an AUC of 0.887 (95% CI: 
0.821 - 0.953) with 80.0% sensitivity, 84.4% specificity and 83.3% accuracy.  
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4.7   Functional and miRNA:mRNA target validation studies  
The subsequent phase of the research was the investigation on the roles and targets of 
miR-193a-3p, miR-23a and miR-338-5p. Two CRC cell lines (SW480 and SW620) 
with same genetic background but different metastatic potential were utilised. The 
presence of the three miRNAs in both cell lines was verified via RT-qPCR, with CT 
values less than 36. The functional assays tested were cell viability, apoptosis, migration 
and invasion assays using miRNA mimics and inhibitors. Luciferase assays were 
performed for the validation of target mRNAs. The expression levels of target mRNAs 
and proteins in the CRC cell lines and clinical samples were assessed using RT-qPCR 
and Western blot.  
 
4.7.1   miR-193a-3p transfection  
4.7.1.1   Effect on cell viability rate following miR-193a-3p transfection  
Cell viability studies of SW480 and SW620 cells post-transfections (24 h, 48 h and 72 h) 
were performed using MTT assay. The transfection of miR-193a-3p mimic or miR-
193a-3p inhibitor in both cell lines did not significantly increase or decrease cell 
viability (p > 0.05) (Figure 4.27A, B). The cells were highly viable even after 72 h of 
transfection. 
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Figure 4.27: Cell viability of (A) SW480 and (B) SW620 cells following miR-193a-3p 
transfection. No statistical significance was observed (p > 0.05). Data are presented as 
mean ± SEM (n = 3).  
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4.7.1.2   Effect on apoptosis rate following miR-193a-3p transfection 
Apoptosis assay was conducted using Annexin V and PI double staining procedure. Cell 
proportions in live, dead and apoptotic stages were quantitated using Invitrogen Tali 
image-based cytometer (Table 4.6). A sample of the cell analysis report is shown in 
Appendix 9. Doxorubicin, a well-known apoptosis-inducing agent, was used as the 
positive control. It is capable of inducing DNA damage by intercalating and cross-
linking DNA double helix (Lüpertz et al., 2008). The miR-193a-3p mimic or miR-193a-
3p inhibitor transfection did not produce any significant effect to the relative apoptosis 
rate of SW480 and SW620 cells (p > 0.05) (Figure 4.28).  
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Table 4.6: Quantification of live, dead and apoptotic cells in SW480 and SW620 cells using Invitrogen Tali image-based cytometer (miR-193a-3p 
transfection). Data are presented as mean ± SEM (n = 3).  
Treatment SW480 SW620 
Live (%) Dead (%) Apoptotic (%) Live (%) Dead (%) Apoptotic (%) 
NTC 84.33 ± 0.33 10.33 ± 0.33 5.33 ± 0.33 84.00 ± 2.00 12.33 ± 1.76 3.67 ± 0.67 
Mock 87.00 ± 1.53 11.00 ± 0.00 2.00 ± 1.53 81.67 ± 0.67 16.00 ± 0.58 2.00 ± 0.00 
miR-193a-3p mimic 75.67 ± 0.33 22.00 ± 0.58 2.33 ± 0.88 79.67 ± 0.33 17.00 ± 2.00 3.33 ± 1.86 
Mimic NC 83.67 ± 0.88 13.00 ± 0.58 2.67 ± 0.33 78.33 ± 0.88 14.00 ± 0.58 7.33 ± 0.88 
miR-193a-3p inhibitor 84.67 ±1.33 14.00 ± 1.53 2.00 ± 0.58 77.33 ± 1.45 17.67 ± 0.33 5.00 ± 1.73 
Inhibitor NC 85.00 ± 1.53 11.67 ± 0.67 3.67 ± 1.20 78.67 ± 1.20 15.00 ± 0.58 6.00 ± 1.15 
Doxorubicin 54.33 ± 4.67 23.67 ± 0.88 22.33 ± 5.33 48.33 ± 4.84 27.00 ± 2.08 24.33 ± 2.91 
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Figure 4.28: Relative apoptosis rate of SW480 and SW620 cells following miR-193a-3p 
transfection. No statistical significance was determined (p > 0.05). Data are presented as 
mean ± SEM (n = 3). 
 
4.7.1.3   Effect on migration and invasion activity following miR-193a-3p 
transfection   
The migration and invasion potential of SW480 and SW620 cells was evaluated. 
Significant results were obtained from miR-193a-3p mimic and miR-193a-3p inhibitor 
transfections (p < 0.01). The relative migration activity was increased by 1.62 ± 0.06-
fold (SW480) and 1.78 ± 0.09-fold (SW620) in miR-193a-3p mimic-transfected cells 
and decreased by 0.52 ± 0.03-fold (SW480) and 0.45 ± 0.01-fold (SW620) in miR-
193a-3p inhibitor-transfected cells. On the contrary, the relative invasion activity was 
increased by 1.39 ± 0.07-fold (SW480) and 1.83 ± 0.05-fold (SW620) in miR-193a-3p 
mimic-transfected cells and decreased by 0.58 ± 0.01-fold (SW480) and 0.63 ± 0.01-
fold (SW620) in miR-193a-3p inhibitor-transfected cells. Normalised data are expressed 
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as relative value against the respective negative controls. Figure 4.29A-D shows the 
relative migration and invasion activity of SW480 and SW620 cells.  
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Figure 4.29: Relative migration and invasion activity of SW480 and SW620 cells 
following miR-193a-3p transfection. (A, B) Representative fields of migratory (left) and 
invasive (right) cells on plate insert. (C, D) Bar charts of relative migration and invasion 
activity. Data are presented as mean ± SEM (n = 3). ** p < 0.01. 
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4.7.1.4   Screening of miR-193a-3p targets 
miRNA target prediction was computed using miRWalk database, whereby an 
informative prediction was assumed when a putative target was concordantly identified 
by five of the most common algorithms (DIANA-MicroT, miRanda, miRWalk, 
MirTarget2/miRDB, PicTar, RNA22, RNAhybrid and TargetScan Human). The 
preliminary screening process yielded a long list of mRNAs. Comprehensive literature 
search on CRC relevant genes was conducted. Five highly cited review papers were 
used as the basis of the search (Markowitz & Bertagnolli, 2009; Schetter, Okayama, & 
Harris, 2012; Slaby et al., 2009; Søreide et al., 2009; Vermaat et al., 2012). Several 
putative targets of miR-193a-3p that have been found to be associated with CRC were 
obtained, namely, ACVR2B, AXIN2, CCND1, FAS, FOXO4, FZD4, FZD5, KRAS, 
MAPK1, PDGFRA, PTEN, SMAD4, SOS2 and TGFBR1 (Appendix 10). Among these, 
forkhead box O4 (FOXO4) gene was selected for further investigation, with the 
consideration of its role as a tumour suppressor and possible implication in cell 
migration and invasion.  
 
4.7.1.5   Construction of FOXO4 luciferase reporters  
The miRNA recognition site on the 3’-UTR of FOXO4 mRNA was predicted using 
TargetScan Human 6.2. The recognition site that revealed the highly conserved seed 
match was used in the cloning assay. 
FOXO4 (NM_005938.3) mRNA consists of 3365 bp. The length of the 3’-UTR is 1413 
bp. A fragment of the FOXO4 3’-UTR containing the recognition site for miR-193a-3p 
at nucleotide position 2192-2491 was cloned via GeneArt gene synthesis service 
(Invitrogen, Carlsbad, CA, USA) (Appendix 11). The corresponding site-directed 
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mutant containing the mutated seed sequence (5’-GGCCAGU-3’ to 5’-GCCGAUU-3’) 
was also constructed (Appendix 12). Each customised fragment was inclusive of the 
HindIII and SpeI restriction sites (312 bp). The predicted pairing region between miR-
193a-3p and FOXO4 mRNA is presented in Table 4.7. Two luciferase reporter 
constructs containing the wild-type FOXO4 3’-UTR fragment (Luc-FOXO4-wt) and the 
mutated FOXO4 3’-UTR fragment (Luc-FOXO4-mt) were generated by sub-cloning the 
respective gene fragments from the GeneArt pMA-T vectors (Figure 4.30A, B) into the 
pMIR-REPORT firefly luciferase reporter vector (Figure 4.31) at the HindIII and SpeI 
sites. A luciferase vector without FOXO4 3’-UTR (Luc-FOXO4-ctl) was used as the 
experimental control. All constructs were verified by DNA sequencing.  
 
Table 4.7: Conserved miR-193a-3p target site on human FOXO4 3’-UTR 
(NM_005938.3). FOXO4 3’-UTR length: 1413 bp. Seed match region at nucleotide 
position 444-450 is shown in bold italics. Mutations are marked with the symbol †. 
 
 
 
FOXO4 3’-UTR  
 
hsa-miR-193a-3p 
5'  ...UGCAGUGGCCCCUUAGGCCAGUG... 
                                                   |  |  |  |  |  |  |  
3'        UGACCCUGAAACAUCCGGUCAA  
Mutated FOXO4 3’-UTR  
 
hsa-miR-193a-3p 
5'  ...UGCAGUGGCCCCUUAGCCGAUUG ... 
                                                   |  † |  † | † |   
3'        UGACCCUGAAACAUCCGGUCAA  
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Figure 4.30: Images of customised GeneArt pMA-T vectors containing (A) FOXO4 3’-
UTR fragment and (B) mutated FOXO4 3’-UTR fragment. The pMA-T vectors were 
sub-cloned into the pMIR-REPORT firefly luciferase reporter vector at the HindIII and 
SpeI sites to generate the Luc-FOXO4-wt and Luc-FOXO4-mt constructs.  
 
 
Figure 4.31: Image of pMIR-REPORT firefly luciferase reporter vector. Gene fragment 
from the GeneArt pMA-T vector was sub-cloned into the pMIR-REPORT firefly 
luciferase vector at the HindIII and SpeI sites.  
(Image source: Invitrogen, Carlsbad, CA, USA) 
 
B A 
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4.7.1.6   miR-193a-3p:FOXO4 target validation study  
The functional interaction between miR-193a-3p and FOXO4 3’-UTR was investigated 
via luciferase assay. Co-transfection of SW480 cells with Luc-FOXO4-wt and miR-
193a-3p mimic has resulted in a significant down-regulation of luciferase activity (0.77 
± 0.06-fold; p = 0.005) with respect to the Luc-FOXO4-ctl while co-transfection with 
Luc-FOXO4-mt and miR-193a-3p mimic has resulted in a significant up-regulation of 
luciferase activity (1.10 ± 0.04-fold; p = 0.008) when compared to the Luc-FOXO4-wt 
(Figure 4.32). No significant differences were observed following co-transfections of 
Luc-FOXO4-ctl, Luc-FOXO4-wt or Luc-FOXO4-mt with miR-193a-3p inhibitor (p > 
0.05). Mutagenesis at the seed match region of FOXO4 3’-UTR has successfully 
attenuated the miR-193a-3p-induced decrease of luciferase activity. Therefore, miR-
193a-3p could modulate the expression of FOXO4 via the regulatory element exhibited 
in the 3’-UTR region.  
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Figure 4.32: Relative luciferase activity following co-transfection of FOXO4 luciferase 
reporters and miR-193a-3p into SW480 cells. Luminescence values obtained from the 
transfected cells were background-subtracted with the non-transfected cells. 
Firefly/Renilla luciferase activities were expressed as relative value against the 
respective negative controls. Functional interaction between Luc-FOXO4-wt and miR-
193a-3p mimic was depicted via the down-regulation of luciferase activity with respect 
to Luc-FOXO4-ctl. Restoration of luciferase activity was observed in the co-
transfection of Luc-FOXO4-mt and miR-193a-3p mimic with respect to Luc-FOXO4-
wt. Fold change below 1 indicates down-regulation. Data are presented as mean ± SEM 
(n = 3). ** p < 0.01. 
 
4.7.1.7   Modulation of FOXO4 expression in SW480 and SW620 cell lines 
The CRC cell lines studied were the non-metastatic SW480 and the metastatic SW620. 
In the RT-qPCR experiment for miRNA, RNU48 was used as the endogenous control. 
miRNA inhibitor positive control that targets the endogenous miR-16 was included. The 
transfection procedure was a success as the miR-16 level showed significant down-
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regulation in both SW480 (0.06 ± 0.02-fold; p = 0.012) and SW620 (0.04 ± 0.01-fold; p 
= 0.008) cells. In the RT-qPCR experiment for mRNA, β-actin was used as the 
endogenous control. miRNA mimic positive control that targets the 3’-UTR of the 
housekeeping GAPDH gene was included. The GAPDH level revealed significant 
down-regulation in both SW480 (0.16 ± 0.01-fold; p = 0.021) and SW620 (0.18 ± 0.03-
fold; p = 0.013) cells.  
Following the transfection with miR-193a-3p mimic or inhibitor (Table 4.8), monitoring 
of FOXO4 mRNA and FOXO4 protein expression levels was conducted via RT-qPCR 
and Western blot, respectively. As depicted in Figure 4.33, FOXO4 mRNA expression 
was significantly down-regulated in SW480 (0.32 ± 0.07-fold; p = 0.006) and SW620 
(0.49 ± 0.11-fold; p = 0.016) cells transfected with miR-193a-3p mimic and 
significantly up-regulated in SW480 (7.76 ± 1.26-fold; p = 0.004) and SW620 (3.63 ± 
0.57-fold; p < 0.001) cells transfected with miR-193a-3p inhibitor. Alteration in the 
mRNA expression was reflected in the protein expression as well. The Western blot 
analysis showed that the level of FOXO4 protein was significantly decreased by 0.72 ± 
0.07-fold; p = 0.047 (SW480) and 0.73 ± 0.07-fold; p = 0.049 (SW620) following miR-
193a-3p mimic transfection and significantly increased by 1.77 ± 0.16-fold; p = 0.048 
(SW480) and 1.45 ± 0.05-fold; p = 0.042 (SW620) following miR-193a-3p inhibitor 
transfection (Figure 4.34A, B). The transfection of miR-193a-3p inhibitor has resulted 
in a relatively higher induction of FOXO4 mRNA and FOXO4 protein in the SW480 
cells when compared to the SW620 cells.  
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Table 4.8: Relative miR-193a-3p expression in SW480 and SW620 cells following 
miR-193a-3p mimic or miR-193a-3p inhibitor transfection. Values are fold changes 
expressed as relative value against the respective negative controls. Fold change above 
1 indicates up-regulation while fold change below 1 indicates down-regulation. Data are 
presented as mean ± SEM (n = 3). 
Treatment Relative miR-193a-3p expression 
 SW480 SW620 
miR-193a-3p  mimic 211.63 ± 41.79 177.53 ± 55.93 
miR-193a-3p  inhibitor 0.05 ± 0.01 0.18 ± 0.06 
 
 
 
Figure 4.33: Relative FOXO4 mRNA expression in SW480 and SW620 cells following 
miR-193a-3p transfection. FOXO4 expression was down-regulated in miR-193a-3p 
mimic-transfected cells and up-regulated in miR-193a-3p inhibitor-transfected cells. 
Data are presented as mean ± SEM (n = 3). * p < 0.05; ** p < 0.01. 
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Figure 4.34: Relative FOXO4 protein expression in SW480 and SW620 cells following 
miR-193a-3p transfection. (A) FOXO4 expression was down-regulated in miR-193a-3p 
mimic-transfected cells and up-regulated in miR-193a-3p inhibitor-transfected cells. 
Data are presented as mean ± SEM (n = 3). * p < 0.05. (B) Representative blots of 
FOXO4 protein expression in SW480 and SW620 cells. β-actin was used as the loading 
control.  
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4.7.1.8   FOXO4 expression in clinical CRC samples 
The expression of FOXO4 in CRC was evaluated using 102 whole blood samples (70 
patients; 32 healthy controls) and 30 paired cancer tissues. β-actin was chosen as the 
endogenous control in RT-qPCR analysis. β-actin was also used as the loading control 
in Western blot analysis. The presence of FOXO4 and β-actin mRNAs in the clinical 
samples was confirmed by RT-qPCR (Figure 4.35).  
 
 
Figure 4.35: CT values of blood and tissue FOXO4 and β-actin. Colour legend, black: 
blood FOXO4; red: blood β-actin, green: tissue FOXO4; blue: tissue β-actin. 
 
No significant differences were observed in the levels of β-actin mRNA (p = 0.992 in 
blood; p = 0.065 in tissue) and β-actin protein (p = 0.069 in tissue) between the cancer 
and normal/control samples. In contrast, FOXO4 mRNA expression was found to be 
significantly down-regulated in the blood (p = 0.017) and tissue (p < 0.001) samples 
obtained from CRC patients. Pearson’s correlation between the blood and tissue FOXO4 
levels was 0.549 (p = 0.002). A decreasing trend of expression was observed as the 
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tumour progressed from stage I-II to stage III-IV (Figures 4.36 and 4.37). The FOXO4 
mRNA expression of each sample is shown in Appendices 7 and 8. In addition, FOXO4 
protein expression was determined to be lower in the cancer tissue when compared with 
the normal colonic mucosa (p < 0.001) (Figure 4.38A, B). The FOXO4 protein 
expression of each sample is shown in Appendix 13.  
 
  
Figure 4.36: Blood FOXO4 mRNA expression. The basal fold change of the control 
group was set at 1. Data are expressed as fold change of TNM stage versus control. Fold 
change below 1 indicates down-regulation. Data are presented as mean ± SEM. * p < 
0.05. 
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Figure 4.37: Paired tissue FOXO4 mRNA expression. Relative expression is expressed 
as fold change of cancer tissue versus normal colonic mucosa. Fold change below 1 
indicates down-regulation. Data are presented as mean ± SEM. ** p < 0.01. 
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Figure 4.38: Paired tissue FOXO4 protein expression. (A) Relative expression is 
expressed as fold change of cancer tissue versus normal colonic mucosa. Fold change 
below 1 indicates down-regulation. Data are presented as mean ± SEM. **p < 0.01. (B) 
Representative blots of FOXO4 protein expression in stage I-II and stage III-IV paired 
cancer tissues (N: normal colonic mucosa; C: cancer tissue). β-actin was used as the 
loading control.  
 
Next, the relationship between miR-193a-3p and FOXO4 mRNA or FOXO4 protein 
levels was analysed (Figure 4.39A-C). However, only tissue miR-193a-3p and tissue 
FOXO4 mRNA showed significant negative correlation (r = -0.384; p = 0.036). No 
significant negative correlation was detected between blood miR-193a-3p and blood 
FOXO4 mRNA (r = -0.138; p = 0.168) or between tissue miR-193a-3p and tissue 
FOXO4 protein (r = -0.094; p = 0.620). The expression between tissue FOXO4 mRNA 
and FOXO4 protein was also found to be insignificantly correlated (r = 0.218; p = 
0.248). 
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Figure 4.39: Correlation between miR-193a-3p and FOXO4 mRNA or FOXO4 protein. 
(A) Blood miR-193a-3p and blood FOXO4 mRNA. (B) Tissue miR-193a-3p and tissue 
FOXO4 mRNA. (C) Tissue miR-193a-3p and tissue FOXO4 protein. * p < 0.05. 
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4.7.2   miR-23a transfection 
4.7.2.1   Effect on cell viability rate following miR-23a transfection 
Cell viability studies of SW480 and SW620 cells post-transfections (24 h, 48 h and 72 h) 
were conducted using MTT assay. No significant difference was observed at 24 h (p > 
0.05). The cell viability of SW480 cells was significantly increased (118.08 ± 3.51%; p 
= 0.003) and decreased (67.94 ± 1.77%; p < 0.001) at 48 h following miR-23a mimic 
and miR-23a inhibitor transfections, respectively (Figure 4.40A). The cell viability of 
SW620 cells was also significantly increased (121.46 ± 2.70%; p = 0.002) and 
decreased (70.22 ± 2.56%; p < 0.001) at 48 h following miR-23a mimic and miR-23a 
inhibitor transfections, respectively (Figure 4.40B). At 72 h, only miR-23a inhibitor 
transfection revealed significant reduction of cell viability in both SW480 (67.85 ± 
0.72%; p < 0.001) and SW620 (71.24 ± 4.26%; p = 0.003) cells. The miR-23a mimic 
transfection has no effect on cell viability after 72 h. The cells may have entered the 
stationary phase due to prolonged transfection, whereby cell proliferation is greatly 
reduced and further increase in cell viability is no longer possible (Davis, 2011). The 
optimal transfection period in the cell viability assay was 48 h. 
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Figure 4.40: Cell viability of (A) SW480 and (B) SW620 cells following miR-23a 
transfection. The miR-23a inhibitor transfection has successfully reduced cell viability 
at 48 h and 72 h. Data are presented as mean ± SEM (n = 3). ** p < 0.01. 
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4.7.2.2   Effect on apoptosis rate following miR-23a transfection 
Apoptosis assay was conducted using Annexin V and PI double staining procedure. Cell 
populations in live, dead and apoptotic stages were quantitated using Invitrogen Tali 
image-based cytometer (Table 4.9). The cytometric analysis demonstrated low 
percentages of apoptotic cells in the SW480 and SW620 cells following miR-23a mimic 
transfection and high percentages of apoptotic cells following miR-23a inhibitor 
transfection. Moreover, signs of apoptosis such as distorted cell morphology, membrane 
blebbling and cell lysis were noted under the microscope. The relative apoptosis rate 
was then calculated and the transfection of miR-23a inhibitor resulted in a significantly 
higher proportion of apoptotic cells in both SW480 (8.11 ± 1.93-fold; p < 0.001) and 
SW620 cells (3.24 ± 0.65-fold; p = 0.002) when compared to the miRNA inhibitor NC 
(Figure 4.41).  
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Table 4.9: Quantification of live, dead and apoptotic cells in SW480 and SW620 cells using Invitrogen Tali image-based cytometer (miR-23a 
transfection). Data are presented as mean ± SEM (n = 3).  
Treatment SW480 SW620 
Live (%) Dead (%) Apoptotic (%) Live (%) Dead (%) Apoptotic (%) 
NTC 84.33 ± 0.33 10.33 ± 0.33 5.33 ± 0.33 84.00 ± 2.00 12.33 ± 1.76 3.67 ± 0.67 
Mock 87.00 ± 1.53 11.00 ± 0.00 2.00 ± 1.53 81.67 ± 0.67 16.00 ± 0.58 2.00 ± 0.00 
miR-23a mimic 85.33 ± 1.20 13.00 ± 1.00 1.33 ± 0.88 85.00 ± 1.15 10.00 ± 0.00 5.00 ± 1.15 
Mimic NC 83.67 ± 0.88 13.00 ± 0.58 2.67 ± 0.33 78.33 ± 0.88 14.00 ± 0.58 7.33 ± 0.88 
miR-23a inhibitor 65.67 ±1.45 9.00 ± 1.00 25.33 ± 1.86 68.00 ± 1.73 13.33 ± 0.67 18.33 ± 2.60 
Inhibitor NC 85.00 ± 1.53 11.67 ± 0.67 3.67 ± 1.20 78.67 ± 1.20 15.00 ± 0.58 6.00 ± 1.15 
Doxorubicin 54.33 ± 4.67 23.67 ± 0.88 22.33 ± 5.33 48.33 ± 4.84 27.00 ± 2.08 24.33 ± 2.91 
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Figure 4.41: Relative apoptosis rate of SW480 and SW620 cells following miR-23a 
transfection. The miR-23a inhibitor transfection has successfully elevated cell 
apoptosis. Data are presented as mean ± SEM (n = 3). ** p < 0.01. 
 
4.7.2.3   Effect on caspase 3/7 activity following miR-23a transfection 
Caspase 3/7 activation analysis was performed to further elucidate the apoptotic role of 
miR-23a in CRC. The miR-23a inhibitor transfection induced significant activation of 
caspase 3/7 activity in both SW480 (198.42 ± 20.57%; p = 0.003) and SW620 (183.27 ± 
7.60%; p = 0.004) cells (Figure 4.42). However, only SW480 cells showed significant 
reduction of caspase 3/7 activity (84.67 ± 4.12%; p = 0.048) following miR-23a mimic 
transfection. 
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Figure 4.42: Caspase 3/7 activity of SW480 and SW620 cells following miR-23a 
transfection. The miR-23a inhibitor transfection has successfully increased caspase 3/7 
activity. Data are presented as mean ± SEM (n = 3). * p < 0.05; ** p < 0.01.  
 
4.7.2.4   Effect on migration and invasion activity following miR-23a transfection 
The migratory and invasive ability of CRC cells was determined. However, no 
significant difference was observed in the relative migration and invasion activity of 
SW480 and SW620 cells following miR-23a transfection (p > 0.05) (Figure 4.43A-D).  
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Figure 4.43: Relative migration and invasion activity of SW480 and SW620 cells 
following miR-23a transfection. (A, B) Representative fields of migratory (left) and 
invasive (right) cells on plate insert. (C, D) Bar charts of relative migration and invasion 
activity. No statistical significance was determined (p > 0.05). Data are presented as 
mean ± SEM (n = 3).  
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4.7.2.5   Screening of miR-23a targets 
Similarly to section 4.7.1.4, miRNA target prediction for miR-23a was computed using 
miRWalk database. The initial screening process yielded a long list of mRNAs. Based 
on the comprehensive literature search on CRC relevant genes, several putative targets 
of miR-23a that have been found to be associated with CRC were determined, namely, 
ACVR1C, ACVR2A, ACVR2B, APAF1, CASP7, CCND1, CREBBP, FAS, FZD4, FZD5, 
FZD7, ID4, PIK3R3, PTEN, RBL2, SMAD4, SOS1 and TGFBR2 (Appendix 14). 
Among these, apoptotic peptidase activating factor 1 (APAF1) gene was selected for 
further investigation, with the consideration of its role in cell apoptosis.  
 
4.7.2.6   Construction of APAF1 luciferase reporters 
Cloning of the APAF1 3’-UTR fragment was performed to verify a putative target site 
of miR-23a. The highly conserved site based on the TargetScan Human 6.2 prediction 
was chosen.  
APAF1 (NM_013229.2) mRNA consists of 7171 bp. The length of the 3’-UTR is 2836 
bp. A fragment of the APAF1 3’-UTR containing the recognition site for miR-23a at 
nucleotide position 5615-5914 was constructed via GeneArt gene synthesis service 
(Invitrogen, Carlsbad, CA, USA) (Appendix 15). The corresponding site-directed 
mutant containing the mutated seed sequence (5’-AAUGUGAA-3’ to 5’-AUUCUGCA-
3’) was also generated (Appendix 16). Each customised fragment was inclusive of the 
HindIII and SpeI restriction sites (312 bp). The predicted pairing region between miR-
23a and APAF1 mRNA is presented in Table 4.10. The wild-type and mutated APAF1 
3’-UTR fragments (Figure 4.44A, B) were cloned into the pMIR-REPORT firefly 
luciferase reporter vector (Figure 4.31) at the HindIII and SpeI sites and designated as 
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Luc-APAF1-wt and Luc-APAF1-mt, respectively. A luciferase vector without APAF1 
3’-UTR (Luc-APAF1-ctl) was used as the experimental control. All constructs were 
verified by DNA sequencing.   
 
Table 4.10: Conserved miR-23a target site on human APAF1 3’-UTR (NM_013229.2). 
APAF1 3’-UTR length: 2836 bp. Seed match region at nucleotide position 1474-1481 is 
shown in bold italics. Mutations are marked with the symbol †. 
 
 
 
Figure 4.44: Images of customised GeneArt pMA-T vectors containing (A) APAF1 3’-
UTR fragment and (B) mutated APAF1 3’-UTR fragment. The pMA-T vectors were 
sub-cloned into the pMIR-REPORT firefly luciferase reporter vector at the HindIII and 
SpeI sites to generate the Luc-APAF1-wt and Luc-APAF1-mt constructs.  
APAF1 3’-UTR  
 
hsa-miR-23a 
5'  ...AAGAUUUUUCUAAGAAAUGUGAA... 
                                                    |  |  |  |  |  |  |  
3'           CCUUUAGGGACCGUUACACUA  
Mutated APAF1 3’-UTR  
 
hsa-miR-23a 
5'  ...AAGAUUUUUCUAAGAAUUCUGCA... 
                                                    | † |  † |  |  †   
3'           CCUUUAGGGACCGUUACACUA  
A B 
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4.7.2.7   miR-23a:APAF1 target validation study  
The functional interaction between miR-23a and APAF1 3’-UTR was determined using 
luciferase assay. Co-transfection of SW480 cells with Luc-APAF1-wt and miR-23a 
mimic has resulted in a significant down-regulation of luciferase activity (0.72 ± 0.05-
fold; p = 0.001) with respect to the Luc-APAF1-ctl while co-transfection with Luc-
APAF1-mt and miR-23a mimic has resulted in a significant up-regulation of luciferase 
activity (1.11 ± 0.04-fold; p = 0.003) when compared to the Luc-APAF1-wt (Figure 
4.45). No significant differences were observed following co-transfections of Luc-
APAF1-ctl, Luc-APAF1-wt or Luc-APAF1-mt with miR-23a inhibitor (p > 0.05). 
Mutation of the miR-23a target site in the APAF1 3’-UTR has successfully weakened 
the miR-23a-induced decrease of luciferase activity. Thus, miR-23a could influence the 
regulation of APAF1 via the regulatory element present in the 3’-UTR region.  
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Figure 4.45: Relative luciferase activity following co-transfection of APAF1 luciferase 
reporters and miR-23a into SW480 cells. Luminescence values obtained from the 
transfected cells were background-subtracted with the non-transfected cells. 
Firefly/Renilla luciferase activities were expressed as relative value against the 
respective negative controls. Functional interaction between Luc-APAF1-wt and miR-
23a mimic was depicted via the down-regulation of luciferase activity with respect to 
Luc-APAF1-ctl. Restoration of luciferase activity was observed in the co-transfection of 
Luc-APAF1-mt and miR-23a mimic with respect to Luc-APAF1-wt. Fold change below 
1 indicates down-regulation. Data are presented as mean ± SEM (n = 3). ** p < 0.01. 
 
4.7.2.8   Modulation of APAF1 expression in SW480 and SW620 cell lines 
Following the transfection with miR-23a mimic or inhibitor (Table 4.11), monitoring of 
APAF1 mRNA and APAF1 protein expression levels were conducted via RT-qPCR and 
Western blot, respectively. As depicted in Figure 4.46, APAF1 mRNA expression was 
significantly down-regulated in SW480 (0.43 ± 0.11-fold; p = 0.015) and SW620 (0.62 
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± 0.11-fold; p = 0.048) cells transfected with miR-23a mimic and significantly up-
regulated in SW480 (8.42 ± 1.99-fold; p = 0.041) and SW620 (3.24 ± 0.49-fold; p = 
0.018) cells transfected with miR-23a inhibitor. Alteration in the mRNA expression was 
reflected in the protein expression as well. The Western blot analysis showed that the 
level of APAF1 protein was significantly decreased by 0.51 ± 0.08-fold; p = 0.006 
(SW480) and 0.46 ± 0.17-fold; p = 0.033 (SW620) following miR-23a mimic 
transfection and significantly increased by 1.76 ± 0.28-fold; p = 0.043 (SW480) and 
1.60 ± 0.22-fold; p = 0.049 (SW620) following miR-23a inhibitor transfection (Figure 
4.47A, B). The transfection of miR-23a inhibitor has resulted in a relatively higher 
induction of APAF1 mRNA and APAF1 protein in the non-metastatic SW480 cells 
when compared to the metastatic SW620 cells.  
 
Table 4.11: Relative miR-23a expression in SW480 and SW620 cells following miR-
23a mimic or miR-23a inhibitor transfection. Values are fold changes expressed as 
relative value against the respective negative controls. Fold change above 1 indicates 
up-regulation while fold change below 1 indicates down-regulation. Data are presented 
as mean ± SEM (n = 3). 
Treatment Relative miR-23a expression 
 SW480 SW620 
miR-23a mimic 285.17 ± 50.11 234.59 ± 8.98 
miR-23a inhibitor 0.03 ± 0.003 0.04 ± 0.005 
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Figure 4.46: Relative APAF1 mRNA expression in SW480 and SW620 cells following 
miR-23a transfection. APAF1 expression was down-regulated in miR-23a mimic-
transfected cells and up-regulated in miR-23a inhibitor-transfected cells. Data are 
presented as mean ± SEM (n = 3). * p < 0.05. 
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Figure 4.47: Relative APAF1 protein expression in SW480 and SW620 cells following 
miR-23a transfection. (A) APAF1 expression was down-regulated in miR-193a-3p 
mimic-transfected cells and up-regulated in miR-23a inhibitor-transfected cells. Data 
are presented as mean ± SEM (n = 3). * p < 0.05. (B) Representative blots of APAF1 
protein expression in SW480 and SW620 cells. β-actin was used as the loading control. 
 
4.7.2.9   APAF1 expression in clinical CRC samples 
Likewise in section 4.7.1.8, the expression of APAF1 in CRC was evaluated using 102 
whole blood samples (70 patients; 32 healthy controls) and 30 paired cancer tissues. The 
presence of APAF1 and β-actin mRNAs in the clinical samples was confirmed by RT-
qPCR (Figure 4.48).  
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Figure 4.48: CT values of blood and tissue APAF1 and β-actin. Colour legend, black: 
blood APAF1; red: blood β-actin, green: tissue APAF1; blue: tissue β-actin. 
 
No significant differences were observed in the levels of β-actin mRNA (p = 0.992 in 
blood; p = 0.065 in tissue) and β-actin protein (p = 0.069 in tissue) between the cancer 
and normal/control samples. In contrast, APAF1 mRNA expression was determined to 
be significantly down-regulated in the blood (p = 0.002) and tissue (p < 0.001) samples 
obtained from CRC patients. Pearson’s correlation between the blood and tissue APAF1 
levels was 0.378 (p = 0.039). A decreasing trend of expression was observed as the 
tumour progressed from stage I-II to stage III-IV (Figures 4.49 and 4.50). The APAF1 
mRNA expression of each sample is shown in Appendices 7 and 8. Besides that, 
APAF1 protein expression was determined to be lower in the cancer tissue when 
compared with the normal colonic mucosa (p < 0.001) (Figure 4.51A, B). The APAF1 
protein expression of each sample is shown in Appendix 13. 
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Figure 4.49: Blood APAF1 mRNA expression. The basal fold change of the control 
group was set at 1. Data are expressed as fold change of TNM stage versus control. Fold 
change below 1 indicates down-regulation. Data are presented as mean ± SEM. ** p < 
0.01. 
 
 
Figure 4.50: Paired tissue APAF1 mRNA expression. Relative expression is expressed 
as fold change of cancer tissue versus normal colonic mucosa. Fold change below 1 
indicates down-regulation. Data are presented as mean ± SEM. ** p < 0.01. 
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Figure 4.51: Paired tissue APAF1 protein expression. (A) Relative expression is 
expressed as fold change of cancer tissue versus normal colonic mucosa. Fold change 
below 1 indicates down-regulation. Data are presented as mean ± SEM. ** p < 0.01. (B) 
Representative blots of APAF1 protein expression in stage I-II and stage III-IV paired 
cancer tissues (N: normal colonic mucosa; C: cancer tissue). β-actin was used as the 
loading control. 
 
Next, the relationship between miR-23a and APAF1 mRNA or APAF1 protein levels 
was analysed (Figure 4.52A-C). Although significant negative correlation was not 
detected between miR-23a and APAF1 mRNA (r = -0.135; p = 0.177) in the blood 
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samples, miR-23a was found to be inversely correlated with APAF1 mRNA (r = -0.364; 
p = 0.048) and APAF1 protein (r = -0.443; p = 0.014) in the paired tissue samples. 
Moreover, the expression between tissue APAF1 mRNA and APAF1 protein was also 
determined to be significantly correlated (r = 0.372; p = 0.043).  
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Figure 4.52: Correlation between miR-23a and APAF1 mRNA or APAF1 protein. (A) 
Blood miR-23a and blood APAF1 mRNA. (B) Tissue miR-23a and tissue APAF1 
mRNA. (C) Tissue miR-23a and tissue APAF1 protein. * p < 0.05. 
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4.7.3   miR-338-5p transfection 
4.7.3.1   Effect on cell viability rate following miR-338-5p transfection 
The transfection of miR-338-5p mimic or miR-338-5p inhibitor in SW480 and SW620 
cells did not significantly increase or decrease cell viability (p > 0.05) (Figure 4.53).  
 
 
 
Figure 4.53: Cell viability of (A) SW480 and (B) SW620 cells following miR-338-5p 
transfection. No statistical significance was observed (p > 0.05). Data are presented as 
mean ± SEM (n = 3).  
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4.7.3.2   Effect on apoptosis rate following miR-338-5p transfection 
Determination of cell apoptosis following miR-338-5p transfection was conducted. Cell populations in live, dead and apoptotic stages were quantitated 
using Invitrogen Tali image-based cytometer (Table 4.12). The relative apoptosis rate of SW480 and SW620 cells following miR-338-5p mimic or 
miR-338-5p inhibitor transfection was not statistically significant (p > 0.05) (Figure 4.54).  
 
Table 4.12: Quantification of live, dead and apoptotic cells in SW480 and SW620 cells using Invitrogen Tali image-based cytometer (miR-338-5p 
transfection). Data are presented as mean ± SEM (n = 3).  
Treatment SW480 SW620 
Live (%) Dead (%) Apoptotic (%) Live (%) Dead (%) Apoptotic (%) 
NTC 84.33 ± 0.33 10.33 ± 0.33 5.33 ± 0.33 84.00 ± 2.00 12.33 ± 1.76 3.67 ± 0.67 
Mock 87.00 ± 1.53 11.00 ± 0.00 2.00 ± 1.53 81.67 ± 0.67 16.00 ± 0.58 2.00 ± 0.00 
miR-338-5p mimic 85.00 ±0.58 13.00 ± 0.58 1.67 ± 0.67 71.00 ± 2.65 16.33 ± 2.40 12.33 ± 0.33 
Mimic NC 83.67 ± 0.88 13.00 ± 0.58 2.67 ± 0.33 78.33 ± 0.88 14.00 ± 0.58 7.33 ± 0.88 
miR-338-5p inhibitor 85.33 ±2.19 11.33 ± 1.45 3.33 ± 1.20 75.67 ± 0.67 18.00 ± 3.06 6.33 ± 2.67 
Inhibitor NC 85.00 ± 1.53 11.67 ± 0.67 3.67 ± 1.20 78.67 ± 1.20 15.00 ± 0.58 6.00 ± 1.15 
Doxorubicin 54.33 ± 4.67 23.67 ± 0.88 22.33 ± 5.33 48.33 ± 4.84 27.00 ± 2.08 24.33 ± 2.91 
 169 
 
 
Figure 4.54: Relative apoptosis rate of SW480 and SW620 cells following miR-338-5p 
transfection. No statistical significance was determined (p > 0.05). Data are presented as 
mean ± SEM (n = 3). 
 
4.7.3.3   Effect on migration and invasion activity following miR-338-5p 
transfection 
The transfection of miR-338-5p mimic or miR-338-5p inhibitor in SW480 and SW620 
cells did not significantly increase or decrease cell migration and invasion activity (p > 
0.05) (Figure 4.55A-D).  
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Figure 4.55: Relative migration and invasion activity of SW480 and SW620 cells 
following miR-338-5p transfection. (A, B) Representative fields of migratory (left) and 
invasive (right) cells on plate insert. (C, D) Bar charts of relative migration and invasion 
activity. No statistical significance was determined (p > 0.05). Data are presented as 
mean ± SEM (n = 3).  
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4.7.3.4   Screening of miR-338-5p targets 
Despite the insignificant findings from the functional assays, in silico analysis was still 
being carried out to identify the possible targets of miR-338-5p. Several putative gene 
targets include ACVR2A, APPL1, CCND1, CREBBP, EP300, FZD7, ID1, ID4, KRAS, 
MAPK1, MET, PDGFRA, PTEN, RBL2, RBX1, SMAD4, SMAD5, SOS1, SOS2 and 
TGFBR1 (Appendix 17). Other functional experiments are required to further elucidate 
the role of miR-338-5p in CRC. 
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CHAPTER 5  
DISCUSSION 
 
5.1   Identification of differentially expressed miRNAs in CRC 
5.1.1   Quality and integrity of extracted total RNA 
The tissue and blood samples collected in this study were preserved in Ambion 
RNAlater reagent. Samples stored in RNAlater are protected from RNases and 
compatible with most RNA isolation procedures (Mutter et al., 2004). Samples 
preserved in this manner could be stored for extended periods at -80°C. As described in 
section 4.2, the extracted total RNA samples were deemed suitable for miRNA 
microarray and RT-qPCR assays. The samples were confirmed to be of high quality and 
integrity. 
 
5.1.2   Marker discovery by miRNA microarray 
The miRNA microarray is a high-throughput assay capable of screening the expression 
of thousands of miRNAs in a single experiment. The platform for Affymetrix GeneChip 
miRNA array used in this study is based on an enzymatic-labelling approach involving 
poly-adenosine tailling of the miRNA followed by ligation of a biotinylated signal 
molecule. The technology works on the basis of nucleic acid hybridisation between the 
target miRNAs and their corresponding complementary probes. The present study was 
designed to investigate the association between tissue and blood miRNA expression 
levels in CRC. Two independent miRNA profiling studies of tissue and blood samples 
were conducted. The tissue array revealed a panel of 72 differentially regulated 
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miRNAs (Table 4.3) while the blood array revealed a panel of 24 differentially 
regulated miRNAs (Table 4.4). The microarray data reported in this study are in 
accordance with the MIAME guidelines, which describe the minimum information for 
reporting microarray-based gene expression data (Brazma et al., 2001). The miRNAs 
that were concurrently expressed in the tissue and blood arrays were selected for further 
validation, i.e. miR-150, miR-193a-3p, miR-23a, miR-23b, miR-338-5p, miR-342-3p 
and miR-483-3p (Figure 4.9). This selection technique was proposed as a better method 
for marker validation, as compared to the classical procedure of selecting the highly 
expressed genes (Detours, Dumont, Bersini, & Maenhaut, 2003).   
The Affymetrix GeneChip miRNA array platform has been employed by many research 
groups in the identification of miRNA biomarkers in cancer, in particularly CRC 
(Ahmed et al., 2012; Godfrey et al., 2013; Lajer et al., 2011; Piepoli et al., 2012). 
Although the differentially expressed miRNAs generated from multiple studies could be 
versatile, the presence of overlapping miRNAs has affirmed the reliability of the tissue 
and blood miRNA arrays data obtained in this study. Moreover, the reproducibility of 
certain miRNAs may provide valuable insights into their involvement in the 
carcinogenesis of CRC. For instance, a total of 17 miRNAs, namely, miR-10b, miR-
1246, miR-138, miR-139-5p, miR-140-3p, miR-149, miR-182, miR-195, miR-21*, 
miR-224, miR-28-3p, miR-342-3p, miR-378, miR-422a, miR-429, miR-503 and miR-
99a identified in the present tissue array, have been found to overlap with that of the 
tissue array performed by Piepoli et al. (2012). Moreover, the expression levels of miR-
105, miR-1247, miR-139-5p, miR-195, miR-378, miR-378c, miR-383, miR-422a, miR-
483-3p, miR-552 and miR-96 identified in the present tissue array, have been shown to 
be in agreement with those reported by Hamfjord et al. (2012). A recent miRNA 
profiling study by Perilli et al. (2014) has also revealed an overlap of miR-10b, miR-
138, miR-150, miR-20a, miR-203, miR-21*, miR-215, miR-30a and miR-30a* in CRC 
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tissue. On the other hand, the first study that reported the applicability of the Affymetrix 
GeneChip miRNA array platform for blood-based miRNA profiling in CRC was 
conducted by Ahmed et al. (2012). miR-150, which was discovered to be down-
regulated in the present blood array, was also found to be significantly down-regulated 
in their study.  
Tissue-based miRNA profiling is known to provide a relatively sensitive and specific 
representation of miRNA deregulation in cancer (Callari et al., 2012; Piepoli et al., 
2012). Although blood-based miRNA profiling is still far behind the advancement in 
tissue-based miRNA profiling, it offers the potential for early, non-invasive disease 
detection (Ahmed et al., 2012). Circulating miRNAs have recently emerged as 
candidate biomarkers for many diseases (Häusler et al., 2010; Z. Huang et al., 2010; 
Karolina et al., 2011; Schrauder et al., 2012; Sepramaniam et al., 2014). The circulating 
miRNAs are generally Ago-bound and protected from endogenous RNases, which 
enable them to serve as stable blood-based biomarkers (Kosaka, Iguchi, & Ochiya, 2010; 
Turchinovich, Weiz, Langheinz, & Burwinkel, 2011).  
Tumour-derived miRNAs have been identified in plasma, serum and whole blood. The 
first discovery of tumour-derived miRNAs in plasma was done by Mitchell et al. (2008) 
when they identified that plasma miR-629* and miR-660 could be used to differentiate 
xenografted mice with prostate cancer from the controls. On the other hand, the first 
serum miRNA biomarker discovered was miR-21, when Lawrie and his colleagues 
indicated that elevated serum levels of miR-21 in patients with diffuse large B-cell 
lymphoma was associated with higher relapse-free survival (Lawrie et al., 2008). The 
first study on the use of whole blood as miRNA biomarker was reported by Heneghan et 
al. (2010). They have demonstrated that the up-regulation of miR-195 in the whole 
blood of breast cancer patients was reflective of that in the breast tumour tissues. Since 
the usage of plasma, serum and whole blood has been proven suitable for investigations 
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as blood-based biomarkers, whole blood was utilised in the present investigation. Whole 
blood includes all possible sources of circulating miRNAs from red blood cells, white 
blood cells and plasma (J. Wang, Zhang, Liu, & Sen, 2014). Previously, Heneghan et al. 
(2010) have reported a strong preference of using whole blood to plasma or serum for 
systemic miRNA detection and quantification. They have discovered a higher yield of 
miRNAs in the whole blood, as compared to plasma or serum. Moreover, the white cell 
counts, haemoglobin and haematocrit levels have been determined to be similar in the 
cancer and control samples, hence ruling out any potential bias attributed to cellular and 
protein components (Heneghan et al., 2010). In addition, the presence of cellular 
fraction in the whole blood has been suggested to ameliorate the miRNA profiles of 
cancer patients, as the immunosuppressive and pro-angiogenic signals sent out during 
tumour formation are commonly imprinted in the blood cells (Häusler et al., 2010). 
Thus, the detection of miRNA deregulation at early stages of tumour development is 
possible with the use of whole blood (J. Wang et al., 2014). Nevertheless, the actual 
mechanism on how tumour-derived miRNAs enter the blood circulation remains to be 
clarified. Chin and Slack (2008) have proposed two possibilities regarding this issue. 
First, tumour miRNAs may be present in the bloodstream due to tumour cell death and 
lyses. Second, tumour cells may secrete miRNAs into the tumour microenvironment 
and intravasate into the bloodstream via exosome transfer. It is clear that the present 
investigation was necessary to determine whether the differentially expressed miRNAs 
identified in the circulating blood of primary CRC patients would be reflective of those 
in the cancer tissue. 
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5.1.3   Marker validation by RT-qPCR 
The RT-qPCR is an established technique for miRNA quantification. It is recognised as 
the gold standard for the validation of microarray data (Min & Yoon, 2010). The 
validation of differentially expressed miRNAs using an independent set of samples is 
necessary before drawing any conclusion from the microarray experiment. The samples 
in this study were grouped into early (stage I-II) and advanced (stage III-IV) CRC for 
statistical analysis. The rationality behind this conformed to one of the study objectives, 
i.e. to determine the feasibility of the miRNA biomarkers for discriminating early and 
advanced CRC. The cases were grouped on the basis of their similarities in clinical 
pathophysiology and tumour stromal microenvironmental elements (Compton et al., 
2012). Stage I and II tumours are localised to the bowel and have not spread to lymph 
nodes or distant organs, hence the growth usually could be treated effectively with 
surgery alone without any adjuvant systemic therapy. However, for stage III and IV 
tumours, the growth has spread beyond the bowel, thus systemic treatment is needed to 
treat the residual cancer after surgery. The miRNAs that could discriminate between 
early and advanced CRC may serve as diagnostic and prognostic biomarkers for 
improving patient treatment protocols. 
In the present study, the RT-qPCR validation procedure using miRNA-specific primer 
and TaqMan probe was performed in accordance with the Minimum Information for 
Publication of Quantitative Real-time PCR Experiments (MIQE) guidelines (Bustin et 
al., 2009). The TaqMan assay involves the utilisation of a fluorogenic-labelled probe 
that has a fluorescent reporter dye attached to its 5’ end and a quencher dye at its 3’ end 
(Heid, Stevens, Livak, & Williams, 1996). In the presence of the target sequence, the 
fluorogenic probe anneals downstream from one of the primer sites and is cleaved by 
the 5’ nuclease activity of the Taq DNA polymerase, resulting in fluorescence emission 
(Arya et al., 2005). In contrast, the fluorescence emission of the reporter dye is 
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quenched when the probe is in an intact form. The fluorescence intensity is directly 
proportional to the amount of product amplified in each PCR cycle (Overbergh et al., 
2003). Post-PCR processing is not required. This assay is specific as proper 
hybridisation between the probe and target is needed to generate fluorescent signals 
(Ginzinger, 2002). Moreover, the probes can be labelled with distinct reporter dyes that 
allow the amplification and detection of two different sequences in one reaction 
(Overbergh et al., 2003). The primary disadvantage of the TaqMan chemistry is the 
requirement to synthesise multiple probes for different sequences, which increases assay 
setup and cost (Arya et al., 2005).  
The validation analyses of the concurrently identified miRNAs (miR-150, miR-193a-3p, 
miR-23a, miR-23b, miR-338-5p, miR-342-3p and miR-483-3p) are discussed in the 
following sub-sections. These miRNAs are suggested to be biologically and clinically 
relevant to the carcinogenesis of CRC.  
 
5.1.3.1   miR-150  
In the present study, miR-150 expression was determined to be significantly down-
regulated in the tissue and blood miRNA arrays. Even though significant down-
regulation of miR-150 expression was not detected in the blood RT-qPCR analysis 
(Figure 4.19), the miR-150 expression was reported to be significantly down-regulated 
in the tissue RT-qPCR analysis (Figure 4.11). Furthermore, the down-regulation of 
miR-150 level in CRC has been reported by other research groups (C. Guo et al., 2008; 
Y. Ma et al., 2012; Q. Wang et al., 2012). Y. Ma et al. (2012) have indicated that the 
low expression levels of miR-150 in both colorectal adenoma and carcinoma tissues 
were associated with shorter survival and worse response to adjuvant chemotherapy. 
The miR-150 expression has been discovered to be significantly down-regulated in the 
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plasma CRC samples and several CRC cell lines, i.e. V9m, V855, V410 and V478 (C. 
Guo et al., 2008; Q. Wang et al., 2012). The miR-150 gene locus is located on 
chromosomal region 19q13.33 (Y. Ma et al., 2012). Based on the available literature, 
the validation of miR-150 target genes in CRC has not been confirmed. The lack of 
knowledge on the target genes has hindered the detailed understanding of miR-150 
function in CRC. Nevertheless, the deregulation of miR-150 and its target genes has 
been detected in other gastrointestinal diseases. The miR-150 has been shown to be 
down-regulated in pancreatic cancer, and the restoration of the level has been found to 
suppress pancreatic cell growth, clonogenicity, migration and invasion by modulating 
the expression of mucin 4 (MUC4) gene (Srivastava et al., 2011). On the other hand, 
miR-150 has been reported to be up-regulated in irritable bowel syndrome (Fourie et al., 
2014). It has been found to target the serine-threonine protein kinase AKT2 gene, which 
is an important regulator in inflammatory pathways (Anderson & Wong, 2010; Fourie et 
al., 2014). Moreover, miR-150 has been determined to promote gastric cancer cell 
proliferation by negatively regulating the pro-apoptotic early growth response 2 (EGR2) 
gene (Q. Wu et al., 2010).  
In this context, the variances in miR-150 expression indicate cell type-specific 
regulation of this miRNA. Thus, more studies are needed to identify the functions and 
targets of miR-150 in CRC.  
 
5.1.3.2   miR-193a-3p 
The information on the role of miR-193a-3p in colorectal carcinogenesis remains 
largely unknown. The miR-193a-3p is derived from the 3’ arm of miR-193a. The gene 
locus for miR-193a is found on chromosomal region 17q11.2 (Nakano, Yamada, 
Miyazawa, & Yoshida, 2013). The present study has been published as the first study on 
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the up-regulation of miR-193a-3p in CRC (Yong, Law, & Wang, 2013). This miRNA 
was found to be significantly up-regulated in the miRNA array and RT-qPCR validation 
studies (Figures 4.12 and 4.20). Moreover, the miR-193a-3p expression was ascertained 
to be positively correlated in the tissue and blood samples. This miRNA has been 
chosen for further functional studies and is reported in section 5.2.1.  
Recently, Ragusa and his co-workers have demonstrated an up-regulation of miR-193a-
3p expression in the cells and exosomes secreted by Caco2 and HCT116 CRC cells 
(Ragusa et al., 2014). The level of miR-193a-3p was successfully altered in Caco2 cells 
following Cetuximab treatment while no effect was observed in HCT116 cells, 
indicating the responsiveness of miR-193a-3p modulation in Caco2 cells. However, 
without specifying the arm origin, Iliopoulous and his colleagues have reported a down-
regulation of miR-193a expression in colon-derived mice xenografts (Iliopoulos, Rotem, 
& Struhl, 2011). The contradicting results may be due to the specificity of the arm 
origin in cellular transformation and tumour growth, and the differences in genetically 
distinct CRC cells. Clearly, the role of miR-193a-3p in CRC has to be robustly 
investigated.  
The miR-193a-3p level has been reported with varying conclusions in different cancers. 
The up-regulation of miR-193a-3p has been shown in pancreatic and bladder cancers 
while the down-regulation has been demonstrated in oral and ovarian cancers (Dyrskjøt 
et al., 2009; Kozaki, Imoto, Mogi, Omura, & Inazawa, 2008; Nakano et al., 2013; J. Yu, 
Li, Hong, Hruban, & Goggins, 2012). Moreover, miR-193a-3p has been reported to 
mediate the chemosensitivity of 5-FU and sorafenib drugs in hepatocellular carcinoma 
by targeting the serine/arginine-rich splicing factor 2 (SRSF2) and uPA genes, 
respectively (K. Ma et al., 2012; Salvi et al., 2013).  
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5.1.3.3   miR-23a 
Based on the miRNA array and RT-qPCR analyses (Figures 4.13 and 4.21), the level of 
miR-23a was shown to be significantly elevated in CRC. Strong positive correlation 
was observed between the tissue and blood samples. In view of the present results, 
mounting evidence has suggested that miR-23a may serve as a promising biomarker in 
CRC. Ogata-Kawata et al. (2014) have found that miR-23a was over-expressed in the 
serum exosome of primary CRC patients and the level was remarkably reduced after 
tumour resection. X. Chen et al. (2008) have demonstrated a common up-regulation of 
blood miR-23a in CRC and lung cancer patients. Their study serves as a preliminary 
investigation that highlights the common physiological functions and relationship 
between CRC and lung cancer. The miR-23a level has also been detected to be higher in 
HCT116, HT29, RKO, SW48 and SW480 CRC cells when compared to normal colon-
derived FHC cells (Ogata-Kawata et al., 2014). Furthermore, Jahid et al. (2012) have 
shown that miR-23a is involved in the promotion of CRC cell migration and invasion 
by down-regulating the metastasis suppressor 1 (MTSS1) gene. Apart from CRC, the 
up-regulation of miR-23a has been reported in other gastrointestinal cancers. Bao et al. 
(2014) have demonstrated that the increase of miR-23a expression in hepatocellular 
carcinoma was significantly associated with TNM stage and tumour size. The miR-23a 
has also been suggested to regulate the chemosensitivity of HepG2 hepatocellular 
carcinoma cells to etoposide drug (N. Wang et al., 2013). Furthermore, by using 
MGC803 gastric adenocarcinoma cell line, Zhu et al. (2010) have revealed a growth-
promoting function of miR-23a via the regulation of interleukin 6 receptor (IL6R) gene. 
Subsequently, X. Liu et al. (2013) have shown that miR-23a can promote cellular 
proliferation and suppress paclitaxel-induced apoptosis in MGC803 cells by targeting 
the interferon regulatory factor 1 (IRF1) gene at the post-transcriptional level.  
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Besides the individualistic functions, miR-23a has also been shown to possess 
cooperative functions with miR-24 and miR-27a (Chhabra, Dubey, & Saini, 2010). The 
three miRNAs are derived from a single primary transcript, located on chromosomal 
locus 19p13.13 (Sikand, Slane, & Shukla, 2009). These miRNAs have been 
bioinformatically predicted to regulate the initiation of adenoma-carcinoma sequence in 
CRC via Wnt/β-catenin signalling pathway (Willert & Jones, 2006). In brief, miR-23a 
holds much potential as a biomarker in cancer. This miRNA has been selected for 
further functional studies and is reported in section 5.2.2.  
 
5.1.3.4   miR-23b 
In the present study, miR-23b level was found to be significantly up-regulated in the 
tissue and blood miRNA arrays. Although there was no elevation of miR-23b 
expression in the tissue RT-qPCR analysis (Figure 4.14), the miR-23b level was 
reported to be highly expressed in the blood samples of CRC patients (Figure 4.22). The 
miR-23b gene locus is found on chromosomal region 9q22.32 (Sikand et al., 2009). 
Prior to this study, H. Zhang et al. (2011) have introduced a self-assembled cell 
microarray that can be used to screen all potential miRNAs known to regulate 
metastasis-relevant cell behaviours. From their genome-wide screening, miR-23b has 
been identified as a miRNA with migratory function in CRC. It has been suggested to 
mediate tumour growth, invasion and angiogenesis by targeting a cohort of pro-
metastatic genes (e.g. frizzled class receptor 7 [FZD7], mitogen-activated protein kinase 
kinase kinase 1 [MAP3K1], p21 protein [Cdc42/Rac]-activated kinase 2 [PAK2], 
TGFBR2, related RAS viral oncogene homologue 2 [RRAS2] and uPA) (H. Zhang et al., 
2011). Recently, proline oxidase (POX), a p53-induced gene that is involved in the 
modulation of cell apoptosis and tumour growth in many gastrointestinal cancers, has 
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been identified as a direct target of miR-23b in renal cancer (W. Liu et al., 2010). Hence, 
miR-23b is predicted to be involved in the post-transcriptional regulation of POX gene 
in CRC as well (Y. Liu, Borchert, Surazynski, & Phang, 2008). In other instance, miR-
23b, which is a paralog of miR-23a, has been demonstrated to possess an amplification 
effect with miR-23a in regulating the TGF-β signalling by targeting SMAD genes 
(Rogler et al., 2009). Moreover, both miR-23a and miR-23b have been reported to play 
certain roles in glutamine catabolism, cell cycle regulation and glucose metabolism via 
c-MYC regulation in CRC (Chhabra et al., 2010; Gao et al., 2009). 
 
5.1.3.5   miR-338-5p 
The miR-338-5p is derived from the 5’ arm of miR-338. The gene encoding miR-338 is 
located in an intronic region within the apoptosis-associated tyrosine kinase (AATK) 
gene on chromosomal region 17q25.3 (Barik, 2008). In general, the over-expression of 
miR-338 has been observed in CRC, hepatocellular carcinoma and oral cancer (Budhu 
et al., 2008; T. S. Wong et al., 2008). Schetter et al. (2008) have found 37 miRNAs, 
including miR-338, to be differentially expressed in CRC tissues when compared with 
paired normal colonic tissues. The findings from the tissue and blood miRNA arrays in 
this work are in agreement with other reported studies, whereby mir-338-5p expression 
was shown to be up-regulated in the primary CRC patients. Furthermore, the RT-qPCR 
validation has revealed a significant positive correlation in the tissue and blood levels of 
miR-338-5p (Figures 4.15 and 4.23). The high level of expression was significantly 
associated with the advanced tumour (stage III-IV).  
Recently, miR-338-5p has been discovered to be positively correlated with tumour 
metastasis in recurrent CRC (Ju et al., 2012). The study has been extended and Ju et al. 
(2013) have found that miR-338-5p can induce cell migration and suppress cell 
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autophagy by down-regulating the phosphatidylinositol 3-kinase, catalytic sub-unit type 
3 (PIK3C3) and microtubule-associated protein 1A/1B-light chain 3 (LC3) genes. 
Moreover, miR-338-5p is predicted to suppress the carcinoma-related EF-hand (CREF) 
gene in many cancers, including CRC (Delgado, Brandao, Hamid, & Narayanan, 2013). 
The CREF encodes a calcium binding protein that can act as a tumour promoter or a 
tumour suppressor in different cell types (Salama, Malone, Mihaimeed, & Jones, 2008). 
In view of the clinical importance of miR-338-5p in CRC, patients who did not benefit 
from standard adjuvant chemotherapy have been determined to express higher 
expression levels of miR-338-5p as compared to those who benefited (Dou et al., 2013). 
Thus, miR-338-5p holds the potential as a predictive marker in monitoring patients’ 
response to chemotherapy. This miRNA has been selected for further functional studies 
and is discussed in section 5.2.3.   
 
5.1.3.6   miR-342-3p  
The miR-342-3p is derived from the 3’ arm of miR-342. The miR-342 gene locus is 
located between third and fourth exons of the Enah/Vasp-like (EVL) gene on 
chromosomal region 14q32.2 (Grady et al., 2008). This miRNA is known to be 
epigenetically silenced via CpG island methylation in CRC. Generally, methylation of 
the EVL gene could be found in approximately 86% and 67% of colorectal 
adenocarcinomas and adenomas, respectively (Grady et al., 2008). The miR-342-3p has 
been determined to play important roles in cell cycle control, proliferation, migration 
and angiogenesis (Ronchetti et al., 2008). It has been suggested to function as a tumour 
suppressor in CRC. Moreover, two independent miRNA profiling studies by 
Faltejskova et al. (2012) and Gaedcke et al. (2012) have demonstrated a significant 
down-regulation of miR-342-3p expression in CRC. The results obtained in the present 
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investigation are in agreement with the reported studies, whereby miR-342-3p was 
shown to be significantly down-regulated in both tissue and blood miRNA arrays. 
However, as shown in Figures 4.16 and 4.24, statistical significance was only achieved 
in the tissue RT-qPCR validation but not in the blood RT-qPCR validation. In line with 
this, Luo and his group have also obtained a similar discrepancy whereby their blood 
RT-qPCR validation analysis for miR-342-3p did not correlate significantly with the 
microarray data (Luo, Stock, Burwinkel, & Brenner, 2013). A validation study using a 
larger sample size is required to address the high variation of blood miR-342-3p 
expression. 
On the contrary, the miR-342-3p expression has been shown to be up-regulated in 
patients with irritable bowel syndrome (Fourie et al., 2014). This miRNA may regulate 
inflammatory, pain signalling, smooth muscle contractility and gastrointestinal tract 
motility pathways (Fourie et al., 2014). The up-regulation of miR-342-3p expression has 
also been reported in patients with Hepatitis B virus (HBV) infection and HBV-positive 
hepatocellular carcinoma (L. M. Li et al., 2010). Furthermore, the miR-342-3p level has 
been shown to be affected by the treatment of cisplatin drug in KYSE410 oesophageal 
squamous cell carcinoma cell line (Hummel et al., 2011). On the basis of the evidence 
on miR-342-3p deregulation in the gastrointestinal system, the down-regulation of miR-
342-3p expression appears to be specific for CRC. Further investigation may provide 
insight into the potential application of miR-342-3p as a biomarker in CRC.  
 
5.1.3.7   miR-483-3p 
The over-expression of miR-483-3p has been observed in many cancers such as Wilms’ 
tumour, breast, colorectal, liver and pancreatic cancers (Hao, Zhang, Zhou, Hu, & Shao, 
2011; N. Ma et al., 2012; Veronese et al., 2010). In this study, both of the miRNA array 
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and RT-qPCR validation analyses have revealed significant up-regulation of miR-483-
3p expression levels in CRC tissue and blood samples (Figures 4.17 and 4.25). 
Although miR-483-3p was not chosen for further investigation due to the low 
correlation value between the tissue and blood RT-qPCR data, mounting evidence has 
suggested that this miRNA may act as an oncomiR in CRC (Oberg et al., 2011; Ragusa 
et al., 2012; Veronese, 2012).  
The miR-483-3p is derived from the 3’ arm of miR-483. The gene encoding miR-483 is 
located within intron two of the insulin-like growth factor 2 (IGF2) gene on 
chromosomal locus 11p15.5 (Veronese et al., 2010). A direct association between the 
over-expression of miR-483-3p and IGF2 in CRC has been determined. Moreover, 
treatment with 5-FU chemotherapeutic drug has been found to result in the reduction of 
both miR-483-3p and IGF2 levels in CRC (Veronese, 2012). Generally, the IGF2 is 
epigenetically regulated and involved in cell growth and differentiation, mostly during 
foetal stage (Chao & D'Amore, 2008). The over-expression of IGF2 in adult tissue may 
lead to tumour development. The loss of IGF2 imprinting, commonly observed in 30% 
of CRC patients, is recognised as an early event in colorectal carcinogenesis (Cui et al., 
2003). The miR-483-3p can function cooperatively with IGF2 or independently as an 
autonomous oncogene by suppressing the level of pro-apoptotic BCL2-binding 
component 3 (BBC3) gene in CRC (Veronese et al., 2010). The encoded BBC3 protein 
is an essential mediator of p53-dependent and -independent apoptotic pathways that 
promotes apoptosis by inhibiting the anti-apoptotic factors BCL2 and BCLXL (Jeffers 
et al., 2003). In addition, the miR-483-3p can target the upstream stimulating factor 1 
(USF1) gene via β-catenin induction (Veronese et al., 2011). The encoded USF1 protein 
is an evolutionarily conserved transcription factor that interacts at high affinity with E-
box regulatory elements (Ratajewski, Walczak-Drzewiecka, Salkowska, & Dastych, 
2012). The USF1 is a key regulator in stress and immune responses, cell cycle and 
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proliferation, and lipid and glucose metabolisms (Corre & Galibert, 2005). Since β-
catenin is also a target of miR-483-3p, the negative regulatory loop that controls the 
miR-483-3p and β-catenin levels has to be tightly regulated to prevent aberrant cell 
proliferation (Veronese et al., 2011). On the other hand, the miR-483-3p has been 
validated to promote cellular proliferation by suppressing the expression levels of 
SMAD4 in pancreatic cancer and suppressor of cytokine signalling 3 (SOCS3) in 
hepatocellular carcinoma (Hao et al., 2011; N. Ma et al., 2012).   
 
5.2   Functional and target validation studies of miR-193a-3p, miR-23a and 
miR-338-5p  
The present research aimed to identify the potential miRNA biomarkers for early 
detection of CRC. Through comprehensive miRNA microarray and RT-qPCR 
validation analyses, three miRNAs, namely, miR-193a-3p, miR-23a and miR-338-5p, 
were shown to be significantly up-regulated and highly correlated in the CRC tissue and 
blood samples. The triple miRNA classifier of miR-193a-3p, miR-23a and miR-338-5p 
was of high sensitivity (80.0%), specificity (84.4%) and accuracy (83.3%) in defining 
CRC (Table 4.5 and Figure 4.26).  
In the subsequent study, a focused approach was adopted to examine the role of the 
individual miRNA in cell viablity, apoptosis, migration and invasion using SW480 and 
SW620 CRC cell lines. Functional and target validation experiments were performed to 
verify and establish the causal associations between the differentially expressed 
miRNAs and the predicted target genes. Generally, the common approach for 
miRNA:mRNA target validation is based on the combination of computational 
prediction and experimental validation. The binding of a mature miRNA to its target is 
largely dependent on the free energy of binding between the seed region of miRNA and 
 189 
 
the 3’-UTR of mRNA (Doench & Sharp, 2004). A minute change in miRNA expression 
has been shown to have large-scale effects in fundamental cellular processes (Meltzer, 
2005).  
The SW480 cell line was derived from a primary Dukes’ type B tumour obtained from 
the colon of a 50-year-old male Caucasian. The SW620 cell line was cultured a year 
later from a lymph node metastasis in the same patient diagnosed with metastatic Dukes’ 
type C tumour  (Leibovitz et al., 1976). The SW480 and SW620 cell lines have same 
genetic background but different metastatic potential (Hewitt et al., 2000). The two cell 
lines possess distinct appearances in culture (Leibovitz et al., 1976). Under light 
microscope, the SW480 cells are characterised by a spreading, epithelial-type 
morphology and form large, cohesive aggregates. On the contrary, the SW620 cells 
have a rounded, spindle-shaped, fibroblast-like morphology and form small, less 
cohesive aggregates. The SW480 and SW620 cell lines underlie the gene product 
modifications that have occurred as the cells acquire metastatic potential. The two cell 
lines serve as a useful model for studying the molecular events in CRC progression 
(Ghosh et al., 2011). In the current in vitro study, both cell lines were transiently 
transfected with synthetic miRNAs and/or plasmid DNAs through lipofection method 
by using Invitrogen Lipofectamine 2000 reagent. This method involves the injection of 
nucleic acids into the cells by means of cationic liposome formulations that can 
overcome the electrostatic repulsion of the cell membrane (Dalby et al., 2004). This 
method is well-known for its ease of use, limited toxicity and ability to transfect a wide 
range of cell types with relatively high efficiency (Ke et al., 2014; Salimzadeh, 
Jaberipour, Hosseini, & Ghaderi, 2013). Transiently transfected genetic materials are 
generally short-lived as the nucleic acids are not integrated into the genome and will be 
lost due to environmental factors and cell division (T. K. Kim & Eberwine, 2010). The 
peak transient expression is generally seen at 24 to 72 h following transfection (Dalby et 
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al., 2004). Thus, most analyses in this work were optimised to be carried out at 48 h 
post-transfection with the exception of cell viability assay, whereby the analysis was 
conducted at the periods of 24, 48 and 72 h post-transfections. A stable transfection 
method is not needed as the main purpose of the present transfection study was to 
demonstrate the interaction between a particular miRNA and its target gene with respect 
to its biological function. 
 
5.2.1   Involvement of miR-193a-3p:FOXO4 regulation axis in cell invasion and 
metastasis 
Metastasis is a major cause of cancer-related death. It involves a series of interrelated 
events known as the invasion-metastasis cascade. Metastatic progression begins with (1) 
epithelial cells detachment from a well-confined primary tumour; (2) local invasion into 
the surrounding ECM and stromal cell layers; (3) transition of epithelial to 
mesenchymal phenotypes; (4) intravasation into blood or lymphatic vessels; (5) survival 
in the systemic circulation; (6) extravasation into the parenchyma of distant tissues; (7) 
micrometastasis formation and metastatic colonisation in the foreign microenvironments; 
and eventually (8) proliferation into clinically detectable metastatic growths (Liotta et 
al., 1991; Wan et al., 2013). A metastatic cancer is typically incurable due to its 
systemic dissemination and resistance to existing anti-cancer therapies (Valastyan & 
Weinberg, 2011). A huge repertoire of proteases, adhesion molecules, growth factors 
and transcription factors are involved in the regulation of cancer invasion and metastasis. 
Despite the substantial efforts in the search of suitable cancer biomarkers, a sensitive 
marker for the detection of early metastasis in CRC has not been discovered. A number 
of studies have indicated that miRNA regulation is important in the development and 
 191 
 
progression of CRC. Several miRNAs with validated involvement in cell migration and 
invasion have been described in section 2.2.7.5.  
The present investigation has shown that miR-193a-3p could act as a pro-metastasis 
miRNA in CRC via the promotion of cell migration and invasion. The miR-193a-3p 
expression was determined to be up-regulated in the clinical CRC tissue and blood 
samples. The effect of miR-193a-3p modulation in CRC cell progression was elucidated 
through the use of non-metastatic SW480 and metastatic SW620 cell lines. The findings 
from the functional studies revealed that the inhibition of miR-193a-3p in both cell lines 
has significantly impeded cell migration and invasion without the destruction of cellular 
viability (Figures 4.27 and 4.29). The over-expression of miR-193a-3p has no effect on 
cell viability as well, but it was sufficient to promote cell migration and invasion. 
Moreover, no significant finding was detected from the apoptosis assay (Figure 4.28). 
Hence, these results indicated that miR-193a-3p was necessary for the migration and 
invasion of CRC cells but not required for viability and apoptosis.  
The use of Matrigel basement membrane matrix has facilitated the in vitro study of 
miR-193a-3p modulation on ECM-associated cancer cell growth (Price et al., 2012). As 
described previously by Cai, Mulatz, Ard, Nguyen, and Gee (2014), the capability of the 
SW620 cells to invade through the Matrigel-coated transwell inserts is greater than the 
SW480 cells. The migratory and invasive potential of the CRC cells is largely 
dependent on the cell capability for attachment (Hewitt et al., 2000). Thus, the higher 
capability of the SW620 cells for migration and invasion in this study was consistent 
with the more aggressive phenotype of the cells. Previous reports have demonstrated 
that the SW620 cells express a lower level of E-cadherin epithelial marker and a higher 
level of vimentin mesenchymal marker when compared to the SW480 cells (Katayama 
et al., 2006; Yehezkel, Cohen, Kliger, Manor, & Khalaila, 2012; Zirvi, Keogh, 
Slomiany, & Slomiany, 1991). The SW620 cells also display a greater metastatic ability 
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than the SW480 cells (Hewitt et al., 2000). Importantly, the SW620 cells secrete high 
levels of uPA and MMP proteinases that are needed for ECM breakdown (Takayama et 
al., 2006). Although the exact molecular mechanism on miR-193a-3p regulation in CRC 
metastasis is still ambiguous, the miR-193a-3p has been shown to affect in vitro cell 
migration and invasion and in vivo lung metastasis in non-small-cell lung cancer models 
by targeting the ERBB4 and S6 kinase 2 (S6K2) genes (T. Yu et al., 2014). Moreover, 
the miR-193a-3p has been reported to be highly up-regulated in metastastic medullary 
thyroid carcinoma (Santarpia et al., 2013).  
FOXO4 was identified as a target gene of miR-193a-3p in this study. This is the first 
study that reveals an interaction between miR-193a-3p and FOXO4 in CRC via the 
luciferase assay (Figure 4.32). Mutagenesis at the seed match region of FOXO4 3’-UTR 
has confirmed the specificity of miR-193a-3p recognition. The over-expression of miR-
193a-3p has caused a further decrease in the levels of FOXO4 mRNA and FOXO4 
protein while the forced inhibition of miR-193a-3p has resulted in the up-regulation of 
FOXO4 mRNA and FOXO4 protein (Figures 4.33 and 4.34). The effects of these 
modulations were relatively stronger in the SW480 cells when compared to the SW620 
cells. These findings have shown that miR-193a-3p could regulate CRC cell migration 
and invasion by targeting FOXO4. Based on the available literature, FOXO4 has only 
been reported to be targeted by miR-214 in non-small-cell lung cancer, miR-223 in 
HBV-related hepatocellular carcinoma, miR-421 in nasopharyngeal carcinoma and 
miR-499-5p in CRC (L. Chen, Tang, Wang, Yan, & Xu, 2013; X. Liu et al., 2011; 
Salim et al., 2012; X. Xu et al., 2013). Such evidence implied that the study of miRNA-
mediated control of FOXO4 activity in cancer is still at its preliminary stage.  
Generally, FOXO transcription factors belong to a large forkhead box (FOX) family of 
proteins (Katoh & Katoh, 2004). At least 19 sub-classes of FOX proteins have been 
determined, from A to S. The FOX domain is a conserved DNA binding domain 
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responsible for the recognition of protein-encoding genes and the recruitment of distinct 
factors needed for an activation or repression of gene transcription (Arden, 2006). The 
human FOXO family comprises of FOXO1 (also known as FKHR), FOXO3 (FKHRL1), 
FOXO4 (AFX) and FOXO6 (FOXO2) (Greer & Brunet, 2005). FOXO transcription 
factors are ubiquitously expressed in all mammalian tissues. Among these, FOXO1, 
FOXO3 and FOXO4 genes are commonly found at chromosomal translocations in 
human tumours, hence suggesting their involvement in carcinogenesis (Greer & Brunet, 
2005). FOXO proteins regulate a series of target genes involved in cell growth, cell 
cycle arrest, DNA repair, stress, invasion and metastasis (X. Zhang, Tang, Hadden, & 
Rishi, 2011). FOXO proteins act as potent transcriptional activators when present in the 
nucleus. The transcriptional functions of FOXO proteins are often regulated by post-
translational modifications, i.e. phosphorylation, ubiquitination and acetylation (Fu & 
Tindall, 2008). Firstly, FOXO phosphorylation is mainly regulated by the PI3K-AKT 
pathway in response to growth factor stimulation (Burgering & Kops, 2002). A variety 
of growth factors such as epidermal growth factors, insulin, insulin-like growth factors 
and erythropoietin can bind to the tyrosine kinase receptors and activate the 
serine/threonine kinases necessary for FOXO phosphorylation (Arden, 2006; Reagan-
Shaw & Ahmad, 2007). Typically, the AKT serine/threonine kinases phosphorylate 
FOXO transcription factors at three regulatory sites conserved from C. elegans to 
mammals (threonine 28, serine 193, serine 258 in the FOXO4 sequence) and bind to 14-
3-3 proteins, leading to the nuclear translocation of FOXO proteins into the cytoplasm 
and inhibition of FOXO-dependent transcription (Arden, 2006). Other serine/threonine 
kinases that have been shown to phosphorylate FOXO proteins include serum and 
glucocorticoid-inducible kinase (SGK), casein kinase 1 (CK1), dual-specificity tyrosine-
phosphorylated and regulated kinase 1A (DYRK1A) and Ras-Ral pathway kinases 
(Greer & Brunet, 2005; Reagan-Shaw & Ahmad, 2007) (Figure 5.1). In contrast, 
 194 
 
phosphorylation of FOXO proteins by JNK upon stress stimulation allows the nuclear 
import of FOXO proteins to restore the transcriptional regulatory potential (Kawamori 
et al., 2006). Several examples of stress stimuli are ultraviolet (UV) radiation, oxidative 
stress and heat shock. Secondly, the ubiquitination process via ubiquitin-proteasome 
pathway is involved in the degradation of FOXO proteins (Reagan-Shaw & Ahmad, 
2007). The degradation of FOXO proteins often follows with cellular transformation in 
carcinogenesis (Greer & Brunet, 2005). FOXO ubiquitination is regulated by ubiquitin 
ligases and requires AKT phosphorylation as well. S-phase kinase-associated protein 2 
(SKP2) and inhibitor kappa-B kinase β (IKKB) are the two common ubiquitin ligases 
that catalyse the degradation of FOXO1 and FOXO3, respectively (Hu et al., 2004; H. 
Huang et al., 2005). The impact of ubiquitination in the degradation of FOXO4 and 
FOXO6 remains to be clarified. The next mechanism involved in the modulation of 
FOXO-dependent transcription is the acetylation and deacetylation of FOXO proteins. 
The binding of FOXO proteins to the transcriptional co-activator and co-repressor 
complexes influences the FOXO acetylation levels (Reagan-Shaw & Ahmad, 2007). For 
instance, FOXO acetylation by the co-activators cAMP response element-binding 
protein (CREB)-binding protein (CREBBP) and p300/CBP-associated factor (PCAF) 
allows the activation of FOXO-mediated transcriptional activity (van der Heide & 
Smidt, 2005). On the other hand, FOXO deacetylation by the deacetylase SIRT1 in 
response to oxidative stress stimulates the activation of genes involved in stress and 
apoptosis resistance (van der Horst et al., 2004). In view of the critical roles of FOXO 
proteins in maintaining proper cell function and tumour suppression, the loss of FOXO4 
activity could contribute to tumourigenesis (X. Q. Liu, Tang, Zhang, & Jin, 2011). 
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Figure 5.1: Conformation and phosphorylation sites of FOXO transcription factors. The 
main components of FOXO are forkhead domain, nuclear localisation sequence (NLS) 
and nuclear export sequence (NES). FOXO-dependent transcription is mainly 
modulated by phosphorylation in response to growth factors and stress stimuli. The 
kinases involved are AKT, SGK, CK1, DYRK1A, Ral-Ras and JNK. The 
phosphorylation sites (T1, S1, S2, S3, S4, S5, T2, T3) with specific amino acid 
positions are shown.  
(Source: Arden, 2006) 
 
The gene that encodes FOXO4 is located on chromosomal locus Xq13.1 (Greer & 
Brunet, 2005). The down-regulation of FOXO4 transcription factor has been discovered 
in various types of epithelial cancer (Reagan-Shaw & Ahmad, 2007). An increase in 
HIF1 signalling due to low FOXO4 expression has been reported to be associated with 
tumour angiogenesis, invasion and metastasis (Dansen & Burgering, 2008). Yang, Zhao, 
Yang, and Lee (2005) have reported that FOXO4 positively regulates the cyclin-
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dependent kinase inhibitor p27KIP1 gene in cancers that over-express the HER2 (also 
known as ERBB2) oncogene. HER2 over-expression has been detected in numerous 
cancers, including gastric and CRC (Blok, Kuppen, van Leeuwen, & Sier, 2013; 
Jørgensen & Hersom, 2012). The restoration of FOXO4 expression in nude mice 
transplanted with NIH3T3 fibroblast cells expressing the FOXO4A3 gene has been 
shown to inhibit the HER2-activated cell growth and reduce tumour onset, size and 
progression (Yang et al., 2005). Annexin A8 (ANXA8) gene, which is associated with 
focal adhesion kinase expression and altered F-actin dynamics during EMT process, has 
been found to be transcriptionally down-regulated by epidermal growth factor-mediated 
FOXO4 phosphorylation (M. J. Lee et al., 2009). Furthermore, FOXO4-dependent 
transcription overlaps with the p53 pathway in the regulation of cell cycle control and 
tumour progression in CRC (Dansen & Burgering, 2008). FOXO4 has been shown to 
indirectly down-regulate the level of BCLXL via the induction of the BCL6 
transcriptional repressor (Tang et al., 2002). This notion is further substantiated by the 
evidence that growth arrest and DNA damage-inducible protein 45 (GADD45), wild-
type p53-induced phosphatase 1 (WIP1) and SIRT1 genes are regulated by both FOXO4 
and p53 pathways (Fiscella et al., 1997; Kastan et al., 1992; van der Horst et al., 2004). 
The transactivation activity of FOXO4 on GADD45 has been determined to be 
suppresed by nicotinamide and enhanced by resveratrol through SIRT1 interaction in 
HCT116 CRC cells (Y. Kobayashi et al., 2005). Besides that, FOXO4 can form a 
complex with β-catenin and sequester it from the TCF-dependent transcription to inhibit 
tumour progression in CRC (Kwon et al., 2010). The possible interaction between miR-
193a-3p and FOXO4 in CRC progression is summarised in Figure 5.2. 
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Figure 5.2: miR-193a-3p regulation on FOXO4 transcription factor in CRC progression. 
Generally, in the absence of growth factors, FOXO4 is localised in the nucleus and the 
FOXO4-dependent transcription is activated. miRNA regulation represents another 
level of modulation for FOXO4. In the present study, FOXO4 has been identified as a 
direct target of miR-193a-3p. This miRNA may suppress the expression of FOXO4 and 
lead to the repression of FOXO4-dependent transcription and promotion of cancer 
progression. HIF1, p27KIP1, ANXA8, GADD45, WIP1 and SIRT1 are examples of 
genes associated with tumour angiogenesis, invasion and metastasis. 
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The presence of negative correlation between miR-193a-3p and FOXO4 mRNA or 
FOXO4 protein has been investigated. Significant inverse correlation between tissue 
miR-193a-3p and tissue FOXO4 mRNA was detected (Figure 4.39B). Unfortunately, no 
statistical significance was determined in the negative correlation between blood miR-
193a-3p and blood FOXO4 mRNA (Figure 4.39A) or between tissue miR-193a-3p and 
tissue FOXO4 protein (Figure 4.39C). Despite the miRNA:mRNA target validation 
between miR-193a-3p and FOXO4, the exact correlation of tumour-derived miR-193a-
3p and FOXO4 expression levels in the clinical setting could not be elucidated in this 
study. However, individual deregulation of miR-193a-3p (r = 0.811) and FOXO4 
mRNA (r = 0.549) in the blood has been proven to be reflective of that in the CRC 
tissue. Pearson’s correlation has been widely used as the statistical approach to 
determine the correlation between miRNAs and mRNAs in normally distributed data 
(Hauke & Kossowski, 2011; Roldo et al., 2006; F. Wang, Zheng, Guo, & Ding, 2010). 
As supported by Y. Li, Liang, Wong, Jin, and Zhang (2014), a larger number of samples 
may ameliorate the lack of negative correlations between certain miRNA:mRNA 
interactions in miRNA-based studies. Nevertheless, as the tumour progressed from the 
early-stage (I-II) to the advanced-stage (III-IV), an increasing trend of miR-193a-3p 
expression levels (Figures 4.12 and 4.20) and a decreasing trend of FOXO4 mRNA and 
FOXO4 protein expression levels (Figures 4.36, 4.37 and 4.38) were observed in both 
tissue and blood samples. The results obtained are in agreement with the published 
report by X. Q. Liu et al. (2011), whereby FOXO4 expression was determined to be 
remarkably decreased and associated with tumour stage in CRC. The present work 
should therefore be seen as an exploratory study that highlights the role of miR-193a-3p 
as a pro-metastatic miRNA in CRC.   
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5.2.2   Involvement of miR-23a:APAF1 regulation axis in apoptosis 
Apoptosis is a coordinated, energy-dependent cell death process that involves the 
activation of a group of cysteine proteases known as caspases (Elmore, 2007). 
Apoptosis is viewed as an irreversible commitment to programmed cell death. Caspases 
are synthesised as inactive zymogens, which are activated by proteolytic cleavage at the 
aspartate cleavage sites in response to apoptotic stimuli (Degterev, Boyce, & Yuan, 
2003). At least 14 different mammalian caspases have been discovered (Fan, Han, Cong, 
& Liang, 2005). A complex cascade of caspases activation is observed during apoptosis. 
Caspases are both the initiators and executioners in apoptotic cell death (Riedl & Shi, 
2004; Shi, 2002). The two common pathways in apoptosis are extrinsic (death receptor) 
and intrinsic (mitochondrial) pathways (R. S. Y. Wong, 2011). Caspase-8 is the initiator 
caspase in the death receptor pathway that cleaves other effector caspases such as 
caspase-3 and -7 (Degterev et al., 2003). On the other hand, the mitochondrial pathway 
requires the generation of an apoptosome complex that recruits caspase-9 as the initiator 
caspase to activate downstream caspase-3 and -7 (Elmore, 2007). Caspase-3 and -7 are 
the main executioner caspases in apoptosis. Activated caspase-3 and -7 cleave distinct 
inhibitory sub-units of endonuclease family, cytoskeletal proteins, protein kinases and 
DNA repair proteins, leading to the formation of apoptotic bodies (Fan et al., 2005; R. S. 
Y. Wong, 2011). In the present study, caspase 3/7 activation assay was conducted to 
evaluate the execution event in the cultured cells following miR-23a transfection.  
The morphological and biochemical hallmarks of apoptosis include cell shrinkage, 
chromatin condensation, nuclear fragmentation, DNA and protein breakdown, 
membrane blebbling and recognition by phagocytic cells (Hengartner, 2000). Apoptotic 
cell death occurs through both p53-dependent and -independent manners (Benchimol, 
2001; Pan & Griep, 1995; Violette et al., 2002). Generally, apoptosis occurs during 
tissue development and aging as a homeostatic mechanism to maintain cell populations. 
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Apoptosis also occurs as a defence mechanism towards immune reactions and cell 
damages caused by diseases, radiation, drugs or chemicals. Therefore, resistance to 
apoptosis contributes to carcinogenesis and chemoradioresistance in cancer treatment. 
Mechanisms that lead to the evasion of apoptosis in cancer include impaired death 
receptor signalling, disrupted balance of BCL2 family of pro-apoptotic and anti-
apoptotic proteins, defects or mutation in the TP53 gene, reduced expression of caspases 
and increased expression of inhibitor of apoptosis proteins (R. S. Y. Wong, 2011). On 
top of that, miRNA deregulation also contributes to the aberration in apoptotic 
regulation. For instance, over-expression of miR-92a has been reported to cause 
uncontrollable cell proliferation in CRC via the down-regulation of pro-apoptotic 
molecule BCL2-interacting mediator of cell death (BIM) (Tsuchida et al., 2011). 
PDCD4, a tumour suppressor protein that is commonly down-regulated in CRC, has 
been determined to be associated with the up-regulation of miR-21 (Asangani et al., 
2008; Yamamichi et al., 2009). Moreover, T. C. Chang et al. (2007) have shown the 
significance of miR-34a in the regulation of p53 network of cell cycle control and 
apoptosis in CRC. Based on a recent review by C. Li et al. (2012), numerous miRNAs 
have been reported to regulate the modulators of apoptosis (e.g. BCL2-antagonist/killer 
[BAK], BCL2-associated X protein [BAX], BBC3, BH3-interacting domain death 
antagonist [BID], Fas-associated death domain [FADD], caspase-3, -8 and -9).  
The present investigation has demonstrated that miR-23a could harbour an apoptosis 
resistance function in CRC. The miR-23a expression was determined to be up-regulated 
in the clinical CRC tissue and blood samples. The elucidation of apoptosis function in 
the in vitro system via cell viability, apoptosis and caspase 3/7 activation analyses 
revealed significant reduction of cell viability and promotion of cell apoptosis following 
miR-23a inhibitor transfection (Figures 4.40, 4.41 and 4.42). No significant finding was 
observed in the migration and invasion assay (Figure 4.43). The results obtained have 
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indicated that miR-23a may exclusively regulate cell apoptosis in CRC. Currently, there 
is only a single study by Jahid et al. (2012) who have reported the involvement of miR-
23a in CRC cell migration and invasion by targeting the MTSS1 gene. The actual 
biological relevance of miR-23a in CRC metastasis remains to be clarified.  
In the present study, APAF1 has been determined to be directly targeted by miR-23a 
through the luciferase assay (Figure 4.45). Mutagenesis at the seed match region of 
APAF1 3’-UTR has affirmed the specificity of miR-23a recognition. These findings 
have clearly shown that miR-23a could regulate apoptosis by targeting APAF1. 
Previously, Huerta et al. (2007) have reported that the endogenous APAF1 expression 
was significantly lower in the SW620 than the SW480 cells. The transfection of miR-
23a inhibitor in the present investigation has revealed a relatively stronger induction of 
APAF1 mRNA and APAF1 protein in the non-metastatic SW480 cells when compared 
to the metastatic SW620 cells. The SW620 cell line is believed to have lower 
susceptibility to gene modulation and apoptosis induction due to increased genetic 
mutations (Hewitt et al., 2000; Huerta et al., 2007).  
Typically, APAF1, APAF2 and APAF3 are the three members of the APAF family 
(Cain, Bratton, & Cohen, 2002). APAF1 is the mammalian homologue of the C. elegans 
pro-apoptotic cell death 4 (CED-4) protein (Hickman & Helin, 2002). APAF2 is 
commonly identified as cytochrome c while APAF3 is also known as caspase-9 (P. Li et 
al., 1997; X. Liu, Kim, Yang, Jemmerson, & Wang, 1996). APAF1 has been suggested 
as a tumour suppressor in cancer (Lowe & Lin, 2000). It is one of the key regulators in 
the mitochondrial apoptotic pathway (Zlobec et al., 2007). The gene that encodes 
APAF1 is located on chromosomal locus 12q23 (Umetani et al., 2004). The protein 
molecular weight for APAF1 is 130 kDa (Cain et al., 2002). It is a cytosolic protein that 
consists of three domains, namely, N-terminal caspase recruitment domain (CARD), 
CED-4-like domain necessary for nucleotide binding and C-terminal domain containing 
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multiple repeats of tryptophan and aspartate residues (WD40 repeats) responsible for 
protein-protein interactions (Campioni et al., 2005; Corvaro & Cecconi, 2004) (Figure 
5.3A). In the presence of an apoptotic stimulus, cytochrome c released from the 
mitochondrion binds to the WD40 repeats to reveal the nucleotide binding site for 
deoxyadenosine triphosphate (dATP) (Hickman & Helin, 2002). Following the 
attachment of dATP, APAF1 protein undergoes further conformational changes and 
unmasks the CARD domain, which allows the recruitment of procaspase-9 (Campioni et 
al., 2005). Subsequent oligomerisation of the APAF1 protein through its CED-4-like 
domain permits the formation of a large apoptosome complex (~700-1400 kDa) (Cain et 
al., 2002). The procaspase-9 is activated by autocatalytic cleavage to form active 
caspase-9 necessary for downstream caspases activation (Cecconi, Alvarez-Bolado, 
Meyer, Roth, & Gruss, 1998) (Figure 5.3B). Thus, the absence of APAF1 protein could 
prevent the activation of downstream effector caspases, leading to cellular resistance to 
apoptotic stimuli (Yoshida et al., 1998). 
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Figure 5.3: (A) Conformation of APAF1 protein. (B) Formation and regulation of 
apoptosome complex in apoptosis.  
(Source: Corvaro & Cecconi, 2004) 
 
Independently, studies on miR-23a up-regulation and APAF1 down-regulation in 
relation to apoptosis have been reported. B. Li et al. (2013) have shown the involvement 
of miR-23a in the regulation of cell death in mice thymic lymphoma model by targeting 
the pro-apoptotic factor Fas. The up-regulation of miR-23a has also been reported to 
suppress the expression of UVB-induced topoisomerase 1, caspase-7 and 
serine/threonine kinase 4 (STK4) apoptotic factors in HaCaT keratinocyte cells (Z. Guo 
et al., 2013). On the other hand, APAF1 down-regulation has been linked to decreased 
apoptosis and correlated with an aggressive phenotype and adverse prognosis in CRC 
(Paik et al., 2007; Zlobec et al., 2007). The likelihood of colorectal tumours to undergo 
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apoptosis is lower in the advanced-stage cancer. The APAF1 expression may serve as a 
predictive marker for chemotherapy response and drug resistance in CRC. Hector et al. 
(2012) have reported that patients with higher expression levels of APAF1 protein 
showed better recurrence-free and overall survival following 5-FU-based adjuvant 
chemotherapy. Another study by Zlobec, Vuong, and Compton (2006) has indicated that 
the APAF1 expression is a substantial marker for monitoring tumour regression in rectal 
cancer patients who have received neoadjuvant radiotherapy. The APAF1 mRNA has 
been found to be under epigenetic control, whereby allelic imbalance of the APAF1 
locus may contribute to the development and progression of CRC (Umetani et al., 2004). 
Apart from CRC, APAF1 has also been suggested as a marker of tumour progression in 
brain cancer, melanoma and gastric cancer (Johnson et al., 2007; Mustika, Budiyanto, 
Nishigori, Ichihashi, & Ueda, 2005; H. L. Wang, Bai, Li, Sun, & Wang, 2007). 
Mouhamad, Galluzzi, Zermati, Castedo, and Kroemer (2007) have demonstrated that 
APAF1 suppression in cancer can compromise the arrest of DNA synthesis in response 
to DNA damages by cisplastin, UVC radiation and gamma irradiation.  
Prior to this work, three independent research groups have reported the association 
between miR-23a and APAF1 in apoptosis. Q. Chen et al. (2014) have determined that 
miR-23a can alleviate hypoxia-induced neuronal apoptosis by suppressing the APAF1 
gene. Lian et al. (2013) have shown that the transfection of miR-23a inhibitor in glioma 
cell lines can restore the APAF1 expression and promote cell apoptosis. Shang et al. 
(2014) have revealed that miR-23a inhibition can enhance 5-FU drug chemosensitivity 
through APAF1/caspase-9 apoptotic pathway in HCT116 and HT29 CRC cells. The 
results obtained in this study are comparable with the published reports. In clinical CRC 
tissue samples, the expression level of miR-23a was found to be inversely correlated 
with the expression levels of APAF1 mRNA and APAF1 protein (Figure 4.52B, C). The 
miR-23a has been proven to bind to the 3’-UTR of APAF1 and dramatically decreasing 
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the levels of APAF1 mRNA and APAF1 protein. A limitation in the present study is the 
lack of a statistical power in the negative correlation between miR-23a and APAF1 
mRNA in the CRC blood samples (Figure 4.52A). Nonetheless, individual deregulation 
of miR-23a (r = 0.827) and APAF1 mRNA (r = 0.378) in the blood has been proven to 
be reflective of that in the CRC tissue. In addition, as the tumour progressed from the 
early-stage (I-II) to the advanced-stage (III-IV), an increasing trend of miR-23a 
expression levels (Figures 4.13 and 4.21) and a decreasing trend of APAF1 mRNA and 
APAF1 protein expression levels were noticed in both tissue and blood samples 
(Figures 4.49, 4.50 and 4.51). Blood circulation represents a complex environment in 
the human body (Luo, Burwinkel, Tao, & Brenner, 2011). The relatively small sample 
size in the present study may hinder the absolute confirmation of whether the 
deregulated miR-23a:APAF1 expression in the systemic circulation was related to CRC 
alone or as a general mechanism in histological progression to cancer. This is the first 
report that accesses the clinical correlation between the expression of miR-23a and 
APAF1 in the blood circulation of CRC patients. This study serves as a proof-of-concept 
example to highlight the physiological significance of miR-23a:APAF1 regulation axis 
as a biomarker to monitor tumour progression in CRC. Since apoptosis is the primary 
cytotoxic mechanism of chemotherapeutic agents, grouping the patients into early and 
advanced CRC may provide a general overview of the miR-23a:APAF1 regulation in 
the population that is most likely to be subjected for systemic chemotherapy.  
Recently, N. Wang et al. (2013) have revealed that the expression of miR-23a is 
transcriptional activated by the TP53 gene. Clinically, colorectal tumours tend to 
accumulate p53 mutations as they progress into late stages of carcinogenesis (Huerta et 
al., 2007). The SW480 and SW620 cell lines used in this study have been proven to 
express high levels of mutated p53 proteins (Rodrigues et al., 1990; Violette et al., 
2002). Since p53 mutation is a common genetic abnormality in CRC, the regulation of 
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cell apoptosis via p53-dependent pathway is greatly disrupted (Lacopetta, 2003). 
APAF1, which was found to be down-regulated in the present study, is an essential 
downstream effector of p53-mediated apoptosis (Fortin et al., 2001; Robles, Bemmels, 
Foraker, & Harris, 2001). This defect could lead to decreased apoptosis and thus, may 
contribute to chemoradioresistance. Collectively, the reported findings correspond to 
this notion whereby the increase of APAF1 mRNA and APAF1 protein following miR-
23a inhibition has rescued the downstream caspase-3 and -7 activities, leading to 
promotion of cell apoptosis. The possible involvement of p53 and miR-23a in the 
regulation of APAF1 is illustrated in Figure 5.4.  
 
 
 
 
 
 
 
 
 
Figure 5.4: Involvement of p53 and miR-23a in the regulation of APAF1 in CRC. The 
up-regulation of miR-23a and the increased synthesis of mutated p53 protein may lead 
to the down-regulation of APAF1 that interrupts the normal regulation of cell apoptosis.  
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5.2.3   miR-338-5p transfection in CRC 
miR-338-5p transfection was performed to study the effect of miR-338-5p modulation 
in CRC cells. However, the data from the MTT cell viability, Annexin V-FITC 
apoptosis and Matrigel migration and invasion analyses in both SW480 and SW620 cell 
lines did not reveal any statistical significance. Despite the up-regulation in the clinical 
samples (Figures 4.15 and 4.23), the biological relevance of miR-338-5p in CRC cell 
apoptosis, migration and invasion could not be elucidated in this study. Based on the 
available literature regarding the role of miR-338-5p in CRC (section 5.1.3.5), only Ju 
et al. (2013) have validated the involvement of miR-338-5p in CRC cell migration and 
autophagy. The transfection protocol and experimental assays used by Ju and his 
colleagues were different from the present work. Thus, these differences may account 
for the discrepancy between the two studies. The information on the role and regulation 
of miR-338-5p in CRC is limited. Other functional assays such as wound healing, cell 
cycle, oxidative stress and epigenetics assays could be performed in the future to further 
elucidate the function of miR-338-5p in CRC.  
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CHAPTER 6  
CONCLUSION 
 
6.1   Summary and significance of the study 
The present study was carried out to determine the potential blood miRNA biomarkers 
for early detection of CRC. Seven miRNAs (miR-150, miR-193a-3p, miR-23a, miR-
23b, miR-338-5p, miR-342-3p and miR-483-3p) have been found to be concurrently 
expressed in the tissue and blood miRNA arrays. Through comprehensive RT-qPCR 
validation and statistical analyses, miR-193a-3p, miR-23a and miR-338-5p have been 
demonstrated as a triple miRNA classifier for CRC detection, with an AUC of 0.887 
(80.0% sensitivity, 84.4% specificity and 83.3% accuracy). These miRNAs have been 
determined to be significantly up-regulated and positively correlated in the tissue and 
blood samples obtained from primary CRC patients. The findings have collectively 
implicated that the deregulation of miR-193a-3p, miR-23a and miR-338-5p in the 
circulating blood is reflective of those in the CRC tissue. 
The subsequent work involved the elucidation of miR-193a-3p, miR-23a and miR-338-
5p functions in the carcinogenesis of CRC. Each of these miRNAs was studied 
separately using SW480 and SW620 CRC cell lines. These cell lines have been shown 
to be a useful in vitro model for the analysis of gene expression changes during CRC 
progression. The effects of the deregulated miRNAs in cell viability, apoptosis, 
migration and invasion assays have been examined. Firstly, miR-193a-3p has been 
identified to be involved in the promotion of CRC cell migration and invasion. FOXO4 
has been experimentally validated as a direct target of miR-193a-3p. Clinically, as the 
tumour progressed from the early- to advanced-stage, an increasing trend of miR-193a-
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3p expression and a decreasing trend of FOXO4 expression were observed. Significant 
inverse correlation was detected in the tissue levels of miR-193a-3p and FOXO4 mRNA. 
Secondly, miR-23a has been shown to possess apoptosis resistance function in CRC. 
APAF1 has been experimentally validated as a direct target of miR-23a. Clinically, as 
the tumour progressed from the early- to advanced-stage, an increasing trend of miR-
23a expression and a decreasing trend of APAF1 expression were determined. The miR-
23a up-regulation was negatively correlated with APAF1 mRNA and APAF1 protein 
down-regulation in CRC tissue samples. However, statistical significance was not 
detected in the correlation between miR-193a-3p and FOXO4 mRNA or between miR-
23a and APAF1 mRNA in the blood samples. This is the first study that reports the 
clinical correlation between the expression levels of miR-193a-3p and FOXO4 or miR-
23a and APAF1 in CRC though the expression levels in the blood were not statistically 
significant. Further studies are warranted to explore the existing potential of miR-193a-
3p:FOXO4 and miR-23a:APAF1 regulation axes as biomarkers for miRNA-based 
therapy and prognostication. In this study, the modulation of miR-338-5p expression 
has been concluded with negative findings in the cell viability, apoptosis, migration and 
invasion analyses.  
 
6.2   Limitations and future prospects of the study 
In this research, there is a limitation in the tissue collection of stage I CRC samples. 
Surgically resected growths were usually small and thus the priority was given to the 
pathologists for histological analysis. The present work serves as an exploratory basis 
for further investigations in larger prospective and randomised clinical studies with 
higher number of samples from healthy controls and patients of advanced adenoma and 
various stages of CRC. A non-invasive miRNA screening assay using the triple miRNA 
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classifier of miR-193a-3p, miR-23a and miR-338-5p could then be developed to 
identify asymptomatic individuals with colorectal neoplasia prior to the invasive 
colonoscopy examination. The study may be extended to determine the feasibility of the 
three miRNAs as follow-up markers for the detection of CRC recurrence. Blood sample 
collection during surgical follow-up could be initiated to allow prospective evaluation 
of the changes in miRNA profiles. As technologies continue to advance, miRNA 
profiling will get even easier and cheaper. Moreover, the lack of negative correlations in 
the blood expression levels of miR-193a-3p:FOXO4 and miR-23a:APAF1 may also be 
addressed by a larger sample size.  
The limitation in the present functional study is the inability to screen all the available 
functional assays in cancer due to cost and time constraints. Since miR-338-5p was not 
found to be associated with apoptosis, migration and invasion functions in this 
investigation, future work involving other functional assays such as wound healing, cell 
cycle, oxidative stress and epigenetics assays could be performed to investigate the role 
of miR-338-5p in CRC.  
This research serves as a proof-of-concept example that highlights the potentiality of 
miR-193a-3p:FOXO4 and miR-23a:APAF1 regulation axes as therapeutic targets in 
CRC. The study may be extended into in vivo settings to generate more relevant data 
representing the living systems. Furthermore, it will be of interest to test the changes in 
the miRNA and mRNA levels following exposure to cytotoxic stimuli such as 
chemotherapeutic drugs and radiation in both in vitro and in vivo studies. Another future 
prospect of this study includes the effort to validate other gene targets of miR-193a-3p 
and miR-23a. In silico analysis has predicted the presence of thousands of 
miRNA:mRNA target pairs, of which only a small number have been experimentally 
validated. 
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All in all, the present research provides a promising rationale to explore and translate 
the findings into possible clinical applications in the diagnosis, prognosis and treatment 
of CRC. 
 
 
 
 
  
 212 
 
REFERENCES 
Ahlquist, D. A., Zou, H., Domanico, M., Mahoney, D. W., Yab, T. C., Taylor, W. 
R., . . . Lidgard, G. P. (2012). Next-generation stool DNA test accurately detects 
colorectal cancer and large adenomas. Gastroenterology, 142(2), 248-256.  
Ahmed, F. E., Amed, N. C., Vos, P. W., Bonnerup, C., Atkins, J. N., Casey, M., . . . 
Allison, R. R. (2012). Diagnostic microRNA markers to screen for sporadic 
human colon cancer in blood. Cancer Genomics and Proteomics, 9(4), 179-192.  
Akao, Y., Nakagawa, Y., & Naoe, T. (2006). let-7 microRNA functions as a potential 
growth suppressor in human colon cancer cells. Biological and Pharmaceutical 
Bulletin, 29(5), 903-906.  
Allison, J. E., Tekawa, I. S., Ransom, L. J., & Adrain, A. L. (1996). A comparison of 
fecal occult-blood tests for colorectal-cancer screening. The New England 
Journal of Medicine, 334(3), 155-159.  
Ambros, V., Bartel, B., Bartel, D. P., Burge, C. B., Carrington, J. C., Chen, X., . . . 
Tuschl, T. (2003). A uniform system for microRNA annotation. RNA, 9(3), 277-
279.  
American Cancer Society. (2011). Colorectal cancer facts & figures 2011-2013. Atlanta: 
American Cancer Society. 
Anderson, E. C., & Wong, M. H. (2010). Caught in the Akt: regulation of Wnt signaling 
in the intestine. Gastroenterology, 139(3), 718-722.  
André, T., Boni, C., Navarro, M., Tabernero, J., Hickish, T., Topham, C., . . . de 
Gramont, A. (2009). Improved overall survival with oxaliplatin, fluorouracil, 
and leucovorin as adjuvant treatment in stage II or III colon cancer in the 
MOSAIC trial. Journal of Clinical Oncology, 27(19), 3109-3116.  
Arden, K. C. (2006). Multiple roles of FOXO transcription factors in mammalian cells 
point to multiple roles in cancer. Experimental Gerontology, 41(8), 709-717.  
Arya, M., Shergill, I. S., Williamson, M., Gommersall, L., Arya, N., & Patel, H. R. 
(2005). Basic principles of real-time quantitative PCR. Expert Review of 
Molecular Diagnostics, 5(2), 209-219.  
Asangani, I. A., Rasheed, S. A., Nikolova, D. A., Leupold, J. H., Colburn, N. H., Post, 
S., & Allgayer, H. (2008). MicroRNA-21 (miR-21) post-transcriptionally 
downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation 
and metastasis in colorectal cancer. Oncogene, 27(15), 2128-2136.  
Austin, K. L., Power, E., Solarin, I., Atkin, W. S., Wardle, J., & Robb, K. A. (2009). 
Perceived barriers to flexible sigmoidoscopy screening for colorectal cancer 
among UK ethnic minority groups: a qualitative study. Journal of Medical 
Screening, 16(4), 174-179.  
Babashah, S., & Soleimani, M. (2011). The oncogenic and tumour suppresive roles of 
microRNAs in cancer and apoptosis. European Journal of Cancer, 47(8), 1127-
1137.  
 213 
 
Bader, A. G. (2012). miR-34 - a microRNA replacement therapy is headed to the clinic. 
Frontiers in Genetics, 3, 120.  
Bagga, S., Bracht, J., Hunter, S., Massirer, K., Holtz, J., Eachus, R., & Pasquinelli, A. E. 
(2005). Regulation by let-7 and lin-4 miRNAs results in target mRNA 
degradation. Cell, 122(4), 553-563.  
Bandi, P., Cokkinides, V., Smith, R. A., & Jemal, A. (2012). Trends in colorectal cancer 
screening with home-based fecal occult blood tests in adults ages 50 to 64 years, 
2000-2008. Cancer, 118(20), 5092-5099.  
Bao, L., Zhao, J., Dai, X., Wang, Y., Ma, R., Su, Y., . . . Ren, X. (2014). Correlation 
between miR-23a and onset of hepatocellular carcinoma. Clinics and Research 
in Hepatology and Gastroenterology, 38(3), 318-330.  
Barik, S. (2008). An intronic microRNA silences genes that are functionally 
antagonistic to its host gene. Nucleic Acids Research, 36(16), 5232-5241.  
Bartel, D. P. (2004). MicroRNAs: genomics, biogenesis, mechanism, and function. Cell, 
116(2), 281-297.  
Bartel, D. P. (2009). MicroRNAs: target recognition and regulatory functions. Cell, 
136(2), 215-233.  
Benchimol, S. (2001). p53-dependent pathways of apoptosis. Cell Death and 
Differentiation, 8(11), 1049-1051.  
Berezikov, E., Cuppen, E., & Plasterk, R. H. (2006). Approaches to microRNA 
discovery. Nature Genetics, 38, S2-S7.  
Bhattacharyya, S. N., Habermacher, R., Martine, U., Closs, E. I., & Filipowicz, W. 
(2006). Relief of microRNA-mediated translational repression in human cells 
subjected to stress. Cell, 125(6), 1111-1124.  
Biswas, S., Chytil, A., Washington, K., Romero-Gallo, J., Gorska, A. E., Wirth, P. 
S., . . . Grady, W. M. (2004). Transforming growth factor beta receptor type II 
inactivation promotes the establishment and progression of colon cancer. Cancer 
Research, 64(14), 4687-4692.  
Blok, E. J., Kuppen, P. J. K., van Leeuwen, J. E. M., & Sier, C. F. M. (2013). 
Cytoplasmic overexpression of HER2: a key factor in colorectal cancer. Clinical 
Medicine Insights: Oncology, 7, 41-51.  
Blosser, W., Vakana, E., Wyss, L. V., Swearingen, M. L., Stewart, J., Stancato, L., & 
Tate, C. M. (2014). A method to assess target gene involvement in angiogenesis 
in vitro and in vivo using lentiviral vectors expressing shRNA. PLoS ONE, 9(4), 
e96036.  
Borel, F., van Logtenstein, R., Koornneef, A., Maczuga, P., Ritsema, T., Petry, H., . . . 
Konstantinova, P. (2011). In vivo knock-down of multidrug resistance 
transporters ABCC1 and ABCC2 by AAV-delivered shRNAs and by artificial 
miRNAs. Journal of RNAi and Gene Silencing, 7, 434-442.  
 214 
 
Bouchie, A. (2013). First microRNA mimic enters clinic. Nature Biotechnology, 31(7), 
577.  
Boudreau, R. L., Martins, I., & Davidson, B. L. (2009). Artificial microRNAs as siRNA 
shuttles: improved safety as compared to shRNAs in vitro and in vivo. 
Molecular Therapy, 17(1), 169-175.  
Bray, F., Jemal, A., Grey, N., Ferlay, J., & Forman, D. (2012). Global cancer transitions 
according to the Human Development Index (2008-2030): a population-based 
study. The Lancet Oncology, 13(8), 790-801.  
Brazma, A., Hingamp, P., Quackenbush, J., Sherlock, G., Spellman, P., Stoeckert, 
C., . . . Vingron, M. (2001). Minimum information about a microarray 
experiment (MIAME)-toward standards for microarray data. Nature Genetics, 
29(4), 365-371.  
Bremnes, R. M., Dønnem, T., Al-Saad, S., Al-Shibli, K., Andersen, S., Sirera, R., . . . 
Busund, L. T. (2011). The role of tumor stroma in cancer progression and 
prognosis: emphasis on carcinoma-associated fibroblasts and non-small cell lung 
cancer. Journal of Thoracic Oncology, 6(1), 209-217.  
Brenner, H., Chang-Claude, J., Jansen, L., Knebel, P., Stock, C., & Hoffmeister, M. 
(2013). Reduced risk of colorectal cancer up to 10 years after screening, 
surveillance, or diagnostic colonoscopy. Gastroenterology, 146(3), 709-717.  
Broderick, J. A., & Zamore, P. D. (2011). MicroRNA therapeutics. Gene Therapy, 18, 
1104-1110.  
Bruce, W. R., Wolever, T. M., & Giacca, A. (2000). Mechanisms linking diet and 
colorectal cancer: the possible role of insulin resistance. Nutrition and Cancer, 
37(1), 19-26.  
Budhu, A., Jia, H. L., Forgues, M., Liu, C. G., Goldstein, D., Lam, A., . . . Wang, X. W. 
(2008). Identification of metastasis-related microRNAs in hepatocellular 
carcinoma. Hepatology, 47(3), 897-907.  
Burgering, B. M., & Kops, G. J. (2002). Cell cycle and death control: long live 
Forkheads. Trends in Biochemical Sciences, 27(7), 352-360.  
Burgos, K. L., Javaherian, A., Bomprezzi, R., Ghaffari, L., Rhodes, S., Courtright, 
A., . . . Van Keuren-Jensen, K. (2013). Identification of extracellular miRNA in 
human cerebrospinal fluid by next-generation sequencing. RNA, 19(5), 712-722.  
Burk, U., Schubert, J., Wellner, U., Schmalhofer, O., Vincan, E., Spaderna, S., & 
Brabletz, T. (2008). A reciprocal repression between ZEB1 and members of the 
miR-200 family promotes EMT and invasion in cancer cells. EMBO Reports, 
9(6), 582-589.  
Bustin, S. A., Benes, V., Garson, J. A., Hellemans, J., Huggett, J., Kubista, M., . . . 
Wittwer, C. T. (2009). The MIQE guidelines: minimum information for 
publication of quantitative real-time PCR experiments. Clinical Chemistry, 
55(4), 611-622.  
 215 
 
Cai, K., Mulatz, K., Ard, R., Nguyen, T., & Gee, S. H. (2014). Increased diacylglycerol 
kinase ζ expression in human metastatic colon cancer cells augments Rho 
GTPase activity and contributes to enhanced invasion. BMC Cancer, 14, 208.  
Cain, K., Bratton, S. B., & Cohen, G. M. (2002). The apaf-1 apoptosome: a large 
caspase-activating complex. Biochimie, 84(2-3), 203-214.  
Calin, G. A., Dumitru, C. D., Shimizu, M., Bichi, R., Zupo, S., Noch, E., . . . Croce, C. 
M. (2002). Frequent deletions and down-regulation of micro-RNA genes miR15 
and miR16 at 13q14 in chronic lymphocytic leukemia. Proceedings of the 
National Academy of Sciences of the United States of America, 99(24), 15524-
15529.  
Calin, G. A., Sevignani, C., Dumitru, C. D., Hyslop, T., Noch, E., Yendamuri, S., . . . 
Croce, C. M. (2004). Human microRNA genes are frequently located at fragile 
sites and genomic regions involved in cancers. Proceedings of the National 
Academy of Sciences of the United States of America, 101(9), 2999-3004.  
Callari, M., Dugo, M., Musella, V., Marchesi, E., Chiorino, G., Grand, M. M., . . . De 
Cecco, L. (2012). Comparison of microarray platforms for measuring 
differential microRNA expression in paired normal/cancer colon tissues. PLoS 
ONE, 7(9), e45105.  
Campioni, M., Santini, D., Tonini, G., Murace, R., Dragonetti, E., Spugnini, E. P., & 
Baldi, A. (2005). Role of Apaf-1, a key regulator of apoptosis, in melanoma 
progression and chemoresistance. Experimental Dermatology, 14(11), 811-818.  
Caraguel, C. G. B., Stryhn, H., Gagné, N., Dohoo, I. R., & Hammell, K. L. (2011). 
Selection of a cutoff value for real-time polymerase chain reaction results to fit a 
diagnostic purpose: analytical and epidemiologic approaches. Journal of 
Veterinary Diagnostic Investigation, 23(1), 2-15.  
Carrato, A. (2008). Adjuvant treatment of colorectal cancer. Gastrointestinal Cancer 
Research, 2(4), S42-S46.  
Castanotto, D., Sakurai, K., Lingeman, R., Li, H., Shively, L., Aagaard, L., . . . Rossi, J. 
J. (2007). Combinatorial delivery of small interfering RNAs reduces RNAi 
efficacy by selective incorporation into RISC. Nucleic Acids Research, 35(15), 
5154-5164.  
Castro, G., Azrak, M. F., Seeff, L. C., & Royalty, J. (2013). Outpatient colonoscopy 
complications in the CDC's Colorectal Cancer Screening Demonstration 
Program: a prospective analysis. Cancer, 119(15), 2849-2854.  
Cecconi, F., Alvarez-Bolado, G., Meyer, B. I., Roth, K. A., & Gruss, P. (1998). Apaf1 
(CED-4 homolog) regulates programmed cell death in mammalian development. 
Cell, 94(6), 727-737.  
Chan, S. P., & Slack, F. J. (2006). microRNA-mediated silencing inside P-bodies. RNA 
Biology, 3(3), 97-100.  
Chang, K. H., Mestdagh, P., Vandesompele, J., Kerin, M. J., & Miller, N. (2010). 
MicroRNA expression profiling to identify and validate reference genes for 
relative quantification in colorectal cancer. BMC Cancer, 10, 173.  
 216 
 
Chang, K. H., Miller, N., Kheirelseid, E. A., Ingoldsby, H., Hennessy, E., Curran, C. 
E., . . . Kerin, M. J. (2011). MicroRNA-21 and PDCD4 expression in colorectal 
cancer. European Journal of Surgical Oncology, 37(7), 597-603.  
Chang, T. C., Wentzel, E. A., Kent, O. A., Ramachandran, K., Mullendore, M., Lee, K. 
H., . . . Mendell, J. T. (2007). Transactivation of miR-34a by p53 broadly 
influences gene expression and promotes apoptosis. Molecular Cell, 26(5), 745-
752.  
Chao, W., & D'Amore, P. A. (2008). IGF2: epigenetic regulation and role in 
development and disease. Cytokine and Growth Factor Reviews, 19(2), 111-120.  
Chen, L., Tang, Y., Wang, J., Yan, Z., & Xu, R. (2013). miR-421 induces cell 
proliferation and apoptosis resistance in human nasopharyngeal carcinoma via 
downregulation of FOXO4. Biochemical and Biophysical Research 
Communications, 435(4), 745-750.  
Chen, Q., Xu, J., Li, L., Li, H., Mao, S., Zhang, F., . . . Zhang, Q. (2014). MicroRNA-
23a/b and microRNA-27a/b suppress Apaf-1 protein and alleviate hypoxia-
induced neuronal apoptosis. Cell Death and Disease, 5, e1132.  
Chen, X., Ba, Y., Ma, L., Cai, X., Yin, Y., Wang, K., . . . Zhang, C. Y. (2008). 
Characterization of microRNAs in serum: a novel class of biomarkers for 
diagnosis of cancer and other diseases. Cell Research, 18(10), 997-1006.  
Chen, X., Guo, X., Zhang, H., Xiang, Y., Chen, J., Yin, Y., . . . Zhang, C. Y. (2009). 
Role of miR-143 targeting KRAS in colorectal tumorigenesis. Oncogene, 28(10), 
1385-1392.  
Chhabra, R., Dubey, R., & Saini, N. (2010). Cooperative and individualistic functions 
of the microRNAs in the miR-23a~27a~24-2 cluster and its implication in 
human diseases. Molecular Cancer, 9, 232.  
Chin, L. J., & Slack, F. J. (2008). A truth serum for cancer-microRNAs have major 
potential as cancer biomarkers. Cell Research, 18(10), 983-984.  
Choong, M. K., & Tsafnat, G. (2012). Genetic and epigenetic biomarkers of colorectal 
cancer. Clinical Gastroenterology and Hepatology, 10(1), 9-15.  
Compton, C. C., Byrd, D. R., Garcia-Aguilar, J., Kurtzman, S. H., Olawaiye, A., & 
Washington, M. K. (Eds.). (2012). AJCC Cancer Staging Atlas: a companion to 
the seventh editions of the AJCC Cancer Staging Manual and Handbook. New 
York, NY: Springer. 
Corney, D. C., Flesken-Nikitin, A., Godwin, A. K., Wang, W., & Nikitin, A. Y. (2007). 
MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control 
of cell proliferation and adhesion-independent growth. Cancer Research, 67(18), 
8433-8438.  
Corre, S., & Galibert, M. D. (2005). Upstream stimulating factors: highly versatile 
stress-responsive transcription factors. Pigment Cell Research, 18(5), 337-348.  
 217 
 
Corvaro, M., & Cecconi, F. (2004). APAF1 (apoptotic protease activating factor 1). 
Atlas of Genetics and Cytogenetics in Oncology and Haematology, 8(4), 296-
301.  
Cotton, P. B., Durkalski, V. L., Pineau, B. C., Palesch, Y. Y., Mauldin, P. D., Hoffman, 
B., . . . Butler, H. (2004). Computed tomographic colonography (virtual 
colonoscopy): a multicenter comparison with standard colonoscopy for detection 
of colorectal neoplasia. The Journal of the American Medical Association, 
291(14), 1713-1719.  
Creeden, J., Junker, F., Vogel-Ziebolz, S., & Rex, D. (2011). Serum tests for colorectal 
cancer screening. Molecular Diagnosis and Therapy, 15(3), 129-141.  
Cui, H., Cruz-Correa, M., Giardiello, F. M., Hutcheon, D. F., Kafonek, D. R., 
Brandenburg, S., . . . Feinberg, A. P. (2003). Loss of IGF2 imprinting: a 
potential marker of colorectal cancer risk. Science, 299(5613), 1753-1755.  
Dalby, B., Cates, S., Harris, A., Ohki, E. C., Tilkins, M. L., Price, P. J., & Ciccarone, V. 
C. (2004). Advanced transfection with Lipofectamine 2000 reagent: primary 
neurons, siRNA, and high-throughput applications. Methods, 33(2), 95-103.  
Dansen, T. B., & Burgering, B. M. (2008). Unravelling the tumor-suppressive functions 
of FOXO proteins. Trends in Cell Biology, 18(9), 421-429.  
Davis, J. M. (Ed.). (2011). Animal cell culture: essential methods. New York, NY: John 
Wiley & Sons, Inc. 
Davoren, P. A., McNeill, R. E., Lowery, A. J., Kerin, M. J., & Miller, N. (2008). 
Identification of suitable endogenous control genes for microRNA gene 
expression analysis in human breast cancer. BMC Molecular Biology, 9, 76.  
Degterev, A., Boyce, M., & Yuan, J. (2003). A decade of caspases. Oncogene, 22(53), 
8543-8567.  
Delgado, A. P., Brandao, P., Hamid, S., & Narayanan, R. (2013). Mining the dark 
matter of the cancer proteome for novel biomarkers. Current Cancer Therapy 
Reviews, 9(4), 265-277.  
Detours, V., Dumont, J. E., Bersini, H., & Maenhaut, C. (2003). Integration and cross-
validation of high-throughput gene expression data: comparing heterogeneous 
data sets. FEBS Letters, 546(1), 98-102.  
deVos, T., Tetzner, R., Model, F., Weiss, G., Schuster, M., Distler, J., . . . Lofton-Day, 
C. (2009). Circulating methylated SEPT9 DNA in plasma is a biomarker for 
colorectal cancer. Clinical Chemistry, 55(7), 1337-1346.  
Dews, M., Homayouni, A., Yu, D., Murphy, D., Sevignani, C., Wentzel, E., . . . 
Thomas-Tikhonenko, A. (2006). Augmentation of tumor angiogenesis by a 
Myc-activated microRNA cluster. Nature Genetics, 38(9), 1060-1065.  
Doench, J. G., & Sharp, P. A. (2004). Specificity of microRNA target selection in 
translational repression. Genes and Development, 18(5), 504-511.  
 218 
 
Dou, R., Deng, Y., Huang, L., Fu, S., Tan, S., Wang, L., . . . Wang, J. (2013). Multi-
microarray identifies lower AQP9 expression in adjuvant chemotherapy 
nonresponders with stage III colorectal cancer. Cancer Letters, 336(1), 106-113.  
Dukes, C. E., & Bussey, H. J. R. (1958). The spread of rectal cancer and its effect on 
prognosis. British Journal of Cancer, 12(3), 309-320.  
Dweep, H., Sticht, C., Pandey, P., & Gretz, N. (2011). miRWalk - database: prediction 
of possible miRNA binding sites by "walking" the genes of three genomes. 
Journal of Biomedical Informatics, 44(5), 839-847.  
Dyrskjøt, L., Ostenfeld, M. S., Bramsen, J. B., Silahtaroglu, A. N., Lamy, P., 
Ramanathan, R., . . . Orntoft, T. F. (2009). Genomic profiling of microRNAs in 
bladder cancer: miR-129 is associated with poor outcome and promotes cell 
death in vitro. Cancer Research, 69(11), 4851-4860.  
Earle, J. S. L., Luthra, R., Romans, A., Abraham, R., Ensor, J., Yao, H., & Hamilton, S. 
R. (2010). Association of microRNA expression with microsatellite instability 
status in colorectal adenocarcinoma. The Journal of Molecular Diagnostics, 
12(4), 433-440.  
Ebert, M. S., & Sharp, P. A. (2010). MicroRNA sponges: progress and possibilities. 
RNA, 16(11), 2043-2050.  
Edge, S. B., & Compton, C. C. (2010). The American Joint Committee on Cancer: the 
7th edition of the AJCC Cancer Staging Manual and the future of TNM. Annals 
of Surgical Oncology, 17(6), 1471-1474.  
Eis, P. S., Tam, W., Sun, L., Chadburn, A., Li, Z., Gomez, M. F., . . . Dahlberg, J. E. 
(2005). Accumulation of miR-155 and BIC RNA in human B cell lymphomas. 
Proceedings of the National Academy of Sciences of the United States of 
America, 102(10), 3627-3632.  
Elmore, S. (2007). Apoptosis: a review of programmed cell death. Toxicologic 
Pathology, 35(4), 495-516.  
Enright, A. J., John, B., Gaul, U., Tuschl, T., Sander, C., & Marks, D. S. (2003). 
MicroRNA targets in Drosophila. Genome Biology, 5(1), R1.  
Esau, C., Davis, S., Murray, S. F., Yu, X. X., Pandey, S. K., Pear, M., . . . Monia, B. P. 
(2006). miR-122 regulation of lipid metabolism revealed by in vivo antisense 
targeting. Cell Metabolism, 3(2), 87-98.  
Esau, C. C., & Monia, B. P. (2007). Therapeutic potential for microRNAs. Advanced 
Drug Delivery Reviews, 59(2-3), 101-114.  
Esquela-Kerscher, A., & Slack, F. J. (2006). Oncomirs - microRNAs with a role in 
cancer. Nature Reviews Cancer, 6(4), 259-269.  
Faltejskova, P., Svoboda, M., Srutova, K., Mlcochova, J., Besse, A., Nekvindova, J., . . . 
Slaby, O. (2012). Identification and functional screening of microRNAs highly 
deregulated in colorectal cancer. Journal of Cellular and Molecular Medicine, 
16(11), 2655-2666.  
 219 
 
Fan, T. J., Han, L. H., Cong, R. S., & Liang, J. (2005). Caspase family proteases and 
apoptosis. Acta Biochimica et Biophysica Sinica, 37(11), 719-727.  
Fang, J. Y., & Richardson, B. C. (2005). The MAPK signalling pathways and colorectal 
cancer. The Lancet Oncology, 6(5), 322-327.  
Fearon, E. R., & Vogelstein, B. (1990). A genetic model for colorectal tumorigenesis. 
Cell, 61(5), 759-767.  
Feng, B., Dong, T. T., Wang, L. L., Zhou, H. M., Zhao, H. C., Dong, F., & Zheng, M. H. 
(2012). Colorectal cancer migration and invasion initiated by microRNA-106a. 
PLoS ONE, 7(8), e43452.  
Fenlon, H. M., Nunes, D. P., Schroy III, P. C., Barish, M. A., Clarke, P. D., & Ferrucci, 
J. T. (1999). A comparison of virtual and conventional colonoscopy for the 
detection of colorectal polyps. The New England Journal of Medicine, 341(20), 
1496-1503.  
Ferlay, J., Soerjomataram, I., Ervik, M., Dikshit, R., Eser, S., Mathers, C., . . . Bray, F. 
(2013). Cancer incidence and mortality worldwide: IARC CancerBase No. 11  
Retrieved July 23, 2014, from http://globocan.iarc.fr 
Filipowicz, W. (2005). RNAi: the nuts and bolts of the RISC machine. Cell, 122(1), 17-
20.  
Fiscella, M., Zhang, H., Fan, S., Sakaguchi, K., Shen, S., Mercer, W. E., . . . Appella, E. 
(1997). Wip1, a novel human protein phosphatase that is induced in response to 
ionizing radiation in a p53-dependent manner. Proceedings of the National 
Academy of Sciences of the United States of America, 94(12), 6048-6053.  
Flitcroft, K. L., Irwig, L. M., Carter, S. M., Salkeld, G. P., & Gillespie, J. A. (2012). 
Colorectal cancer screening: why immunochemical fecal occult blood tests may 
be the best option. BMC Gastroenterology, 12, 183.  
Fortin, A., Cregan, S. P., MacLaurin, J. G., Kushwaha, N., Hickman, E. S., Thompson, 
C. S., . . . Slack, R. S. (2001). APAF1 is a key transcriptional target for p53 in 
the regulation of neuronal cell death. The Journal of Cell Biology, 155(2), 207-
216.  
Fourie, N. H., Peace, R. M., Abey, S. K., Sherwin, L. B., Rahim-Williams, B., Smyser, 
P. A., . . . Henderson, W. A. (2014). Elevated circulating miR-150 and miR-342-
3p in patients with irritable bowel syndrome. Experimental and Molecular 
Pathology, 96(3), 422-425.  
Fu, Z., & Tindall, D. J. (2008). FOXOs, cancer and regulation of apoptosis. Oncogene, 
27(16), 2312-2319.  
Fujita, T., Yanagihara, K., Takeshita, F., Aoyagi, K., Nishimura, T., Takigahira, M., . . . 
Sasaki, H. (2013). Intraperitoneal delivery of a small interfering RNA targeting 
NEDD1 prolongs the survival of scirrhous gastric cancer model mice. Cancer 
Science, 104(2), 214-222.  
 
 220 
 
Gaedcke, J., Grade, M., Camps, J., Søkilde, R., Kaczkowski, B., Schetter, A. J., . . . 
Litman, T. (2012). The rectal cancer microRNAome - microRNA expression in 
rectal cancer and matched normal mucosa. Clinical Cancer Research, 18(18), 
4919-4930.  
Gao, P., Tchernyshyov, I., Chang, T. C., Lee, Y. S., Kita, K., Ochi, T., . . . Dang, C. V. 
(2009). c-Myc suppression of miR-23 enhances mitochondrial glutaminase and 
glutamine metabolism. Nature, 458(7239), 762-765.  
Garzon, R., Calin, G. A., & Croce, C. M. (2009). MicroRNAs in cancer. Annual Review 
of Medicine, 60, 167-179.  
Geng, L., Sun, B., Gao, B., Wang, Z., Quan, C., Wei, F., & Fang, X. D. (2014). 
MicroRNA-103 promotes colorectal cancer by targeting tumor suppressor 
DICER and PTEN. International Journal of Molecular Sciences, 15(5), 8458-
8472.  
Ghosh, D., Yu, H., Tan, X. F., Lim, T. K., Zubaidah, R. M., Tan, H. T., . . . Lin, Q. 
(2011). Identification of key players for colorectal cancer metastasis by iTRAQ 
quantitative proteomics profiling of isogenic SW480 and SW620 cell lines. 
Journal of Proteome Research, 10(10), 4373-4387.  
Gibbons, F. D., & Roth, F. P. (2002). Judging the quality of gene expression-based 
clustering methods using gene annotation. Genome Research, 12(10), 1574-1581.  
Giles, R. H., van Es, J. H., & Clevers, H. (2003). Caught up in a Wnt storm: Wnt 
signaling in cancer. Biochimica et Biophyisica Acta, 1653(1), 1-24.  
Ginzinger, D. G. (2002). Gene quantification using real-time quantitative PCR: an 
emerging technology hits the mainstream. Experimental Hematology, 30(6), 
503-512.  
Gluecker, T. M., Johnson, C. D., Harmsen, W. S., Offord, K. P., Harris, A. M., Wilson, 
L. A., & Ahlquist, D. A. (2003). Colorectal cancer screening with CT 
colonography, colonoscopy, and double-contrast barium enema examination: 
prospective assessment of patient perceptions and preferences. Radiology, 
227(2), 378-384.  
Godfrey, A. C., Xu, Z., Weinberg, C. R., Getts, R. C., Wade, P. A., Deroo, L. A., . . . 
Taylor, J. A. (2013). Serum microRNA expression as an early marker for breast 
cancer risk in prospectively collected samples from the Sister Study cohort. 
Breast Cancer Research, 15, R42.  
Gold, P., & Freedman, S. O. (1965). Specific carcinoembryonic antigens of the human 
digestive system. The Journal of Experimental Medicine, 122(3), 467-481.  
Grada, A., & Weinbrecht, K. (2013). Next-generation sequencing: methodology and 
application. Journal of Investigative Dermatology, 133(8), e11.  
Grady, W. M., Myeroff, L. L., Swinler, S. E., Rajput, A., Thiagalingam, S., Lutterbaugh, 
J. D., . . . Markowitz, S. (1999). Mutational inactivation of transforming growth 
factor beta receptor type II in microsatellite stable colon cancers. Cancer 
Research, 59(2), 320-324.  
 221 
 
Grady, W. M., Parkin, R. K., Mitchell, P. S., Lee, J. H., Kim, Y. H., Tsuchiya, K. D., . . . 
Tewari, M. (2008). Epigenetic silencing of the intronic microRNA hsa-miR-342 
and its host gene EVL in colorectal cancer. Oncogene, 27(27), 3880-3888.  
Gramantieri, L., Ferracin, M., Fornari, F., Veronese, A., Sabbioni, S., Liu, C. G., . . . 
Negrini, M. (2007). Cyclin G1 is a target of miR-122a, a microRNA frequently 
down-regulated in human hepatocellular carcinoma. Cancer Research, 67(13), 
6092-6099.  
Greer, E. L., & Brunet, A. (2005). FOXO transcription factors at the interface between 
longevity and tumor suppression. Oncogene, 24(50), 7410-7425.  
Griffiths-Jones, S., Grocock, R. J., van Dongen, S., Bateman, A., & Enright, A. J. 
(2006). miRBase: microRNA sequences, targets and gene nomenclature. Nucleic 
Acids Research, 34, D140-D144.  
Grimm, D., Streetz, K. L., Jopling, C. L., Storm, T. A., Pandey, K., Davis, C. R., . . . 
Kay, M. A. (2006). Fatality in mice due to oversaturation of cellular 
microRNA/short hairpin RNA pathways. Nature, 441(7092), 537-541.  
Guo, C., Sah, J. F., Beard, L., Willson, J. K., Markowitz, S. D., & Guda, K. (2008). The 
noncoding RNA, miR-126, suppresses the growth of neoplastic cells by 
targeting phosphatidylinositol 3-kinase signaling and is frequently lost in colon 
cancers. Genes, Chromosomes and Cancer, 47(11), 939-946.  
Guo, Z., Zhou, B., Liu, W., Xu, Y., Wu, D., Yin, Z., . . . Luo, D. (2013). MiR-23a 
regulates DNA damage repair and apoptosis in UVB-irradiated HaCaT cells. 
Journal of Dermatological Science, 69(1), 68-76.  
Gupta, A., Swaminathan, G., Martin-Garcia, J., & Navas-Martin, S. (2012). 
MicroRNAs, hepatitis C virus, and HCV/HIV-1 co-infection: new insights in 
pathogenesis and therapy. Viruses, 4(11), 2485-2513.  
Half, E., Bercovich, D., & Rozen, P. (2009). Familial adenomatous polyposis. Orphanet 
Journal of Rare Diseases, 4, 22.  
Halligan, S., Wooldrage, K., Dadswell, E., Kralj-Hans, I., von Wagner, C., Edwards, 
R., . . . Atkin, W. (2013). Computed tomographic colonography versus barium 
enema for diagnosis of colorectal cancer or large polyps in symptomatic patients 
(SIGGAR): a multicentre randomised trial. The Lancet, 381(9873), 1185-1193.  
Hamfjord, J., Stangeland, A. M., Hughes, T., Skrede, M. L., Tveit, K. M., Ikdahl, T., & 
Kure, E. H. (2012). Differential expression of miRNAs in colorectal cancer: 
comparison of paired tumor tissue and adjacent normal mucosa using high-
throughput sequencing. PLoS ONE, 7(4), e34150.  
Hamilton, S. R., & Aaltonen, L. A. (Eds.). (2000). Pathology and genetics of tumours of 
the digestive system. Lyon: IARC Press. 
Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. Cell, 
144(5), 646-674.  
 222 
 
Hao, J., Zhang, S., Zhou, Y., Hu, X., & Shao, C. (2011). MicroRNA 483-3p suppresses 
the expression of DPC4/Smad4 in pancreatic cancer. FEBS Letters, 585(1), 207-
213.  
Hari, D. M., Leung, A. M., Lee, J. H., Sim, M. S., Vuong, B., Chiu, C. G., & Bilchik, A. 
J. (2013). AJCC Cancer Staging Manual 7th edition criteria for colon cancer: do 
the complex modifications improve prognostic assessment? Journal of the 
American College of Surgeons, 217(2), 181-190.  
Harrison, S., & Benziger, H. (2011). The molecular biology of colorectal carcinoma and 
its implications: a review. The Surgeon, 9(4), 200-210.  
Hauke, J., & Kossowski, T. (2011). Comparison of values of Pearson's and Spearman's 
correlation coefficients on the same sets of data. Quaestiones Geographicae, 
30(2), 87-93.  
Häusler, S. F., Keller, A., Chandran, P. A., Ziegler, K., Zipp, K., Heuer, S., . . . 
Wischhusen, J. (2010). Whole blood-derived miRNA profiles as potential new 
tools for ovarian cancer screening. British Journal of Cancer, 103(5), 693-700.  
He, L., & Hannon, G. J. (2004). MicroRNAs: small RNAs with a big role in gene 
regulation. Nature Reviews Genetics, 5(7), 522-531.  
Hector, S., Conlon, S., Schmid, J., Dicker, P., Cummins, R. J., Concannon, C. G., . . . 
Prehn, J. H. (2012). Apoptosome-dependent caspase activation proteins as 
prognostic markers in Stage II and III colorectal cancer. British Journal of 
Cancer, 106(9), 1499-1505.  
Heichman, K. A. (2014). Blood-based testing for colorectal cancer screening. Molecular 
Diagnosis and Therapy, 18(2), 127-135.  
Heid, C. A., Stevens, J., Livak, K. J., & Williams, P. M. (1996). Real time quantitative 
PCR. Genome Research, 6(10), 986-994.  
Heneghan, H. M., Miller, N., Lowery, A. J., Sweeney, K. J., Newell, J., & Kerin, M. J. 
(2010). Circulating microRNAs as novel minimally invasive biomarkers for 
breast cancer. Annals of Surgery, 251(3), 499-505.  
Hengartner, M. O. (2000). The biochemistry of apoptosis. Nature, 407(6805), 770-776.  
Hewitt, R. E., McMarlin, A., Kleiner, D., Wersto, R., Martin, P., Tsokos, M., . . . 
Stetler-Stevenson, W. G. (2000). Validation of a model of colon cancer 
progression. The Journal of Pathology, 192(4), 446-454.  
Hickman, E. S., & Helin, K. (2002). The regulation of APAF1 expression during 
development and tumourigenesis. Apoptosis, 7(2), 167-171.  
Hong, X., Chen, G., Wang, M., Lou, C., Mao, Y., Li, Z., & Zhang, Y. (2012). STAT5a-
targeting miRNA enhances chemosensitivity to cisplatin and 5-fluorouracil in 
human colorectal cancer cells. Molecular Medicine Reports, 5(5), 1215-1219.  
Hu, M. C., Lee, D. F., Xia, W., Golfman, L. S., Ou-Yang, F., Yang, J. Y., . . . Hung, M. 
C. (2004). IkappaB kinase promotes tumorigenesis through inhibition of 
forkhead FOXO3a. Cell, 117(2), 225-237.  
 223 
 
Huang, H., Regan, K. M., Wang, F., Wang, D., Smith, D. I., van Deursen, J. M., & 
Tindall, D. J. (2005). Skp2 inhibits FOXO1 in tumor suppression through 
ubiquitin-mediated degradation. Proceedings of the National Academy of 
Sciences of the United States of America, 102(5), 1649-1654.  
Huang, Z., Huang, D., Ni, S., Peng, Z., Sheng, W., & Du, X. (2010). Plasma 
microRNAs are promising novel biomarkers for early detection of colorectal 
cancer. International Journal of Cancer, 127(1), 118-126.  
Huerta, S., Heinzerling, J. H., Anguiano-Hernandez, Y. M., Huerta-Yepez, S., Lin, J., 
Chen, D., . . . Livingston, E. H. (2007). Modification of gene products involved 
in resistance to apoptosis in metastatic colon cancer cells: roles of Fas, Apaf-1, 
NFkappaB, IAPs, Smac/DIABLO, and AIF. Journal of Surgical Research, 
142(1), 184-194.  
Hummel, R., Wang, T., Watson, D. I., Michael, M. Z., Van der Hoek, M., Haier, J., & 
Hussey, D. J. (2011). Chemotherapy-induced modification of microRNA 
expression in esophageal cancer. Oncology Reports, 26(4), 1011-1017.  
Idogawa, M., Sasaki, Y., Suzuki, H., Mita, H., Imai, K., Shinomura, Y., & Tokino, T. 
(2009). A single recombinant adenovirus expressing p53 and p21-targeting 
artificial microRNAs efficiently induces apoptosis in human cancer cells. 
Clinical Cancer Research, 15(11), 3725-3732.  
Iliopoulos, D., Rotem, A., & Struhl, K. (2011). Inhibition of miR-193a expression by 
Max and RXRα activates K-Ras and PLAU to mediate distinct aspects of 
cellular transformation. Cancer Research, 71(15), 5144-5153.  
Imperiale, T. F., Ransohoff, D. F., Itzkowitz, S. H., Turnbull, B. A., & Ross, M. E. 
(2004). Fecal DNA versus fecal occult blood for colorectal-cancer screening in 
an average risk population. The New England Journal of Medicine, 351(26), 
2704-2714.  
Irizarry, R. A., Hobbs, B., Collin, F., Beazer-Barclay, Y. D., Antonellis, K. J., Scherf, 
U., & Speed, T. P. (2003). Exploration, normalization, and summaries of high 
density oligonucleotide array probe level data. Biostatistics, 4(2), 249-264.  
Jahid, S., Sun, J., Edwards, R. A., Dizon, D., Panarelli, N. C., Milsom, J. W., . . . Lipkin, 
S. M. (2012). miR-23a promotes the transition from indolent to invasive 
colorectal cancer. Cancer Discovery, 2(6), 540-553.  
Jansen, A. P., Camalier, C. E., & Colburn, N. H. (2005). Epidermal expression of the 
translation inhibitor programmed cell death 4 suppresses tumourigenesis. 
Cancer Research, 65(14), 6034-6041.  
Janssen, H. L., Reesink, H. W., Lawitz, E. J., Zeuzem, S., Rodriguez-Torres, M., Patel, 
K., . . . Hodges, M. R. (2013). Treatment of HCV infection by targeting 
microRNA. The New England Journal of Medicine, 368(18), 1685-1694.  
Jeffers, J. R., Parganas, E., Lee, Y., Yang, C., Wang, J., Brennan, J., . . . Zambetti, G. P. 
(2003). Puma is an essential mediator of p53-dependent and -independent 
apoptotic pathways. Cancer Cell, 4(4), 321-328.  
 224 
 
John, M., Constien, R., Akinc, A., Goldberg, M., Moon, Y. A., Spranger, M., . . . 
Bumcrot, D. (2007). Effective RNAi-mediated gene silencing without 
interruption of the endogenous microRNA pathway. Nature, 449(7163), 745-747.  
Johnson, C. E., Huang, Y. Y., Parrish, A. B., Smith, M. I., Vaughn, A. E., Zhang, Q., . . . 
Deshmukh, M. (2007). Differential Apaf-1 levels allow cytochrome c to induce 
apoptosis in brain tumors but not in normal neural tissues. Proceedings of the 
National Academy of Sciences of the United States of America, 104(52), 20820-
20825.  
Jordan, J. A., & Durso, M. B. (2005). Real-time polymerase chain reaction for detecting 
bacterial DNA directly from blood of neonates being evaluated for sepsis. The 
Journal of Molecular Diagnostics, 7(5), 575-581.  
Jørgensen, J. T., & Hersom, M. (2012). HER2 as a prognostic marker in gastric cancer - 
a systematic analysis of data from the literature. Journal of Cancer, 3, 137-144.  
Josse, C., Bouznad, N., Geurts, P., Irrthum, A., Huynh-Thu, V. A., Servais, L., . . . Oury, 
C. (2014). Identification of a microRNA landscape targeting the PI3K/Akt 
signaling pathway in inflammation-induced colorectal carcinogenesis. American 
Journal of Physiology - Gastrointestinal and Liver Physiology, 306(3), G229-
G243.  
Ju, J. A., Huang, C. T., Lan, S. H., Wang, T. H., Lin, P. C., Lee, J. C., . . . Liu, H. S. 
(2013). Characterization of a colorectal cancer migration and autophagy-related 
microRNA miR-338-5p and its target gene PIK3C3. Biomarkers and Genomic 
Medicine, 5(3), 74-78.  
Ju, J. A., Huang, Y. C., Lan, S. H., Wang, T. H., Lin, P. C., Lee, J. C., . . . Liu, H. S. 
(2012). Identification of colorectal cancer recurrence-related microRNAs. 
Genomic Medicine, Biomarkers, and Health Sciences, 4(1-2), 19-20.  
Juven-Gershon, T., & Oren, M. (1999). Mdm2: the ups and downs. Molecular Medicine, 
5(2), 71-83.  
Kahi, C. J., Imperiale, T. F., Juliar, B. E., & Rex, D. K. (2009). Effect of screening 
colonoscopy on colorectal cancer incidence and mortality. Clinical 
Gastroenterology and Hepatology, 7(7), 770-775.  
Karolina, D. S., Armugam, A., Tavintharan, S., Wong, M. T., Lim, S. C., Sum, C. F., & 
Jeyaseelan, K. (2011). MicroRNA 144 impairs insulin signaling by inhibiting 
the expression of insulin receptor substrate 1 in type 2 diabetes mellitus. PLoS 
ONE, 6(8), e22839.  
Kastan, M. B., Zhan, Q., el-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., . . . 
Fornace Jr, A. J. (1992). A mammalian cell cycle checkpoint pathway utilizing 
p53 and GADD45 is defective in ataxia-telangiectasia. Cell, 71(4), 587-597.  
Katayama, M., Nakano, H., Ishiuchi, A., Wu, W., Oshima, R., Sakurai, J., . . . Otsubo, T. 
(2006). Protein pattern difference in the colon cancer cell lines examined by 
two-dimensional differential in-gel electrophoresis and mass spectrometry. 
Surgery Today, 36(12), 1085-1093.  
 225 
 
Katoh, M., & Katoh, M. (2004). Human FOX gene family (Review). International 
Journal of Oncology, 25(5), 1495-1500.  
Kawamori, D., Kaneto, H., Nakatani, Y., Matsuoka, T. A., Matsuhisa, M., Hori, M., & 
Yamasaki, Y. (2006). The forkhead transcription factor Foxo1 bridges the JNK 
pathway and the transcription factor PDX-1 through its intracellular 
translocation. The Journal of Biological Chemistry, 281(2), 1091-1098.  
Ke, T. W., Hsu, H. L., Wu, Y. H., Chen, W. T. L., Cheng, Y. W., & Cheng, C. W. 
(2014). MicroRNA-224 suppresses colorectal cancer cell migration by targeting 
Cdc42. Disease Markers, 2014, 617150.  
Khvorova, A., Reynolds, A., & Jayasena, S. D. (2003). Functional siRNAs and 
miRNAs exhibit strand bias. Cell, 115(2), 209-216.  
Kim, T. K., & Eberwine, J. H. (2010). Mammalian cell transfection: the present and the 
future. Analytical and Bioanalytical Chemistry, 397(8), 3173-3178.  
Kim, V. N., Han, J., & Siomi, M. C. (2009). Biogenesis of small RNAs in animals. 
Nature Reviews Molecular Cell Biology, 10(2), 126-139.  
Kluiver, J., Gibcus, J. H., Hettinga, C., Adema, A., Richter, M. K. S., Halsema, N., . . . 
van den Berg, A. (2012). Rapid generation of microRNA sponges for microRNA 
inhibition. PLoS ONE, 7(1), e29275.  
Kobayashi, H., Mochizuki, H., Sugihara, K., Morita, T., Kotake, K., Teramoto, T., . . . 
Muto, T. (2007). Characteristics of recurrence and surveillance tools after 
curative resection for colorectal cancer: a multicenter study. Surgery, 141(1), 67-
75.  
Kobayashi, Y., Furukawa-Hibi, Y., Chen, C., Horio, Y., Isobe, K., Ikeda, K., & 
Motoyama, N. (2005). SIRT1 is critical regulator of FOXO-mediated 
transcription in response to oxidative stress. International Journal of Molecular 
Medicine, 16(2), 237-243.  
Konishi, M., Kikuchi-Yanoshita, R., Tanaka, K., Muraoka, M., Onda, A., Okumura, 
Y., . . . Miyaki, M. (1996). Molecular nature of colon tumors in hereditary 
nonpolyposis colon cancer, familial polyposis, and sporadic colon cancer. 
Gastroenterology, 111(2), 307-317.  
Kosaka, N., Iguchi, H., & Ochiya, T. (2010). Circulating microRNA in body fluid: a 
new potential biomarker for cancer diagnosis and prognosis. Cancer Science, 
101(10), 2087-2092.  
Koturbash, I., Zemp, F. J., Pogribny, I., & Kovalchuk, O. (2011). Small molecules with 
big effects: the role of the microRNAome in cancer and carcinogenesis. 
Mutation Research/Genetic Toxicology and Environmental Mutagenesis, 722(2), 
94-105.  
Kozaki, K., Imoto, I., Mogi, S., Omura, K., & Inazawa, J. (2008). Exploration of tumor-
suppressive microRNAs silenced by DNA hypermethylation in oral cancer. 
Cancer Research, 68(7), 2094-2105.  
 226 
 
Kozomara, A., & Griffiths-Jones, S. (2014). miRBase: annotating high confidence 
microRNAs using deep sequencing data. Nucleic Acids Research, 42, D68-D73.  
Krasinskas, A. M. (2011). EGFR signaling in colorectal carcinoma. Pathology Research 
International, 2011, 932932.  
Krek, A., Grün, D., Poy, M. N., Wolf, R., Rosenberg, L., Epstein, E. J., . . . Rajewsky, 
N. (2005). Combinatorial microRNA target predictions. Nature Genetics, 37(5), 
495-500.  
Krichevsky, A. M., & Gabriely, G. (2009). miR-21: a small multi-faceted RNA. Journal 
of Cellular and Molecular Medicine, 13(1), 39-53.  
Krützfeldt, J., Rajewsky, N., Braich, R., Rajeev, K. G., Tuschl, T., Manoharan, M., & 
Stoffel, M. (2005). Silencing of microRNAs in vivo with 'antagomirs'. Nature, 
438(7068), 685-689.  
Kwon, I. K., Wang, R., Thangaraju, M., Shuang, H., Liu, K., Dashwood, R., . . . 
Browning, D. D. (2010). PKG inhibits TCF signaling in colon cancer cells by 
blocking beta-catenin expression and activating FOXO4. Oncogene, 29(23), 
3423-3434.  
Labianca, R., Nordlinger, B., Beretta, G. D., Brouquet, A., & Cervantes, A. (2010). 
Primary colon cancer: ESMO Clinical Practice Guidelines for diagnosis, 
adjuvant treatment and follow-up. Annals of Oncology, 21(5), v70-v77.  
Lacopetta, B. (2003). TP53 mutation in colorectal cancer. Human Mutation, 21(3), 271-
276.  
Lagos-Quintana, M., Rauhut, R., Lendeckel, W., & Tuschl, T. (2001). Identification of 
novel genes coding for small expressed RNAs. Science, 294(5543), 853-858.  
Lajer, C. B., Nielsen, F. C., Friis-Hansen, L., Norrild, B., Borup, R., Garnæs, E., . . . 
von Buchwald, C. (2011). Different miRNA signatures of oral and pharyngeal 
squamous cell carcinomas: a prospective translational study. British Journal of 
Cancer, 104(5), 830-840.  
Lamouille, S., Subramanyam, D., Blelloch, R., & Derynck, R. (2013). Regulation of 
epithelial–mesenchymal and mesenchymal–epithelial transitions by microRNAs. 
Current Opinion in Cell Biology, 25(2), 200-207.  
Lanza, G., Ferracin, M., Gafà, R., Veronese, A., Spizzo, R., Pichiorri, F., . . . Negrini, M. 
(2007). mRNA/microRNA gene expression profile in microsatellite unstable 
colorectal cancer. Molecular Cancer, 6, 54.  
Lawrie, C. H., Gal, S., Dunlop, H. M., Pushkaran, B., Liggins, A. P., Pulford, K., . . . 
Harris, A. L. (2008). Detection of elevated levels of tumour-associated 
microRNAs in serum of patients with diffuse large B-cell lymphoma. British 
Journal of Haematology, 141(5), 672-675.  
le Sage, C., Nagel, R., Egan, D. A., Schrier, M., Mesman, E., Mangiola, A., . . . Agami, 
R. (2007). Regulation of the p27(Kip1) tumor suppressor by miR-221 and miR-
222 promotes cancer cell proliferation. The EMBO Journal, 26(15), 3699-3708.  
 227 
 
Lee, M. J., Yu, G. R., Yoo, H. J., Kim, J. H., Yoon, B. I., Choi, Y. K., & Kim, D. G. 
(2009). ANXA8 down-regulation by EGF-FOXO4 signaling is involved in cell 
scattering and tumor metastasis of cholangiocarcinoma. Gastroenterology, 
137(3), 1138-1150.  
Lee, R. C., Feinbaum, R. L., & Ambros, V. (1993). The C. elegans heterochronic gene 
lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell, 75(5), 
843-854.  
Lee, S., Cho, N. Y., Yoo, E. J., Kim, J. H., & Kang, G. H. (2008). CpG island 
methylator phenotype in colorectal cancers: comparison of the new and classic 
CpG island methylator phenotype marker panels. Archives of Pathology and 
Laboratory Medicine, 132(10), 1657-1665.  
Leibovitz, A., Stinson, J. C., McCombs III, W. B., McCoy, C. E., Mazur, K. C., & 
Mabry, N. D. (1976). Classification of human colorectal adenocarcinoma cell 
lines. Cancer Research, 36(12), 4562-4569.  
Lennox, K. A., & Behlke, M. A. (2010). A direct comparison of anti-microRNA 
oligonucleotide potency. Pharmaceutical Research, 27(9), 1788-1799.  
Levin, B., Lieberman, D. A., McFarland, B., Smith, R. A., Brooks, D., Andrews, K. 
S., . . . Winawer, S. J. (2008). Screening and surveillance for the early detection 
of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the 
American Cancer Society, the US Multi-Society Task Force on Colorectal 
Cancer, and the American College of Radiology. CA: A Cancer Journal for 
Clinicians, 58(3), 130-160.  
Levine, A. J. (1997). p53, the cellular gatekeeper for growth and division. Cell, 88(3), 
323-331.  
Lewis, B. P., Burge, C. B., & Bartel, D. P. (2005). Conserved seed pairing, often 
flanked by adenosines, indicates that thousands of human genes are microRNA 
targets. Cell, 120(1), 15-20.  
Lewis, B. P., Shih, I. H., Jones-Rhoades, M. W., Bartel, D. P., & Burge, C. B. (2003). 
Prediction of mammalian microRNA targets. Cell, 115(7), 787-798.  
Li, B., Sun, M., Gao, F., Liu, W., Yang, Y., Liu, H., . . . Cai, J. (2013). Up-regulated 
expression of miR-23a/b targeted the pro-apoptotic Fas in radiation-induced 
thymic lymphoma. Cellular Physiology and Biochemistry, 32(6), 1729-1740.  
Li, C., Hashimi, S. M., Good, D. A., Cao, S., Duan, W., Plummer, P. N., . . . Wei, M. Q. 
(2012). Apoptosis and microRNA aberrations in cancer. Clinical and 
Experimental Pharmacology and Physiology, 39(8), 739-746.  
Li, L. C., Okino, S. T., Zhao, H., Pookot, D., Place, R. F., Urakami, S., . . . Dahiya, R. 
(2006). Small dsRNAs induce transcriptional activation in human cells. 
Proceedings of the National Academy of Sciences of the United States of 
America, 103(46), 17337-17342.  
 
 228 
 
Li, L. M., Hu, Z. B., Zhou, Z. X., Chen, X., Liu, F. Y., Zhang, J. F., . . . Zen, K. (2010). 
Serum microRNA profiles serve as novel biomarkers for HBV infection and 
diagnosis of HBV-positive hepatocarcinoma. Cancer Research, 70(23), 9798-
9807.  
Li, P., Nijhawan, D., Budihardjo, I., Srinivasula, S. M., Ahmad, M., Alnemri, E. S., & 
Wang, X. (1997). Cytochrome c and dATP-dependent formation of Apaf-
1/caspase-9 complex initiates an apoptotic protease cascade. Cell, 91(4), 479-
489.  
Li, S., Li, Y., Wen, Z., Kong, F., Guan, X., & Liu, W. (2014). microRNA-206 
overexpression inhibits cellular proliferation and invasion of estrogen receptor 
α-positive ovarian cancer cells. Molecular Medicine Reports, 9(5), 1703-1708.  
Li, Y., Liang, C., Wong, K. C., Jin, K., & Zhang, Z. (2014). Inferring probabilistic 
miRNA–mRNA interaction signatures in cancers: a role-switch approach. 
Nucleic Acids Research, 42(9), e76.  
Lian, S., Shi, R., Bai, T., Liu, Y., Miao, W., Wang, H., . . . Fan, Y. (2013). Anti-
miRNA-23a oligonucleotide suppresses glioma cells growth by targeting 
apoptotic protease activating factor-1. Current Pharmaceutical Design, 19(35), 
6382-6389.  
Lin, P. C., Lin, J. K., Lin, C. C., Wang, H. S., Yang, S. H., Jiang, J. K., . . . Chang, S. C. 
(2012). Carbohydrate antigen 19-9 is a valuable prognostic factor in colorectal 
cancer patients with normal levels of carcinoembryonic antigen and may help 
predict lung metastasis. International Journal of Colorectal Disease, 27(10), 
1333-1338.  
Lin, S. L., Chang, S. J., & Ying, S. Y. (2006). Transgene-like animal models using 
intronic microRNAs. Methods in Molecular Biology, 342, 321-334.  
Link, A., Balaguer, F., Shen, Y., Nagasaka, T., Lozano, J. J., Boland, C. R., & Goel, A. 
(2010). Fecal microRNAs as novel biomarkers for colon cancer screening. 
Cancer Epidemiology, Biomarkers and Prevention, 19(7), 1766-1774.  
Liotta, L. A., Steeg, P. S., & Stetler-Stevenson, W. G. (1991). Cancer metastasis and 
angiogenesis: an imbalance of positive and negative regulation. Cell, 64(2), 327-
336.  
Liu, C., Dong, B., Lu, A., Qu, L., Xing, X., Meng, L., . . . Shou, C. (2010). Synuclein 
gamma predicts poor clinical outcome in colon cancer with normal levels of 
carcinoembryonic antigen. BMC Cancer, 10, 359.  
Liu, C., Kelnar, K., Liu, B., Chen, X., Calhoun-Davis, T., Li, H., . . . Tang, D. G. (2011). 
The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by 
directly repressing CD44. Nature Medicine, 17(2), 211-215.  
Liu, C., Li, Y., Semenov, M., Han, C., Baeg, G. H., Tan, Y., . . . He, X. (2002). Control 
of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell, 
108(6), 837-847.  
 229 
 
Liu, K., Zhao, H., Yao, H., Lei, S., Lei, Z., Li, T., & Qi, H. (2013). MicroRNA-124 
regulates the proliferation of colorectal cancer cells by targeting iASPP. Biomed 
Research International, 2013, 867537.  
Liu, L., Chen, L., Xu, Y., Li, R., & Du, X. (2010). microRNA-195 promotes apoptosis 
and suppresses tumorigenicity of human colorectal cancer cells. Biochemical 
and Biophysical Research Communications, 400(2), 236-240.  
Liu, L., Nie, J., Chen, L., Dong, G., Du, X., Wu, X., . . . Han, W. (2013). The oncogenic 
role of microRNA-130a/301a/454 in human colorectal cancer via targeting 
Smad4 expression. PLoS ONE, 8(2), e55532.  
Liu, W., Zabirnyk, O., Wang, H., Shiao, Y. H., Nickerson, M. L., Khalil, S., . . . Phang, 
J. M. (2010). miR-23b targets proline oxidase, a novel tumor suppressor protein 
in renal cancer. Oncogene, 29(35), 4914-4924.  
Liu, X., Fortin, K., & Mourelatos, Z. (2008). MicroRNAs: biogenesis and molecular 
functions. Brain Pathology, 18(1), 113-121.  
Liu, X., Kim, C. N., Yang, J., Jemmerson, R., & Wang, X. (1996). Induction of 
apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. 
Cell, 86(1), 147-157.  
Liu, X., Ru, J., Zhang, J., Zhu, L. H., Liu, M., Li, X., & Tang, H. (2013). miR-23a 
targets interferon regulatory factor 1 and modulates cellular proliferation and 
paclitaxel-induced apoptosis in gastric adenocarcinoma cells. PLoS ONE, 8(6), 
e64707.  
Liu, X., Zhang, Z., Sun, L., Chai, N., Tang, S., Jin, J., . . . Fan, D. (2011). microRNA-
499-5p promotes cellular invasion and tumor metastasis in colorectal cancer by 
targeting FOXO4 and PDCD4. Carcinogenesis, 32(12), 1798-1805.  
Liu, X. Q., Tang, S. H., Zhang, Z. Y., & Jin, H. F. (2011). Expression and clinical 
significance of FOX04 in colorectal cancer. Chinese Journal of Cellular and 
Molecular Immunology, 27(9), 969-971.  
Liu, Y., Borchert, G. L., Surazynski, A., & Phang, J. M. (2008). Proline oxidase, a p53-
induced gene, targets COX-2/PGE2 signaling to induce apoptosis and inhibit 
tumor growth in colorectal cancers. Oncogene, 27(53), 6729-6737.  
Liu, Z., Sall, A., & Yang, D. (2008). MicroRNA: an emerging therapeutic target and 
intervention tool. International Journal of Molecular Sciences, 9(6), 978-999.  
Lofton-Day, C., Model, F., Devos, T., Tetzner, R., Distler, J., Schuster, M., . . . 
Sledziewski, A. (2008). DNA methylation biomarkers for blood-based colorectal 
cancer screening. Clinical Chemistry, 54(2), 414-423.  
Lowe, S. W., & Lin, A. W. (2000). Apoptosis in cancer. Carcinogenesis, 21(3), 485-
495.  
Luo, X., Burwinkel, B., Tao, S., & Brenner, H. (2011). MicroRNA signatures: novel 
biomarker for colorectal cancer? Cancer Epidemiology, Biomarkers and 
Prevention, 20(7), 1272-1286.  
 230 
 
Luo, X., Stock, C., Burwinkel, B., & Brenner, H. (2013). Identification and evaluation 
of plasma microRNAs for early detection of colorectal cancer. PLoS ONE, 8(5), 
e62880.  
Lüpertz, R., Chovolou, Y., Unfried, K., Kampkötter, A., Wätjen, W., & Kahl, R. (2008). 
The forkhead transcription factor FOXO4 sensitizes cancer cells to doxorubicin-
mediated cytotoxicity. Carcinogenesis, 29(11), 2045-2052.  
Lynch, H. T., & Lynch, J. F. (2005). What the physician needs to know about Lynch 
syndrome: an update. Oncology (Williston Park), 19(4), 455-463.  
Ma, K., He, Y., Zhang, H., Fei, Q., Niu, D., Wang, D., . . . Zhu, J. (2012). DNA 
methylation-regulated miR-193a-3p dictates resistance of hepatocellular 
carcinoma to 5-fluorouracil via repression of SRSF2 expression. The Journal of 
Biological Chemistry, 287(8), 5639-5649.  
Ma, N., Li, F., Li, D., Hui, Y., Wang, X., Qiao, Y., . . . Gao, X. (2012). Igf2-derived 
intronic miR-483 promotes mouse hepatocellular carcinoma cell proliferation. 
Molecular and Cellular Biochemistry, 361(1-2), 337-343.  
Ma, Q., Wang, X., Li, Z., Li, B., Ma, F., Peng, L., . . . Jiang, B. (2013). microRNA-16 
represses colorectal cancer cell growth in vitro by regulating the p53/survivin 
signaling pathway. Oncology Reports, 29(4), 1652-1658.  
Ma, Y., Zhang, P., Wang, F., Zhang, H., Yang, J., Peng, J., . . . Qin, H. (2012). miR-150 
as a potential biomarker associated with prognosis and therapeutic outcome in 
colorectal cancer. Gut, 61(10), 1447-1453.  
Maczuga, P., Koornneef, A., Borel, F., Petry, H., van Deventer, S., Ritsema, T., & 
Konstantinova, P. (2012). Optimization and comparison of knockdown efficacy 
between polymerase II expressed shRNA and artificial miRNA targeting 
luciferase and Apolipoprotein B100. BMC Biotechnology, 12, 42.  
Maragkakis, M., Alexiou, P., Papadopoulos, G. L., Reczko, M., Dalamagas, T., 
Giannopoulos, G., . . . Hatzigeorgiou, A. G. (2009). Accurate microRNA target 
prediction correlates with protein repression levels. BMC Bioinformatics, 10, 
295.  
Markowitz, S. D., & Bertagnolli, M. M. (2009). Molecular basis of colorectal cancer. 
The New England Journal of Medicine, 361(25), 2449-2460.  
Marshall, K. W., Mohr, S., Khettabi, F. E., Nossova, N., Chao, S., Bao, W., . . . Liew, C. 
C. (2010). A blood-based biomarker panel for stratifying current risk for 
colorectal cancer. International Journal of Cancer, 126(5), 1177-1186.  
Massagué, J., Blain, S. W., & Lo, R. S. (2000). TGFbeta signaling in growth control, 
cancer, and heritable disorders. Cell, 103(2), 295-309.  
McFarland, E. G., Levin, B., Lieberman, D. A., Pickhardt, P. J., Johnson, C. D., Glick, 
S. N., . . . Smith, R. A. (2008). Revised colorectal screening guidelines: joint 
effort of the American Cancer Society, U.S. Multisociety Task Force on 
Colorectal Cancer, and American College of Radiology. Radiology, 248(3), 717-
720.  
 231 
 
McKenna, E. S., & Roberts, C. W. M. (2009). Epigenetics and cancer without genomic 
instability. Cell Cycle, 8(1), 23-26.  
McManus, M. T., Petersen, C. P., Haines, B. B., Chen, J., & Sharp, P. A. (2002). Gene 
silencing using micro-RNA designed hairpins. RNA, 8(6), 842-850.  
Meltzer, P. S. (2005). Cancer genomics: small RNAs with big impacts. Nature, 
435(7043), 745-746.  
Min, H., & Yoon, S. (2010). Got target?: computational methods for microRNA target 
prediction and their extension. Experimental and Molecular Medicine, 42(4), 
233-244.  
Miranda, K. C., Huynh, T., Tay, Y., Ang, Y. S., Tam, W. L., Thomson, A. M., . . . 
Rigoutsos, I. (2006). A pattern-based method for the identification of microRNA 
binding sites and their corresponding heteroduplexes. Cell, 126(6), 1203-1217.  
Mitchell, P. S., Parkin, R. K., Kroh, E. M., Fritz, B. R., Wyman, S. K., Pogosova-
Agadjanyan, E. L., . . . Tewari, M. (2008). Circulating microRNAs as stable 
blood-based markers for cancer detection. Proceedings of the National Academy 
of Sciences of the United States of America, 105(30), 10513-10518.  
Moawad, F. J., Maydonovitch, C. L., Cullen, P. A., Barlow, D. S., Jenson, D. W., & 
Cash, B. D. (2010). CT colonography may improve colorectal cancer screening 
compliance. American Journal of Roentgenology, 195(5), 1118-1123.  
Monteleone, G., Pallone, F., & Stolfi, C. (2012). The dual role of inflammation in colon 
carcinogenesis. International Journal of Molecular Sciences, 13(9), 11071-
11084.  
Morimoto, L. M., Newcomb, P. A., Ulrich, C. M., Bostick, R. M., Lais, C. J., & Potter, 
J. D. (2002). Risk factors for hyperplastic and adenomatous polyps: evidence for 
malignant potential? Cancer Epidemiology, Biomarkers and Prevention, 11(10), 
1012-1018.  
Mouhamad, S., Galluzzi, L., Zermati, Y., Castedo, M., & Kroemer, G. (2007). Apaf-1 
deficiency causes chromosomal instability. Cell Cyle, 6(24), 3103-3107.  
Mustika, R., Budiyanto, A., Nishigori, C., Ichihashi, M., & Ueda, M. (2005). Decreased 
expression of Apaf-1 with progression of melanoma. Pigment Cell Research, 
18(1), 59-62.  
Mutter, G. L., Zahrieh, D., Liu, C., Neuberg, D., Finkelstein, D., Baker, H. E., & 
Warrington, J. A. (2004). Comparison of frozen and RNALater solid tissue 
storage methods for use in RNA expression microarrays. BMC Genomics, 5, 88.  
Nagel, R., le Sage, C., Diosdado, B., van der Waal, M., Oude Vrielink, J. A. F., Bolijn, 
A., . . . Agami, R. (2008). Regulation of the adenomatous polyposis coli gene by 
the miR-135 family in colorectal cancer. Cancer Research, 68(14), 5795-5802.  
Nakano, H., Yamada, Y., Miyazawa, T., & Yoshida, T. (2013). Gain-of-function 
microRNA screens identify miR-193a regulating proliferation and apoptosis in 
epithelial ovarian cancer cells. International Journal of Oncology, 42(6), 1875-
1882.  
 232 
 
Natalwala, A., Spychal, R., & Tselepis, C. (2008). Epithelial-mesenchymal transition 
mediated tumourigenesis in the gastrointestinal tract. World Journal of 
Gastroenterology, 14(24), 3792-3797.  
Neri, E., Faggioni, L., Cerri, F., Turini, F., Angeli, S., Cini, L., . . . Bartolozzi, C. (2010). 
CT colonography versus double-contrast barium enema for screening of 
colorectal cancer: comparison of radiation burden. Abdominal Imaging, 35(5), 
596-601.  
Nicolas, F. E. (2011). Experimental validation of microRNA targets using a luciferase 
reporter system. Methods in Molecular Biology, 732, 139-152.  
Nielsen, B. S. (2012). MicroRNA in situ hybridization. Methods in Molecular Biology, 
822, 67-84.  
Novak, D. J., Liew, G. J., & Liew, C. C. (2012). GeneNews Limited: bringing the blood 
transcriptome to personalized medicine. Pharmacogenomics, 13(4), 381-385.  
Oberg, A. L., French, A. J., Sarver, A. L., Subramanian, S., Morlan, B. W., Riska, S. 
M., . . . Thibodeau, S. N. (2011). miRNA expression in colon polyps provides 
evidence for a multihit model of colon cancer. PLoS ONE, 6(6), e20465.  
Obrocea, F. L., Sajin, M., Marinescu, E. C., & Stoica, D. (2011). Colorectal cancer and 
the 7th revision of the TNM staging system: review of changes and suggestions 
for uniform pathologic reporting. Romanian Journal of Morphology and 
Embryology, 52(2), 537-544.  
Obuchowski, N. A. (2005). ROC analysis. American Journal of Roentgenology, 184(2), 
364-372.  
Ogata-Kawata, H., Izumiya, M., Kurioka, D., Honma, Y., Yamada, Y., Furuta, K., . . . 
Tsuchiya, N. (2014). Circulating exosomal microRNAs as biomarkers of colon 
cancer. PLoS ONE, 9(4), e92921.  
Overbergh, L., Giulietti, A., Valckx, D., Decallonne, R., Bouillon, R., & Mathieu, C. 
(2003). The use of real-time reverse transcriptase PCR for the quantification of 
cytokine gene expression. Journal of Biomolecular Techniques, 14(1), 33-43.  
Paik, S. S., Jang, K. S., Song, Y. S., Jang, S. H., Min, K. W., Han, H. X., . . . Jang, S. J. 
(2007). Reduced expression of Apaf-1 in colorectal adenocarcinoma correlates 
with tumor progression and aggressive phenotype. Annals of Surgical Oncology, 
14(12), 3453-3459.  
Pan, H., & Griep, A. E. (1995). Temporally distinct patterns of p53-dependent and p53-
independent apoptosis during mouse lens development. Genes and Development, 
9(17), 2157-2169.  
Paterson, E. L., Kazenwadel, J., Bert, A. G., Khew-Goodall, Y., Ruszkiewicz, A., & 
Goodall, G. J. (2013). Down-regulation of the miRNA-200 family at the 
invasive front of colorectal cancers with degraded basement membrane indicates 
EMT is involved in cancer progression. Neoplasia, 15(2), 180-191.  
 233 
 
Perilli, L., Pizzini, S., Bisognin, A., Mandruzzato, S., Biasiolo, M., Facciolli, A., . . . 
Zanovello, P. (2014). Human miRNome profiling in colorectal cancer and liver 
metastasis development. Genomics Data, 2, 184-188.  
Piepoli, A., Tavano, F., Copetti, M., Mazza, T., Palumbo, O., Panza, A., . . . Andriulli, 
A. (2012). Mirna expression profiles identify drivers in colorectal and pancreatic 
cancers. PLoS ONE, 7(3), e33663.  
Place, R. F., Li, L. C., Pookot, D., Noonan, E. J., & Dahiya, R. (2008). MicroRNA-373 
induces expression of genes with complementary promoter sequences. 
Proceedings of the National Academy of Sciences of the United States of 
America, 105(5), 1608-1613.  
Price, K. J., Tsykin, A., Giles, K. M., Sladic, R. T., Epis, M. R., Ganss, R., . . . Leedman, 
P. J. (2012). Matrigel basement membrane matrix influences expression of 
microRNAs in cancer cell lines. Biochemical and Biophysical Research 
Communications, 427(2), 343-348.  
Quintero, E., Castells, A., Bujanda, L., Cubiella, J., Salas, D., Lanas, Á., . . . González-
Navarro, A. (2012). Colonoscopy versus fecal immunochemical testing in 
colorectal-cancer screening. The New England Journal of Medicine, 366(8), 
697-706.  
Ragusa, M., Statello, L., Maugeri, M., Barbagallo, C., Passanis, R., Alhamdani, M. 
S., . . . Purrello, M. (2014). Highly skewed distribution of miRNAs and proteins 
between colorectal cancer cells and their exosomes following Cetuximab 
treatment: biomolecular, genetic and translational implications. Oncoscience, 
1(2), 132-157.  
Ragusa, M., Statello, L., Maugeri, M., Majorana, A., Barbagallo, D., Salito, L., . . . 
Purrello, M. (2012). Specific alterations of the microRNA transcriptome and 
global network structure in colorectal cancer after treatment with MAPK/ERK 
inhibitors. Journal of Molecular Medicine, 90(12), 1421-1438.  
Ratajewski, M., Walczak-Drzewiecka, A., Salkowska, A., & Dastych, J. (2012). 
Upstream stimulating factors regulate the expression of RORγT in human 
lymphocytes. The Journal of Immunology, 189(6), 3034-3042.  
Reagan-Shaw, S., & Ahmad, N. (2007). The role of Forkhead-box Class O (FoxO) 
transcription factors in cancer: a target for the management of cancer. 
Toxicology and Applied Pharmacology, 224(3), 360-368.  
Redfern, A. D., Colley, S. M., Beveridge, D. J., Ikeda, N., Epis, M. R., Li, X., . . . 
Leedman, P. J. (2013). RNA-induced silencing complex (RISC) proteins PACT, 
TRBP, and Dicer are SRA binding nuclear receptor coregulators. Proceedings of 
the National Academy of Sciences of the United States of America, 110(16), 
6536-6541.  
Rehmsmeier, M., Steffen, P., Hochsmann, M., & Giegerich, R. (2004). Fast and 
effective prediction of microRNA/target duplexes. RNA, 10(10), 1507-1517.  
 
 234 
 
Reid, J. F., Sokolova, V., Zoni, E., Lampis, A., Pizzamiglio, S., Bertan, C., . . . Pierotti, 
M. A. (2012). miRNA profiling in colorectal cancer highlights miR-1 
involvement in MET-dependent proliferation. Molecular Cancer Research, 
10(4), 504-515.  
Reinhart, B. J., Slack, F. J., Basson, M., Pasquinelli, A. E., Bettinger, J. C., Rougvie, A. 
E., . . . Ruvkun, G. (2000). The 21-nucleotide let-7 RNA regulates 
developmental timing in Caenorhabditis elegans. Nature, 403(6772), 901-906.  
Riedl, S. J., & Shi, Y. (2004). Molecular mechanisms of caspase regulation during 
apoptosis. Nature Reviews Molecular Cell Biology, 5(11), 897-907.  
Robinson, K. L., Liu, T., Vandrovcova, J., Halvarsson, B., Clendenning, M., Frebourg, 
T., . . . Lindblom, A. (2007). Lynch syndrome (hereditary nonpolyposis 
colorectal cancer) diagnostics. Journal of the National Cancer Institute, 99(4), 
291-299.  
Robles, A. I., Bemmels, N. A., Foraker, A. B., & Harris, C. C. (2001). APAF-1 is a 
transcriptional target of p53 in DNA damage-induced apoptosis. Cancer 
Research, 61(18), 6660-6664.  
Rodrigues, N. R., Rowan, A., Smith, M. E., Kerr, I. B., Bodmer, W. F., Gannon, J. V., 
& Lane, D. P. (1990). p53 mutations in colorectal cancer. Proceedings of the 
National Academy of Sciences of the United States of America, 87(19), 7555-
7559.  
Rogler, C. E., Levoci, L., Ader, T., Massimi, A., Tchaikovskaya, T., Norel, R., & 
Rogler, L. E. (2009). MicroRNA-23b cluster microRNAs regulate transforming 
growth factor-beta/bone morphogenetic protein signaling and liver stem cell 
differentiation by targeting Smads. Hepatology, 50(2), 575-584.  
Roldo, C., Missiaglia, E., Hagan, J. P., Falconi, M., Capelli, P., Bersani, S., . . . Croce, 
C. M. (2006). MicroRNA expression abnormalities in pancreatic endocrine and 
acinar tumors are associated with distinctive pathologic features and clinical 
behavior. Journal of Clinical Oncology, 24(29), 4677-4684.  
Ronchetti, D., Lionetti, M., Mosca, L., Agnelli, L., Andronache, A., Fabris, S., . . . Neri, 
A. (2008). An integrative genomic approach reveals coordinated expression of 
intronic miR-335, miR-342, and miR-561 with deregulated host genes in 
multiple myeloma. BMC Medical Genomics, 1, 37.  
Rossi, S., Kopetz, S., Davuluri, R., Hamilton, S. R., & Calin, G. A. (2010). MicroRNAs, 
ultraconserved genes and colorectal cancers. The International Journal of 
Biochemistry and Cell Biology, 42(8), 1291-1297.  
Sachdeva, M., & Mo, Y. Y. (2010). miR-145-mediated suppression of cell growth, 
invasion and metastasis. American Journal of Translational Research, 2(2), 170-
180.  
Salama, I., Malone, P. S., Mihaimeed, F., & Jones, J. L. (2008). A review of the S100 
proteins in cancer. European Journal of Surgical Oncology, 34(4), 357-364.  
 
 235 
 
Salim, H., Akbar, N. S., Zong, D., Vaculova, A. H., Lewensohn, R., Moshfegh, A., . . . 
Zhivotovsky, B. (2012). miRNA-214 modulates radiotherapy response of non-
small cell lung cancer cells through regulation of p38MAPK, apoptosis and 
senescence. British Journal of Cancer, 107(8), 1361-1373.  
Salimzadeh, L., Jaberipour, M., Hosseini, A., & Ghaderi, A. (2013). Non-viral 
transfection methods optimized for gene delivery to a lung cancer cell line. 
Avicenna Journal of Medical Biotechnology, 5(2), 68-77.  
Salvi, A., Conde, I., Abeni, E., Arici, B., Grossi, I., Specchia, C., . . . De Petro, G. 
(2013). Effects of miR-193a and sorafenib on hepatocellular carcinoma cells. 
Molecular Cancer, 12, 162.  
Santarpia, L., Calin, G. A., Adam, L., Ye, L., Fusco, A., Giunti, S., . . . Gagel, R. F. 
(2013). A miRNA signature associated with human metastatic medullary thyroid 
carcinoma. Endocrine-Related Cancer, 20(6), 809-823.  
Schepeler, T., Reinert, J. T., Ostenfeld, M. S., Christensen, L. L., Silahtaroglu, A. N., 
Dyrskjøt, L., . . . Andersen, C. L. (2008). Diagnostic and prognostic microRNAs 
in stage II colon cancer. Cancer Research, 68(15), 6416-6424.  
Schetter, A. J., Leung, S. Y., Sohn, J. J., Zanetti, K. A., Bowman, E. D., Yanaihara, 
N., . . . Harris, C. C. (2008). MicroRNA expression profiles associated with 
prognosis and therapeutic outcome in colon adenocarcinoma. The Journal of the 
American Medical Association, 299(4), 425-436.  
Schetter, A. J., Okayama, H., & Harris, C. C. (2012). The role of microRNAs in 
colorectal cancer. Cancer Journal, 18(3), 244-252.  
Schmittgen, T. D., & Livak, K. J. (2008). Analyzing real-time PCR data by the 
comparative C(T) method. Nature Protocols, 3(6), 1101-1108.  
Schoen, R. E., Pinsky, P. F., Weissfeld, J. L., Yokochi, L. A., Church, T., Laiyemo, A. 
O., . . . Berg, C. D. (2012). Colorectal-cancer incidence and mortality with 
screening flexible sigmoidoscopy. The New England Journal of Medicine, 
366(25), 2345-2357.  
Schrauder, M. G., Strick, R., Schulz-Wendtland, R., Strissel, P. L., Kahmann, L., 
Loehberg, C. R., . . . Fasching, P. A. (2012). Circulating micro-RNAs as 
potential blood-based markers for early stage breast cancer detection. PLoS ONE, 
7(1), e29770.  
Schroeder, A., Mueller, O., Stocker, S., Salowsky, R., Leiber, M., Gassmann, M., . . . 
Ragg, T. (2006). The RIN: an RNA integrity number for assigning integrity 
values to RNA measurements. BMC Molecular Biology, 7, 3.  
Sepramaniam, S., Tan, J. R., Tan, K. S., DeSilva, D. A., Tavintharan, S., Woon, F. 
P., . . . Jeyaseelan, K. (2014). Circulating microRNAs as biomarkers of acute 
stroke. International Journal of Molecular Sciences, 15(1), 1418-1432.  
Seto, A. G. (2010). The road toward microRNA therapeutics. The International Journal 
of Biochemistry and Cell Biology, 42(8), 1298-1305.  
 236 
 
Shang, J., Yang, F., Wang, Y., Wang, Y., Xue, G., Mei, Q., . . . Sun, S. (2014). 
MicroRNA-23a antisense enhances 5-fluorouracil chemosensitivity through 
APAF-1/caspase-9 apoptotic pathway in colorectal cancer cells. Journal of 
Cellular Biochemistry, 115(4), 772-784.  
Shen, L., Toyota, M., Kondo, Y., Lin, E., Zhang, L., Guo, Y., . . . Issa, J. P. (2007). 
Integrated genetic and epigenetic analysis identifies three different subclasses of 
colon cancer. Proceedings of the National Academy of Sciences of the United 
States of America, 104(47), 18654-18659.  
Shi, Y. (2002). Mechanisms of caspase activation and inhibition during apoptosis. 
Molecular Cell, 9(3), 459-470.  
Sikand, K., Slane, S. D., & Shukla, G. C. (2009). Intrinsic expression of host genes and 
intronic miRNAs in prostate carcinoma cells. Cancer Cell International, 9, 21.  
Simons, P. C., Van Steenbergen, L. N., De Witte, M. T., & Janssen-Heijnen, M. L. 
(2013). Miss rate of colorectal cancer at CT colonography in average-risk 
symptomatic patients. European Radiology, 23(4), 908-913.  
Sisik, A., Kaya, M., Bas, G., Basak, F., & Alimoglu, O. (2013). CEA and CA 19-9 are 
still valuable markers for the prognosis of colorectal and gastric cancer patients. 
Asian Pacific Journal of Cancer Prevention, 14(7), 4289-4294.  
Skrypina, N. A., Timofeeva, A. V., Khaspekov, G. L., Savochkina, L. P., & 
Beabealashvilli, R. S. (2003). Total RNA suitable for molecular biology analysis. 
Journal of Biotechnology, 105(1-2), 1-9.  
Slaby, O., Svoboda, M., Michalek, J., & Vyzula, R. (2009). MicroRNAs in colorectal 
cancer: translation of molecular biology in clinical application. Molecular 
Cancer, 8, 102.  
Song, M. S., & Rossi, J. J. (2014). The anti-miR21 antagomir, a therapeutic tool for 
colorectal cancer, has a potential synergistic effect by perturbing an 
angiogenesis-associated miR30. Frontiers in Genetics, 4, 301.  
Søreide, K., Nedrebø, B. S., Knapp, J. C., Glomsaker, T. B., Søreide, J. A., & Kørner, H. 
(2009). Evolving molecular classification by genomic and proteomic biomarkers 
in colorectal cancer: potential implications for the surgical oncologist. Surgical 
Oncology, 18(1), 31-50.  
Sotillo, E., & Thomas-Tikhonenko, A. (2011). Shielding the messenger (RNA): 
microRNA-based anti cancer therapies. Pharmacology and Therapeutics, 131(1), 
18-32.  
Srivastava, S. K., Bhardwaj, A., Singh, S., Arora, S., Wang, B., Grizzle, W. E., & Singh, 
A. P. (2011). MicroRNA-150 directly targets MUC4 and suppresses growth and 
malignant behavior of pancreatic cancer cells. Carcinogenesis, 32(12), 1832-
1839.  
Strillacci, A., Griffoni, C., Sansone, P., Paterini, P., Piazzi, G., Lazzarini, G., . . . 
Tomasi, V. (2009). MiR-101 downregulation is involved in cyclooxygenase-2 
overexpression in human colon cancer cells. Experimental Cell Research, 315(8), 
1439-1447.  
 237 
 
Su, B. B., Shi, H., & Wan, J. (2012). Role of serum carcinoembryonic antigen in the 
detection of colorectal cancer before and after surgical resection. World Journal 
of Gastroenterology, 18(17), 2121-2126.  
Suehiro, Y., Wong, C. W., Chirieac, L. R., Kondo, Y., Shen, L., Webb, C. R., . . . 
Hamilton, S. R. (2008). Epigenetic-genetic interactions in the APC/WNT, 
RAS/RAF, and P53 pathways in colorectal carcinoma. Clinical Cancer 
Research, 14(9), 2560-2569.  
Sun, X., Dong, B., Yin, L., Zhang, R., Du, W., Liu, D., . . . Mao, L. (2013). PMTED: a 
plant microRNA target expression database. BMC Bioinformatics, 14, 174.  
Sung, J. J. Y., Lau, J. Y. W., Goh, K. L., & Leung, W. K. (2005). Increasing incidence 
of colorectal cancer in Asia: implications for screening. The Lancet Oncology, 
6(11), 871-876.  
Tai, J., Wang, G., Liu, T., Wang, L., Lin, C., & Li, F. (2012). Effects of siRNA 
targeting c-Myc and VEGF on human colorectal cancer Volo cells. Journal of 
Biochemical and Molecular Toxicology, 26(12), 499-505.  
Takane, K., Fujishima, K., Watanabe, Y., Sato, A., Saito, N., Tomita, M., & Kanai, A. 
(2010). Computational prediction and experimental validation of evolutionarily 
conserved microRNA target genes in bilaterian animals. BMC Genomics, 11, 
101.  
Takayama, T., Miyanishi, K., Hayashi, T., Sato, Y., & Niitsu, Y. (2006). Colorectal 
cancer: genetics of development and metastasis. Journal of Gastroenterology, 
41(3), 185-192.  
Tan, E., Gouvas, N., Nicholls, R. J., Ziprin, P., Xynos, E., & Tekkis, P. P. (2009). 
Diagnostic precision of carcinoembryonic antigen in the detection of recurrence 
of colorectal cancer. Surgical Oncology, 18(1), 15-24.  
Tang, T. T., Dowbenko, D., Jackson, A., Toney, L., Lewin, D. A., Dent, A. L., & Lasky, 
L. A. (2002). The forkhead transcription factor AFX activates apoptosis by 
induction of the BCL-6 transcriptional repressor. The Journal of Biological 
Chemistry, 277(16), 14255-14265.  
Tao, W., & Levine, A. J. (1999). P19(ARF) stabilizes p53 by blocking nucleo-
cytoplasmic shuttling of Mdm2. Proceedings of the National Academy of 
Sciences of the United States of America, 96(12), 6937-6941.  
Tejpar, S., & Van Cutsem, E. (2002). Molecular and genetic defects in colorectal 
tumorigenesis. Best Practice and Research Clinical Gastroenterology, 16(2), 
171-185.  
ten Dijke, P., & Hill, C. S. (2004). New insights into TGF-beta-Smad signalling. Trends 
in Biochemical Sciences, 29(5), 265-273.  
Teodoridis, J. M., Hardie, C., & Brown, R. (2008). CpG island methylator phenotype 
(CIMP) in cancer: causes and implications. Cancer Letters, 268(2), 177-186.  
 238 
 
Thorn, C. F., Marsh, S., Carrillo, M. W., McLeod, H. L., Klein, T. E., & Altman, R. B. 
(2011). PharmGKB summary: fluoropyrimidine pathways. Pharmacogenetics 
and Genomics, 21(4), 237-242.  
Tortora, G. J., & Derrickson, B. H. (2007). Principles of anatomy and physiology. 
Hoboken, NJ: John Wiley & Sons, Inc. 
Toyota, M., Ahuja, N., Ohe-Toyota, M., Herman, J. G., Baylin, S. B., & Issa, J. P. 
(1999). CpG island methylator phenotype in colorectal cancer. Proceedings of 
the National Academy of Sciences of the United States of America, 96(15), 8681-
8686.  
Tsai, W. C., Hsu, P. W., Lai, T. C., Chau, G. Y., Lin, C. W., Chen, C. M., . . . Tsou, A. 
P. (2009). MicroRNA-122, a tumor suppressor microRNA that regulates 
intrahepatic metastasis of hepatocellular carcinoma. Hepatology, 49(5), 1571-
1582.  
Tsang, W. P., & Kwok, T. T. (2009). The miR-18a* microRNA functions as a potential 
tumor suppressor by targeting on K-Ras. Carcinogenesis, 30(6), 953-959.  
Tsuchida, A., Ohno, S., Wu, W., Borjigin, N., Fujita, K., Aoki, T., . . . Kuroda, M. 
(2011). miR-92 is a key oncogenic component of the miR-17-92 cluster in colon 
cancer. Cancer Science, 102(12), 2264-2271.  
Turchinovich, A., Weiz, L., Langheinz, A., & Burwinkel, B. (2011). Characterization of 
extracellular circulating miRNA. Nucleic Acids Research, 39(16), 7223-7233.  
U.S. Preventive Services Task Force. (2008). Screening for colorectal cancer: U.S. 
Preventive Services Task Force recommendation statement. Annals of Internal 
Medicine, 149(9), 627-637.  
Umetani, N., Fujimoto, A., Takeuchi, H., Shinozaki, M., Bilchik, A. J., & Hoon, D. S. 
(2004). Allelic imbalance of APAF-1 locus at 12q23 is related to progression of 
colorectal carcinoma. Oncogene, 23(50), 8292-8300.  
United Nations Population Division. (2013). World population prospects: the 2012 
revision, highlights and advance tables. New York, NY: United Nations. 
Valastyan, S., Reinhardt, F., Benaich, N., Calogrias, D., Szász, A. M., Wang, Z. C., . . . 
Weinberg, R. A. (2009). A pleiotropically acting microRNA, miR-31, inhibits 
breast cancer metastasis. Cell, 137(6), 1032-1046.  
Valastyan, S., & Weinberg, R. A. (2011). Tumor metastasis: molecular insights and 
evolving paradigms. Cell, 147(2), 275-292.  
van der Heide, L. P., & Smidt, M. P. (2005). Regulation of FoxO activity by CBP/p300-
mediated acetylation. Trends in Biochemical Sciences, 30(2), 81-86.  
van der Horst, A., Tertoolen, L. G., de Vries-Smits, L. M., Frye, R. A., Medema, R. H., 
& Burgering, B. M. (2004). FOXO4 is acetylated upon peroxide stress and 
deacetylated by the longevity protein hSir2(SIRT1). The Journal of Biological 
Chemistry, 279(28), 28873-28879.  
 239 
 
van Zijl, F., Krupitza, G., & Mikulits, W. (2011). Initial steps of metastasis: cell 
invasion and endothelial transmigration. Mutation Research, 728(1-2), 23-34.  
Vara, J. A. F., Casado, E., de Castro, J., Cejas, P., Belda-Iniesta, C., & González-Barón, 
M. (2004). PI3K/Akt signalling pathway and cancer. Cancer Treatment Reviews, 
30(2), 193-204.  
Vermaat, J. S., Nijman, I. J., Koudijs, M. J., Gerritse, F. L., Scherer, S. J., Mokry, 
M., . . . Voest, E. E. (2012). Primary colorectal cancers and their subsequent 
hepatic metastases are genetically different: implications for selection of patients 
for targeted treatment. Clinical Cancer Research, 18(3), 688-699.  
Veronese, A. (2012). Regulation of miR-483 locus in hepatocarcinoma cancer cells. 
Journal of Cancer Science and Therapy, 4(10), 51.  
Veronese, A., Lupini, L., Consiglio, J., Visone, R., Ferracin, M., Fornari, F., . . . Negrini, 
M. (2010). Oncogenic role of miR-483-3p at the IGF2/483 locus. Cancer 
Research, 70(8), 3140-3149.  
Veronese, A., Visone, R., Consiglio, J., Acunzo, M., Lupini, L., Kim, T., . . . Croce, C. 
M. (2011). Mutated beta-catenin evades a microRNA-dependent regulatory loop. 
Proceedings of the National Academy of Sciences of the United States of 
America, 108(12), 4840-4845.  
Violette, S., Poulain, L., Dussaulx, E., Pepin, D., Faussat, A. M., Chambaz, J., . . . 
Lesuffleur, T. (2002). Resistance of colon cancer cells to long-term 5-
fluorouracil exposure is correlated to the relative level of bcl-2 and bcl-xl in 
addition to bax and p53 status. International Journal of Cancer, 98(4), 498-504.  
Volinia, S., Calin, G. A., Liu, C. G., Ambs, S., Cimmino, A., Petrocca, F., . . . Croce, C. 
M. (2006). A microRNA expression signature of human solid tumors defines 
cancer gene targets. Proceedings of the National Academy of Sciences of the 
United States of America, 103(7), 2257-2261.  
Wan, L., Pantel, K., & Kang, Y. (2013). Tumor metastasis: moving new biological 
insights into the clinic. Nature Medicine, 19(11), 1450-1464.  
Wan Puteh, S. E., Saad, N. M., Aljunid, S. M., Abdul Manaf, M. R., Sulong, S., Sagap, 
I., . . . Muhammad Annuar, M. A. (2013). Quality of life in Malaysian colorectal 
cancer patients. Asia-Pacific Psychiatry, 5(1), 110-117.  
Wang, F., Zheng, Z., Guo, J., & Ding, X. (2010). Correlation and quantitation of 
microRNA aberrant expression in tissues and sera from patients with breast 
tumor. Gynecologic Oncology, 119(3), 586-593.  
Wang, H. L., Bai, H., Li, Y., Sun, J., & Wang, X. Q. (2007). Rationales for expression 
and altered expression of apoptotic protease activating factor-1 gene in gastric 
cancer. World Journal of Gastroenterology, 13(38), 5060-5064.  
Wang, J., Zhang, K. Y., Liu, S. M., & Sen, S. (2014). Tumor-associated circulating 
microRNAs as biomarkers of cancer. Molecules, 19(2), 1912-1938.  
 240 
 
Wang, N., Zhu, M., Tsao, S. W., Man, K., Zhang, Z., & Feng, Y. (2013). MiR-23a-
mediated inhibition of topoisomerase 1 expression potentiates cell response to 
etoposide in human hepatocellular carcinoma. Molecular Cancer, 12, 119.  
Wang, Q., Huang, Z., Ni, S., Xiao, X., Xu, Q., Wang, L., . . . Du, X. (2012). Plasma 
miR-601 and miR-760 are novel biomarkers for the early detection of colorectal 
cancer. PLoS ONE, 7(9), e44398.  
Wang, X. (2008). miRDB: a microRNA target prediction and functional annotation 
database with a wiki interface. RNA, 14(6), 1012-1017.  
Wang, X., Lam, E. K., Zhang, J., Jin, H., & Sung, J. J. (2009). MicroRNA-122a 
functions as a novel tumor suppressor downstream of adenomatous polyposis 
coli in gastrointestinal cancers. Biochemical and Biophysical Research 
Communications, 387(2), 376-380.  
Wang, Y., Tang, Q., Li, M., Jiang, S., & Wang, X. (2014). MicroRNA-375 inhibits 
colorectal cancer growth by targeting PIK3CA. Biochemical and Biophysical 
Research Communications, 444(2), 199-204.  
Warren, J. D., Xiong, W., Bunker, A. M., Vaughn, C. P., Furtado, L. V., Roberts, W. 
L., . . . Heichman, K. A. (2011). Septin 9 methylated DNA is a sensitive and 
specific blood test for colorectal cancer. BMC Medicine, 9, 133.  
Weber, J. A., Baxter, D. H., Zhang, S., Huang, D. Y., Huang, K. H., Lee, M. J., . . . 
Wang, K. (2010). The microRNA spectrum in 12 body fluids. Clinical 
Chemistry, 56(11), 1733-1741.  
Wei, X., Lv, T., Chen, D., & Guan, J. (2014). Lentiviral vector mediated delivery of 
RHBDD1 shRNA down regulated the proliferation of human glioblastoma cells. 
Technology in Cancer Research and Treatment, 13(1), 87-93.  
Weimer, E. A. C. (2007). The role of microRNAs in cancer: no small matter. European 
Journal of Cancer, 43(10), 1529-1544.  
Weisenberger, D. J., Siegmund, K. D., Campan, M., Young, J., Long, T. I., Faasse, M. 
A., . . . Laird, P. W. (2006). CpG island methylator phenotype underlies sporadic 
microsatellite instability and is tightly associated with BRAF mutation in 
colorectal cancer. Nature Genetics, 38(7), 787–793.  
Willert, K., & Jones, K. A. (2006). Wnt signaling: is the party in the nucleus? Genes 
and Development, 20(11), 1394-1404.  
Winter, J., Jung, S., Keller, S., Gregory, R. I., & Diederichs, S. (2009). Many roads to 
maturity: microRNA biogenesis pathways and their regulation. Nature Cell 
Biology, 11(3), 228-234.  
Wolpin, B. M., Meyerhardt, J. A., Mamon, H. J., & Mayer, R. J. (2007). Adjuvant 
treatment of colorectal cancer. CA: A Cancer Journal for Clinicians, 57(3), 168-
185.  
Wong, R. S. Y. (2011). Apoptosis in cancer: from pathogenesis to treatment. Journal of 
Experimental and Clinical Cancer Research, 30, 87.  
 241 
 
Wong, T. S., Liu, X. B., Wong, B. Y. H., Ng, R. W. M., Yuen, A. P. W., & Wei, W. I. 
(2008). Mature miR-184 as potential oncogenic microRNA of squamous cell 
carcinoma of tongue. Clinical Cancer Research, 14(9), 2588-2592.  
Wu, L., Fan, J., & Belasco, J. G. (2006). MicroRNAs direct rapid deadenylation of 
mRNA. Proceedings of the National Academy of Sciences of the United States of 
America, 103(11), 4034-4039.  
Wu, Q., Jin, H., Yang, Z., Luo, G., Lu, Y., Li, K., . . . Fan, D. (2010). MiR-150 
promotes gastric cancer proliferation by negatively regulating the pro-apoptotic 
gene EGR2. Biochemical and Biophysical Research Communications, 392(3), 
340-345.  
Xu, H., He, J. H., Xiao, Z. D., Zhang, Q. Q., Chen, Y. Q., Zhou, H., & Qu, L. H. (2010). 
Liver-enriched transcription factors regulate microRNA-122 that targets CUTL1 
during liver development. Hepatology, 52(4), 1431-1442.  
Xu, X., Fan, Z., Kang, L., Han, J., Jiang, C., Zheng, X., . . . Ye, Q. (2013). Hepatitis B 
virus X protein represses miRNA-148a to enhance tumorigenesis. The Journal 
of Clinical Investigation, 123(2), 630-645.  
Xu, Y., & Pasche, B. (2007). TGF-beta signaling alterations and susceptibility to 
colorectal cancer. Human Molecular Genetics, 16(R1), R14-R20.  
Yamakuchi, M., Ferlito, M., & Lowenstein, C. J. (2008). miR-34a repression of SIRT1 
regulates apoptosis. Proceedings of the National Academy of Sciences of the 
United States of America, 105(36), 13421-13426.  
Yamakuchi, M., Lotterman, C. D., Bao, C., Hruban, R. H., Karim, B., Mendell, J. T., . . . 
Lowenstein, C. J. (2010). P53-induced microRNA-107 inhibits HIF-1 and tumor 
angiogenesis. Proceedings of the National Academy of Sciences of the United 
States of America, 107(14), 6334-6339.  
Yamamichi, N., Shimomura, R., Inada, K., Sakurai, K., Haraguchi, T., Ozaki, Y., . . . 
Iba, H. (2009). Locked nucleic acid in situ hybridization analysis of miR-21 
expression during colorectal cancer development. Clinical Cancer Research, 
15(12), 4009-4016.  
Yan, X., Liang, H., Deng, T., Zhu, K., Zhang, S., Wang, N., . . . Chen, X. (2013). The 
identification of novel targets of miR-16 and characterization of their biological 
functions in cancer cells. Molecular Cancer, 12, 92.  
Yang, H., Zhao, R., Yang, H. Y., & Lee, M. H. (2005). Constitutively active FOXO4 
inhibits Akt activity, regulates p27 Kip1 stability, and suppresses HER2-
mediated tumorigenicity. Oncogene, 24(11), 1924-1935.  
Yeh, L. C., & Lee, J. C. (1988). Probing the RNA structure within the yeast 5 S 
RNA.L1a protein complex by fluorescence and enzymatic digestion. The 
Journal of Biological Chemistry, 263(34), 18213-18219.  
 
 
 242 
 
Yehezkel, G., Cohen, L., Kliger, A., Manor, E., & Khalaila, I. (2012). O-linked β-N-
acetylglucosaminylation (O-GlcNAcylation) in primary and metastatic 
colorectal cancer clones and effect of N-acetyl-β-D-glucosaminidase silencing 
on cell phenotype and transcriptome. The Journal of Biological Chemistry, 
287(34), 28755-28769.  
Yip, K. T., Das, P. K., Suria, D., Lim, C. R., Ng, G. H., & Liew, C. C. (2010). A case-
controlled validation study of a blood-based seven-gene biomarker panel for 
colorectal cancer in Malaysia. Journal of Experimental and Clinical Cancer 
Research, 29, 128.  
Yong, F. L., Law, C. W., & Wang, C. W. (2013). Potentiality of a triple microRNA 
classifier: miR-193a-3p, miR-23a and miR-338-5p for early detection of 
colorectal cancer. BMC Cancer, 13, 280.  
Yoshida, H., Kong, Y. Y., Yoshida, R., Elia, A. J., Hakem, A., Hakem, R., . . . Mak, T. 
W. (1998). Apaf1 is required for mitochondrial pathways of apoptosis and brain 
development. Cell, 94(6), 739-750.  
Young, P. E., & Womeldorph, C. M. (2013). Colonoscopy for colorectal cancer 
screening. Journal of Cancer, 4(3), 217-226.  
Yu, D. C., Li, Q. C., Ding, X. W., & Ding, Y. T. (2011). Circulating microRNAs: 
potential biomarkers for cancer. International Journal of Molecular Sciences, 
12(3), 2055-2063.  
Yu, J., Li, A., Hong, S. M., Hruban, R. H., & Goggins, M. (2012). MicroRNA 
alterations of pancreatic intraepithelial neoplasias. Clinical Cancer Research, 
18(4), 981-992.  
Yu, T., Li, J., Yan, M., Liu, L., Lin, H., Zhao, F., . . . Yao, M. (2014). MicroRNA-193a-
3p and -5p suppress the metastasis of human non-small-cell lung cancer by 
downregulating the ERBB4/PIK3R3/mTOR/S6K2 signaling pathway. Oncogene. 
doi: 10.1038/onc.2013.574. 
Yuan, J. S., Reed, A., Chen, F., & Stewart Jr, C. N. (2006). Statistical analysis of real-
time PCR data. BMC Bioinformatics, 7, 85.  
Zainal Ariffin, O., & Nor Saleha, I. T. (2011). National Cancer Registry Report 2007: 
Ministry of Health, Malaysia. 
Zhang, G., Zhou, H., Xiao, H., Liu, Z., Tian, H., & Zhou, T. (2014). MicroRNA-92a 
functions as an oncogene in colorectal cancer by targeting PTEN. Digestive 
Diseases and Sciences, 59(1), 98-107.  
Zhang, H., Hao, Y., Yang, J., Zhou, Y., Li, J., Yin, S., . . . Xi, J. J. (2011). Genome-
wide functional screening of miR-23b as a pleiotropic modulator suppressing 
cancer metastasis. Nature Communications, 2, 554.  
Zhang, J., Guo, H., Qian, G., Ge, S., Ji, H., Hu, X., & Chen, W. (2010). MiR-145, a new 
regulator of the DNA Fragmentation Factor-45 (DFF45)-mediated apoptotic 
network. Molecular Cancer, 9, 211.  
 243 
 
Zhang, J., Lu, Y., Yue, X., Li, H., Luo, X., Wang, Y., . . . Wan, J. (2013). MiR-124 
suppresses growth of human colorectal cancer by inhibiting STAT3. PLoS ONE, 
8(8), e70300.  
Zhang, J., & Ma, L. (2012). MicroRNA control of epithelial-mesenchymal transition 
and metastasis. Cancer and Metastasis Reviews, 31(3-4), 653-662.  
Zhang, X., Tang, N., Hadden, T. J., & Rishi, A. K. (2011). Akt, FoxO and regulation of 
apoptosis. Biochimica et Biophyisica Acta, 1813(11), 1978-1986.  
Zhu, L. H., Liu, T., Tang, H., Tian, R. Q., Su, C., Liu, M., & Li, X. (2010). MicroRNA-
23a promotes the growth of gastric adenocarcinoma cell line MGC803 and 
downregulates interleukin-6 receptor. FEBS Journal, 277(18), 3726-3734.  
Zirvi, K. A., Keogh, J. P., Slomiany, A., & Slomiany, B. L. (1991). Transglutaminase 
activity in human colorectal carcinomas of differing metastatic potential. Cancer 
Letters, 60(1), 85-92.  
Zlobec, I., Minoo, P., Baker, K., Haegert, D., Khetani, K., Tornillo, L., . . . Lugli, A. 
(2007). Loss of APAF-1 expression is associated with tumour progression and 
adverse prognosis in colorectal cancer. European Journal of Cancer, 43(6), 
1101-1107.  
Zlobec, I., Vuong, T., & Compton, C. C. (2006). The predictive value of apoptosis 
protease-activating factor 1 in rectal tumors treated with preoperative, high-
dose-rate brachytherapy. Cancer, 106(2), 284-286.  
Zou, H., Taylor, W. R., Harrington, J. J., Hussain, F. T. N., Cao, X., Loprinzi, C. L., . . . 
Ahlquist, D. A. (2009). High detection rates of colorectal neoplasia by stool 
DNA testing with a novel digital melt curve assay. Gastroenterology, 136(2), 
459-470.  
 
 
  
 244 
 
APPENDICES 
Appendix 1: Approval letter for ethical clearance (reference number: 805.9). 
 
  
 245 
 
Appendix 2: Demographic data of 50 healthy controls (CTL) and 112 CRC patients (C).             
 No. Sample Age Race Gender TNM Location Grading 
Blood 
sample 
Paired 
tissue 
sample 
1 CTL_UA 70 Indian Female       √ - 
2 CTL_UD 65 Chinese Female       √ - 
3 CTL_UE 70 Chinese Male       √ - 
4 CTL_UF 75 Indian Female       √ - 
5 CTL_UH 71 Indian Female       √ - 
6 CTL_UI 68 Indian Male       √ - 
7 CTL_UJ 70 Chinese Female       √ - 
8 CTL_UM 65 Malay Male       √ - 
9 CTL_UP 70 Indian Female       √ - 
10 CTL_UW 66 Chinese Female       √ - 
11 CTL_VA 73 Chinese Female       √ - 
12 CTL_VD 62 Indian Male       √ - 
13 CTL_VH 63 Indian Male       √ - 
14 CTL_VN 66 Indian Female       √ - 
15 CTL_VO 60 Malay Female       √ - 
16 CTL_VV 73 Indian Female       √ - 
17 CTL_VZ 66 Malay Female       √ - 
18 CTL_WA 69 Malay Female       √ - 
19 CTL_WB 59 Indian Female       √ - 
20 CTL_WC 52 Indian Female       √ - 
21 CTL_WD 72 Indian Female       √ - 
22 CTL_WF 54 Indian Female       √ - 
23 CTL_XF 44 Malay Male       √ - 
24 CTL_XL 73 Malay Male       √ - 
25 CTL_XM 51 Indian Female       √ - 
26 CTL_XU 44 Malay Male       √ - 
27 CTL_XZ 52 Malay Male       √ - 
28 CTL_YA 44 Chinese Male       √ - 
29 CTL_YC 48 Chinese Male       √ - 
30 CTL_YD 47 Chinese Male       √ - 
31 CTL_YF 51 Chinese Female       √ - 
32 CTL_YH 40 Chinese Female       √ - 
33 CTL_YJ 72 Chinese Female       √ - 
34 CTL_YL 54 Chinese Female       √ - 
35 CTL_YN 73 Chinese Female       √ - 
36 CTL_YO 57 Chinese Female       √ - 
37 CTL_YQ 68 Chinese Female       √ - 
38 CTL_YW 60 Chinese Female       √ - 
39 CTL_ZB 68 Malay Male       √ - 
40 CTL_ZF 54 Malay Male       √ - 
41 CTL_ZJ 42 Malay Male       √ - 
42 CTL_ZM 80 Malay Male       √ - 
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Appendix 2: continued. 
 No. Sample Age Race Gender TNM Location Grading 
Blood 
sample 
Paired 
tissue 
sample 
43 CTL_ZN 44 Chinese Male       √ - 
44 CTL_ZP 69 Chinese Male       √ - 
45 CTL_ZQ 56 Malay Male       √ - 
46 CTL_ZR 59 Malay Male       √ - 
47 CTL_ZT 69 Malay Male       √ - 
48 CTL_ZW 68 Chinese Male       √ - 
49 CTL_ZY 65 Chinese Male       √ - 
50 CTL_ZZ 66 Chinese Male       √ - 
51 C_AA 65 Chinese Female I Colon G2 √ - 
52 C_AB 55 Indian Female I Colon G2 √ - 
53 C_AC 64 Indian Female II Colon G2 √ √ 
54 C_AE 68 Indian Female I Rectum G2 √ - 
55 C_AF 56 Chinese Female III Colon G2 √ √ 
56 C_AH 70 Indian Male III Colon G2 √ √ 
57 C_AI 72 Malay Female III Colon G2 √ √ 
58 C_AJ 63 Malay Male II Colon G2 √ √ 
59 C_AK 74 Indian Male II Colon G2 √ √ 
60 C_AN 70 Chinese Male II Colon G2 √ √ 
61 C_AP 55 Malay Male II Colon G2 √ √ 
62 C_AQ 65 Chinese Male II Colon G2 √ √ 
63 C_AR 61 Indian Male III Colon G2 √ √ 
64 C_AS 63 Indian Female IV Colon G2 √ √ 
65 C_AT 52 Malay Female IV Colon G2 √ √ 
66 C_AU 59 Indian Male IV Colon G2 √ √ 
67 C_AV 52 Indian Female II Rectum G2 √ - 
68 C_AX 76 Chinese Female III Rectum G2 √ - 
69 C_AZ 78 Indian Female IV Rectum G2 √ - 
70 C_BA 71 Indian Female IV Rectum G2 √ - 
71 C_BB 60 Malay Male IV Colon G2 √ √ 
72 C_BC 64 Indian Female II Rectum G2 √ - 
73 C_BF 65 Malay Male II Colon G2 √ √ 
74 C_BH 80 Indian Female I Rectum G2 √ - 
75 C_BI 50 Indian Female I Colon G2 √ - 
76 C_BK 64 Malay Female II Colon G2 √ √ 
77 C_BM 66 Indian Female III Colon G2 √ √ 
78 C_BN 52 Indian Female II Colon G2 √ √ 
79 C_BO 68 Indian Female III Colon G2 √ √ 
80 C_BP 56 Malay Male III Colon G2 √ √ 
81 C_BQ 71 Indian Female III Colon G2 √ √ 
82 C_BS 61 Malay Male IV Colon G2 √ √ 
83 C_BU 76 Malay Female I Rectum G2 √ - 
84 C_BV 63 Indian Female II Rectum G2 √ - 
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Appendix 2: continued. 
 No. Sample Age Race Gender TNM Location Grading 
Blood 
sample 
Paired 
tissue 
sample 
85 C_BW 73 Malay Female III Rectum G2 √ - 
86 C_BX 66 Chinese Female IV Rectum G2 √ - 
87 C_BZ 54 Chinese Male IV Colon G2 √ √ 
88 C_C 71 Chinese Female IV Colon G2 √ √ 
89 C_CB 46 Malay Female IV Colon G2 √ √ 
90 C_D 60 Chinese Female III Colon G2 √ √ 
91 C_E 63 Indian Female IV Colon G2 √ √ 
92 C_F 61 Malay Male I Colon G2 √ - 
93 C_G 44 Chinese Male II Rectum G1 √ - 
94 C_H 66 Chinese Female IV Rectum G2 √ - 
95 C_I 60 Indian Female IV Colon G2 √ √ 
96 C_J 54 Indian Female III Rectum G2 √ - 
97 C_KA 68 Chinese Male II Rectum G3 √ - 
98 C_KB 76 Chinese Male II Colon G1 √ √ 
99 C_KD 68 Malay Male I Colon G2 √ - 
100 C_KF 55 Chinese Male II Colon G2 √ √ 
101 C_KG 56 Chinese Female IV Colon G1 √ √ 
102 C_KH 58 Chinese Male II Rectum G1 √ - 
103 C_KI 72 Chinese Male II Colon G1 √ √ 
104 C_KJ 46 Malay Male I Colon G1 √ - 
105 C_KK 76 Chinese Male I Colon G1 √ - 
106 C_KM 73 Chinese Male II Colon G2 √ √ 
107 C_KN 71 Chinese Male II Colon G2 √ √ 
108 C_KR 75 Malay Male I Colon G2 √ - 
109 C_KS 58 Chinese Female IV Colon G2 √ √ 
110 C_KT 56 Malay Male I Rectum G3 √ - 
111 C_KU 64 Chinese Female IV Colon G3 √ √ 
112 C_KX 60 Chinese Male III Colon G1 √ √ 
113 C_KY 66 Chinese Male II Colon G3 √ √ 
114 C_KZ 63 Malay Male I Colon G2 √ - 
115 C_LA 63 Malay Male I Rectum G1 √ - 
116 C_LC 55 Chinese Male II Colon G1 √ √ 
117 C_LD 52 Malay Male I Rectum G3 √ - 
118 C_LE 61 Chinese Male II Colon G2 √ √ 
119 C_LF 43 Chinese Male III Colon G1 √ √ 
120 C_LG 56 Malay Male I Colon G2 √ - 
121 C_LI 70 Malay Male I Rectum G2 √ - 
122 C_LJ 52 Chinese Female IV Colon G1 √ √ 
123 C_LK 57 Chinese Female IV Colon G2 √ √ 
124 C_LM 74 Chinese Female IV Colon G2 √ √ 
125 C_LN 72 Malay Male I Rectum G2 √ - 
126 C_LO 63 Chinese Male I Rectum G2 √ - 
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Appendix 2: continued. 
 No. Sample Age Race Gender TNM Location Grading 
Blood 
sample 
Paired 
tissue 
sample 
127 C_LP 69 Chinese Male II Colon G2 √ √ 
128 C_LQ 70 Malay Male I Colon G2 √ - 
129 C_LR 82 Chinese Male III Colon G1 √ √ 
130 C_LS 59 Malay Male I Rectum G1 √ - 
131 C_LU 81 Chinese Male II Rectum G1 √ - 
132 C_LX 49 Chinese Male III Colon G3 √ √ 
133 C_LY 85 Chinese Male III Colon G2 √ √ 
134 C_LZ 54 Chinese Male I Rectum G2 √ - 
135 C_MA 67 Chinese Male II Rectum G3 √ - 
136 C_MB 69 Chinese Male II Rectum G1 √ - 
137 C_MC 63 Chinese Male III Rectum G2 √ - 
138 C_MD 65 Chinese Male III Rectum G1 √ - 
139 C_MG 56 Chinese Male III Rectum G3 √ - 
140 C_MI 58 Chinese Male III Rectum G3 √ - 
141 C_MK 74 Chinese Female III Rectum G1 √ - 
142 C_ML 70 Chinese Female IV Colon G2 √ √ 
143 C_MN 62 Chinese Female IV Colon G2 √ √ 
144 C_MO 57 Chinese Female III Colon G2 √ √ 
145 C_MP 61 Chinese Male I Colon G2 √ - 
146 C_MS 64 Chinese Male II Colon G1 √ √ 
147 C_MV 75 Chinese Female IV Colon G1 √ √ 
148 C_MW 68 Chinese Male III Rectum G2 √ - 
149 C_MX 69 Chinese Male III Rectum G2 √ - 
150 C_MY 58 Chinese Female IV Colon G2 √ √ 
151 C_MZ 77 Chinese Female III Rectum G2 √ - 
152 C_NA 70 Chinese Male III Colon G1 √ √ 
153 C_ND 89 Chinese Male II Rectum G1 √ - 
154 C_NG 60 Malay Male I Rectum G1 √ - 
155 C_NH 64 Chinese Male II Colon G1 √ √ 
156 C_NI 76 Chinese Male III Colon G1 √ √ 
157 C_NL 52 Chinese Male I Rectum G2 √ - 
158 C_NN 78 Chinese Male II Rectum G2 √ - 
159 C_NQ 69 Chinese Male III Colon G3 √ √ 
160 C_NR 70 Chinese Female III Colon G2 √ √ 
161 C_NS 71 Chinese Male II Rectum G3 √ - 
162 C_NV 73 Chinese Male III Colon G2 √ √ 
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Appendix 3: Agarose gel electrophoresis images of extracted total RNA. 
Images of 162 blood samples 
  
CTL_UA        CTL_UD      CTL_UE       CTL_UF CTL_UH    CTL_UI     CTL_UJ     CTL_UM   CTL_UP CTL_UW    CTL_VA    CTL_VD     CTL_VH    CTL_VN    CTL_VO     CTL_VV   CTL_VZ  
CTL_WA      CTL_WB    CTL_WC CTL_WD    CTL_WF     CTL_XF      CTL_XL     CTL_XM     CTL_XU     CTL_XZ      CTL_YA   CTL_YC     CTL_YD    CTL_YF   CTL_YH 
CTL_YJ         CTL_YL          CTL_YN         CTL_YO         CTL_YQ       CTL_YW   CTL_ZB        CTL_ZF        CTL_ZJ    CTL_ZM     CTL_ZN       CTL_ZP     CTL_ZQ       CTL_ZR    CTL_ZT   CTL_ZW 
CTL_ZY    CTL_ZZ       C_AA          C_AB          C_AC           C_AE          C_AF         C_AH          C_AI           C_AJ            C_AK           C_AN        C_AP        C_AQ        C_AR        C_AS       C_AT        C_AU  
   C_AV        C_AX          C_AZ          C_BA             C_BB         C_BC          C_BF           C_BH          C_BI           C_BK          C_BM         C_BN            C_BO          C_BP           C_BQ          C_BS          C_BU         C_AU  
   C_BV       C_BW         C_BX           C_BZ           C_C          C_CB          C_D            C_E           C_F                C_G             C_H              C_I              C_J              C_KA         C_KB          C_KD          C_KF         C_AU  
   C_KG       C_KH       C_KI         C_KJ           C_KK       C_KM           C_KN        C_KR         C_KS             C_KT          C_KU          C_KX        C_KY              C_KZ         C_LA          C_LC          C_LD         C_AU  
    C_LE       C_LF         C_LG         C_LI          C_LJ         C_LK         C_LM        C_LN           C_LO           C_LP           C_LQ           C_LR           C_LS          C_LU           C_LX          C_LY              
   C_LZ       C_MA         C_MB         C_MC           C_MD       C_MG         C_MI        C_MK          C_ML        C_MN         C_MO         C_MP          C_MS           C_MV         C_MW        C_MX             
    C_MY       C_MZ           C_NA          C_ND          C_NG        C_NH             C_NI          C_NL          C_NN           C_NQ           C_NR           C_NS           C_NV            
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Appendix 3: continued. 
Images of 60 paired tissue samples (cancer tissue) 
 
 
 
 
 
 
 
 
 
Images of 60 paired tissue samples (normal colonic tissue)  
 
 
 
 
 
 
 
 
  
    C_AC        C_AF          C_AH          C_AI          C_AJ          C_AK              C_AN          C_AP             C_AQ          C_AR           C_AS           C_AT         C_AU           C_BB          C_BF           C_BK      
     C_BM          C_BN           C_BO            C_BP             C_BQ            C_BS             C_BZ             C_C               C_CB             C_D              C_E              C_I                C_KM           C_MO       
     C_KB        C_KF           C_KG           C_KI           C_KN            C_KS             C_KU            C_KX           C_KY           C_LC               C_LE            C_LF          C_LJ            C_LK          C_LM         C_LP      
     C_AC       C_AF      C_AH       C_AI        C_AJ       C_AK       C_AN        C_AP        C_AQ       C_AR           C_AS            C_AT          C_AU            C_BB          C_BF           C_BK      
     C_KB        C_KF           C_KG          C_KI             C_KN            C_KS            C_KU            C_KX             C_KY           C_LC             C_LE           C_LF           C_LJ           C_LK           
       C_LM         C_LP             C_LR         C_LX           C_LY          C_ML         C_MN        C_MS          C_MV          C_MY           C_NA         C_NH          C_NI          C_NQ         C_NR           C_NV      
    C_LR           C_LX               C_LY            C_ML             C_MN            C_MS              C_MV            C_MY           C_NA           C_NH            C_NI          C_NQ          C_NR         C_NV      
      C_BM       C_BN             C_BO          C_BP          C_BQ          C_BS        C_BZ          C_C           C_CB            C_D           C_E               C_I              C_KM       C_MO       
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Appendix 4: Polyacrylamide gel electrophoresis images of extracted total RNA. 
Images of 162 blood samples 
 
 
 
 
CTL_UA     CTL_UD    CTL_UE    CTL_UF CTL_UH     CTL_UI        CTL_UJ        CTL_UM      CTL_UP      CTL_UW     CTL_VA      CTL_VD     CTL_VH             CTL_VN            CTL_VO      
  CTL_VV        CTL_VZ       CTL_WA               CTL_WB      CTL_WC   CTL_WD CTL_WF       CTL_XF       CTL_XL      CTL_XM      CTL_XU             CTL_XZ        CTL_YA      CTL_YC  
  CTL_YD        CTL_YF     CTL_YH       CTL_YJ            CTL_YL    CTL_YN    CTL_YO     CTL_YQ    CTL_YW     CTL_ZB       CTL_ZF            CTL_ZJ       CTL_ZM    CTL_ZN      CTL_ZP    
   CTL_ZQ              CTL_ZR      CTL_ZT     CTL_ZW               CTL_ZY          CTL_ZZ            C_AA                      C_AB           C_AC            C_AE           C_AF                 C_AH        
     C_AI           C_AJ          C_AK           C_AN              C_AP          C_AQ          C_AR                  C_AS             C_AT            C_AU                  C_AV          C_AX          C_AZ          C_BA               C_BB     
       C_BC           C_BF            C_BH                  C_BI            C_BK          C_BM               C_BN         C_BO            C_BP          C_BQ        C_BS        C_BU        C_BV        C_BW        C_BX        C_BZ            
    C_C            C_CB          C_D                   C_E            C_F            C_G           C_H            C_I                C_J                C_KA         C_KB               C_KD                 C_KF          C_KG         C_KH   
      C_KI           C_KJ          C_KK              C_KM         C_KN         C_KR              C_KS            C_KT          C_KU          C_KX          C_KY                  C_KZ            C_LA           C_LC       
   C_LD          C_LE           C_LF          C_LG                  C_LI           C_LJ            C_LK              C_LM        C_LN        C_LO        C_LP             C_LQ        C_LR        C_LS        C_LU       C_LX        C_LY    
    C_LZ          C_MA        C_MB        C_MC        C_MD                 C_MG          C_MI         C_MK          C_ML         C_MN         C_MO         C_MP                    C_MS            C_MV           C_MW         
    C_MX             C_MY            C_MZ              C_NA                  C_ND          C_NG         C_NH                C_NI               C_NL              C_NN                 C_NQ           C_NR            C_NS            C_NV             
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Appendix 4: continued. 
Images of 60 paired tissue samples (cancer tissue) 
 
 
 
 
 
 
 
 
 
 
 
Images of 60 paired tissue samples (normal colonic tissue) 
  
 
 
     C_AC          C_AF          C_AH          C_AI           C_AJ           C_AK         C_AN          C_AP                  C_AQ            C_AR                 C_AS           C_AT           C_AU             
  C_BB            C_BF           C_BK         C_BM          C_BN           C_BO          C_BP            C_BQ           C_BS           C_BZ                C_C          C_CB           C_D          C_E    
        C_I            C_KM         C_MO         C_KB         C_KF                 C_KG          C_KI         C_KN         C_KS         C_KU               C_KX           C_KY           C_LC                 C_LE         C_LF     
         C_LJ         C_LK         C_LM         C_LP          C_LR             C_LX       C_LY               C_ML          C_MN        C_MS          C_MV              C_MY            
   C_NA           C_NH            C_NI             C_NQ                 C_NR        C_NV          
   C_AC         C_AF           C_AH        C_AI       C_AJ             C_AK         C_AN            C_AP        C_AQ        C_AR        C_AS              C_AT          C_AU         C_BB              C_BF          C_BK            
C_BM         C_BN       C_BO        C_BP       C_BQ                C_BS            C_BZ             C_C               C_CB            C_D               C_E              C_I             C_KM          C_MO   
       C_KB            C_KF          C_KG            C_KI             C_KN           C_KS          C_KU           C_KX            C_KY                C_LC          C_LE           C_LF           C_LJ           C_LK          C_LM             
      C_LP          C_LR        C_LX          C_LY        C_ML       C_MN         C_MS        C_MV             C_MY       C_NA      C_NH              C_NI           C_NQ                 C_NR             C_NV          
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Appendix 5: RIN of total RNA samples used in miRNA microarray. 
Blood  
array RIN 
 Blood 
array RIN 
 Tissue array  
(Cancer) RIN 
Tissue array  
(Normal) RIN 
CTL_UA 7.0  C_BF 7.3  C_AC 7.1 C_AC 9.8 
CTL_UD 8.5  C_BH 7.0  C_AF 7.4 C_AF 9.5 
CTL_UE 7.5  C_BI 7.0  C_AH 7.0 C_AH 9.3 
CTL_UF 8.4  C_BK 8.3  C_AI 9.2 C_AI 8.8 
CTL_UH 8.8  C_BM 8.3  C_AJ 8.1 C_AJ 9.8 
CTL_UI 9.5  C_BN 7.8  C_AK 7.6 C_AK 9.4 
CTL_UJ 8.1  C_BO 7.8  C_AN 9.1 C_AN 9.0 
CTL_UM 8.2  C_BP 7.2  C_AP 7.3 C_AP 8.6 
CTL_UP 7.8  C_BQ 7.3  C_AQ 7.6 C_AQ 10.0 
CTL_UW 8.6  C_BS 7.8  C_AR 8.1 C_AR 8.3 
CTL_VA 7.1  C_BU 7.7  C_AS 7.2 C_AS 9.4 
CTL_VD 7.7  C_BV 8.3  C_AT 7.2 C_AT 8.4 
CTL_VH 8.1  C_BW 7.6  C_AU 9.2 C_AU 8.5 
CTL_VN 8.3  C_BX 7.1  C_BB 7.6 C_BB 9.4 
CTL_VO 8.2  C_BZ 7.0  C_BF 8.0 C_BF 8.6 
CTL_VV 8.0  C_CB 7.1  C_BK 7.3 C_BK 8.8 
CTL_VZ 7.9  C_D 7.1  C_BM 7.4 C_BM 9.8 
CTL_WA 7.5  C_E 7.2  C_BN 8.5 C_BN 9.0 
C_AA 8.5  C_I 7.1  C_BO 7.7 C_BO 8.2 
C_AB 7.2  C_J 7.1  C_BP 7.2 C_BP 7.9 
C_AC 9.2    C_BQ 7.6 C_BQ 8.7 
C_AE 7.3    C_BS 7.7 C_BS 9.7 
C_AF 8.2    C_BZ 7.6 C_BZ 8.4 
C_AH 8.5    C_C       9.1 C_C       10.0 
C_AI 8.5    C_CB 8.6 C_CB 8.2 
C_AJ 8.3    C_D 9.6 C_D 8.1 
C_AK 8.5    C_E 9.6 C_E 8.4 
C_AN 7.3    C_I 9.5 C_I 9.1 
C_AP 9.1    C_KM       8.9 C_KM       8.5 
C_AQ 9.0    C_MO  9.4 C_MO  7.2 
C_AR 9.8    
C_AS 8.2    
C_AT 8.4    
C_AU 9.0    
C_AV 9.5    
C_AX 8.8    
C_AZ 8.5    
C_BA 8.1    
C_BB 7.3    
C_BC 7.5    
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Appendix 6: Samples used in miRNA microarray, RT-qPCR and Western blot. 
Blood microarray 
 Tissue 
microarray 
 
Blood RT-qPCR 
 Tissue RT-qPCR 
& Western blot 
CTL_UA C_BC  C_AC  CTL_WB     C_KF      C_MG       C_KB       
CTL_UD C_BF  C_AF  CTL_WC      C_KG      C_MI       C_KF       
CTL_UE C_BH  C_AH  CTL_WD      C_KH     C_MK       C_KG       
CTL_UF C_BI  C_AI  CTL_WF      C_KI      C_ML       C_KI      
CTL_UH C_BK  C_AJ  CTL_XF  C_KJ      C_MN      C_KN     
CTL_UI C_BM  C_AK  CTL_XL      C_KK     C_MO   C_KS       
CTL_UJ C_BN  C_AN  CTL_XM      C_KM      C_MP       C_KU       
CTL_UM C_BO  C_AP  CTL_XU      C_KN     C_MS       C_KX       
CTL_UP C_BP  C_AQ  CTL_XZ      C_KR C_MV      C_KY    
CTL_UW C_BQ  C_AR  CTL_YA     C_KS      C_MW       C_LC       
CTL_VA C_BS  C_AS  CTL_YC     C_KT      C_MX       C_LE  
CTL_VD C_BU  C_AT  CTL_YD      C_KU      C_MY      C_LF      
CTL_VH C_BV  C_AU  CTL_YF      C_KX      C_MZ    C_LJ      
CTL_VN C_BW  C_BB  CTL_YH      C_KY    C_NA      C_LK      
CTL_VO C_BX  C_BF  CTL_YJ      C_KZ     C_ND       C_LM       
CTL_VV C_BZ  C_BK  CTL_YL      C_LA      C_NG       C_LP       
CTL_VZ C_CB  C_BM  CTL_YN      C_LC      C_NH     C_LR       
CTL_WA C_D  C_BN  CTL_YO      C_LD      C_NI       C_LX       
C_AA C_E  C_BO  CTL_YQ      C_LE  C_NL      C_LY    
C_AB C_I  C_BP  CTL_YW      C_LF      C_NN       C_ML       
C_AC C_J  C_BQ  CTL_ZB      C_LG      C_NQ      C_MN      
C_AE   C_BS  CTL_ZF      C_LI  C_NR       C_MS       
C_AF   C_BZ  CTL_ZJ      C_LJ      C_NS   C_MV      
C_AH   C_C        CTL_ZM     C_LK     C_NV       C_MY      
C_AI   C_CB  CTL_ZN     C_LM        C_NA      
C_AJ   C_D  CTL_ZP      C_LN        C_NH    
C_AK   C_E  CTL_ZQ      C_LO       C_NI       
C_AN   C_I  CTL_ZR      C_LP        C_NQ      
C_AP   C_KM        CTL_ZT      C_LQ       C_NR       
C_AQ   C_MO   CTL_ZW      C_LR        C_NV       
C_AR    CTL_ZY      C_LS        
C_AS    CTL_ZZ      C_LU        
C_AT    C_C       C_LX        
C_AU    C_F  C_LY      
C_AV    C_G     C_LZ        
C_AX    C_H   C_MA        
C_AZ    C_KA   C_MB        
C_BA    C_KB       C_MC      
C_BB    C_KD       C_MD        
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Appendix 7: Fold change (2–ΔΔCT) of miRNAs and mRNAs in paired tissue samples. 
Values are expressed as fold change of cancer tissue versus normal colonic mucosa. 
Sample 
miR- 
150 
miR- 
193a-3p 
miR- 
23a 
miR- 
23b 
miR- 
338-5p 
miR- 
342-3p 
miR- 
483-3p FOXO4 APAF1 
C_KB       0.9330 3.1977 5.6637 1.4008 5.6663 0.7894 12.9880 0.7674 0.1506 
C_KF       1.5611 0.4717 0.5263 0.2091 0.6041 1.6245 0.3773 0.7553 0.3939 
C_KG       1.6043 1.4425 1.0981 1.1764 4.1615 0.9462 0.4616 0.4247 0.3946 
C_KI      1.4866 0.8849 0.6040 2.1829 0.5628 0.8564 0.4127 1.1259 0.7304 
C_KN     0.8706 0.9152 0.3240 0.4397 0.7581 0.6416 2.9063 1.2983 0.2913 
C_KS       0.8706 1.2221 1.7579 2.5377 2.6954 1.9928 2.1554 0.1634 0.1089 
C_KU       0.2102 2.8400 0.7696 0.7019 0.5128 0.5716 1.7106 0.0661 0.0221 
C_KX       1.1070 4.2319 6.6793 0.7623 3.2817 1.1790 0.3108 0.1907 0.0800 
C_KY    0.4196 0.9931 2.0456 0.3283 0.7577 0.4292 0.4341 0.2827 0.1775 
C_LC       0.6186 0.5450 0.5172 0.3608 0.7733 1.1005 0.9558 0.1978 0.4202 
C_LE  0.6035 0.8632 0.8183 0.3724 0.3807 0.6356 0.6474 0.7101 0.3013 
C_LF      1.0169 1.3300 5.0208 0.4662 4.3215 0.5482 1.6594 0.2626 0.1050 
C_LJ      0.9330 2.8564 2.2800 0.6622 3.6548 1.5553 4.1400 0.3818 0.1404 
C_LK      1.3214 5.9716 2.5638 0.9330 3.5777 1.2655 2.5640 0.1787 0.4111 
C_LM       0.4866 0.9385 2.4835 0.1078 2.3345 0.2568 42.0531 0.0852 0.0774 
C_LP       0.2087 0.2480 0.1329 2.2383 0.2660 0.7708 0.3521 1.2079 0.5655 
C_LR       1.0833 0.3339 0.7905 1.6425 0.1319 1.0029 1.7147 0.3537 0.1955 
C_LX       1.4105 2.3295 1.7387 2.0910 2.4196 0.2029 5.5233 0.8050 0.1741 
C_LY    0.8972 1.1683 4.7860 0.4710 1.7289 1.5246 3.9408 0.4525 0.1548 
C_ML       0.3324 0.8417 3.9549 0.3500 1.0937 0.1727 1.7789 0.4722 0.0482 
C_MN      0.1232 2.6371 3.0303 1.1693 3.8745 0.2975 1.4810 0.1369 0.0437 
C_MS       0.5398 1.4681 3.4987 1.0718 4.3790 0.8039 1.5105 0.4158 0.1597 
C_MV      1.3439 1.6046 1.1640 0.9089 1.4105 0.9085 1.9583 0.9373 0.1930 
C_MY      1.3680 3.4960 4.0591 1.1510 3.8906 0.9861 4.1386 0.2048 0.0959 
C_NA      1.2858 1.0129 3.8037 0.3746 2.3329 0.9593 2.2978 1.7366 0.7431 
C_NH    1.2887 0.6120 1.8119 0.3254 3.6569 1.0402 2.2873 1.3262 0.2538 
C_NI       0.0656 1.9421 2.1900 0.4585 1.8374 0.1901 0.9519 1.2643 0.1603 
C_NQ      0.4520 4.5815 1.4088 1.5053 1.4086 1.0057 2.6685 0.2753 0.1835 
C_NR       1.5210 1.7395 0.9086 1.5207 0.9500 0.7970 71.8009 0.2529 0.2163 
C_NV       1.3125 1.0008 0.1988 0.2225 1.1235 1.7980 1.4591 0.6384 0.2330 
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Appendix 8: Fold change (2–ΔΔCT) of miRNAs and mRNAs in blood samples.  
Sample 
miR- 
150 
miR- 
193a-3p 
miR- 
23a 
miR- 
23b 
miR- 
338-5p 
miR- 
342-3p 
miR- 
483-3p FOXO4 APAF1 
CTL_WB     0.5148 0.8405 1.2980 0.6112 0.3373 0.8825 1.5790 1.7702 1.0336 
CTL_WC      0.5817 1.1649 2.1623 0.6657 1.5622 0.8902 1.3521 0.8046 0.6431 
CTL_WD      1.2450 2.6990 2.7579 1.1662 2.3416 1.8772 1.8677 2.2420 0.6115 
CTL_WF      1.1337 0.8774 2.3725 0.9019 1.8282 1.3293 2.3996 0.8526 0.8409 
CTL_XF  2.1334 0.9135 0.5650 3.1998 1.3470 0.8839 0.2895 0.8215 1.8544 
CTL_XL      3.6659 1.1660 0.7041 2.3277 0.9236 1.2778 0.3358 2.7917 2.4242 
CTL_XM      1.5501 4.1288 4.3584 1.6065 2.1822 3.4802 0.9341 1.0873 0.4337 
CTL_XU      3.2698 1.0555 0.9979 3.6872 1.0614 1.2799 0.5817 1.3496 2.1795 
CTL_XZ      2.4999 1.5668 0.6516 3.2005 1.0125 1.0634 0.3910 0.2093 0.9474 
CTL_YA     0.5526 0.3855 0.7401 0.3057 0.7618 1.0487 1.0735 2.6870 1.3008 
CTL_YC     0.4539 0.5346 1.2297 0.4075 1.0818 0.6573 1.7144 1.8532 1.3128 
CTL_YD      0.6237 1.0159 2.2761 0.5946 1.0839 0.8078 0.7617 2.2916 0.9059 
CTL_YF      0.5010 0.5892 0.9529 0.5600 0.4915 0.9909 0.9792 2.3046 2.4128 
CTL_YH      0.8645 1.1384 1.3371 0.7708 1.0238 1.7244 2.2704 4.2278 1.7461 
CTL_YJ      0.7193 0.4389 0.5298 0.2604 0.3323 0.7966 0.3786 2.6727 0.7091 
CTL_YL      0.6510 0.8958 0.7726 0.4833 0.5866 1.0976 0.8882 1.4124 1.2841 
CTL_YN      0.9755 1.3833 2.6184 1.2451 1.4967 1.1041 2.0150 1.8092 1.3244 
CTL_YO      1.1061 2.3960 2.4846 1.2096 1.6672 1.7438 1.9359 0.6643 0.5803 
CTL_YQ      1.0175 1.3190 1.0988 0.5537 0.9596 1.9464 0.4866 2.7797 2.3799 
CTL_YW      0.6041 1.1211 4.5931 0.9252 2.7004 0.9341 0.9658 1.4456 1.8306 
CTL_ZB      1.1121 0.2509 0.1561 0.6379 0.3744 0.4826 0.4829 2.5639 1.2619 
CTL_ZF      0.4490 0.5782 0.1544 0.7890 1.1750 0.3006 1.0352 0.4648 2.5886 
CTL_ZJ      1.2093 0.5034 0.1636 1.2261 0.5196 0.3529 0.5959 0.8421 1.9763 
CTL_ZM     2.2140 0.9388 0.6988 3.9502 1.0326 1.0526 1.2552 0.4372 1.3223 
CTL_ZN     0.9913 1.4371 1.2166 1.0281 0.9876 1.8820 0.7924 0.2647 2.9708 
CTL_ZP      0.8162 1.6426 2.9786 1.2679 1.5254 0.9926 1.7386 0.2875 0.3963 
CTL_ZQ      0.8734 0.7022 0.1874 0.9001 1.3496 0.3207 1.4757 0.1264 0.2099 
CTL_ZR      0.5436 0.6704 0.1758 0.6061 0.6922 0.2863 0.8422 0.0480 0.1302 
CTL_ZT      1.2146 1.3944 0.7534 4.0720 0.8188 0.6795 2.4069 0.1819 0.1883 
CTL_ZW      0.7103 0.6693 1.0035 0.5220 0.6836 0.9098 0.2929 1.4002 0.4654 
CTL_ZY      2.6039 1.9677 1.8724 1.0777 1.2389 3.2129 3.6145 2.6344 1.5038 
CTL_ZZ      0.9834 1.5665 2.9238 1.3432 1.1642 1.7831 1.6147 1.8936 1.0102 
C_C       6.1957 8.0533 10.0868 4.1363 8.5458 4.2075 3.2142 0.8942 1.2307 
C_F  1.2623 1.1553 0.7284 1.9839 2.0375 0.8600 0.7706 0.9369 1.2467 
C_G     1.1652 3.4098 6.7512 14.1024 5.4913 8.6981 47.4744 0.7600 0.3446 
C_H   2.2220 2.0682 1.0948 5.3096 3.9285 1.7042 1.8537 0.1873 0.4548 
C_KA   1.3482 9.4800 4.4825 12.9335 5.2958 2.3098 0.4445 0.7692 0.9426 
C_KB       2.6303 2.6458 4.1912 2.0557 6.1297 1.5744 7.4862 2.2707 0.4696 
C_KD       0.4732 1.9417 1.5969 3.0299 2.1196 0.8059 0.4164 0.0931 0.4207 
C_KF       0.8161 1.4012 0.8814 4.3600 1.5421 0.7355 1.0815 1.1098 1.3852 
C_KG       0.9221 2.5001 0.8886 3.6747 5.0824 0.9959 2.2457 0.4768 0.1956 
C_KH     0.5224 1.7693 1.1223 4.3351 3.0903 0.6985 1.2593 1.9302 1.0171 
C_KI      1.9967 2.4842 0.9392 5.1282 1.4827 0.8835 1.3726 1.5313 1.4141 
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Appendix 8: continued. 
Sample 
miR- 
150 
miR- 
193a-3p 
miR- 
23a 
miR- 
23b 
miR- 
338-5p 
miR- 
342-3p 
miR- 
483-3p FOXO4 APAF1 
C_KJ       1.3969 2.0896 0.8325 2.2056 2.0191 1.1642 6.6554 0.4237 1.3964 
C_KK      1.2236 0.5911 0.7216 0.2142 1.6724 0.3320 1.1983 1.8621 0.5864 
C_KM       2.1609 2.1187 2.2030 0.9751 2.2104 0.8245 1.7451 1.2920 0.3590 
C_KN     1.9242 1.6957 0.7668 8.5535 1.9958 1.1220 3.4084 0.5975 0.2584 
C_KR 1.0673 1.1345 0.9345 3.9710 1.0465 0.8153 0.6064 0.4202 0.3744 
C_KS       0.9361 1.6618 1.1212 4.8922 1.8881 0.7089 0.2589 1.3225 1.0523 
C_KT       0.2138 2.7609 2.6839 1.2310 2.3303 0.9883 2.0306 0.6278 0.8877 
C_KU       2.5974 1.8750 0.7299 3.9708 1.0789 2.0061 0.9572 0.5110 0.2022 
C_KX       0.1924 3.7991 5.1983 2.2036 2.1320 0.7380 3.2047 0.3132 0.3260 
C_KY    0.7850 1.9039 3.9284 1.0965 1.2124 1.2085 0.5733 0.3334 0.4523 
C_KZ      0.5381 2.6302 2.0115 5.6923 3.1027 1.3089 0.5427 0.0815 0.2042 
C_LA       0.8820 1.1830 0.5299 3.6419 2.4120 1.1074 0.6602 0.2725 0.4724 
C_LC       1.5643 0.6633 0.5935 1.8223 2.0416 0.8038 1.2392 0.5318 0.5320 
C_LD       1.2314 1.9230 1.1560 3.5250 2.6334 0.7254 1.3683 1.5404 0.3610 
C_LE  0.3423 1.3028 1.6411 0.8008 0.6248 0.8117 0.7635 0.3958 0.9520 
C_LF      1.7145 1.9319 3.4732 2.2078 5.6306 0.8907 2.7973 0.2153 0.1846 
C_LG       0.3828 0.8291 0.5006 1.9386 1.0354 0.4224 1.9659 0.7420 1.4162 
C_LI  0.1037 1.6444 2.0944 1.0006 0.7318 0.6357 3.8561 0.4361 0.5052 
C_LJ      1.0162 2.8037 1.1709 5.8482 5.1034 1.3237 1.0713 1.2894 0.5610 
C_LK      1.0872 3.7983 1.0853 4.2428 3.1842 1.3124 1.6477 0.8659 0.5820 
C_LM       0.7041 0.7932 0.9533 0.6663 2.7062 0.3707 1.2053 0.4106 0.2313 
C_LN       0.0681 0.4226 0.3992 0.5340 0.1712 0.1592 0.6758 0.5987 0.3053 
C_LO      1.1973 1.2854 1.1179 0.5806 1.6306 0.7322 1.3394 1.1604 1.0678 
C_LP       0.2761 0.3324 0.0724 0.5357 0.4649 0.1281 0.8252 0.7001 0.2916 
C_LQ      1.3791 1.7469 1.4897 1.2030 2.3133 0.8366 2.8221 1.7984 2.5796 
C_LR       0.0709 0.2465 0.2032 0.4398 0.1617 0.0856 0.9231 0.1414 0.1669 
C_LS       2.8222 0.9667 1.2425 0.4128 1.6150 1.2229 3.1891 0.7192 1.4301 
C_LU       0.1975 1.8704 2.6450 0.5019 1.9034 0.5108 1.4818 0.3997 0.2668 
C_LX       0.5310 2.2824 2.0178 0.6205 1.7151 1.1088 1.4419 0.6308 1.3228 
C_LY    0.2733 2.2180 2.9558 0.8798 1.2404 1.2216 0.2170 0.3772 1.1050 
C_LZ       1.2033 0.6999 1.1938 0.5594 0.8463 0.8373 1.3482 0.6872 1.7919 
C_MA       1.8514 0.8333 1.1491 0.7097 2.3880 1.0158 1.3618 0.2753 0.4676 
C_MB       3.4144 1.7721 3.0863 1.5642 1.9739 1.5294 2.1790 0.2186 0.4327 
C_MC    0.7324 0.9900 0.7103 0.4622 2.6603 0.4593 1.7256 0.7576 1.4348 
C_MD       0.1538 1.6968 1.6959 0.6730 0.5103 1.6735 0.8164 0.7178 0.7204 
C_MG       1.3463 1.0218 1.0279 0.9226 2.6900 0.7923 1.5782 1.5938 1.7903 
C_MI       2.4059 1.1287 2.2409 0.8018 4.4161 1.3331 1.1588 1.0142 0.2308 
C_MK       0.5930 5.6016 1.2518 1.1687 0.8202 1.9697 3.5767 0.1255 0.1457 
C_ML       3.3106 0.9478 2.2431 1.2569 1.5769 1.5782 2.1274 0.4392 0.3427 
C_MN      0.9949 2.1148 2.6407 1.3643 5.0855 0.6562 2.4035 1.0570 0.1910 
C_MO  0.1971 1.3115 0.7173 0.2794 1.0175 0.4550 0.7152 0.9434 1.1146 
C_MP       4.6035 3.0007 2.7526 1.8680 3.0106 1.5459 1.6451 1.0648 1.2497 
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Appendix 8: continued. 
Sample 
miR- 
150 
miR- 
193a-3p 
miR- 
23a 
miR- 
23b 
miR- 
338-5p 
miR- 
342-3p 
miR- 
483-3p FOXO4 APAF1 
C_MS       1.2156 1.9210 4.5832 1.8383 7.7985 0.8246 1.9035 1.3226 0.6276 
C_MV      1.3526 1.5578 1.7642 1.0404 2.8597 1.0225 1.1294 0.3422 1.3794 
C_MW       1.5588 1.2663 2.7149 1.4555 3.1267 0.9351 1.0908 1.1201 0.2476 
C_MX       0.4776 1.7500 2.5130 0.8247 1.4438 1.0288 0.5397 0.1181 0.3123 
C_MY      3.9467 2.4471 2.8983 1.2061 3.7175 1.8329 1.0299 0.3613 0.9169 
C_MZ   0.4295 1.4753 1.2831 1.3779 1.3128 0.8209 3.4935 1.3870 0.3894 
C_NA      2.4652 2.0341 1.6145 1.5831 3.5107 1.3855 1.5111 2.2486 1.4826 
C_ND       0.5432 2.3441 2.2929 0.8716 1.3154 0.7943 1.2782 1.2915 1.5791 
C_NG       0.2707 1.5906 1.7315 0.5646 0.7369 0.7476 1.9909 0.8602 1.2542 
C_NH    1.8380 1.3730 1.7607 0.9137 3.1890 1.0121 1.4383 1.6639 1.7045 
C_NI       2.8513 1.9393 2.0009 2.0573 5.3820 1.6473 0.9948 1.7863 0.8834 
C_NL      5.8654 1.6979 2.8009 0.9065 2.7741 2.3815 1.8223 0.9492 1.2504 
C_NN       0.4769 1.3208 1.4899 0.8099 2.2057 0.3765 6.7729 1.0578 0.8348 
C_NQ      1.0347 2.5326 1.7284 0.7883 2.9380 1.5470 2.7320 0.3269 0.2657 
C_NR       0.4221 1.7184 0.9127 1.0829 0.6367 0.9493 4.5663 0.3220 0.1450 
C_NS  0.6419 0.9239 0.8104 0.2674 0.2941 0.8520 0.8940 1.2568 1.3975 
C_NV       0.3099 1.3403 0.7897 0.2285 1.2302 0.5262 1.8883 0.1588 0.1392 
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Appendix 9: Sample of Invitrogen Tali image-based cytometry cell analysis report.  
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Appendix 10: Putative gene targets of miR-193a-3p.  
Putative gene 
(Homo sapiens) 
Full name NCBI reference 
sequence 
Description 
(Source: NCBI database [http://www.ncbi.nlm.nih.gov/]; UniProt database 
[http://www.uniprot.org/]) 
ACVR2B Activin A receptor, 
type 2B 
NM_001106.3 ACVR2B is an activin type 2 receptor that binds activins (dimeric growth and 
differentiation factors) and forms a stable complex with the activin type 1 receptor in 
TGF-β signalling.  
AXIN2 Axin 2 NM_004655.3 Axin 2 is involved in the regulation of β-catenin stability in the Wnt/β-catenin 
pathway. Mutations in this gene have been linked to CRC with defective mismatch 
repair. 
CCND1 Cyclin D1 NM_053056.2 Cyclin D1 is involved in the regulation of cell cycle, in particularly G1/S transition. It 
is a regulator of cyclin-dependent kinases 4 and 6. Mutations and over-expression of 
this gene are common in cancer. 
FAS Fas cell surface 
death receptor 
NM_000043.4 Fas receptor is a member of the tumour necrosis factor receptor superfamily that 
contains a death domain. Fas receptor is involved in the regulation of programmed cell 
death via extrinsic apoptosis pathway. Mutations in this gene have been implicated in 
the pathogenesis of cancer and diseases of the immune system.  
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Appendix 10: continued. 
    
Putative gene 
(Homo sapiens) 
Full name NCBI reference 
sequence 
Description 
(Source: NCBI database [http://www.ncbi.nlm.nih.gov/]; UniProt database 
[http://www.uniprot.org/]) 
FOXO4 Forkhead box O4 NM_005938.3 FOXO4 is a transcription factor that belongs to a large FOX family of proteins. 
FOXO4 is involved in the regulation of cell growth, cell cycle arrest, DNA repair, 
stress, invasion and metastasis. FOXO4 has been identified as a tumour suppressor in 
cancer.  
FZD4 Frizzled class 
receptor 4 
NM_012193.3 FZD4 belongs to a family of G protein-coupled transmembrane proteins that serve as 
receptors in the Wnt/β-catenin pathway. It acts as a positive regulator in the Wnt/β-
catenin signalling. 
FZD5 Frizzled class 
receptor 5 
NM_003468.3 FZD5 belongs to a family of G protein-coupled transmembrane proteins that serve as 
receptors in the Wnt/β-catenin pathway. It acts as a positive regulator in the Wnt/β-
catenin signalling. 
KRAS Kirsten rat sarcoma 
viral oncogene 
homologue 
NM_033360.3 KRAS is an oncogene. It encodes a protein that is a member of the small GTPase 
superfamily. Mutations in this gene have been implicated in various malignancies, 
including CRC.  
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Appendix 10: continued. 
 
  
Putative gene 
(Homo sapiens) 
Full name NCBI reference 
sequence 
Description 
(Source: NCBI database [http://www.ncbi.nlm.nih.gov/]; UniProt database 
[http://www.uniprot.org/]) 
MAPK1 Mitogen-activated 
protein kinase 1 
NM_002745.4 MAPK1 is involved in the regulation of cell proliferation, differentiation and 
transcriptional activation/repression via EGFR pathway.  
PDGFRA Platelet-derived 
growth factor 
receptor, alpha 
polypeptide 
NM_006206.4 PDGFRA is a cell surface tyrosine kinase receptor that binds platelet-derived growth 
factors, which are mitogens for cells of mesenchymal origin. PDGFRA is involved in 
the regulation of organ development, wound healing and tumour progression. 
Mutations in this gene have been associated with numerous cancers. 
PTEN Phosphatase and 
tensin homologue 
NM_000314.4 PTEN is a tumour suppressor gene. It is involved in the regulation of PI3K-AKT 
pathway. Mutations in this gene are common in cancer.  
SMAD4 SMAD family 
member 4 
 
 
NM_005359.5 SMAD4 is a member of the SMAD family of signal transduction proteins. SMAD 
proteins are phosphorylated and activated by transmembrane serine-threonine receptor 
kinases in response to TGF-β signalling. SMAD4 is a tumour suppressor gene. 
Mutations in this gene have been implicated in hereditary haemorrhagic telangiectasia 
syndrome, juvenile polyposis syndrome, pancreatic cancer and CRC. 
    
    
 263 
 
Appendix 10: continued. 
 
Putative gene 
(Homo sapiens) 
Full name NCBI reference 
sequence 
Description 
(Source: NCBI database [http://www.ncbi.nlm.nih.gov/]; UniProt database 
[http://www.uniprot.org/]) 
SOS2  Son of sevenless 
homologue 2 
 
 
NM_006939.2 SOS2 encodes a protein that is a guanine nucleotide exchange factor that binds guanine 
nucleotides and prepares the GTP binding site for Ras proteins binding in the EGFR 
pathway. SOS2-dependent signalling is predominantly short-term, as compared to 
SOS1. Mutations in this gene have been associated with chronic myeloid leukaemia. 
TGFBR1 Transforming 
growth factor 
beta receptor I 
NM_004612.2 Upon binding to TGF-β ligand, TGFBR1 forms a heterodimeric complex with 
TGFBR2 and transmits the TGF-β signal from the cell surface to the cytoplasm. 
Mutations in this gene are common in the malignant transformation of CRC. 
  
 
 
 
264 
 
Appendix 11: FOXO4 3’-UTR fragment (NM_005938.3) containing the seed sequence. The customised fragment was inclusive of the HindIII and 
SpeI restriction sites (312 bp).  
 
SpeI 
Seed sequence 
HindIII 
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Appendix 12: FOXO4 3’-UTR fragment (NM_005938.3) containing the mutated seed sequence. The customised fragment was inclusive of the HindIII 
and SpeI restriction sites (312 bp).  
  
SpeI 
HindIII 
Mutated seed sequence 
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Appendix 13: Western blot images and fold change values of FOXO4 and APAF1 in 
paired tissue samples. β-actin was used as the loading control. N: normal colonic tissue; 
C: cancer tissue. 
Sample      β-actin FOXO4 protein  APAF1 protein 
     N       C      N        C Fold change        N       C  Fold change 
C_KB       
 
0.4103 
 
 
0.4178 
C_KF       
 
0.3521 
 
 
0.7943 
C_KG      
 
 
1.1133 
 
 
0.9720 
C_KI       
 
1.4866 
 
 
1.2070 
C_KN     
 
1.2110 
 
 
1.1646 
C_KS       
 
0.6143 
 
 
0.6136 
C_KU      
  
0.7889 
 
 
1.0867 
C_KX      
 
 
0.7102  
  
0.6592 
C_KY    
 
 
0.6020  
 
0.3421 
C_LC       
 
0.6390 
 
 
0.7827 
C_LE  
 
 
0.7234  
 
0.4469 
C_LF      
 
0.8378 
 
 
0.6098 
C_LJ       
 
0.7568  
 
0.8293 
C_LK     
 
 
0.7909  
 
0.8709 
C_LM       
 
0.2831  
 
0.4970 
C_LP       
 
0.8408 
 
 
0.8649 
C_LR       
 
1.0606 
 
 
1.1586 
C_LX      
 
 
0.5964  
 
0.6734 
C_LY     
 
0.8887  
 
0.5479 
C_ML       
 
0.7191  
 
0.8409 
C_MN      
 
0.5618 
 
 
0.5981 
C_MS       
 
0.8240  
 
0.8361 
C_MV      
 
0.7074  
 
0.3855 
C_MY      
 
0.6290 
 
 
0.5341 
C_NA      
 
0.5493  
 
0.8116 
C_NH     
 
0.7260  
 
0.7696 
C_NI       
 
0.7866  
 
0.4717 
C_NQ      
 
0.8798  
 
0.9567 
C_NR       
 
0.5865  
 
0.5861 
C_NV      
 
 
0.8287  
 
1.1435 
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Appendix 14: Putative gene targets of miR-23a.  
Putative gene 
(Homo sapiens) 
Full name NCBI reference 
sequence 
Description 
(Source: NCBI database [http://www.ncbi.nlm.nih.gov/]; UniProt database 
[http://www.uniprot.org/]) 
ACVR1C Activin A receptor, 
type 1C 
 
NM_145259.2 ACVR1C is an activin type 1 receptor that binds activins (dimeric growth and 
differentiation factors) and forms a stable complex with the activin type 2 receptor in 
TGF-β signalling. 
ACVR2A Activin A receptor, 
type 2A 
NM_001278579.1 ACVR2A is an activin type 2 receptor that binds activins (dimeric growth and 
differentiation factors) and forms a stable complex with the activin type 1 receptor in 
TGF-β signalling. 
ACVR2B Activin A receptor, 
type 2B 
NM_001106.3 ACVR2B is an activin type 2 receptor that binds activins (dimeric growth and 
differentiation factors) and forms a stable complex with the activin type 1 receptor in 
TGF-β signalling.  
APAF1 Apoptotic 
peptidase activating 
factor 1 
NM_013229.2 APAF1 is a cytoplasmic protein that is involved in the regulation of cell apoptosis via 
intrinsic apoptosis pathway.  
CASP7 Caspase-7, 
apoptosis-related 
cysteine peptidase 
NM_001227.4 Caspase-7 is a cysteine aspartic acid protease that plays a central role in the execution 
phase of cell apoptosis.  
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Appendix 14: continued.  
 
  
Putative gene 
(Homo sapiens) 
Full name NCBI reference 
sequence 
Description 
(Source: NCBI database [http://www.ncbi.nlm.nih.gov/]; UniProt database 
[http://www.uniprot.org/]) 
CCND1 Cyclin D1 NM_053056.2 Cyclin D1 is involved in the regulation of cell cycle, in particularly G1/S transition. It 
is a regulator of cyclin-dependent kinases 4 and 6. Mutations and over-expression of 
this gene are common in cancer. 
CREBBP cAMP response 
element-binding 
(CREB)-binding 
protein 
NM_004380.2 CREBBP is ubiquitously expressed and is associated with transcriptional co-activation 
of a variety of transcription factors. It is involved in embryonic development, growth 
control and cellular homeostasis. 
 
FAS Fas cell surface 
death receptor 
NM_000043.4 Fas receptor is a member of the tumour necrosis factor receptor superfamily that 
contains a death domain. Fas receptor is involved in the regulation of programmed cell 
death via extrinsic apoptosis pathway. Mutations in this gene have been implicated in 
the pathogenesis of cancer and diseases of the immune system.  
FZD4 Frizzled class 
receptor 4 
NM_012193.3 FZD4 belongs to a family of G protein-coupled transmembrane proteins that serve as 
receptors in the Wnt/β-catenin pathway. It acts as a positive regulator in the Wnt/β-
catenin signalling. 
    
  
 
 
 
269 
 
Appendix 14: continued. 
 
  
Putative gene 
(Homo sapiens) 
Full name NCBI reference 
sequence 
Description 
(Source: NCBI database [http://www.ncbi.nlm.nih.gov/]; UniProt database 
[http://www.uniprot.org/]) 
FZD5 Frizzled class 
receptor 5 
NM_003468.3 FZD5 belongs to a family of G protein-coupled transmembrane proteins that serve as 
receptors in the Wnt/β-catenin pathway. It acts as a positive regulator in the Wnt/β-
catenin signalling. 
FZD7 Frizzled class 
receptor 7 
NM_003507.1 FZD7 belongs to a family of G protein-coupled transmembrane proteins that serve as 
receptors in the Wnt/β-catenin pathway. FZD7 may down-regulate APC function and 
enhance β-catenin-mediated signals in cancer. 
ID4 Inhibitor of DNA 
binding 4, 
dominant negative 
helix-loop-helix 
protein 
NM_001546.3 ID4 is a basic helix-loop-helix transcription factor. ID4 can act as a tumour suppressor 
though it lacks the DNA binding activity. The activity of ID4 depends on its protein 
binding partner. 
PIK3R3 Phosphoinositide-
3-kinase, 
regulatory sub-unit 
3 (gamma) 
NM_003629.3 PIK3R3 is a lipid kinase that binds to activated protein-tyrosine kinases through its 
SH2 domain and regulates the downstream signalling acitivties. It is involved in the 
regulation of cell proliferation, survival, degranulation, vesicular trafficking and 
migration.  
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Appendix 14: continued. 
 
  
Putative gene 
(Homo sapiens) 
Full name NCBI reference 
sequence 
Description 
(Source: NCBI database [http://www.ncbi.nlm.nih.gov/]; UniProt database 
[http://www.uniprot.org/]) 
PTEN Phosphatase and 
tensin homologue 
NM_000314.4 PTEN is a tumour suppressor gene. It is involved in the regulation of PI3K-AKT 
pathway. Mutations in this gene are common in cancer.  
RBL2 Retinoblastoma-
like 2 
NM_005611.3 RBL2 is a key regulator in cell division. It is involved in heterochromatin formation by 
maintaining the overall chromatin structure. It is a potent inhibitor of E2F-mediated 
transactivation and may act as a tumour suppressor protein. 
SMAD4 SMAD family 
member 4 
 
 
NM_005359.5 SMAD4 is a member of the SMAD family of signal transduction proteins. SMAD 
proteins are phosphorylated and activated by transmembrane serine-threonine receptor 
kinases in response to TGF-β signalling. SMAD4 is a tumour suppressor gene. 
Mutations in this gene have been implicated in hereditary haemorrhagic telangiectasia 
syndrome, juvenile polyposis syndrome, pancreatic cancer and CRC. 
SOS1 Son of sevenless 
homologue 1 
NM_005633.3 SOS1 encodes a protein that is a guanine nucleotide exchange factor that binds guanine 
nucleotides and prepares the GTP binding site for Ras proteins binding in the EGFR 
pathway. Over-expression of SOS1 has been linked to the development of various 
solid tumours. 
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Appendix 14: continued. 
 
  
Putative gene 
(Homo sapiens) 
Full name NCBI reference 
sequence 
Description 
(Source: NCBI database [http://www.ncbi.nlm.nih.gov/]; UniProt database 
[http://www.uniprot.org/]) 
TGFBR2 Transforming 
growth factor 
beta receptor II  
NM_001024847.2 Upon binding to TGF-β ligand, TGFBR2 forms a heterodimeric complex with 
TGFBR1 and transmits the TGF-β signal from the cell surface to the cytoplasm. 
Mutations in this gene are common in the malignant transformation of CRC. 
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Appendix 15: APAF1 3’-UTR fragment (NM_013229.2) containing the seed sequence. The customised fragment was inclusive of the HindIII and SpeI 
restriction sites (312 bp).  
 
SpeI 
HindIII 
Seed sequence 
  
 
 
 
273 
 
Appendix 16: APAF1 3’-UTR fragment (NM_013229.2) containing the mutated seed sequence. The customised fragment was inclusive of the HindIII 
and SpeI restriction sites (312 bp). 
 
SpeI 
HindIII 
Mutated seed sequence 
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Appendix 17: Putative gene targets of miR-338-5p. 
Putative gene 
(Homo sapiens) 
Full name NCBI reference 
sequence 
Description 
(Source: NCBI database [http://www.ncbi.nlm.nih.gov/]; UniProt database 
[http://www.uniprot.org/]) 
ACVR2A Activin A receptor, 
type 2A 
NM_001278579.1 ACVR2A is an activin type 2 receptor that binds activins (dimeric growth and 
differentiation factors) and forms a stable complex with the activin type 1 receptor in 
TGF-β signalling. 
APPL1 Adaptor protein, 
phosphotyrosine 
interaction, PH 
domain and leucine 
zipper containing 1 
NM_012096.2 APPL1 is involved in the regulation of cell proliferation, adiponectin signalling and 
insulin signalling.  
CCND1 Cyclin D1 NM_053056.2 Cyclin D1 is involved in the regulation of cell cycle, in particularly G1/S transition. It 
is a regulator of cyclin-dependent kinases 4 and 6. Mutations and over-expression of 
this gene are common in cancer. 
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Appendix 17: continued. 
 
  
Putative gene 
(Homo sapiens) 
Full name NCBI reference 
sequence 
Description 
(Source: NCBI database [http://www.ncbi.nlm.nih.gov/]; UniProt database 
[http://www.uniprot.org/]) 
CREBBP cAMP response 
element-binding 
(CREB)-binding 
protein 
NM_004380.2 CREBBP is ubiquitously expressed and is associated with transcriptional co-activation 
of a variety of transcription factors. It is involved in embryonic development, growth 
control and cellular homeostasis. 
 
EP300 E1A binding 
protein p300 
NM_001429.3 EP300 encodes the adenovirus E1A-associated cellular p300 transcriptional co-
activator protein. EP300 functions as histone acetyltransferase that regulates cellular 
transcription via chromatin remodelling. It is involved in the regulation of cell 
proliferation and differentiation. Mutations in this gene have been detected in 
epithelial cancer. 
FZD7 Frizzled class 
receptor 7 
NM_003507.1 FZD7 belongs to a family of G protein-coupled transmembrane proteins that serve as 
receptors in the Wnt/β-catenin pathway. FZD7 may down-regulate APC function and 
enhance β-catenin-mediated signals in cancer. 
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Appendix 17: continued. 
 
  
Putative gene 
(Homo sapiens) 
Full name NCBI reference 
sequence 
Description 
(Source: NCBI database [http://www.ncbi.nlm.nih.gov/]; UniProt database 
[http://www.uniprot.org/]) 
ID1 Inhibitor of DNA 
binding 1, 
dominant negative 
helix-loop-helix 
protein 
NM_002165.3 ID1 is a basic helix-loop-helix transcription factor that lacks the DNA binding activity. 
It is involved in the regulation of cell growth, senescence, and differentiation. 
ID4 Inhibitor of DNA 
binding 4, 
dominant negative 
helix-loop-helix 
protein 
NM_001546.3 ID4 is a basic helix-loop-helix transcription factor. ID4 can act as a tumour suppressor 
though it lacks the DNA binding activity. The activity of ID4 depends on its protein 
binding partner. 
KRAS Kirsten rat sarcoma 
viral oncogene 
homologue 
NM_033360.3 KRAS is an oncogene. It encodes a protein that is a member of the small GTPase 
superfamily. Mutations in this gene have been implicated in various malignancies, 
including CRC.  
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Appendix 17: continued. 
 
Putative gene 
(Homo sapiens) 
Full name NCBI reference 
sequence 
Description 
(Source: NCBI database [http://www.ncbi.nlm.nih.gov/]; UniProt database 
[http://www.uniprot.org/]) 
MAPK1 Mitogen-activated 
protein kinase 1 
NM_002745.4 MAPK1 is involved in the regulation of cell proliferation, differentiation and 
transcriptional activation/repression via EGFR pathway.  
MET MET proto-
oncogene, receptor 
tyrosine kinase 
NM_001127500.1 The proto-oncogene MET product is the hepatocyte growth factor receptor with 
tyrosine kinase activity. Mutations in this gene generally lead to carcinogenesis. 
PDGFRA Platelet-derived 
growth factor 
receptor, alpha 
polypeptide 
NM_006206.4 PDGFRA is a cell surface tyrosine kinase receptor that binds platelet-derived growth 
factors, which are mitogens for cells of mesenchymal origin. PDGFRA is involved in 
the regulation of organ development, wound healing and tumour progression. 
Mutations in this gene have been associated with numerous cancers. 
PTEN Phosphatase and 
tensin homologue 
NM_000314.4 PTEN is a tumour suppressor gene. It is involved in the regulation of PI3K-AKT 
pathway. Mutations in this gene are common in cancer.  
RBL2 Retinoblastoma-
like 2 
NM_005611.3 RBL2 is a key regulator in cell division. It is involved in heterochromatin formation by 
maintaining the overall chromatin structure. It is a potent inhibitor of E2F-mediated 
transactivation and may act as a tumour suppressor protein. 
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Appendix 17: continued. 
 
Putative gene 
(Homo sapiens) 
Full name NCBI reference 
sequence 
Description 
(Source: NCBI database [http://www.ncbi.nlm.nih.gov/]; UniProt database 
[http://www.uniprot.org/]) 
RBX1 Ring-box 1, E3 
ubiquitin protein 
ligase 
NM_014248.3 RBX1 is involved in ubiquitination during cell cycle progression.  
SMAD4 SMAD family 
member 4 
 
 
NM_005359.5 SMAD4 is a member of the SMAD family of signal transduction proteins. SMAD 
proteins are phosphorylated and activated by transmembrane serine-threonine receptor 
kinases in response to TGF-β signalling. SMAD4 is a tumour suppressor gene. 
Mutations in this gene have been implicated in hereditary haemorrhagic telangiectasia 
syndrome, juvenile polyposis syndrome, pancreatic cancer and CRC. 
SMAD5 SMAD family 
member 5 
NM_005903.6 SMAD5 is a member of the SMAD family of signal transduction proteins. SMAD 
proteins are phosphorylated and activated by transmembrane serine-threonine receptor 
kinases in response to TGF-β signalling. Mutations in this gene have been detected in 
cancer. 
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Appendix 17: continued. 
 
Putative gene 
(Homo sapiens) 
Full name NCBI reference 
sequence 
Description 
(Source: NCBI database [http://www.ncbi.nlm.nih.gov/]; UniProt database 
[http://www.uniprot.org/]) 
SOS1 Son of sevenless 
homologue 1 
NM_005633.3 SOS1 encodes a protein that is a guanine nucleotide exchange factor that binds guanine 
nucleotides and prepares the GTP binding site for Ras proteins binding in the EGFR 
pathway. Over-expression of SOS1 has been linked to the development of various 
solid tumours. 
SOS2 Son of sevenless 
homologue 2 
 
 
NM_006939.2 SOS2 encodes a protein that is a guanine nucleotide exchange factor that binds guanine 
nucleotides and prepares the GTP binding site for Ras proteins binding in the EGFR 
pathway. SOS2-dependent signalling is predominantly short-term, as compared to 
SOS1. Mutations in this gene have been associated with chronic myeloid leukaemia. 
TGFBR1 Transforming 
growth factor  
beta receptor I 
NM_004612.2 Upon binding to TGF-β ligand, TGFBR1 forms a heterodimeric complex with 
TGFBR2 and transmits the TGF-β signal from the cell surface to the cytoplasm. 
Mutations in this gene are common in the malignant transformation of CRC. 
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Appendix 18: List of publications and papers presented. 
Research article 
BMC Cancer (2013) - Impact factor: 3.32 
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Appendix 18: continued. 
Research article 
International Journal of Molecular Sciences (2014) - Impact factor: 2.34 
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Appendix 18: continued. 
Oral presentation; 6th Postgraduate Forum on Health Systems and Policies (2012)  
BMC Public Health (2012) - Impact factor: 2.32 
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Appendix 18: continued. 
Oral presentation; 2nd International Conference on Bioinformatics and 
Biomedical Science (2013)  
International Journal of Bioscience, Biochemistry and Bioinformatics (2013) - Non-ISI 
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Appendix 18: continued. 
Poster presentation; Coloproctology Conference (2013) 
 
